



Australian Government
Department of Health

*Australian Statistics
on Medicines
2011*





Australian Government

Department of Health

*Australian Statistics
on Medicines*

2011

Acknowledgments

Prepared by Vanna Mabbott, Maxine Robinson and Alicia Segrave of the Pharmaceutical Benefits Division.

We would like to thank the following people for their help in the access and provision of data and information used in this report:

The World Health Organization Collaborating Centre for Drug Statistics Methodology.

Kavita Verma, Pharmaceutical Access, Department of Health.

Christopher Parker, Pharmaceutical Access, Department of Health.

Katherine Gray, Advisory Committee on the Safety of Medicines, Therapeutic Goods Administration.

Rebecca Bennetts, Australian Institute of Health and Welfare.

Australian Statistics on Medicine 2011

Print ISBN: 978-1-74186-083-2

Online ISBN: 978-1-74186-084-9

Publications approval number: 10534

Copyright Statements:

Paper-based publications

© Commonwealth of Australia 2013

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to copyright@health.gov.au.

Internet sites

© Commonwealth of Australia 2013

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to copyright@health.gov.au.

FOREWORD

It is my great pleasure to introduce the 17th Edition of the Australian Statistics on Medicines. This publication provides an extensive and extremely valuable set of statistics on the use of prescription medicines in Australia from 1991 to 2011. Data in this edition were obtained from the Pharmaceutical Benefits Scheme, the Repatriation Pharmaceutical Benefits Scheme and an ongoing survey of a representative sample of community pharmacies.

Knowledge about the usage, cost and trends over time in prescription medications is clearly relevant for all four aspects of the National Medicines Policy: access to medicines; quality, safety and efficacy of medicines, quality use of medicines; and a responsible and viable medicines industry. These data are routinely scrutinized by the Drug Utilisation Sub-Committee (DUSC) which has provided advice to the Pharmaceutical Benefits Advisory Committee and other stakeholders within the National Medicines Policy Framework about the use (predicted and actual) of medicines in Australia since 1988. This advice is critical with the number, usage, cost and complexity of prescription medicines increasing with an ageing population and ongoing development of new and innovative medicines. Data from the Australian Statistics on Medicines and advice from DUSC provide an integral contribution to the monitoring and quality assurance of the Pharmaceutical Benefits Scheme, prescribers and the medicines industry.

This edition of the Australian Statistics on Medicines was prepared by staff of the Pharmaceutical Benefits Division. I acknowledge their skill and expertise and thank them for their extraordinary commitment and hard work. The Australian Statistics on Medicines has a critical role in our health care system and provides information that ultimately improves the health of Australians.

Geoff McColl
FRACP PhD
Chair, Drug Utilisation Sub-Committee

CONTENTS

FOREWORD	iii
INTRODUCTION	1
INFORMATION ON THE AUSTRALIAN STATISTICS ON MEDICINES	2
Overview	2
Pharmaceutical Benefits Advisory Committee	3
Drug Utilisation Sub-Committee	3
National Medicines Policy	3
Drug Classification	4
Measurement Unit	5
Department of Human Services processing	6
Pharmacy Guild Survey data	6
Combined database	7
ADVERSE EVENT REPORTING IN AUSTRALIA IN 2011	9
THE HIGHLY SPECIALISED DRUGS PROGRAMME	13
Overview	13
SUPPLY OF PHARMACEUTICAL BENEFITS TO REMOTE AREA ABORIGINAL HEALTH SERVICES UNDER SECTION 100 OF THE NATIONAL HEALTH ACT	16
HEALTH EXPENDITURE TRENDS	17
DRUG UTILISATION TRENDS	19
TABLES IN THE AUSTRALIAN STATISTICS ON MEDICINES	25
References	25
CAVEATS	26
GLOSSARY OF TERMS	27
Weights and Measures	28
ATC & DDD ADDITIONS AND ALTERATIONS	29
TABLE 1	
2011 COMMUNITY PRESCRIPTION NUMBERS, TOGETHER WITH GOVERNMENT AND PATIENT COSTS FOR PBS LISTED DRUGS	33
TABLE 2	
COMMUNITY PRESCRIPTION DRUG USE, IN DDD/1000/DAY, FOR 2009 TO 2011	191
ATC INDEX 2012	286

TABLES AND FIGURES

List of Tables

Table A:	Highly Specialised Drugs—National Usage and Patient Report in Public Hospitals for the period January 2011 to December 2011	13
Table B (i):	Total expenditure on pharmaceuticals and other medical non-durables as % total expenditure on health, TEH	17
Table B (ii):	Total expenditure on pharmaceuticals & other medical non-durables per capita, US\$ purchasing power parity	17
Table B (iii):	Total expenditure on health as % gross domestic product	17
Tables C:	Prescription numbers by ATC groups	19
Table C (i):	Subsidised prescriptions (PBS/RPBS)	19
Table C (ii):	Estimated non-subsidised prescriptions (Survey)	20
Table D:	Top 10 drugs by defined daily dose/thousand population/day, 2011 (including the contribution of constituents of combination products)	21
Table E:	Top 10 drugs by prescription counts, 2011	21
Table F:	Top 10 PBS/RPBS drugs by total cost to Australia, 2011	22
Table G:	Nurse Practitioner—Top 10 PBS/RPBS drugs by prescription counts, 2011	23
Table H:	Nurse Practitioner—Top 10 PBS/RPBS drugs prescribed by total cost, 2011	24
Table I:	Optometrist—Top 10 PBS/RPBS drugs by prescription counts, 2011	24
Table J:	Optometrist—Top 10 PBS/RPBS drugs prescribed by total cost, 2011	24

List of Figures

Figure A:	Community utilisation of sotalol hydrochloride	8
Figure B:	Origin of adverse event reports received by the TGA (2006–2011)	9
Figure C:	Number of prescriptions by type of service	20
Figure D:	Top 10 subsidised drugs dispensed in 2011	22
Figure E:	Top 10 non-subsidised drugs dispensed in 2011	23

INTRODUCTION

The data contained in the 2011 Australian Statistics on Medicines are drawn from two sources. The first is the Department of Human Services records of prescriptions submitted for payment of a subsidy under the Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS). The second is a survey of a representative sample of community pharmacies, which provides an estimate of the non-subsidised use of prescription medicines in the Australian community. The usage of prescription medicines dispensed to in-patients in public hospitals is not available in this report. The usage of subsidised PBS/RPBS prescription medicines to out-patients and discharged patients in five states of Australia and one territory are included. It is planned that all out-patients and discharged patients will receive PBS subsidised prescriptions in the future. The units of measurement are the prescription and the defined daily dose per 1000 population per day (DDD/1000 population/day). The defined daily dose is established by the World Health Organization Collaborating Centre (WHOCC) for Drug Statistics Methodology on the basis of the assumed average dose per day of the drug, used for its main indication by adults. The drugs presented in this publication are arranged using the Anatomical Therapeutic Chemical (ATC) classification system. For more detail on this classification and the unit of measurement, please read the chapter 'Information on the Australian Statistics on Medicines'. The data are presented in two major tables. Table 1 includes 2011 community (i.e. subsidised and non-subsidised) prescription numbers. These figures are presented together with the government and patient costs for drugs PBS listed and subsidised by the Australian Government only. Cost information on the dispensing of drugs not listed on the PBS and drugs that are PBS-listed but for which no subsidy is claimed from the Australian Government is not available for the period of this report. Collection of under general co-payment PBS volume data commenced on 1 April 2012, and will inform future reports thereafter. Table 2 includes community prescription drug use, in DDDs/1000 population/day, for the years 2009, 2010 and 2011. Table 2 reports the DDDs for each drug, reporting the use in monocomponent ('plain') and in fixed dose combination formulations.

INFORMATION ON THE AUSTRALIAN STATISTICS ON MEDICINES

Overview

The development, monitoring and promotion of rational and cost-effective use of medications in society are dependent on accurate information on patterns of drug prescription and use. Where use is considered to be inappropriate, drug utilisation data can monitor the impact of educational or regulatory interventions, and can guide the interpretation of pharmacoeconomic analysis¹.

In Australia, community prescriptions (i.e. non-public hospital) are dispensed either as private prescriptions, funded by the patient or private health insurer, or under one of two Government subsidisation schemes—the Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS). These schemes were established to provide the general community (PBS) and returned servicemen and women (RPBS) with access to necessary medicinal products which are affordable, available and of acceptable standards. Since 2002 prescriptions for an increasing number of public hospital outpatients and many medicinal products supplied at discharge for in-patients have been included in the dataset. In 2011, the RPBS was 6% of the size of the PBS and a large majority, approximately 93%, of RPBS prescriptions involved PBS listed drugs.

In Australia, a new medicinal drug must gain approval for supply in accordance with the requirements of the *Therapeutic Goods Act 1989*. Approval is also required to extend the indications of an established drug. Applications are dealt with by the Therapeutic Goods Administration (TGA) and, for prescription drugs, advice is sought from an expert committee. From 1963 to 2009 this advice was provided by the Australian Drug Evaluation Committee (ADEC). ADEC was replaced in January 2010 with the Advisory Committee on Prescription Medicines (ACPM).

Once a prescription drug is approved for marketing, the company concerned usually applies to have the drug listed on the PBS. This is the national scheme available to the Australian community for subsidising the cost of pharmaceuticals. The subsidised cost, particularly for newer drugs, reduces consumers' out of pocket expenses therefore many companies seek to have the drug listed on the scheme to facilitate viable marketing.

The Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Australian Government about which drugs should be listed on the PBS. Pre-market evaluation addresses the issues of quality, safety and efficacy, whereas the PBAC considers effectiveness and cost-effectiveness of the product relative to alternatives, as well as the overall cost to the Government. Once the PBAC has recommended a drug for listing on the PBS, the Pharmaceutical Benefits Pricing Authority (PBPA) negotiates the price with the sponsor company. The PBPA consists of government, industry and consumer representatives. After agreement is reached, the Australian Government considers the advice of both the PBAC and the PBPA and makes a decision on whether the drug will be listed on the PBS.

Under the PBS, patient contributions towards medication costs at pharmacies are capped. In 2011, general patients paid the cost of a prescription up to a maximum of \$34.20. Pensioner and concession patients paid \$5.60 per prescription.

In addition, there is a Safety Net Scheme to protect people with high medication needs. In 2011, once general patients and/or their immediate family incurred \$1,317.20 of PBS expenditure (indexed), PBS/RPBS prescriptions for the remainder of the calendar year cost only \$5.60 per prescription. Once pensioners and other concession card holders reached the concession safety net threshold of \$336 expenditure (indexed), they received all remaining prescriptions in 2011 free of charge.

It is important to note that patients may be required to pay a surcharge if a doctor prescribes a more expensive brand of an item, when there are cheaper, equivalent brands of that item listed on the PBS.

As the general patient co-payment rises, the dispensed price of many cheaper medical products fall under this level. In such cases the patient pays the full price and no claim for payment was transmitted under the PBS for the period of this report. In 2011, under co-payment general prescriptions represented around 17.9% of all community prescriptions. There are also many drugs that are not listed on the PBS or RPBS and are available only on private prescription, with the patient paying the full cost. Private prescriptions represented 7.2% of community prescriptions in 2011.

Pharmaceutical Benefits Advisory Committee

The Pharmaceutical Benefits Advisory Committee (PBAC) is an independent statutory body established on 12 May 1954, under section 100A of the *National Health Act 1953*. The role of PBAC is to make recommendations and give advice to the Minister about which drugs and medicinal preparations should be made available as pharmaceutical benefits. No new drug may be made available as a pharmaceutical benefit unless recommended by the PBAC.

The PBAC is required by the Act to consider the effectiveness and cost of a proposed benefit compared to alternative therapies. In making its recommendations, the PBAC, on the basis of expected community usage, recommends maximum quantities and repeats, and may also recommend restrictions as to the indications where PBS subsidy is available. When recommending listings, the PBAC provides advice to the PBPA regarding comparison with alternatives or their cost effectiveness.

Drug Utilisation Sub-Committee

In 1988, the PBAC convened the Drug Utilisation Sub-Committee (DUSC) to assist it in making recommendations for listings on the PBS. Its terms of reference are:

- To develop and advise on the mechanisms for the collection, analysis and interpretation of comprehensive data on utilisation of medicines in Australia.
- To advise PBAC on changes in patterns of utilisation of medicines as a consequence of changes in their availability or subsidy restrictions and to review the utilisation of medicines, including but not restricted to expenditure impacts within the Pharmaceutical Benefits Scheme (PBS).
- To advise stakeholders within the National Medicines Policy framework on the interpretation of patterns of utilisation of medicines, including by placing the results of the data in the context of the limitations of the data.
- To identify potential problems and benefits related to patterns of utilisation of medicines.
- To evaluate policy and other interventions related to the use of medicines.
- To facilitate and promote the dissemination of information on utilisation of medicines.
- To conduct international comparisons of utilisation of medicines by interaction with appropriate international bodies.

National Medicines Policy

The National Medicines Policy (NMP) is a broad framework that aims to improve health outcomes for all Australian's through access to and appropriate use of medicines.

The overall aim of the NMP is to meet medication and related service needs, so that both optimal health outcomes and economic objectives are achieved. In this context "medicines" means prescription, non-prescription and complementary healthcare products.

The NMP has four central objectives:

- timely access to the medicines that Australian's need, at a cost individuals and the community can afford;
- medicines meeting appropriate standards of quality, safety and efficacy;
- quality use of medicines;
- and maintaining a responsible and viable medicines industry.

Further information on the National Medicines Policy is available at: <http://www.health.gov.au/internet/main/publishing.nsf/Content/National+Medicines+Policy-1>

Drug Classification

The DUSC and the Department of Health have adopted the Anatomical Therapeutic Chemical (ATC) code as recommended by the World Health Organization (WHO). It has been a goal of WHO to have an internationally accepted classification for presenting and comparing drug usage data. In 1982, the WHO Collaborating Centre for Drug Statistics Methodology (WHOCC), located in Norway, was established as a central body responsible for coordinating ATC use.

The ATC code itself is a seven digit alphanumeric code, structured in five levels, that classifies drugs according to their site of action and therapeutic and chemical characteristics.

The first level of the code is the anatomical main group. There are 14 anatomical main groups. The second and third levels are for the therapeutic subgroup and pharmacological subgroup, respectively, with a fourth level being either a chemical or therapeutic subgroup. The fifth level is the actual chemical substance.

The five levels thus are:

- anatomical main group
- pharmacological/therapeutic subgroup
- chemical/pharmacological or therapeutic subgroup
- chemical/pharmacological or therapeutic subgroup
- chemical substance (generic drug name)

For example, risperidone has the following code: N 05 A X 08.

N	denotes	Nervous system
05		Psycholeptics
A		Antipsychotics
X		Other antipsychotics
08		Risperidone

ATC system main groups:

The 14 anatomical main groups of the ATC code are:

- A. Alimentary tract and metabolism
- B. Blood and blood forming organs
- C. Cardiovascular system
- D. Dermatologicals
- G. Genitourinary system and sex hormones
- H. Systemic hormonal preparations, excluding sex hormones and insulins
- J. Anti-infectives for systemic use
- L. Antineoplastic and immunomodulating agents
- M. Musculo-skeletal system
- N. Nervous system
- P. Antiparasitic products, insecticides and repellents
- R. Respiratory system
- S. Sensory organs
- V. Various

Although the ATC code extends to the generic drug level, it does not identify dosage forms, pack sizes, strengths or brand names.

The WHOCC, together with the Nordic Council on Medicines, undertakes regular revisions of the ATC system. They receive expert advice from an advisory board and an established procedure exists to manage requests for new classifications and to regularly review the current structure. Changes implemented in 2012 are included in the Anatomical Therapeutic Chemical Index (ATC) & Defined Daily Dose (DDD) additions and alterations section in this publication.

Measurement Unit

The international unit of drug utilisation adopted by the DUSC to accompany this coding system is the defined daily doses, per thousand of the population, per day (DDDs/1000/day). The defined daily dose is established by the Nordic Council on Medicines and the WHO Drug Utilisation Research Group on the basis of the assumed average dose per day of the drug, when used for its main indication by adults³.

Use of DDDs allows for comparisons of drug utilisation independent of differences in price, preparation and quantity per prescription. It also allows comparison of the use of drugs in different therapeutic groups, and between regions and countries. Expressing drug use in DDDs/1000/day allows the aggregation of data for those drugs which have differing daily doses. The DDD, however, is only a technical unit of use and does not necessarily reflect the recommended or average prescribed dose in Australia.

The DDDs/1000/day figure is calculated from prescription data in the following way:

$$\frac{N \times M \times Q \times 1000}{DDD \times P \times D}$$

Where:

- N** is the number of prescriptions dispensed in the year
- M** is the drug mass in each unit (tablet, capsule, injection, pack etc.) (e.g. milligrams or grams, expressed in the same unit as DDD)
- Q** is the average dispensed quantity (ie. number of units)per prescription
- P** is the midyear Australian population for the year of data collection (see Australian Bureau of Statistics website for population figures used in this edition:[http://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/BEC1AAE4C2BED109CA257A8500206850/\\$File/31010_Mar%202012.pdf](http://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/BEC1AAE4C2BED109CA257A8500206850/$File/31010_Mar%202012.pdf))
- D** is the number of days in the year.

The DDDs/1000/day can be calculated over other time periods such as monthly or quarterly.

For PBS items, the mass amount (M) is the amount of active drug contained in an individual dose unit e.g. tablet, capsule, suppository etc. Non-PBS items are estimated from the Pharmacy Guild survey. The data from the survey does not include information on the quantity supplied per prescription, therefore the mass amount for nonsubsidised items is the total amount of active drug contained in the pack.

For prescriptions forwarded for subsidy, the average quantity dispensed (Q), is available from Department of Human Services data. For prescriptions that are priced under the general co-payment, quantity is assumed to be the average quantity of the subsidised prescriptions for that drug (i.e. as concession, safety net and Veterans' Affairs (Repatriation) prescriptions). For private prescriptions, the quantity dispensed is assumed to be the retail pack size.

For a chronically administered drug, the DDDs/1000/day figure indicates how many people, per 1000 of the population, may, in theory, have received a standard dose (as defined by the DDD) daily.

For drugs used intermittently, for example anti-infectives, usage expressed in DDDs/1000 /day may similarly give a rough estimate of the average proportion of the population using these drugs every day. To estimate the number of patients treated during the year supplementary information, such as the average duration of treatment, is necessary³.

The ATC/DDD methodology has a number of limitations. All drugs dispensed are not necessarily consumed and the DDDs/1000/day is calculated for the total population, while drug use may be concentrated in certain age groups or a particular sex.

It is difficult to assign a DDD, and on occasions an ATC code, to some preparations that have multiple active ingredients. For some drug groups, such as the dermatological and antineoplastic drugs, highly individualised use and wide dose ranges, as well as the experimental nature of some of the therapy, make it difficult to define a daily dose. Consequently, there may be a delay between the marketing of a drug and the availability of an ATC code and its associated DDD.

Generally agreed indications for use of a drug may be re-evaluated in light of experience with adverse reactions and other pharmacological effects. Drugs may have multiple indications and it may be difficult to determine a preparation's use. Also, the DDD is based on overseas experience and may not reflect the prescribed adult dose in Australia.

As more medicinal products are listed on the PBS in formulations of two or more combinations the DUSC has considered that it is important to record the contribution, in terms of DDDs, of each constituent where appropriate. Therefore additional information on the contribution of the constituents of combination pharmaceutical items in addition to single component items will be reported in table 2.

Department of Human Services processing

In 1990, the processing of prescriptions submitted for payment of a subsidy under the PBS/RPBS was taken over by the Health Insurance Commission, now the Department of Human Services. Daily data transmissions, containing prescription records that do not allow the identification of an individual patient, are provided by the Department of Human Services to the Department of Health for summarisation.

Pharmacy Guild Survey data

Since 1989, DUSC has commissioned the Pharmacy Guild of Australia to conduct an annual survey to estimate the prescription volumes for drugs in the non-subsidised categories i.e. private prescriptions and PBS prescriptions priced under the general patient co-payment. Total dispensing information is collected each month from pharmacies that are members of the Pharmacy Guild. The sample increased in 2007 from 150 to 370.

Amfac, a major pharmacy computer software supplier, was commissioned to administer the collection of the data in 1988. Under the joint direction of DUSC and the Guild, Amfac contracted a firm of statisticians, specialising in survey design and analysis, to design a stratified random sample, using the Guild membership, which represents approximately 80% of pharmacies in Australia, as the population base. In 1993, the survey sample was reviewed and augmented with the assistance of the Statistical Services Section within the Department. A review of the representativeness, sample size, design and risks for the survey was carried out by the Australian Bureau of Statistics (ABS) in February 2002. It found a small relative standard error, for the sample size of 150 pharmacies, of 4.3%.

In the original form of the survey, dispensing records from the participating pharmacies were sent to Amfac's Canberra premises. Several hundred diskettes were summarised by drug code and category. A single disk was then forwarded to the Department. Details of the dispensing of individual participating pharmacies are not available on these data.

The Survey data was not supplied by the Guild from September 1999 to February 2001. When monthly data collection recommenced in February 2001, retrospective data was retrieved using an internet connection between each participating pharmacy and a software provider. A total of 142 pharmacies participated in this data collection.

Following reinstatement of the Survey, data is now transmitted electronically from the participating pharmacy dispensaries to the software providers. Data is forwarded to the Guild and then to DUSC. The data continues to be de-identified with respect to individual pharmacies and individual patient prescriptions.

The pharmacies in the survey are selected to be representative of the population of operational pharmacies with regard to PBS dispensing volume and geographical location, and are similarly stratified. In order to compare and then extrapolate the survey quantities to estimates of use in Australia, the subsidised PBS prescription data supplied by all pharmacies in Australia are stratified into the same four equal dispensing volume ranges based on their annual average PBS dispensing from the previous year. A weighting factor is calculated for each PBS and Amfac item code by comparing the number of pharmacies and PBS prescriptions in the survey with the total number of pharmacies and PBS prescriptions in Australia for each stratum. Volumes of non-subsidised drug use are calculated by multiplying the survey estimate by the weighting factor, which is assumed to apply equally to the subsidised and non-subsidised prescription volumes.


Combined database

A Departmental database combines the prescription estimates for the non-subsidised sector, under general co-payment and private prescriptions, based on the survey with the actual counts of those prescription categories submitted to the Department of Human Services for payment of a PBS/RPBS subsidy by the Government. A number of other Government subsidised programs and PBS programs subsidised through alternative supply arrangements are not included in the DUSC database. This includes the use of highly specialised drugs available for outpatients through public hospital pharmacies under Section 100 Highly Specialised Drugs Program of the *National Health Act 1953*, supply of drugs to remote area Aboriginal Health Services, Opioid Dependence Scheme, IVF/ GIFT Treatment and Botulinum Toxin Program. Subsidised programs operated by State Health Departments, including supply of drugs to public hospital in-patients, and the Herceptin Program for metastatic breast cancer are also excluded from the DUSC database. The combined dataset does contain information on highly specialised drugs and in-patient drugs provided through private hospitals as this information is collected by the Department of Human Services. Following a range of pharmaceutical reforms a greater number of s100 Highly Specialised Drugs, and outpatient or discharge drugs supplied through public hospital will be included in the DUSC database in the future.

The advantages of the expanded database can be illustrated by using an example involving the drug sotalol hydrochloride. Previously, sotalol hydrochloride had a price per prescription, as a general benefit, above the patient co-payment and, as a consequence, a majority of community use was captured on the PBS/RPBS claims database. In 2008, a reduction in drug price and a small increase in the general patient co-payment in line with the Consumer Price Index (CPI) contributed to the price of sotalol hydrochloride falling below the general patient co-payment. Changes in the capturing of sotalol hydrochloride data from the Department of Human Services claims database to the Pharmacy Guild Survey database can be seen in figure A. The combined database therefore enables the continuation of utilisation estimates for drugs not subsidised through the PBS/RPBS and provides a more comprehensive outlook on drug use within Australia.

Figure A shows the time trends for dispensing of sotalol hydrochloride, by the subsidised and non-subsidised components.

Figure A: Community utilisation of sotalol hydrochloride



Quantities within the PBS Schedule are designed to provide a normal course of treatment for acute conditions, and a month's treatment at usual doses for chronic conditions.

A pattern involving PBS drug utilisation that shows a higher level of usage leading up to the end of a year has been previously reported⁴. This peak is due to the safety net provisions introduced into the PBS in November 1986. These provisions were introduced to financially support patients with multiple medical conditions who genuinely need a number of medicines. Once the out-of-pocket threshold safety net level is reached, prescriptions on the scheme are either free, or available at a greatly reduced co-payment amount. The safety net period is the calendar year, and the highs and lows are due to stockpiling of medication once the safety net level is reached.

The stockpiling of medication has public health, waste and cost implications. Large quantities of potent medicines in the home can be a hazard for other family members, may exceed their expiry date, and has the potential for patient confusion if the dosage or the need for a particular medication is subsequently reviewed by the doctor during this period.

On 1 November 1994 the National Health (Pharmaceutical Benefits) Regulations were amended to increase the period for redispensing chronically used drugs (i.e. those with 5 or more repeats) to a period of no less than 20 days. Exceptions are determined by the PBAC and include eye drops, which tend to be used at a higher rate than other medications. The redispensing period here was amended to four rather than the previous three days.


The pharmacist has the discretion to supply earlier than the statutory period if the circumstances warrant e.g. medicine lost or prescribed dosage requires more frequent dispensing of repeats.

ADVERSE EVENT REPORTING IN AUSTRALIA IN 2011

The Therapeutic Goods Administration (TGA) is responsible for regulating medicines in Australia, including monitoring the ongoing safety of medicines once they have been included on the Australian Register of Therapeutic Goods (ARTG).

The TGA's reporting system for adverse events began in the late 1960's with the computerised database dating back to November 1972. At the end of 2011 there were approximately 247,000 reports of suspected adverse events in the database.

Figure B: Origin of adverse event reports received by the TGA (2006–2011)



Note: A review of the quality control process had an impact on the searchable part of the Adverse Drug Reaction Database, causing a change in the number of events from data published in the Adverse Drug Reaction Reporting in Australia in 2010.

In 2011 the TGA received approximately 14,400 reports with 52% from pharmaceutical companies, 12% from hospitals, 7% from General Practitioners (GPs), 18% from State and Territory Health Departments and 3% from consumers. The sources for other reports (8%) include community pharmacists and specialists (Figure B). On average, in 2011, the TGA received 1,200 reports per month. Health professionals are encouraged to report suspected adverse events directly to the TGA rather than through the sponsor or manufacturer to simplify communication.

The spike in the number of adverse events reported by companies in 2011 is attributed to a number of factors, including a greater number of drugs on the Australian Register of Therapeutic Goods (ARTG); and the possibility that GPs are reporting adverse events via sponsors, which would also account for the slight drop in the reporting rates for GPs. The increases observed in 2009 and 2010, particularly from State and Territory Health Departments and companies, is largely due to reports of adverse events following vaccination with the pandemic (H1N1) influenza vaccine in 2009 and the seasonal trivalent influenza vaccines in 2010.

Processing and use of adverse event reports

Reports are assessed by the Office of Product Review (OPR) within the TGA. This involves checking the report for the presence of ‘minimum’ details, i.e. an individual patient, an adverse event, at least one (suspected) drug, and, preferably, an identifiable reporting health professional. The specific reaction terms are identified along with the suspected, interacting or ‘other’ drugs and these are entered into the database.

The TGA applies a causality rating for the reaction(s) and in some cases requests further clinical or laboratory information from the reporter to allow causality to be assessed. Medical officers review serious reports and staff in OPR regularly analyse reporting data to identify potential safety signals.

Reports are forwarded to the Uppsala Monitoring Centre in Sweden which administers the WHO Collaborating Centre for International Drug Monitoring. This global database began in 1968 as a pilot program involving 10 nations, including Australia, and now receives reports from over 80 nations with over 5 million reports in the database.

Reporting adverse events

The TGA encourages the reporting of all suspected adverse events to medicines available in Australia, including prescription medicines, vaccines, over the counter and complementary medicines. The reporting of seemingly insignificant or common adverse events can contribute to the TGA’s investigation of a potential safety signal.

The TGA particularly requests reports of:

- all suspected reactions to new medicines
- all suspected medicines interactions
- unexpected reactions (i.e. those reactions that are not described in the Product Information)
- suspected reactions causing:
 - death
 - admission to hospital or prolongation of hospitalisation
 - increased investigations or treatment
 - birth defects

Reports of suspected adverse events can be made:

- online at www.tga.gov.au by following the link to ‘Report a Problem’. Health professionals can also submit a report directly from MIMS online.
- using a ‘Blue Card’ available from the TGA’s Office of Product Review (1800 044 114 or adr.reports@tga.gov.au) or downloaded from the TGA website at www.tga.gov.au/safety/problem-medicines-forms-bluecard.htm.

Expert advisory committee

The Advisory Committee on the Safety of Medicines (ACSOM) was established in January 2010 to provide expert advice to the TGA about safety issues under investigation and the appropriateness of Risk Management Plans (RMPs). RMPs outline sponsors’ plans to monitor and communicate risks, and are evaluated as part of the registration process for new medicines. RMPs accompany applications for registration of high risk medicines, such as new chemical entities. RMPs characterise and pro-actively manage risks relating to a medicine over its entire life cycle. ACSOM also provides advice to the TGA on other matters related to pharmacovigilance, including the detection, assessment, understanding and prevention of adverse events.

Medicines Safety Update

The Medicines Safety Update is published six times a year in Australian Prescriber, and also on the TGA website. The Medicines Safety Update replaced the Australian Adverse Drug Reactions Bulletin in 2010.

The following articles were published in Medicines Safety Update in 2011:

- Clozapine and severe constipation
- Drug interaction between tamoxifen and antidepressants
- Methysergide and retroperitoneal fibrosis
- Thank you for your reports
- Suspected adverse reactions to vaccines: a reminder to report
- Drug-induced hyponatraemia
- Rotavirus vaccination and risk of intussusception: investigation of a possible safety signal
- Coversyl and Coumadin: new packaging to reduce potential for dispensing errors
- Risk of hypomagnesaemia with proton pump inhibitors
- Use of 2011 seasonal influenza vaccines in children
- Investigation of Prevenar and deaths in children in Japan: what does it mean for Australia?
- Finding information about adverse reaction reporting on the new TGA website
- Medicine recalls in Australia
- Cramps, quinine and thrombocytopenia
- Venlafaxine and stress cardiomyopathy
- In utero antipsychotic exposure and neonatal extrapyramidal and withdrawal adverse effects
- Prescribing medicines in pregnancy – new TGA database
- Oral contraceptives containing drospirenone (Yaz and Yasmin) and venous thromboembolism
- Pioglitazone and risk of bladder cancer
- Modafinil (Modavigil) – safety update
- Subscribe to TGA email alerts
- Proton Pump Inhibitors (PPIs) and acute interstitial nephritis
- Dabigatran (Pradaxa) and the risk of bleeding
- Reducing the risk of myopathy and rhabdomyolysis with simvastatin – new dosage recommendation

Transparency

Recent reviews of the functions and activities of the TGA have identified a need to ensure the public is aware of the activities undertaken by the TGA to monitor the safety of therapeutic products available to the community. In December 2011 the Government released TGA reforms: a blueprint for TGA's future (the Blueprint) which included plans to improve the Australian community's understanding of the TGA's regulatory processes and decisions and enhance public trust in the safety and quality of therapeutic goods.

The Blueprint consists of a range of interconnected projects the TGA will undertake to achieve more effective and transparent regulation of medicines, meet emerging challenges in the regulation of therapeutic goods and provide more timely information about the goods it regulates.

The TGA applies a risk management approach to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy. Once a therapeutic product is approved, the TGA continues to monitor the product in the market through therapeutic product vigilance activities.

Product vigilance

The aim of therapeutic product vigilance is continually to monitor and evaluate the safety and efficacy (performance) profile of therapeutic products and to manage any risks associated with individual products over the life cycle of a product. The TGA's therapeutic product vigilance framework is available on the TGA website at www.tga.gov.au/safety/tga-therapeutic-product-vigilance.htm.

The maintenance and improvement of health and safety is a shared responsibility. In addition to government and regulated industry, health professionals, consumers and their respective associations play an important role in reporting therapeutic product safety related issues.

Sponsors have the primary responsibility for the safety of any therapeutic products they import into, supply in or export from Australia. Sponsors must comply with legislative requirements for therapeutic product vigilance under the Therapeutic Goods Act 1989 and there are applicable offences and penalties under the Act for not complying. The legislative requirements for therapeutic product vigilance vary depending on the type of therapeutic good.

The TGA maintains up-to-date safety information on therapeutic products that is communicated through a variety of means to health professionals and consumers. The TGA is committed to advancing public health through the market authorisation of beneficial, innovative therapeutic products and by providing timely, evidence-based and authoritative information to allow consumers and health professionals to make informed decisions.

The TGA defines therapeutic product vigilance tools as tools designed to facilitate the collection and evaluation of information pertaining to the benefits and risks associated with the use of therapeutic products. The main product vigilance tools used by OPR are adverse event reports, Risk Management Plans and Periodic Safety Update Reports (PSURs).

Adverse event reports are reports of any untoward occurrence in a patient administered a medicine and which does not necessarily have a causal relationship with the medicine. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicine, whether or not considered related to this medicine.

RMPs provide a summary of the known important safety information about the therapeutic product, plans to identify and characterise known or potential safety concerns and plans to minimise any identified or potential safety risk. A full outline of the scope of RMPs is above (see Expert advisory committee). PSURs give an annual overview of the safety of the drug, including adverse events, a summary of the registration status of the drug world-wide, actions taken for safety reasons, the world-wide usage of the drug and an analysis of safety requirements. Sponsors must submit PSURs for at least three years after registration of a drug.

An important aspect of product vigilance is ensuring there are mechanisms to communicate safety information to both health professionals and consumers. To achieve this, the TGA publishes Australian Public Assessment Reports (AusPARs) about recently registered prescription medicines on the TGA website. The AusPAR outlines the findings of the TGA's evaluation of a product including important effectiveness and safety information. The TGA also publishes the Product Information (PI) and Consumer Medicine Information (CMI) for prescription and some non-prescription medicines, Medicines Safety Update and alerts, which provide important information and recommendations about therapeutic goods.

THE HIGHLY SPECIALISED DRUGS PROGRAMME

Overview

The Australian Government provides funding for certain specialised medications under the Highly Specialised Drugs Programme. Highly specialised drugs (HSDs) are medicines for the treatment of chronic conditions which, because of their clinical use or other special features, are restricted to supply through public and private hospitals having access to appropriate specialist facilities. To prescribe these drugs as pharmaceutical benefit items, medical practitioners are required to be affiliated with these specialist hospital units. A general practitioner or non-specialist hospital doctor may prescribe HSDs to provide maintenance therapy under the guidance of the treating specialist.

The Australian Government provides funding for a HSD to be supplied to community based patients, not in-patients of public hospitals; i.e. persons who are day-admitted patients, outpatients and patients upon discharge.

The subsidies for drugs under this programme commences after approval has been given by the Australian Government. For HSDs prescribed through public and private hospitals, claiming and approval of authority prescriptions is administered by the Department of Human Services.

From 1 July 2013, public hospitals transitioned to online claiming arrangements for HSDs (with the exception of clozapine). This transition enables more efficient claiming processes and reduces the administrative burden on public hospitals. In addition, it enables data to be collected at the individual script level rather than summarised at the itemcode level, allowing easier comparison with private hospital data.

Table A: Highly Specialised Drugs—National Usage and Patient Report in Public Hospitals for the period January 2011 to December 2011

Drug Name	Total Cost (\$Aus)	Pack Numbers
ABACAVIR	\$1,573,933	5,683
ABACAVIR + LAMIVUDINE	\$18,087,292	31,256
ABACAVIR + LAMIVUDINE + ZIDOVUDINE	\$1,455,722	1,658
ABATACEPT	\$8,423,165	16,154
ADALIMUMAB	\$1,351,408	793
ADEFOVIR DIPIVOXIL	\$4,124,100	7,421
AMBRISENTAN	\$7,626,514	1,864
APOMORPHINE	\$2,837,927	34,135
ATAZANAVIR	\$18,424,121	32,956
AZACITIDINE	\$9,217,270	16,729
AZITHROMYCIN	\$66,883	1,168
BACLOFEN	\$1,187,954	8,009
BOSENTAN	\$32,875,171	8,045
CIDOFOVIR	\$5,400	6
CINACALCET	\$6,611,120	14,465
CLARITHROMYCIN	\$112,908	2,098
CLOZAPINE	\$42,706,724	158,474
CYCLOSPORIN	\$9,693,191	120,431
DARBEOETIN ALFA	\$52,611,173	88,973
DARUNAVIR	\$10,039,593	9,424
DEFERASIROX	\$13,519,820	16,276
DEFERIPRONE	\$624,724	1,411

Drug Name	Total Cost (\$Aus)	Pack Numbers
DEFERRIOXAMINE	\$802,738	16,037
DIDANOSINE	\$350,454	1,271
DORNASE ALFA	\$10,126,752	8,578
DOXORUBICIN HYDROCHLORIDE-PEGYLATED LIPOSOMAL	\$148,895	239
EFAVIRENZ	\$5,032,726	10,902
ELTROMBOPAG	\$36,560	15
EMTRICITABINE	\$155,870	551
ENFUVRTIDE	\$462,517	209
ENTECAVIR	\$11,193,542	26,661
EPOETIN ALFA	\$20,995,075	31,834
EPOETIN BETA	\$9,227,218	14,255
EPOETIN LAMBDA	\$107,736	171
EPOPROSTENOL	\$1,811,782	22,027
ETANERCEPT	\$2,572,834	2,608
ETRAVIRINE	\$3,520,591	5,634
EVEROLIMUS	\$6,397,008	9,743
FILGRASTIM	\$12,068,609	7,775
FOSAMPRENAVIR	\$550,466	1,462
FOSCARNET	\$1,188	3
GANCICLOVIR	\$112,014	380
IBANDRONIC ACID	\$453,667	1,329
ILOPROST	\$1,829,539	1,657
INDINAVIR	\$75,553	166
INFLIXIMAB	\$45,824,399	60,172
INTERFERON ALFA-2A	\$35,011	981
INTERFERON ALFA-2B	\$496,788	1,342
INTERFERON GAMMA-1B	\$471,089	346
LAMIVUDINE	\$4,040,646	21,074
LAMIVUDINE + ZIDOVUDINE	\$3,873,947	6,669
LANREOTIDE	\$6,161,662	3,384
LANTHANUM	\$1,732,821	4,763
LENALIDOMIDE	\$27,240,973	4,213
LENOGRASTIM	\$237,241	276
LEVODOPA + CARBIDOPA ANHYDROUS	\$127,792	89
LOPINAVIR + RITONAVIR	\$11,038,876	16,402
MARAVIROC	\$1,533,798	1,935
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	\$4,677,379	7,571
MYCOPHENOLATE	\$19,958,297	96,292
NATALIZUMAB	\$26,936,210	13,213
NEVIRAPINE	\$8,811,745	31,874
OCTREOTIDE	\$12,294,556	10,696
OMALIZUMAB	\$249,345	579
PAMIDRONATE DISODIUM	\$1,240,631	4,658
PEGFILGRASTIM	\$49,237,207	25,578
PEGINTERFERON ALFA-2A	\$1,909,230	1,427
PEGINTERFERON ALFA-2A (&) RIBAVIRIN	\$29,278,215	17,889
PEGINTERFERON ALFA-2B	\$8,602	4
PEGINTERFERON ALFA-2B (&) RIBAVIRIN	\$9,877,876	5,238
RALTEGRAVIR	\$15,265,306	22,738
RIFABUTIN	\$42,020	286

Drug Name	Total Cost (\$Aus)	Pack Numbers
RITONAVIR	\$1,841,951	47,521
RITUXIMAB	\$6,389,339	2,807
ROMIPLOSTIM	\$4,312,328	2,982
SAQUINAVIR	\$443,639	850
SEVELAMER	\$3,265,291	10,533
SILDENAFIL	\$1,489,525	1,590
SIROLIMUS	\$2,718,799	3,275
SITAXENTAN	\$2,744	1
STAVUDINE	\$188,052	453
TACROLIMUS	\$21,787,047	64,599
TELBIVUDINE	\$13,073	52
TENOFOVIR	\$11,052,302	22,737
TENOFOVIR + EMTRICITABINE	\$39,701,628	51,121
TENOFOVIR + EMTRICITABINE + EFAVIRENZ	\$44,233,573	35,714
THALIDOMIDE	\$7,803,113	15,828
TIPRANAVIR	\$174,005	162
TOCILIZUMAB	\$7,611,632	13,838
VALACICLOVIR	\$219,300	565
VALGANCICLOVIR	\$13,308,216	6,149
ZIDOVUDINE	\$313,044	1,444
ZOLEDRONIC ACID	\$13,609,580	30,239
Grand Total	\$794,289,288	1,413,083

SUPPLY OF PHARMACEUTICAL BENEFITS TO REMOTE AREA ABORIGINAL HEALTH SERVICES UNDER SECTION 100 OF THE NATIONAL HEALTH ACT

The S100 Supply Arrangements for Remote Area Aboriginal Health Services (AHSs) improve access to the PBS for clients of remote area AHSs under Section 100 of the *National Health Act 1953*.

Under these arrangements, clients of participating AHSs are able to receive PBS medicines directly from the AHS at the point of consultation, without the need for a normal prescription form, and without charge.

The eligibility criteria for participation in the program are given below.

Eligibility criteria

1. The health service must have a primary function of meeting the health care needs of Aboriginal and Torres Strait Islander peoples.
2. The clinic or other health care facility operated by the AHS from which pharmaceuticals are supplied to patients must be in a remote zone as defined in the Rural, Remote and Metropolitan Areas Classification 1991 Census Edition.
3. The AHS must not be a party to an arrangement, such as a coordinated care trial, for which funds from the PBS have already been provided.
4. The AHS must employ or be in a contractual relationship with health professionals who are suitably qualified under relevant State/Territory legislation to supply all medications covered by the Section 100 arrangements and undertake that all supply of benefit items will be under the direction of such qualified persons.
5. The clinic or other health care facility operated by the AHS from which pharmaceuticals are supplied must have storage facilities that will:
 - prevent access by unauthorised persons;
 - maintain the quality (eg chemical and biological stability and sterility) of the pharmaceutical; and
 - comply with any special conditions specified by the manufacturer of the pharmaceutical.

Expenditure

In 2011, 173 remote area Aboriginal Health Services (AHS) were approved to participate in the S100 remote area AHS Program and 162 AHS actually received supply of PBS medicines in that period (note: although approved, some AHS may elect not to participate, or may participate on an intermittent basis). Participating AHS in 2011 were from remote locations in Northern Territory, Queensland, Western Australia, South Australia, New South Wales and Tasmania. S100 remote area AHS expenditure for PBS medicines in 2011 was \$44.1 million (GST Inclusive).

HEALTH EXPENDITURE TRENDS

Table B (i): Total expenditure on pharmaceuticals and other medical non-durables as % total expenditure on health, TEH

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Australia	14.8	15.1	14.5	15.0	14.8	14.3	14.3	14.3	14.6	14.7	n.a.
Canada	15.9	16.2	16.7	17.0	17.3	17.2	17.4	17.2	17.0	17.0	16.7
France	16.5	16.9	16.8	16.7	16.8	16.7	16.3	16.4	16.4	16.1	16.0
Germany	13.5	14.1	14.3	14.4	13.8	15.0	14.7	15.0	15.0	14.9	14.8
New Zealand	n.a.	n.a.	n.a.	n.a.	10.8	10.7	11.3	10.4	9.7	9.5	9.4
United Kingdom	14.2	13.9	13.5	13.5	13.3	12.8	12.3	12.1	11.8	n.a.	n.a.
United States	11.3	11.7	11.9	12.1	12.2	12.2	12.4	12.3	12.1	12.2	11.9

Table B (ii): Total expenditure on pharmaceuticals & other medical non-durables per capita, US\$ purchasing power parity

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Australia	336	361	370	400	425	426	453	480	503	541	n.a.
Canada	401	442	478	520	554	593	638	663	679	732	741
France	420	460	490	498	523	551	569	603	613	632	634
Germany	362	397	422	445	438	505	526	559	595	629	640
New Zealand	n.a.	n.a.	n.a.	n.a.	213	227	270	254	261	279	285
United Kingdom	260	278	296	313	337	346	363	366	369	n.a.	n.a.
United States	540	600	665	727	778	819	881	920	941	977	983

Table B (iii): Total expenditure on health as % gross domestic product

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Australia	8.0	8.1	8.4	8.3	8.5	8.4	8.5	8.5	8.7	9.1	n.a.
Canada	8.8	9.3	9.6	9.8	9.8	9.8	10.0	10.0	10.3	11.4	11.4
France	10.1	10.2	10.6	10.9	11.0	11.2	11.0	11.0	11.0	11.7	11.6
Germany	10.4	10.5	10.7	10.9	10.7	10.8	10.6	10.5	10.7	11.7	11.6
New Zealand	7.6	7.7	8.0	7.9	8.0	8.4	8.8	8.5	9.3	10.0	10.1
United Kingdom	7.0	7.3	7.6	7.8	8.0	8.2	8.5	8.5	8.8	9.8	9.6
United States	13.7	14.3	15.1	15.7	15.8	15.8	15.9	16.2	16.6	17.7	17.6

Legend

n.a.: Not available (data not provided to the Organisation for Economic Co-operation and Development (OECD) by these countries for these years)

Sources: OECD Health Data 2012—Version June 2012

(a) 'Pharmaceuticals' defined

The OECD definition of pharmaceuticals has been used, as described in its *System of Health Accounts* (SHA). The OECD defines pharmaceuticals as 'pharmaceuticals and other medical non-durables dispensed to out-patients', which comprises prescription medicines, over-the-counter medicines and other medical non-durables. Pharmaceuticals dispensed to, or used by admitted patients in hospital are not included.

Broadly speaking, these include medicinal preparations, branded and generic medicines, drugs, patent medicines, serums and vaccines, vitamins and minerals, and oral contraceptives and a wide range of medical non-durable goods, which are either single use items, for example bandaids and condoms, or have limited re-usage, for example, bandages.

Prescribed medicines are medicines exclusively sold to customers with a medical voucher, irrespective of whether it is covered by public or private funding and include branded and generic products. In the SHA, this includes the full price with a breakdown for cost-sharing.

Expenditure by private households or over-the-counter medicines (OTC medicines) is included in pharmaceutical expenditure.

Other medical non-durables comprise items such as bandages, elastic stockings, incontinence articles, condoms and other mechanical contraceptive devices.

Pharmaceutical expenditure is also reported in *Health Expenditure Australia 2009–10*. In this report, the Australian Institute of Health and Welfare (AIHW) splits medication expenditure into two categories, 'benefit paid pharmaceuticals' and 'all other medications'.

'Benefit paid pharmaceuticals' are pharmaceuticals in the Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS) for which the Australian Government paid a benefit.

'All other medications' are medications for which no PBS or RPBS benefit was paid and includes the following components, which are reported separately:

- pharmaceuticals listed in the PBS or RPBS, where the total costs are equal to, or less than, the statutory patient contribution for the class of patient concerned ('under co-payment' drugs);
- medicines dispensed through private prescriptions for items not listed in the PBS or RPBS or which do not meet PBS criteria for dispensing through the PBS; and
- over-the-counter medicines such as aspirin, cough and cold medicines, vitamins and minerals, some herbal and other complementary medicines and medical non-durable goods, as listed above.

Under the AIHW definitions used in *Health expenditure Australia*, highly specialised drugs are included as part of hospital expenditure, not as part of medications expenditure. Under the OECD definition, highly specialised drugs are included in 'Pharmaceutical' expenditure.

(b) Health expenditure recorded here is according to the OECD definition and excludes health research expenditure.

DRUG UTILISATION TRENDS

Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDD) 2012 is used in all statistics published in this edition (refer to WHO collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2012).

Listed below are the prescription counts for 2009, 2010 and 2011 by ATC anatomical main group. The data from the two sources are enumerated separately. Table C (i) shows subsidised prescriptions (PBS/RPBS) and Table C (ii) shows the estimate of nonsubsidised prescriptions (Survey).

Tables C: Prescription numbers by ATC groups

Table C (i): Subsidised prescriptions (PBS/RPBS)


ATC Group	2009	2010	2011
(A) Alimentary Tract	28,400,464	28,934,869	28,741,866
(B) Blood and blood forming	8,640,003	8,961,287	9,011,672
(C) Cardiovascular system	67,302,312	69,501,887	71,052,963
(D) Dermatologicals	2,980,367	3,044,864	3,100,758
(G) Genitourinary system	3,172,962	3,016,920	3,054,098
(H) Hormonal preparations	2,906,146	3,028,197	3,107,836
(J) Antiinfectives	13,546,581	13,603,470	14,086,713
(L) Antineoplastic	2,098,520	2,282,769	2,400,647
(M) Musculo-skeletal	9,262,036	9,044,116	8,871,353
(N) Nervous system	38,838,056	41,109,237	43,141,389
(P) Antiparasitic products	583,591	619,618	662,647
(R) Respiratory system	10,544,777	10,924,181	11,222,832
(S) Sensory Organs	8,718,735	8,826,316	8,839,667
(V) Various	646,443	627,657	614,535
Other	209,959	234,134	237,869
Total	197,850,952	203,759,522	208,146,845

Table C (ii): Estimated non-subsidised prescriptions (Survey)

ATC Group	2009	2010	2011
(A) Alimentary Tract	5,394,413	5,443,423	6,778,526
(B) Blood and blood forming	826,678	799,144	795,439
(C) Cardiovascular system	13,069,382	12,749,658	12,459,359
(D) Dermatologicals	2,998,874	3,090,690	3,107,951
(G) Genitourinary system	7,319,091	7,241,951	7,237,305
(H) Hormonal preparations	1,600,906	1,673,213	1,709,388
(J) Antiinfectives	15,530,330	15,262,828	15,802,547
(L) Antineoplastic	118,612	134,160	150,004
(M) Musculo-skeletal	3,168,661	3,088,987	3,106,030
(N) Nervous system	12,106,849	12,179,569	12,804,813
(P) Antiparasitic products	691,724	671,856	688,164
(R) Respiratory system	2,696,789	2,648,049	2,586,732
(S) Sensory Organs	2,400,492	2,294,943	2,155,669
(V) Various	19,842	21,220	26,030
Other	220,046	232,186	245,644
Total	68,162,689	67,531,877	69,653,601

Estimated changes from 2002 to 2011 in the number of prescriptions dispensed under the PBS (concession and general), RPBS, under co-payment and private categories, are presented in Figure C.

Figure C: Number of prescriptions by type of service



Most commonly used drugs in the Australian community for 2011

Table D shows the top 10 drugs dispensed in the Australian community by DDDs/1000 population/day, which adjusts for the quantity dispensed per prescription. This DDDs/1000/day information shows both the subsidised (PBS/RPBS) and non-subsidised (Guild survey) components, as well as total community use. Changes and alterations from the previous years are also shown.

Table D: Top 10 drugs by defined daily dose/thousand population/day, 2011 (including the contribution of constituents of combination products)

Drug	PBS/RPBS	Guild Survey	Total
ATORVASTATIN	85.043	0.139	85.182
IRBESARTAN	33.007	10.187	43.194
PERINDOPRIL	31.124	11.129	42.253
ROSUVASTATIN	36.158	0.067	36.225
RAMIPRIL	25.910	8.813	34.723
CANDESARTAN	26.960	5.265	32.225
PARACETAMOL	28.990	2.559	31.549
AMLODIPINE	22.105	3.991	26.096
SIMVASTATIN	23.654	0.672	24.325
ESOMEPRAZOLE	21.454	2.700	24.154

Changes from 2010:

UP: Rosuvastatin (5→4)
Amlodipine (9→8)

DOWN: Ramipril (4→5)
Simvastatin (8→9)

The top 10 drugs dispensed in the Australian community in 2011, ranked by prescription count, are shown in table E. Table F ranks the 2011 top 10 drugs by total cost to Australia, i.e. subsidised prescriptions only (total cost is the sum of patient contribution and cost to Government).

Table E: Top 10 drugs by prescription counts, 2011

Drug	PBS/RPBS	Guild Survey	Total Community use
ATORVASTATIN	11,100,222	20,422	11,120,644
ESOMEPRAZOLE	5,890,893	1,088,070	6,978,963
ROSUVASTATIN	6,595,316	12,321	6,607,637
AMOXYCILLIN	2,592,120	3,670,480	6,262,600
PARACETAMOL	5,181,539	276,598	5,458,137
PERINDOPRIL	3,971,080	1,468,112	5,439,192
CEFALEXIN	2,740,226	2,380,837	5,121,063
PANTOPRAZOLE	3,700,004	844,942	4,544,946
METFORMIN HYDROCHLORIDE	3,432,146	1,092,602	4,524,748
AMOXYCILLIN with CLAVULANIC ACID	2,014,812	2,376,545	4,391,357

Changes from 2010:

UP: Rosuvastatin (5→3)
Paracetamol (6→5)
Pantoprazole (10→8)

DOWN: Amoxicillin (3→4)
Perindopril (4→6)

IN: Amoxicillin with Clavulanic acid (13→10)

OUT: Simvastatin (8→12)

Table F: Top 10 PBS/RPBS drugs by total cost to Australia, 2011

Drug	PBS/RPBS DDD/1000/DAY	PBS/RPBS Scripts	Total Cost (\$)
ATORVASTATIN	85.043	11,100,222	784,927,075
ROSUVASTATIN	36.158	6,595,316	467,425,285
RANIBIZUMAB		160,813	342,880,160
ESOMEPRAZOLE	21.454	5,890,893	230,060,391
SALMETEROL and FLUTICASONE		3,124,942	221,699,121
ADALIMUMAB	0.368	107,020	192,726,034
CLOPIDOGREL	11.179	2,706,737	187,035,815
OLANZAPINE	3.084	967,080	174,280,242
SIMVASTATIN	23.654	4,087,534	161,894,597
VENLAFAXINE	12.150	2,598,159	140,328,907

No information on cost for private and under co-payment prescriptions is available.

Changes from 2010:

UP: Salmeterol and Fluticasone (6→5)
Adalimumab (9→6)

DOWN: Clopidogrel (5→7)
Simvastatin (7→9)

Figure D shows the top 10 subsidised drugs dispensed in 2011.

Figure D: Top 10 subsidised drugs dispensed in 2011





Figure E represents the top 10 non-subsidised drugs for 2011.

Figure E: Top 10 non-subsidised drugs dispensed in 2011



Nurse Prescribing

From 1 November 2010, authorised nurse practitioners can write PBS/RPBS prescriptions listed in the PBS Schedule with a flag of “NP”. Medicines without this flag are not to be prescribed by authorised nurse practitioners. Refer to Schedule of Pharmaceutical Benefits available on www.pbs.gov.au for details of subsidised medicines.

Information for how nurse practitioners can become authorised PBS prescribers is available from the Department of Human and Services website: <http://www.medicareaustralia.gov.au/provider/other-healthcare/nurse-midwives.jsp>

Table G shows the top 10 PBS/RPBS drugs prescribed by nurse practitioners and dispensed in 2011. Table H ranks the 2011 top 10 drugs prescribed by total cost.

Table G: Nurse Practitioner—Top 10 PBS/RPBS drugs by prescription counts, 2011

Drug	PBS/RPBS Scripts
CEPHALEXIN	1,137
ATORVASTATIN	1,013
AMOXYCILLIN with CLAVULANIC ACID	750
CODEINE PHOSPHATE with PARACETAMOL	732
OXYCODONE HYDROCHLORIDE	713
PARACETAMOL	685
AMOXYCILLIN	635
FLUCLOXACILLIN	549
ROSUVASTATIN	536
FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE	523

Table H: Nurse Practitioner—Top 10 PBS/RPBS drugs prescribed by total cost, 2011

Drug	Total Cost (\$)
ATORVASTATIN	72,512
RISPERIDONE	69,855
PANCREATIC EXTRACT	67,913
OLANZAPINE	46,693
QUETIAPINE	37,390
ROSUVASTATIN	37,185
FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE	35,858
VALACICLOVIR	26,348
INSULIN GLARGINE	24,006
POSACONAZOLE	23,109

Optometrist Prescribing

Since 1 January 2008, authorised optometrists are able to prescribe medicines listed in the optometrist section of the Pharmaceutical Benefits Schedule. Refer to Pharmaceutical Benefits Schedule for a list of medicines that can be prescribed by authorised optometrists: <http://www.pbs.gov.au/browse/optometrical>

Table I shows the top 10 PBS/RPBS drugs prescribed by optometrists and dispensed in 2011. Table H ranks the 2011 top 10 drugs prescribed by total cost.

Table I: Optometrist—Top 10 PBS/RPBS drugs by prescription counts, 2011

Drug	PBS/RPBS Scripts
LATANOPROST	8,022
POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL	7,754
CHLORAMPHENICOL	5,781
FLUOROMETHOLONE	4,864
CARMELLOSE SODIUM	3,635
HYPROMELLOSE	2,244
LATANOPROST with TIMOLOL MALEATE	2,031
HYPROMELLOSE with CARBOMER 980	1,983
PARAFFIN	1,760
FLUOROMETHOLONE ACETATE	1,704

Table J: Optometrist—Top 10 PBS/RPBS drugs prescribed by total cost, 2011

Drug	Total Cost (\$)
LATANOPROST	338,041
LATANOPROST with TIMOLOL MALEATE	94,649
POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL	91,663
CHLORAMPHENICOL	60,839
CARMELLOSE SODIUM	60,402
BIMATOPROST	57,479
FLUOROMETHOLONE	51,607
TRAVOPROST	41,466
PARAFFIN	35,296
BIMATOPROST with TIMOLOL MALEATE	27,074

TABLES IN THE AUSTRALIAN STATISTICS ON MEDICINES

The data are presented in two major tables. Table 1 provides an estimate of the 2011 community (i.e. subsidised and non-subsidised) prescription numbers, together with the costs for PBS-listed drugs, which include an estimate of the cost of under co-payment PBS prescriptions. Cost information on the dispensing of private prescriptions is not available. The defined daily dose (DDD), where available, is also included for the drugs covered in the report.

Table 2 includes community prescription drug use, in DDDs/1000 population/day, for the years 2009, 2010 and 2011. In this edition, DDDs/1000 population/day for combination products is also reported in terms of DDDs of each constituent. One main advantage of reporting combinations as if they were administered as two or more single component products is that total DDDs remain constant as patients switch to combination products, if the amounts of constituent drugs consumed by patients remain the same.

Note that not all combination products are included in table 2. Combination drugs will only be reported in terms of DDD of each constituent where:

- the constituent drugs were available as plain drugs on the PBS;
- the combination was a frequently prescribed form;
- the constituent drugs had independent actions; and
- the WHO Defined Daily Dose was consistent across the various formulations of the constituent drugs.

Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDD) 2012 is used in statistics published in this edition (refer to WHO collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2012).

References

- (1) Edmonds DJ, Dumbrell DM, Primrose JG, McManus P, Birkett DJ, Demirian V. Development of an Australian drug utilisation database: a report from the Drug Utilisation Subcommittee of the Pharmaceutical Benefits Advisory Committee, *PharmacoEconomics* 1993; 3(6): 427432.
- (2) Hurley SF, McNeil JJ. Drugcoding systems: why so many? *Med J Aust* 1989; 151: 308.
- (3) Nordic Council on Medicines. *Nordic Statistics on Medicines 1987–1989*. NLN publication number 3, Uppsala, Sweden, 1990.
- (4) McManus P. Drug utilisation (letter) *Med J Aust* 1993; 158: 724.

CAVEATS

It needs to be borne in mind that these utilisation data do not include a large proportion of public hospital drug usage, over the counter purchases (except for S3 Recordable), or the supply of highly specialised drugs to outpatients through public hospitals, under Section 100 of the *National Health Act 1953*. Some extemporaneously prepared items may also not be included.

Comments on classifications, omissions or errata appearing in this edition of the Australian Statistics on Medicines may be sent to:

Alicia Segrave
Secretary
Drug Utilisation Sub-Committee (DUSC)
Department of Health
GPO Box 9848
CANBERRA ACT 2601.

e-mail: DUSC@health.gov.au

GLOSSARY OF TERMS

Actu	Actuated	Lin	Liniment
Adhes	Adhesive	Liq	Liquid
Admin	Administration	Loz	Lozenge
Aero	Aerosol	Ltn	Lotion
Amp(s)	Ampoule(s)	Metronid	Metronidazole
Applic	Applicator	Mixt	Mixture
Aqu	Aqueous	Nas	Nasal
Breth	Breath	Nebu	Nebuliser
Calc	Calcium	Not<	Not less than
Cap(s)	Capsule(s)	Oint	Ointment
Cart	Cartridge	Ophth	Ophthalmic
CD	Controlled delivery	Paed	Paediatric
Chew	Chewable	Pdr	Powder
Clean	Cleansing	Pell(s)	Pellet(s)
Coat	Coated	Pess	Pessary
Co	Compound	Phos	Phosphorus
Conc	Concentrated	Pot	Potassium
Cont	Contained	Prep	Preparation
CR	Controlled release	Press	Pressurised
Crm	Cream	Prot	Protective
Crush	Crushable	Pst	Paste
D	Dose	Reag	Reagent
Dev	Device	Rel	Release
Diag	Diagnostic	Requ	Required
Dil	Diluted	Sach(s)	Sachet(s)
Disp	Dispersable	SF	Sugar free
Dres	Dressing	Sng	Single
Drp	Drops	Sod	Sodium
Ds	Doses	Sol	Soluble
Dust	Dusting	Soln	Solution
Efferv	Effervescent	Solv	Solvent
Elix	Elixir	Spr	Spray
Enter	Enteric	Ster	Sterile
Emulsif	Emulsifying	Sulph	Sulphate
Equiv	Equivalent	Suppl	Supplement
Extend	Extended	Suppos	Suppository
Ferr	Ferrous	Supres	Suppression
Gran	Granules	Susp	Suspension
Inf	Infusion	Sust	Sustained
Inhal	Inhalation	Syrp	Syrup
Inj(s)	Injection(s)	Syrng	Syringe
Inrt	Inert	Tab(s)	Tablet(s)
Ins	Insert	Td	Transdermal
Intracav	Intracavernosal	Tinct	Tincture
Intranas	Intranasal	Top	Topical
Insuff	Insufflator	Unt(s)	Unit(s)
Irrig	Irrigation	wps	Wipes
Jel	Jelly		
Linct	Linctus		

Weights and Measures

cm	centimetre(s)
E	unit(s)
g	gram(s)
kg	kilogram(s)
iu	international unit
L	litre(s)
m	metre(s)
ME	million units
mm	millimetre(s)
mg	milligram(s)
mL	millilitre(s)
mmol	millimole
TE	thousand units
ug	micrograms(s)

ATC & DDD ADDITIONS AND ALTERATIONS

Alterations in ATC classification

Drug/drug group	Previous ATC code	New ATC code
C1-inhibitor, plasma derived*	B02AB03	B06AC01
Icatibant	C01EB19	B06AC02
Alitretinoin	D11AX19	D11AH04

*New 5th level name

Alterations in ATC level classification

ATC code	Previous ATC level name	New ATC level name
A12AX	Calcium, combinations with other drugs	Calcium, combinations with vitamin D and/or other drugs
B06AC		Drugs used in hereditary angioedema
D11AH	Agents for atopic dermatitis, excluding corticosteroids	Agents for dermatitis, excluding corticosteroids
G04CX01	Pygeum africanum	Prunus africanae cortex
G04CX02	Serenoa repens	Sabalis serrulatae fructus
H01CB	Antigrowth hormones	Somatostatin and analogues
J07AH03	Meningococcus, bivalent purified polysaccharides antigen	Meningococcus A,C, bivalent purified polysaccharides antigen
J07AH04	Meningococcus, tetravalent purified polysaccharides antigen	Meningococcus A, C, Y, W – 135, tetravalent purified polysaccharides antigen
J05AH08	Meningococcus, tetravalent purified polysaccharides antigen conjugated	Meningococcus A, C, Y, W – 135, tetravalent purified polysaccharides antigen conjugated
L02BG	Enzyme inhibitors	Aromatase inhibitors
N05CM09	Valerian	Valerianae radix
N06DX02	Ginkgo biloba	Ginkgo folium
R05X	Other cold combination preparations	Other cold preparations

Allocation of new ATC codes

New ATC Code	ATC level name
A02BC06	Dexlansoprazole
A10BD10	Metformin and saxagliptin
A10BD11	Metformin and linagliptin
A10BX09	Dapagliflozin
A16AX08	Teduglutide
B01AA12	Fluindione
B02BD10	Von willebrand factor
B02BD11	Catridecacog
B06AC03	Ecallantide
B06AC04	Conestat alfa
C05CX03	Hippocastani semen
C09BB07	Ramipril and amlodipine
C09CA09	Azilsartan medoxomil
C09DB06	Losartan and amlodipine
C10AX11	Mipomersen
D03AX11	Tetrachlorodecaoxide
D06BB12	Sinecatechins

New ATC Code	ATC level name
G03DB08	Dienogest
G04BX15	Pentosan polysulfate sodium
H01AC06	Tesamorelin
H01CB05	Pasireotide
J01CA19	Aspoxicillin
J01DC12	Cefminox
J01DC13	Cefbuperazone
J01DC14	Flomoxef
J01DF02	Carumonam
J01GB13	Bekanamycin
J05AE11	Telaprevir
J05AG05	Rilpivirine
J06BB17	Motavizumab
J07AH09	Meningococcus B, multicomponent vaccine
L01CD04	Cabazitaxel
L01XC11	Ipilimumab
L01XC12	Brentuximab vedotin
L01XE14	Bosutinib
L01XE15	Vemurafenib
L01XE16	Crizotinib
L01XE17	Axitinib
L01XE18	Ruxolitinib
L01XX42	Panobinostat
L02BX03	Abiraterone
L03AX17	Sipuleucel-T
L04AC10	Seculinumab
L04AX05	Pirfenidone
M01AC56	Meloxicam, combinations
M01AE56	Naproxen and misoprostol
N03AX22	Perampanel
N05AX14	lloperidone
N06AX24	Vilazodone
N06AX25	Hyperici herba
N06DA52	Donepezil and memantine
N07BC05	Levomethadone
N07XX08	Tafamidis
P03AX05	Dimeticone
R06AA59	Doxylamine, combinations
S01LA05	Aflibercept
S02DA04	Cinchocaine

Allocation of new DDDs

ATC level name	ATC code	New DDD
A03AE04	Prucalopride	2 mg O
A16AB10	Velaglucerasa alfa	300 U P
B01AC24	Ticagrelor	0.18 g O
B02BX05	Eltrombopag	50 mg O
B06AC04	Conestat alfa	3.5 TU P
C01BG11	Vernakalant	0.2 g P
G03DB08	Dienogest	2 mg O
G03GA09	Corifollitropin alfa	0.15 mg P
H01CA03	Histrelin	0.137 g ²⁾ implant
J01CA19	Aspoxicillina	4 g P
J01DC12	Cefminox	4 g P
J01DC13	Cefbuperazone	2 g P
J01DC14	Flomoxef	2 g P
J01DF01	Aztreonam	0.225 g Inhal. solution
J01DF02	Carumonam	2 g P
J01GB10	Ribostamycin	1 g P
J01GB11	Isepamicin	0.4 g P
J01GB13	Bekanamycin	0.6 g P
L03AX15	Mifamurtide	0.7 mg P
L04AA27	Fingolimod	0.5 mg O
M01AB51	Indomethacin, combinations	0.1 g ¹⁾ O,R
N02AX06	Tapentadol	0.4 g O
N02BG07	Flupirtine	0.4 g O
N05AH05	Asenapine	20 mg O
N06AX23	Desvenlafaxine	50 mg O
N07XX07	Fampridine	20 mg O
R03AC18	Indacaterol	0.15 mg Inhal. powder
R03DX07	Roflumilast	0.5 mg O

1) refers to indomethacin

2) DDD assigned according to the total content of the implant

Full details on current ATC coding and defined daily doses (DDD) can be obtained from the DUSC Secretary, Department of Health, GPO Box 9848, Canberra ACT 2601, or direct from the coordinating body: the WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, PO BOX 4404 Nydalen 0403 Oslo Norway, or at their website: www.whocc.no

TABLE 1

2011 COMMUNITY PRESCRIPTION NUMBERS, TOGETHER WITH GOVERNMENT AND PATIENT COSTS FOR PBS LISTED DRUGS

Table 1 includes an estimate of community prescription numbers for the 2011 calendar year, costs (government and patient contribution) for the items with a four digit PBS/RPBS code, together with the defined daily dose (DDD) where assigned. There is no cost information available for items with a five digit Amfac drug code. Table 1 excludes the presentation of information on any item with an estimated community use of less than 110 prescriptions in 2011.

The prescription items are arranged by ATC code on generic name, and by form and strength using either the PBS drug code (4 digit plus alpha) or, for non-PBS items, the Amfac drug code (5 digit). Where “Item type” is P, this refers to PBS drug code and A refers to Amfac drug code.

Note that Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDDs) 2012 is used in all statistics published in this edition (refer to WHO collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2012).

An index by second level of the ATC classification follows:

ALIMENTARY TRACT AND METABOLISM	36
A01 STOMATOLOGICAL PREPARATIONS	36
A02 DRUGS FOR ACID RELATED DISORDERS	37
A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	40
A04 ANTIEMETICS AND ANTINAUSEANTS	41
A05 BILE AND LIVER THERAPY	42
A06 LAXATIVES	43
A07 ANTIDIARR. INTEST. ANTIINFL./ANTIINFECT. AGENTS	45
A08 ANTI OBESITY PREPARATIONS EXCL DIET PRODUCTS	47
A09 DIGESTIVES INCL ENZYMES	48
A10 ANTIDIABETIC THERAPY	49
A11 VITAMINS	52
A12 MINERAL SUPPLEMENTS	53
A14 ANABOLIC AGENTS FOR SYSTEMIC USE	54
BLOOD AND BLOOD FORMING ORGANS	55
B01 ANTITHROMBOTIC AGENTS	55
B02 ANTIHAEMORRHAGICS	58
B03 ANTIANAEMIC PREPARATIONS	59
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS	61

CARDIOVASCULAR SYSTEM	62
C01 CARDIAC THERAPY	62
C02 ANTIHYPERTENSIVES	64
C03 DIURETICS	65
C04 PERIPHERAL VASODILATORS	66
C05 VASOPROTECTIVES	66
C07 BETA BLOCKING AGENTS	67
C08 CALCIUM CHANNEL BLOCKERS	68
C09 AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM	69
C10 LIPID MODIFYING AGENTS PLAIN	74
DERMATOLOGICALS	76
D01 ANTIFUNGALS FOR DERMATOLOGICAL USE	76
D02 EMOLLIENTS AND PROTECTIVES	78
D03 PREPARATIONS FOR TREATMENT OF WOUNDS & ULCERS	79
D04 ANTIPRURITICS,INCL ANTIHIST,ANESTHET,ETC.	80
D05 ANTIPSORIATICS	81
D06 ANTIBIOTICS AND CHEMOTHER. FOR DERMATOLOGICAL USE	82
D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	83
D08 ANTISEPTICS AND DISINFECTANTS	85
D09 MEDICATED DRESSINGS	86
D10 ANTI-ACNE PREPARATIONS	87
D11 OTHER DERMATOLOGICAL PREPARATIONS	88
GENITO URINARY SYSTEM AND SEX HORMONES	89
G01 GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS	89
G02 OTHER GYNAECOLOGICALS	90
G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	91
G04 UROLOGICALS	96
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES	98
H01 PITUITARY, HYPOTHALAMIC HORMONES AND ANALOGUES	98
H02 CORTICOSTEROIDS FOR SYSTEMIC USE	99
H03 THYROID THERAPY	100
H04 PANCREATIC HORMONES	101
H05 CALCIUM HOMEOSTASIS	102
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE	103
J01 ANTIBACTERIALS FOR SYSTEMIC USE	103
J02 ANTIMYCOTICS FOR SYSTEMIC USE	109
J04 ANTIMYCOBACTERIALS	110
J05 ANTIVIRALS FOR SYSTEMIC USE	111
J07 VACCINES	113

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	115
L01 ANTINEOPLASTIC AGENTS	115
L02 ENDOCRINE THERAPY	126
L03 IMMUNOSTIMULANTS	128
L04 IMMUNOSUPPRESSANTS	129
MUSCULO-SKELETAL SYSTEM	133
M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	133
M02 TOPICAL PRODUCTS FOR JOINT and MUSCULAR PAIN	137
M03 MUSCLE RELAXANTS	138
M04 ANTIGOUT PREPARATIONS	139
M05 DRUGS FOR TREATMENT OF BONE DISEASES	140
NERVOUS SYSTEM	142
N01 ANAESTHETICS	142
N02 ANALGESICS	143
N03 ANTIEPILEPTICS	150
N04 ANTI-PARKINSON DRUGS	153
N05 PSYCHOLEPTICS	155
N06 PSYCHOANALEPTICS	162
N07 OTHER NERVOUS SYSTEM DRUGS	167
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	169
P01 ANTIPROTOZOALS	169
P02 ANTHELMINTICS	170
P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLANTS	171
RESPIRATORY SYSTEM	172
R01 NASAL PREPARATIONS	172
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	175
R05 COUGH AND COLD PREPARATIONS	178
R06 ANTIHISTAMINES FOR SYSTEMIC USE	179
SENSORY ORGANS	181
S01 OPHTHALMOLOGICALS	181
S02 OTOLOGICALS	187
S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	188
VARIOUS	189
V01 ALLERGENS	189
V03 ALL OTHER THERAPEUTIC PRODUCTS	190

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
STOMATOLOGICAL PREPARATIONS							
STOMATOLOGICAL PREPARATIONS							
ANTIINFECTIVES FOR LOCAL ORAL TREATMENT							
A01AB04			AMPHOTERICIN				
	P	2931G	Lozenge 10mg	40.00	MG	148,438	1,839,338
	P	3306B	Lozenge 10mg	40.00	MG	3,767	45,298
A01AB03			CHLORHEXIDINE				
	A	21081	Mouth wash 2mg per mL (0.2%) 300mL	30.00	MG	835	–
	P	4204G	Mouth wash 2mg per mL (0.2%) 300mL	30.00	MG	1,590	25,464
A01AB09			MICONAZOLE				
	A	13832	Oral gel 20mg per mL (2%) 20g	0.20	GM	2,685	–
	A	14054	Oral gel 40mg per mL (2%) 40g	0.20	GM	2,114	–
A01AB11			NYSTATIN				
	P	3033P	Oral suspension 100,000 units per mL 24mL	1500.00	TE	148,521	1,636,666
	P	3343Y	Oral suspension 100,000 units per mL 24mL	1500.00	TE	956	10,406
CORTICOSTEROIDS FOR LOCAL ORAL TREATMENT							
A01AC01			TRIAMCINOLONE ACETONIDE with PECTIN				
	A	11075	Paste 1% 5gm	–	–	11,933	–
OTHER AGENTS FOR LOCAL ORAL TREATMENT							
A01AD02			BENZYDAMINE HYDROCHLORIDE				
	P	1121B	Mouth and throat rinse 22.5mg per 15mL 500mL	–	–	3,933	83,728
	P	5032W	Mouth and throat rinse 22.5mg per 15mL 500mL	–	–	190	4,221
	P	5385K	Mouth and throat rinse 22.5mg per 15mL 500mL	–	–	260	6,134
A01AD02			BENZYDAMINE with CHLORHEXIDINE				
	A	14359	Solution 200mL	–	–	217	–
A01AD11			CHOLINE SALICYLATE with CETALKONIUM CHLORIDE				
	A	12855	Gel 10g 1	–	–	1,943	–
A01AD11			SALIVA SUBSTITUTE				
	P	4568K	Solution 25mL	–	–	385	4,253
	P	4569L	Solution 100mL	–	–	683	9,695
A01AD11			VARIOUS				
	P	5334R	Spray 10mg per mL 100mL	–	–	173	2,332

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
ALIMENTARY TRACT AND METABOLISM							
DRUGS FOR ACID RELATED DISORDERS							
ANTACIDS							
ALUMINIUM COMPOUNDS							
A02AB01			ALUMINIUM HYDROXIDE				
	A	10038	Tablet 600mg 100	-	-	2,956	-
CALCIUM COMPOUNDS							
A02AC10			CALCIUM CARBONATE with GLYCINE				
	P	4055K	Tablet 420mg-180mg	-	-	506	11,828
COMBS.AND COMPLEXES OF ALUMINIUM,CALCIUM AND MAGNESIUM COMPOUNDS							
A02AD			ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE				
	P	2157M	Oral suspension 200mg-200mg per 5mL 500mL	-	-	89,527	1,375,886
	P	4118R	Oral suspension 400mg-400mg-30mg per 5mL	-	-	1,871	41,738
A02AD			ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE with SIMETHICONE				
	A	20644	Chewable tablet 200mg-200mg-20mg 100	-	-	126	-
	P	4453J	Tablet 400mg-400mg-40mg 200	-	-	1,243	55,850
A02AD			ALUMINIUM HYDROXIDE with MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE				
	P	2159P	Oral suspension 250mg-120mg-120mg per 5mL	-	-	16,883	292,640
DRUGS FOR PEPTIC ULCER AND GORD							
H2-RECEPTOR ANTAGONISTS							
A02BA01			CIMETIDINE				
	P	1157X	Tablet 200mg	0.80	GM	938	12,710
	P	1158Y	Tablet 400mg	0.80	GM	4,020	73,667
	P	1159B	Tablet 800mg	0.80	GM	988	18,574
A02BA03			FAMOTIDINE				
	P	2487X	Tablet 20mg	40.00	MG	39,288	662,829
	P	2488Y	Tablet 40mg	40.00	MG	49,746	890,048
A02BA04			NIZATIDINE				
	P	1504E	Capsules 300mg 30	0.30	GM	71,717	1,353,059
	P	1505F	Capsules 150mg 30	0.30	GM	85,373	1,574,240
A02BA02			RANITIDINE HYDROCHLORIDE				
	P	1937Y	Effervescent tablet 150mg (base)	0.30	GM	41,009	708,025
	P	1977C	Tablet 300mg (base)	0.30	GM	274,134	4,850,962
	P	1978D	Tablet 150mg (base)	0.30	GM	538,072	9,265,705
	P	8162N	Syrup 150mg (base) per 10mL 300mL	0.30	GM	25,325	510,769
	P	8903N	Effervescent tablet 150mg (base)	0.30	GM	1,047	22,799
	P	8905Q	Syrup 150mg (base) per 10mL 300mL	0.30	GM	585	15,282
PROSTAGLANDINS							
A02BB01			ISOPROSTOL				
	P	1648R	Tablet 200ug	0.80	MG	2,046	106,026

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
DRUGS FOR ACID RELATED DISORDERS							
DRUGS FOR PEPTIC ULCER AND GORD							
PROTON PUMP INHIBITORS							
A02BC05	ESOMEPRAZOLE						
A	20665	Sachet granules 10mg 30		30.00	MG	7,264	–
P	3401B	Tablet 40mg (enteric coated) 30		30.00	MG	45,887	2,608,186
P	8600P	Tablet 20mg (enteric coated) 30		30.00	MG	4,004,220	125,045,481
P	8601Q	Tablet 40mg (enteric coated) 30		30.00	MG	2,791,158	132,488,955
P	8886Q	Tablet 20mg (enteric coated) 30		30.00	MG	130,397	4,051,301
A02BC03	LANSOPRAZOLE						
P	2240X	Capsule 30mg 28		30.00	MG	3,639	107,752
P	2241Y	Capsule 30mg 28		30.00	MG	121,002	3,516,631
P	8198L	Capsule 15mg 28		30.00	MG	3,459	69,902
P	9331D	Capsule 15mg 28		30.00	MG	18,012	338,344
P	9477T	Tablet 30mg (orally disintegrating) 28		30.00	MG	12,329	348,423
P	9478W	Tablet 30mg (orally disintegrating) 28		30.00	MG	433,333	13,820,017
A02BC01	OMEPRAZOLE						
P	1326T	Capsule 20mg		20.00	MG	6,794	189,891
P	1327W	Capsule 20mg		20.00	MG	181,744	6,052,848
P	8331L	Tablet 20mg (as magnesium salt) 30		20.00	MG	45,590	1,161,582
P	8332M	Tablet 10mg (as magnesium salt) 30		20.00	MG	70,823	1,604,361
P	8333N	Tablet 20mg (as magnesium salt) 30		20.00	MG	989,364	28,689,105
P	9109K	Tablet 20mg (as magnesium salt) 30		20.00	MG	34,684	974,893
P	9110L	Tablet 20mg (as magnesium salt) 30		20.00	MG	1,681,829	58,230,855
A02BC02	PANTOPRAZOLE						
A	20488	Tablet (enteric coated) equivalent to 20mg 7		40.00	MG	381	–
A	20489	Tablet (enteric coated) equivalent to 20mg 14		40.00	MG	1,370	–
A	21229	Tablet (enteric coated) equivalent to 20mg 14		40.00	MG	141	–
P	8007K	Tablet (enteric coated) equivalent to 40mg		40.00	MG	394,965	11,960,309
P	8008L	Tablet (enteric coated) equivalent to 40mg		40.00	MG	3,596,247	119,982,837
P	8399C	Tablet (enteric coated) equivalent to 20mg		40.00	MG	513,893	9,518,568
P	9423Y	Sachet containing granules 40mg 30		40.00	MG	4,277	130,322
P	9424B	Sachet containing granules 40mg 30		40.00	MG	33,536	1,074,357
A02BC04	RABEPRAZOLE						
A	17042	Tablet 10mg 7		20.00	MG	131	–
A	21419	Tablet 10mg 14		20.00	MG	238	–
P	8507R	Tablet 10mg 30		20.00	MG	79,844	2,873,533
P	8508T	Tablet 20mg 30		20.00	MG	2,307,116	89,389,670
P	8509W	Tablet 20mg 30		20.00	MG	239,671	8,507,492

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
DRUGS FOR ACID RELATED DISORDERS							
DRUGS FOR PEPTIC ULCER AND GORD							
COMBINATIONS FOR ERADICATION OF HELICOBACTER PYLORI							
A02BD06			ESOMEPRAZOLE AMOXICILAN and CLARITHROMYCIN				
	P	8738X	Pack 14 tabs(ent coated)equiv 20mg esomeprazole	-	-	86,235	6,713,133
A02BD05			OMEPRAZOLE and CLARITHROMYCIN and AMOXYCILLIN				
	P	8272J	Pack 14 caps 20mg,14 tabs 500mg,28 caps 500mg	-	-	7,108	464,015
OTHER DRUGS FOR PEPTIC ULCER AND GORD							
A02BX13			SODIUM ALGINATE with CALCIUM CARBONATE and SODIUM BICARBONATE				
	P	2014B	Oral liquid 1gm-320mg in 20mL 500mL	-	-	111,380	1,631,322
A02BX02			SUCRALFATE				
	P	2055E	Tablet 1g	4.00	GM	16,616	389,048
ANTIFLATULENTS							
ANTIFLATULENTS							
A02DA			PEPPERMINT OIL				
	A	13210	Capsule 0.2mL 63	-	-	778	-

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS							
DRUGS FOR FUNCTIONAL BOWEL DISORDERS							
SYNT ANTICHOLIN,ESTERS WITH TERTIARY AMINO GROUP							
A03AA04			MEBEVERINE HYDROCHLORIDE				
	A	12730	Tablet 135mg 30	0.30	GM	16,166	–
	A	14130	Tablet 135mg 30	0.30	GM	11,045	–
	P	4328T	Tablet 135mg	0.30	GM	60,233	1,809,221
SYNT ANTICHOLINERGICS,ESTERS,QUATER AMMONIUM COMPOUND							
A03AB05			PROPANTHELINE				
	P	1953T	Tablet 15mg	60.00	MG	15,859	403,508
OTHER DRUGS FOR FUNCTIONAL BOWEL DISORDERS							
A03AX13			SIMETHICONE				
	A	13445	Capsule 100mg 30	–	–	134	–
BELLADONNA AND DERIVATIVES PLAIN							
BELLADONNA ALKALOIDS TERTIARY AMINES							
A03BA01			ATROPINE				
	P	1089H	Injection 600ug in 1mL 10	1.50	MG	2,940	38,036
	P	3453R	Injection 600ug in 1mL 10	1.50	MG	6,880	140,049
BELLADONNA ALKALOIDS SEMISYNT QUATER AMMONIUM COMPOUND							
A03BB01			BUTYLSCOPOLAMINE				
	A	12939	Tablet 10mg 100	60.00	MG	9,964	–
	A	15287	Tablet 10mg	60.00	MG	7,849	–
	P	3473T	Injection 20mg in 1mL 5	60.00	MG	6,797	164,471
	P	4279F	Injection 20mg in 1mL	60.00	MG	4,133	176,530
	P	5317W	Injection 20mg in 1mL	60.00	MG	1,916	256,767
	P	5318X	Injection 20mg in 1mL	60.00	MG	812	103,405
A03BB			HYOSCINE HYDROBROMIDE				
	A	10972	Ampoule 400ug 5	–	–	9,418	–
PROPULSIVES							
PROPULSIVES							
A03FA03			DOMPERIDONE				
	A	11309	Tablet 10mg 100	30.00	MG	17,576	–
	P	1347X	Tablet 10mg	30.00	MG	348,065	4,423,328
A03FA01			METOCLOPRAMIDE HYDROCHLORIDE				
	A	11138	Tablet 10mg 100	30.00	MG	2,639	–
	P	1206L	Injection 10mg in 2mL	30.00	MG	45,196	657,177
	P	1207M	Tablet 10mg	30.00	MG	822,073	7,101,214
	P	3476Y	Injection 10mg in 2mL	30.00	MG	28,267	366,744
	P	5151D	Tablet 10mg	30.00	MG	557	4,509

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
ANTIEMETICS AND ANTINAUSEANTS							
ANTIEMETICS AND ANTINAUSEANTS							
SEROTONIN (5HT3) ANTAGONISTS							
A04AA04			DOLASETRON MESYLATE				
	P	8191D	Tablet 200mg	0.20	GM	2,350	127,372
	P	8192E	I.V. injection 100mg in 5mL	0.10	GM	545	18,030
A04AA02			GRANISETRON				
	P	5898K	Tablet 2mg (base) 2	2.00	MG	8,811	498,084
	P	5899L	Concentrated injection 3mg (base) in 3mL	3.00	MG	8,950	236,723
	P	8728J	Tablet 2mg (base) 2	2.00	MG	34,227	2,207,167
	P	8729K	Concentrated injection 3mg (base) in 3mL	3.00	MG	38,631	1,560,739
	P	8873B	Tablet 2mg (base) 5	2.00	MG	1,063	212,100
A04AA01			ONDANSETRON				
	P	1594X	Tablet 4mg	16.00	MG	7,083	545,130
	P	1595Y	Tablet 8mg	16.00	MG	8,105	970,905
	P	5471Y	Tablet (orally disintegrating) 8mg 4	16.00	MG	115	5,463
	P	5967C	Tablet 4mg	16.00	MG	763	20,718
	P	5968D	Tablet 8mg	16.00	MG	18,040	670,561
	P	5969E	Wafer 4mg 4	16.00	MG	134	4,559
	P	5970F	Wafer 8mg 4	16.00	MG	1,222	62,348
	P	5972H	I.V. injection 8mg in 4mL	16.00	MG	13,443	212,150
	P	8224W	Tablet 4mg	16.00	MG	15,987	607,366
	P	8225X	Tablet 8mg	16.00	MG	51,457	2,722,953
	P	8226Y	I.V. injection 4mg in 2mL	16.00	MG	2,420	47,031
	P	8227B	I.V. injection 8mg in 4mL	16.00	MG	18,672	595,894
	P	8233H	Syrup 4mg per 5mL 50mL	16.00	MG	126	15,135
	P	8410P	Wafer 4mg 4	16.00	MG	35,853	1,287,731
	P	8411Q	Wafer 8mg 4	16.00	MG	25,304	1,499,780
	P	8412R	Wafer 4mg 10	16.00	MG	13,132	1,081,046
	P	8413T	Wafer 8mg 10	16.00	MG	12,370	1,565,176
	P	9441X	Syrup 4mg per 5mL 50mL 1	16.00	MG	263	26,686
A04AA05			PALONOSETRON				
	P	5295Q	Injection 250ug (as hydrochloride) in 5mL 1	0.25	MG	40,834	1,917,786
	P	5853C	Injection 250ug (as hydrochloride) in 5mL	0.25	MG	3,493	120,157
A04AA03			TROPISETRON				
	P	2745L	Capsule 5mg (base)	5.00	MG	16,955	999,640
	P	2746M	I.V. injection 5mg/5mL	5.00	MG	9,949	344,405
	P	5986C	Capsule 5mg (base)	5.00	MG	5,200	183,453
	P	5987D	I.V. injection 5mg/5mL	5.00	MG	4,342	81,530
VARIOUS ANTIEMETICS							
A04AD12			APREPITANT				
	P	5888X	Pack 1 cap 125mg and 2 cap 80mg	95.00	MG	12,562	1,407,070
	P	8808N	Pack 1 cap 125mg and 2 cap 80mg	95.00	MG	35,174	4,824,412
A04AD01			SCOPOLAMINE				
	A	20612	Tablet 20mg 10	60.00	MG	968	—

<i>ATC</i>	<i>ITEM TYPE</i>	<i>CODE</i>	<i>FORM AND STRENGTH</i>	<i>2011</i>			
				<i>DDD</i>	<i>UNITS</i>	<i>SCRIPTS</i>	<i>COST(\$)</i>
ALIMENTARY TRACT AND METABOLISM							
BILE AND LIVER THERAPY							
<i>BILE THERAPY</i>							
BILE ACID PREPARATIONS							
A05AA02			URSODEOXYCHOLIC ACID				
	P	8448P	Capsule 250mg 200	0.75	GM	28,220	9,996,969

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
ALIMENTARY TRACT AND METABOLISM							
LAXATIVES							
LAXATIVES							
SOFTENERS EMOLLIENTS							
A06AA02			DOCUSATE SODIUM				
	A	16099	Tablet 120mg 100	0.15	GM	10,849	–
	P	4200C	Tablet 50mg	0.15	GM	9,436	135,168
A06AA01			LIQUID PARAFFIN				
	A	10108	Oral suspension vanilla 500mL	15.00	GM	519	–
	A	10120	Oral suspension strawberry 500mL	15.00	GM	156	–
A06AA			POLOXALKOL				
	A	10469	Drop 10% 30mL 1	–	–	1,427	–
CONTACT LAXATIVES							
A06AB02			BISACODYL				
	A	10635	Tablet 5mg 200	10.00	MG	382	–
	P	1258F	Suppositories 10mg 12	10.00	MG	3,466	62,058
	P	1259G	Tablet 5mg	10.00	MG	26,841	376,477
	P	1260H	Suppositories 10mg 10	10.00	MG	30,370	616,263
	P	3250C	Suppositories 10mg 10	10.00	MG	595	23,485
	P	5303D	Suppositories 10mg 10	10.00	MG	179	3,932
A06AB56			DOCUSATE SODIUM with SENNA				
	A	12753	Tablet 30	–	–	5,586	–
	P	4028B	Tablet 50mg–8mg 100	–	–	15,686	226,834
	P	4198Y	Tablet 50mg–8mg 90	–	–	233,283	3,899,346
A06AB06			SENNA STANDARDISED				
	P	4455L	Tablet 7.5mg	–	–	9,006	125,332
BULK PRODUCERS							
A06AC51			ISPAGHULA COMBINATIONS				
	P	4416K	Oral Powder 440g	–	–	592	12,652
A06AC01			PSYLLIUM HYDROPHILIC MUCILLOID				
	A	11156	Powder 500g 1	7.00	GM	962	–
	A	11273	Powder 500g 1	7.00	GM	390	–
	P	4285M	Sachets 3.5g 30	7.00	GM	2,213	44,489
	P	4419N	Oral powder(orange-flavour sugar free)315g	7.00	GM	20,359	456,491
	P	4422R	Oral powder (non-flavoured) 375g	7.00	GM	11,705	261,632
A06AC53			STERCULIA with FRANGULA BARK				
	P	1104D	Granules 620mg–80mg per g (62%–8%) 500g	–	–	70,371	1,768,572
	P	3275J	Granules 620mg–80mg per g (62%–8%) 500g	–	–	807	25,712
	P	4558X	Granules 620mg–80mg per g (62%–8%) 500g	–	–	5,428	136,948
A06AC53			STERCULIA, COMBINATIONS				
	P	5322D	Granules 620mg–80mg per g (62%–8%) 500g	–	–	302	7,952

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
LAXATIVES							
LAXATIVES							
OSMOTICALLY ACTING LAXATIVES							
A06AD11			LACTULOSE				
	P	3064G	Mixture 3.34g per 5mL 500mL	6.70	GM	345,133	4,789,487
	P	5387M	Mixture 3.34g per 5mL 500mL 1	6.70	GM	7,360	167,243
	P	5388N	Mixture 3.34g per 5mL 500mL 1	6.70	GM	1,138	32,003
A06AD11			LACTULOSE with GALACTOSE with LACTOSE with EPILACTOSE				
	A	10693	Syrup 200mL 1	6.70	GM	478	–
A06AD15			MACROGOL				
	P	3278M	Sachets powder 13.125g with electrolytes 2	10.00	GM	1,162	28,980
	P	3416T	Powder for oral solution 510g	10.00	GM	34,938	719,586
	P	5389P	Sachets powder 13.125g with electrolytes 30	10.00	GM	6,795	238,181
	P	5390Q	Sachets powder 13.125g with electrolytes 30	10.00	GM	1,648	59,056
	P	5426N	Powder for oral solution 510g	10.00	GM	242	8,085
	P	8612G	Sachets powder 13.125g with electrolytes 30	10.00	GM	893,738	18,628,515
A06AD			SORBITOL				
	A	14787	Liquid 70% 500mL	–	–	17,224	–
ENEMAS							
A06AG02			BISACODYL				
	P	1263L	Enemas 10mg in 5mL 25	–	–	9,608	415,704
	P	3263R	Enemas 10mg in 5mL 25	–	–	3,447	191,213
	P	5302C	Enemas 10mg in 5mL 25	10.00	MG	349	16,123
A06AG20			COMBINATION (SORBITOL/SODIUM CITRATE/SODIUM LAURYL SULFOACETATE)				
	P	2091C	Enemas 3.125g–450mg–45mg in 5mL 12	–	–	46,943	1,514,964
	P	3274H	Enemas 3.125g–450mg–45mg in 5mL 12	–	–	4,309	195,042
	P	4462W	Enemas 3.125g–450mg–45mg in 5mL 4	–	–	2,483	32,683
	P	5331N	Enemas 3.125g–450mg–45mg in 5mL 12	–	–	1,183	42,469
	P	5332P	Enemas 3.125g–450mg–45mg in 5mL 12	–	–	261	10,540
A06AG01			SODIUM PHOSPHATE				
	A	15629	Laxative Mixt 3.3G/5mL	–	–	677	–
PERIPHERAL OPIOID RECEPTOR ANTAGONISTS							
A06AH01			METHYLNALTREXONE BROMIDE				
	P	5423K	Solution for injection 12mg in 0.6mL 7	6.00	MG	216	30,898
	P	5424L	Solution for injection 12mg in 0.6mL 7	6.00	MG	122	44,611
OTHER LAXATIVES							
A06AX01			GLYCEROL				
	P	2555L	Suppositories 700mg (for infants) 12	–	–	394	6,575
	P	2556M	Suppositories 1.4g (for children) 12	–	–	769	14,174
	P	2557N	Suppositories 2.8g (for adults) 12	–	–	9,213	172,117
	P	3267Y	Suppositories 2.8g (for adults) 12	–	–	238	7,238
	P	4246L	Suppositories 2.8g (for adults) 12	–	–	186	3,404

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
ANTIDIARR. INTEST. ANTIINFL./ANTIINFECT. AGENTS							
INTESTINAL ANTIINFECTIVES							
ANTIBIOTICS							
A07AA01			NEOMYCIN SULPHATE				
	P	2325J	Tablet 500mg	5.00	GM	1,062	13,747
A07AA02			NYSTATIN				
	P	1696G	Tablet 500,000 units	1500.00	TE	19,975	399,729
	P	1699K	Capsule 500,000 units	1500.00	TE	29,924	659,557
A07AA09			VANCOMYCIN				
	P	3113W	Capsule 125 mg (125,000 i.u.) vancomycin activity	2.00	GM	858	221,228
	P	3114X	Capsule 250 mg (250,000 i.u.) vancomycin activity	2.00	GM	978	553,372
<i>ELECTROLYTES WITH CARBOHYDRATES</i>							
ORAL REHYDRATION SALT FORMULATIONS							
A07CA			ELECTROLYTE REPLACEMENT (ORAL)				
	P	3196F	Sachets of powder for oral solution 4.87g 10	–	–	23,754	370,773
<i>ANTIPROPULSIVES</i>							
ANTIPROPULSIVES							
A07DA01			DIPHENOXYLATE HYDROCHLORIDE with ATROPINE SULPHATE				
	A	11123	Tablet 2.5mg–25ug 100	15.00	MG	1,319	–
	A	16260	Tablet 2.5mg–25ug 8	15.00	MG	1,658	–
	P	2501P	Tablet 2.5mg–25ug	15.00	MG	223,401	2,257,444
A07DA03			LOPERAMIDE HYDROCHLORIDE				
	P	1571Q	Capsule 2mg	10.00	MG	255,518	4,143,511
	A	16133	Tablet 2mg 8	10.00	MG	163	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
ANTIDIARR. INTEST. ANTIINFL./ANTIINFECT. AGENTS							
INTESTINAL ANTIINFLAMMATORY AGENTS							
CORTICOSTEROIDS FOR LOCAL USE							
A07EA02			HYDROCORTISONE ACETATE				
	P	1502C	Rectal foam 125mg per applicator (10%) aerosol	–	–	11,434	429,097
A07EA01			PREDNISOLONE SODIUM PHOSPHATE				
	P	1920C	Retention enema equivalent to 20mg prednisolone	–	–	5,303	1,090,194
	P	2554K	Suppositories equivalent to 5mg prednisolone 10	–	–	7,914	327,539
AMINOSALICYLIC ACID AND SIMILAR AGENTS							
A07EC04			BALSALAZIDE				
	P	8845M	Capsule 750mg	6.75	GM	22,856	3,227,643
A07EC02			MESALAZINE				
	P	1611T	Tablet 250mg	1.50	GM	51,054	8,102,603
	P	2214M	Tablet 500mg (prolonged release) 200	1.50	GM	7,413	2,146,218
	P	2234N	Oral granules (prolonged release) 1g per sachet 100	1.50	GM	2,507	782,813
	P	2287J	Oral granules (prolonged release) 2g per sachet 60	1.50	GM	14,454	4,555,558
	P	3413P	Tablet 1g (prolonged release) 120	1.50	GM	6,308	2,030,875
	P	5461K	Suppository (moulded) 1g 30	1.50	GM	645	87,922
	P	8598M	Oral granules 500mg per sachet 100	1.50	GM	2,134	552,816
	P	8599N	Oral granules 1 mg per sachet 100	1.50	GM	18,956	5,592,491
	P	8616L	Enemas 2g in 60mL 7	1.50	GM	2,758	918,209
	P	8617M	Enemas 4g in 60mL 7	1.50	GM	7,826	3,493,222
	P	8731M	Tablet 500mg (enteric coated)	1.50	GM	56,113	16,508,377
	P	8752P	Suppository 1g 28	1.50	GM	11,087	1,443,267
	P	8753Q	Enemas 1g in 100mL 7	1.50	GM	1,257	417,418
	P	8768L	Rectal foam 1g per app, 14 apps aerosol 80g 4	1.50	GM	1,679	553,061
	P	9206M	Sachet containing granules 1.5g per sachet	1.50	GM	8,111	2,059,647
	P	9353G	Tablet 1.2g (prolonged release) 60	1.50	GM	10,559	2,723,348
A07EC03			OLSALAZINE SODIUM				
	P	1728Y	Capsule 250mg	1.00	GM	4,553	374,744
	P	8086N	Capsule 500mg	1.00	GM	12,875	1,651,153
A07EC01			SULPHASALAZINE				
	P	2093E	Tablet 500mg	2.00	GM	25,483	1,272,506
	P	2096H	Tablet 500mg (enteric coated)	2.00	GM	192,262	10,447,065
	P	9208P	Tablet 500mg 200	2.00	GM	1,182	59,224
	P	9209Q	Tablet 500mg (enteric coated) 200	2.00	GM	7,373	399,311

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
ALIMENTARY TRACT AND METABOLISM							
ANTI OBESITY PREPARATIONS EXCL DIET PRODUCTS							
ANTI OBESITY PREPARATIONS EXCL DIET PRODUCTS							
CENTRALLY ACTING ANTI OBESITY PRODUCTS							
A08AA01 PHENTERMINE							
A	10636		Capsule 15mg 30	15.00	MG	19,752	—
A	10637		Capsule 30mg 30	15.00	MG	84,886	—
A	10638		Capsule 40mg 30	15.00	MG	63,180	—
A	20783		Capsule 15mg 30	15.00	MG	315	—
A	20784		Capsule 30mg 30	15.00	MG	45,427	—
A	20785		Capsule 40mg 30	15.00	MG	35,465	—
PERIPHERALLY ACTING ANTI OBESITY PRODUCTS							
A08AB01 ORLISTAT							
A	18494		Capsule 120mg 84	0.36	GM	1,059	—
P	4570M		Capsule 120mg 84	0.36	GM	2,186	306,670

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
ALIMENTARY TRACT AND METABOLISM							
DIGESTIVES INCL ENZYMES							
DIGESTIVES INCL ENZYMES							
ENZYME PREPARATIONS							
A09AA02 PANCREATIC EXTRACT							
P	5453B		Granules (enteric coated) providing not less than 5000 BP units of lipase activity per 100mg 20g 3	–	–	1,486	205,267
P	5454C		Granules (enteric coated) providing not less than 5000 units of lipase activity per 100mg 20g 3	–	–	361	48,046
P	8020D		Capsule (containing enteric coated microspheres) provided not less than 10,000 BP units of lipase activity	–	–	24,520	4,065,209
P	8021E		Capsule (containing enteric coated microspheres) provided not less than 25,000 BP units of lipase activity	–	–	35,922	5,742,153
P	8556H		Capsule (containing enteric coated microspheres) provided not less than 5,000 BP units of lipase activity	–	–	727	77,875
P	9225M		Capsule (containing enteric coated microspheres) provided not less than 5,000 BP units of lipase activity	–	–	120	13,623
P	9226N		Capsule (containing enteric coated microspheres) provided not less than 10,000 BP units of lipase activity	–	–	4,673	744,517
P	9227P		Capsule (containing enteric coated microspheres) provided not less than 25,000 BP units of lipase activity	–	–	6,338	876,091
P	9229R		Capsule (containing enteric coated microspheres) provided not less than 25,000 BP units of lipase activity	–	–	355	52,034
P	9412J		Capsule (containing enteric coated microspheres) provided not less than 40000 BP units of lipase activity 200	–	–	7,499	1,747,784
P	9413K		Capsule (containing enteric coated microspheres) provided not less than 40000 BP units of lipase activity 200	–	–	1,410	297,844
A09AA02 PANCRELIPASE							
P	8366H		Capsule (containing enteric coated microspheres) provided not less than 25,000 BP units of lipase activity	–	–	2,666	376,273

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
ANTIDIABETIC THERAPY							
INSULINS AND ANALOGUES							
INSULINS AND ANALOGUES FAST-ACTING							
A10AB02	INSULIN (BEEF)						
	P	1713E	Injection 100 units per mL 10mL	40.00	IE	341	58,302
A10AB01	INSULIN (HUMAN)						
	P	1531N	Injection 100 units per mL 10mL	40.00	IE	8,279	1,064,135
	P	1762R	Injection 100 units per mL 3mL 5	40.00	IE	19,408	4,149,325
A10AB05	INSULIN ASPART						
	P	8435Y	Injection (human) 100 units per mL 3mL 5	40.00	IE	173,524	44,839,686
	P	8571D	Injection (human) 100 units per mL 10mL 5	40.00	IE	12,572	1,982,742
A10AB06	INSULIN GLULISINE						
	P	1921D	Injection (human) 100 units per mL 3mL 5	40.00	IE	13,168	3,440,179
	P	9224L	Injection (human) 100 units per mL 10mL 5	40.00	IE	226	33,547
A10AB04	INSULIN LISPRO						
	P	8084L	Injection 100 units per mL 10mL	40.00	IE	6,744	1,073,498
	P	8212F	Injection 100 units per mL 3mL 5	40.00	IE	35,333	9,245,371
INSULINS AND ANALOGUES INTERMEDIATE-ACTING							
A10AC02	INSULIN (BEEF)						
	P	1711C	Injection 100 units per mL 10mL	40.00	IE	576	98,278
A10AC01	INSULIN (HUMAN)						
	P	1533Q	Injection 100 units per mL 10mL	40.00	IE	13,171	1,757,778
	P	1761Q	Injection 100 units per mL 3mL 5	40.00	IE	38,729	8,366,065
INSULINS AND ANALOGUES INTERMEDIATE ACTING COMBINED WITH FAST-ACTING							
A10AD01	INSULIN (HUMAN)						
	P	1426C	Injection 100 units per mL (30 units–70 units)	40.00	IE	1,767	237,644
	P	1763T	Injection 100 units per mL (30 units–70 units)	40.00	IE	76,985	17,041,449
	P	2062M	Injection 100 units per mL (50 units–50 units)	40.00	IE	3,644	804,588
A10AD30	INSULIN ASPART/PROTAMINE ASPART						
	P	8609D	Injection (human analogue) 30/70 units per mL	40.00	IE	155,105	40,439,920
A10AD04	INSULIN LISPRO						
	P	8390N	Injection (human analogue) 100 units per mL 3mL 5	40.00	IE	18,198	4,774,672
	P	8874C	Inj (human analogue) 100 units(50/50)per mL 3mL 5	40.00	IE	5,516	1,448,982
INSULINS AND ANALOGUES LONG-ACTING							
A10AE05	INSULIN DETEMIR						
	P	9040T	Injection 100 units per mL 3mL 5	40.00	IE	35,829	15,343,456
A10AE04	INSULIN GLARGINE						
	A	18353	Injection 100 units per mL 10mL	40.00	IE	547	–
	P	9039R	Injection 100 units per mL 3mL 5	40.00	IE	257,833	109,484,665

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
ANTIDIABETIC THERAPY							
ORAL BLOOD GLUCOSE LOWERING DRUGS							
BIGUANIDES							
A10BA02	METFORMIN	HYDROCHLORIDE					
P	1801T	Tablet 850mg		2.00	GM	301,591	3,942,179
A	21261	Tablet 500mg (extended release) 90		2.00	GM	179	–
P	2430X	Tablet 500mg		2.00	GM	1,290,364	16,460,656
P	3439B	Tablet 1g (extended release) 60		2.00	GM	381,603	6,308,162
P	8607B	Tablet 1000mg		2.00	GM	1,215,949	21,139,343
P	9435N	Tablet 500mg (extended release) 120		2.00	GM	1,335,037	21,964,663
SULFONAMIDES UREA DERIVATIVES							
A10BB01	GLIBENCLAMIDE						
P	2939Q	Tablet 5mg		10.00	MG	83,450	952,196
A10BB09	GLICLAZIDE						
P	2449X	Tablet 80mg 100		60.00	MG	257,742	3,390,924
P	8535F	Tablet 30mg (modified release) 100		60.00	MG	355,405	4,722,109
P	9302N	Tablet 60mg (modified release) 60		60.00	MG	1,222,829	17,969,372
A10BB12	GLIMEPIRIDE						
P	8450R	Tablet 1mg 30		2.00	MG	55,024	494,304
P	8451T	Tablet 2mg 30		2.00	MG	76,430	866,163
P	8452W	Tablet 4mg 30		2.00	MG	203,107	2,895,328
P	8533D	Tablet 3mg 30		2.00	MG	29,316	372,847
A10BB07	GLIPIZIDE						
P	2440K	Tablet 5mg 100		10.00	MG	55,571	659,949
BIGUANIDES AND SULFONAMIDES IN COMBINATION							
A10BD02	METFORMIN and SULFONAMIDES						
P	8811R	Tablet 500mg–5mg 90		–	–	79,548	1,346,722
P	8838E	Tablet 250mg–1.25 90		–	–	2,613	34,572
A10BD02	METFORMIN with GLIBENCLAMIDE						
P	8810Q	Tablet 500mg–2.5mg 90		–	–	37,576	583,115
A10BD08	METFORMIN with VILDAGLIPTIN						
P	5474D	Tablet containing 50mg vildagliptin with 500mg metformin hydrochloride 60		–	–	7,646	747,607
P	5475E	Tablet containing 50mg vildagliptin with 850mg metformin hydrochloride 60		–	–	4,723	472,876
P	5476F	Tablet containing 50mg vildagliptin with 1000mg metformin hydrochloride 60		–	–	28,310	2,862,831
A10BD03	ROSIGLITAZONE with METFORMIN						
P	9059T	Tablet 2mg(base)–500mg 56		–	–	3,864	255,969
P	9060W	Tablet 2mg(base)–1000mg 56		–	–	10,137	696,089
P	9061X	Tablet 4mg(base)–500mg 56		–	–	3,748	356,282
P	9062Y	Tablet 4mg(base)–1000mg 56		–	–	19,508	1,915,157
A10BD07	SITAGLIPTIN with METFORMIN						
P	9449H	Tablet 50mg (as phosphate monohydrate) – 500mg 56		–	–	51,057	4,835,444
P	9450J	Tablet 50mg (as phosphate monohydrate) – 850mg 56		–	–	33,118	3,213,666
P	9451K	Tablet 50mg (as phosphate monohydrate) – 1000mg 56		–	–	190,807	18,618,892

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
ANTIDIABETIC THERAPY							
ORAL BLOOD GLUCOSE LOWERING DRUGS							
ALPHA GLUCOSIDASE INHIBITORS							
A10BF01	ACARBOSE						
	P	8188Y	Tablet 50mg	0.30	GM	27,471	863,688
	P	8189B	Tablet 100mg	0.30	GM	23,691	1,008,487
THIAZOLIDINEDIONES							
A10BG03	PIOGLITAZONE HYDROCHLORIDE						
	P	8694N	Tablet 15mg (base) 28	30.00	MG	83,898	4,628,526
	P	8695P	Tablet 30mg (base) 28	30.00	MG	225,166	18,238,325
	P	8696Q	Tablet 45mg (base) 28	30.00	MG	143,160	14,753,594
A10BG02	ROSIGLITAZONE						
	P	8689H	Tablet 4mg (base) 28	6.00	MG	19,484	1,237,488
	P	8690J	Tablet 8mg (base) 28	6.00	MG	20,513	1,885,801
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS							
A10BH03	SAXAGLIPTIN						
	P	8983T	Tablet 5mg (as hydrochloride) 28	5.00	MG	13,430	1,225,196
A10BH01	SITAGLIPTIN						
	P	9180E	Tablet 25mg (as phosphate monohydrate) 28	0.10	GM	23,219	2,138,362
	P	9181F	Tablet 50mg (as phosphate monohydrate) 28	0.10	GM	64,853	5,974,761
	P	9182G	Tablet 100mg (as phosphate monohydrate) 28	0.10	GM	270,711	24,720,021
A10BH02	VILDAGLIPTIN						
	P	3415R	Tablet 50mg 60	0.10	GM	59,648	5,795,595
OTHER BLOOD GLUCOSE LOWERING DRUGS							
A10BX04	EXENATIDE						
	P	3423E	Injection solution 5ug per dose in pre-filled pen 60 doses 1	0.02	MG	17,448	3,082,452
	P	3424F	Injection solution 10ug per dose in pre-filled pen 60 doses 1	0.02	MG	39,570	6,982,641
A10BX02	REPAGLINIDE						
	A	16646	Tablet 1mg 90	6.00	MG	263	—
	A	16647	Tablet 2mg 90	6.00	MG	1,053	—

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
VITAMINS							
VITAMIN A AND D INCL COMBINATIONS OF THE TWO							
VITAMIN A PLAIN							
A11CA01	VITAMIN A						
	A	12182	Capsule 50 000 units 100	50.00	TE	521	–
VITAMIN D AND ANALOGUES							
A11CC04	CALCITRIOL						
	P	2502Q	Capsule 0.25ug	1.00	UG	146,883	6,242,866
A11CC01	ERGOCALCIFEROL						
	A	16060	Capsule 25ug 60	–	–	875,087	–
VITAMIN B1,PLAIN AND IN COMB. WITH VITAMIN B6 AND B12							
THIAMINE (VITAMIN B1) PLAIN							
A11DA01	THIAMINE HYDROCHLORIDE						
	P	1070H	Tablet 100mg	50.00	MG	34,951	388,032
	P	4043T	Tablet 100mg	50.00	MG	26,066	289,117
VITAMIN B-COMPLEX INCL COMBINATIONS							
VITAMIN B-COMPLEX PLAIN							
A11EA	VITAMIN B GROUP COMPLEX						
	P	4493L	Oral liquid 200mL	–	–	10,226	137,042
OTHER PLAIN VITAMIN PREPARATIONS							
OTHER PLAIN VITAMIN PREPARATIONS							
A11HA02	PYRIDOXINE HYDROCHLORIDE						
	A	11648	Tablet 25mg 100	160.00	MG	2,068	–
	A	11649	Tablet 100mg 50	160.00	MG	1,403	–
OTHER VITAMIN PRODUCTS COMBINATIONS							
VITAMINS WITH MINERALS							
A11JB	VITAMINS with MINERALS						
	A	12947	Capsule 100	–	–	140	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ALIMENTARY TRACT AND METABOLISM							
MINERAL SUPPLEMENTS							
CALCIUM							
CALCIUM							
A12AA04			CALCIUM CARBONATE				
	A	20271	Tablet 600mg (as carbonate) 120	3.00	GM	43,767	–
	P	3116B	Tablet (chewable) 500mg (as carbonate)	3.00	GM	15,098	427,794
	P	3117C	Tablet 600mg (as carbonate) 240	3.00	GM	4,121	76,528
	P	4082W	Tablet (chewable) 600mg (as carbonate) 120	3.00	GM	8,122	115,793
	P	4094L	Tablet (chewable) 500mg (as carbonate)	3.00	GM	1,817	50,532
	P	4142B	Tablet 600mg (as carbonate) 240	3.00	GM	1,179	24,742
	P	4333C	Tablet (chewable) 500mg (as carbonate) 120	3.00	GM	5,613	102,439
A12AA			CALCIUM CITRATE				
	A	20956	Tablet 250mg (as citrate) 120	–	–	1,313	–
CALCIUM, COMBINATIONS WITH VITAMIN D AND/OR OTHER DRUGS							
A12AX			CALCIUM CARBONATE with CHOLECALCIFEROL				
	A	10600	Tablet 600mg 60	3.00		13,490	–
POTASSIUM							
POTASSIUM							
A12BA01			POTASSIUM CHLORIDE				
	P	2642C	Tablet 600mg (sustained release)	3.00	GM	297,926	3,751,387
	P	3012M	Effervescent tabs 14mmol K,8mmol Cl ions	3.00	GM	31,396	494,148
OTHER MINERAL SUPPLEMENTS							
ZINC							
A12CB01			ZINC SULPHATE				
	A	12264	Capsule 50mg 100	0.60	GM	303	–
MAGNESIUM							
A12CC05			MAGNESIUM ASPARTATE				
	A	11226	Tablet 100	–	–	2,322	–
	P	4321K	Tablet 37.4mg (as aspartate dihydrate)	–	–	49,265	808,311

<i>ATC</i>	<i>ITEM TYPE</i>	<i>CODE</i>	<i>FORM AND STRENGTH</i>	<i>2011</i>			
				<i>DDD</i>	<i>UNITS</i>	<i>SCRIPTS</i>	<i>COST(\$)</i>
ALIMENTARY TRACT AND METABOLISM							
ANABOLIC AGENTS FOR SYSTEMIC USE							
ANABOLIC STEROIDS							
ESTREN DERIVATIVES							
A14AB01			NANDROLONE DECANOATE				
	P	1671Y	Injection 50mg in 1mL disposable syringe	2.00	MG	4,552	102,291

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
BLOOD AND BLOOD FORMING ORGANS							
ANTITHROMBOTIC AGENTS							
ANTITHROMBOTIC AGENTS							
VITAMIN K ANTAGONISTS							
B01AA03 WARFARIN							
	P	2209G	Tablet 2mg	7.50	MG	1,004,645	12,794,232
	P	2211J	Tablet 5mg	7.50	MG	726,645	10,137,522
	P	2843P	Tablet 1mg	7.50	MG	1,142,531	14,169,034
	P	2844Q	Tablet 3mg	7.50	MG	333,939	4,198,194
HEPARIN GROUP							
B01AB04 DALTEPARIN							
	P	2816F	Inj 5,000 units (anti-Xa) in 0.2mL syringe	2.50	TE	6,875	485,015
	P	8269F	Inj 10,000 units (anti-Xa) in 1mL syringe	2.50	TE	333	94,169
	P	8271H	Inj 7,500 units (anti-Xa) in 0.75mL syringe	2.50	TE	278	63,280
	P	8603T	Inj 2,500 units (anti-Xa) in 0.2mL syringe	2.50	TE	3,897	230,103
	P	8641T	Inj 2,500 units (anti-Xa) in 0.2mL syringe	2.50	TE	1,434	117,702
	P	8642W	Inj 5,000 units (anti-Xa) in 0.2mL syringe	2.50	TE	2,209	193,265
	P	8643X	Inj 7,500 units (anti-Xa) in 0.75mL syringe	2.50	TE	313	47,400
B01AB05 ENOXAPARIN							
	A	18880	Inj 120mg (12000u anti-Xa) in 0.8mL syringe 10	2.00	TE	112	—
	P	5434B	Inj 80mg (8000u anti-Xa) in 0.8 mL prefilled syringe 20	2.00	TE	4,177	624,895
	P	5435C	Inj 100mg (10000u anti-Xa) in 1 mL prefilled syringe 20	2.00	TE	3,789	701,904
	P	8262W	Inj 60mg (6000u anti-Xa) in 0.6mL syringe	2.00	TE	31,992	3,901,553
	P	8263X	Inj 80mg (8000u anti-Xa) in 0.8mL syringe	2.00	TE	59,101	8,410,260
	P	8264Y	Inj 100mg (10000u anti-Xa) in 1 mL syringe	2.00	TE	63,485	11,056,805
	P	8510X	Inj 40mg (4000u anti-Xa) in 0.4 mL syringe 20	2.00	TE	111,074	9,203,048
	P	8558K	Inj 20mg (2000u anti-Xa) in 0.2mL syringe 20	2.00	TE	39,612	2,939,908
	P	8639Q	Inj 40mg (4000u anti-Xa) in 0.4mL syringe	2.00	TE	30,256	2,809,507
	P	8640R	Inj 60mg (6000u anti-Xa) in 0.6mL syringe	2.00	TE	16,781	2,256,126
	P	8716R	Inj 20mg (2000u anti-Xa) in 0.2mL syringe	2.00	TE	10,791	948,725
	P	9195Y	Solution for injection 40mg (4000 i.u. anti-Xa) 20	2.00	TE	15,398	1,546,216
	P	9196B	Solution for injection 40mg (4000 i.u. anti-Xa) 20	2.00	TE	6,679	645,930
B01AB01 HEPARIN SODIUM							
	P	1076P	Injection 35,000 units in 35mL 12	10.00	TE	1,207	296,910
	P	1463B	Injection 5,000 units in 5mL	10.00	TE	8,548	548,041
	P	1466E	Injection 5,000 units in 0.2mL	10.00	TE	43,174	678,478

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
BLOOD AND BLOOD FORMING ORGANS							
ANTITHROMBOTIC AGENTS							
ANTITHROMBOTIC AGENTS							
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN							
B01AC13	ABCIXIMAB						
	P	8048N	I.V.injection 10mg in 5mL	25.00	MG	1,181	1,650,496
B01AC06	ASPIRIN						
	A	10544	Tablet 100mg 30	0.10	GM	803	–
	A	10599	Tablet 100mg 28	0.10	GM	17,070	–
	A	13020	Capsule 100mg 28	0.10	GM	633	–
	P	4076M	Tablet 100mg (enteric coated)	0.10	GM	13,072	204,446
	P	4077N	Tablet 100mg (enteric coated)	0.10	GM	85,663	1,171,836
	P	4078P	Capsule 100mg (enteric coated pellets)	0.10	GM	11,529	168,299
	P	8202Q	Tablet 100mg	0.10	GM	1,104,501	8,835,207
B01AC04	CLOPIDOGREL						
	P	4179Y	Tablet 75mg (as hydrogen sulfate) 28	75.00	MG	657	45,343
	P	5436D	Tablet 75mg 28	75.00	MG	425	27,212
	P	8358X	Tablet 75mg (as hydrogen sulfate) 28	75.00	MG	2,331,877	161,155,943
	P	9317J	Tablet 75mg (as hydrogen sulfate) 28	75.00	MG	119,971	8,287,333
	P	9354H	Tablet 75mg (as hydrogen sulfate) 28	75.00	MG	270,817	18,692,942
B01AC30	CLOPIDOGREL with ASPIRIN						
	P	9296G	Tablet 75mg (as hydrogen sulfate)–100mg 30	–	–	510,540	38,192,131
B01AC07	DIPYRIDAMOLE						
	A	13040	Tablet 100mg 100	0.40	GM	447	–
	P	8335Q	Capsule 200mg (sustained release)	0.40	GM	38,165	1,408,043
B01AC30	DIPYRIDAMOLE with ASPRIN						
	P	8382E	Capsule 200mg (sustained release)–25mg	–	–	501,828	18,620,884
B01AC16	EPTIFIBATIDE						
	P	8683B	Solution for I.V. injection 20mg (base) in 10mL	0.20	GM	523	124,890
	P	8684C	Solution for I.V. infusion 75mg (base) in 100mL	0.20	GM	373	321,179
B01AC22	PRASUGREL						
	P	9495R	Tablet 5mg (as hydrochloride) 28	10.00	MG	1,933	187,098
	P	9496T	Tablet 10mg (as hydrochloride) 28	10.00	MG	29,991	3,176,949
B01AC05	TICLOPIDINE HYDROCHLORIDE						
	P	2095G	Tablet 250mg	0.50	GM	672	92,756
B01AC17	TIROFIBAN						
	P	8350L	Solution concentrate I.V. infusion 12.5mg in 50mL	10.00	MG	1,309	509,350

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
BLOOD AND BLOOD FORMING ORGANS							
ANTITHROMBOTIC AGENTS							
ANTITHROMBOTIC AGENTS							
ENZYMES							
B01AD11	TENECTEPLASE						
P	8527T		Powder for injection 50mg with solvent	40.00	MG	207	435,079
DIRECT THROMBIN INHIBITORS							
B01AE06	BIVALIRUDIN						
P	8844L		Powder for I.V. injection 250mg (base)	0.25	GM	2,540	1,809,429
B01AE07	DABIGATRAN						
A	21574		Capsule 150mg (as mesilate) 60	0.22	GM	356	–
P	9319L		Capsule 110mg (as mesilate) 20	0.22	GM	302	52,579
P	9321N		Capsule 110mg (as mesilate) 60	0.22	GM	1,691	368,598
OTHER ANTITHROMBOTIC AGENTS							
B01AX06	RIVAROXABAN						
P	9465E		Tablet 10mg 10	10.00	MG	372	58,704
P	9466F		Tablet 10mg 15	10.00	MG	2,844	569,024
P	9467G		Tablet 10mg 30	10.00	MG	3,406	976,317
P	9468H		Tablet 10mg 10	10.00	MG	758	77,254
P	9469J		Tablet 10mg 15	10.00	MG	6,290	890,265

B

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
BLOOD AND BLOOD FORMING ORGANS							
ANTIHAEMORRHAGICS							
ANTIFIBRINOLYTICS							
AMINO ACIDS							
B02AA02			TRANEXAMIC ACID				
	P	2180R	Tablet 500mg	2.00	GM	46,396	2,379,392
VITAMIN K AND OTHER HAEMOSTATICS							
VITAMIN K							
B02BA01			PHYTOMENADIONE				
	A	16049	Ampoule 10mg/mL 5	20.00	MG	1,511	–
	A	16648	Ampoule 2mg/0.2mL 5	20.00	MG	295	–
OTHER SYSTEMIC HEMOSTATICS							
B02BX04			ROMIPLOSTIM				
	P	9697J	Powder for inj. 375ug (250ug in 0.5mL when reconstituted)	30.00	UG	230	675,482
	P	9699L	Powder for inj. 625ug (500ug in 1mL when reconstituted)	30.00	UG	112	768,794

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
BLOOD AND BLOOD FORMING ORGANS							
ANTIANAEMIC PREPARATIONS							
IRON PREPARATIONS							
IRON BIVALENT, ORAL PREPARATIONS							
B03AA02			FERROUS FUMARATE				
	P	8985X	Tablet 200mg (equivalent to 65.7mg iron) 60	0.20	GM	2,788	32,257
B03AA07			FERROUS SULPHATE				
	A	16996	Tablet	0.20	GM	57,944	–
	P	8815Y	Oral liquid 30mg per mL, 250mL	0.20	GM	44,392	869,040
IRON TRIVALENT, PARENTERAL PREPARATIONS							
B03AC03			IRON POLYMALTOSE COMPLEX				
	P	2593L	Injection 100mg (iron) in 2mL	0.10	GM	56,388	3,087,497
B03AC02			SACCHARATED IRON OXIDE				
	P	8807M	Concent for soln for infus 2.7g =100mg iron in 5mL	0.10	GM	376	51,625
IRON IN COMBINATION WITH FOLIC ACID							
B03AD02			FERROUS FUMARATE with FOLIC ACID				
	P	9011G	Tablet 310mg–350ug	–	–	260,664	3,321,226
B03AD03			FERROUS SULPHATE DRIED with FOLIC ACID				
	A	14528	Capsule 270mg–300ug (delayed release)	–	–	1,664	–
	A	18904	Tablet 270mg–300ug (sustained release)	–	–	20,032	–
VITAMIN B12 AND FOLIC ACID							
VITAMIN B12 (CYANOCOBALAMIN AND DERIVATIVES)							
B03BA03			HYDROXOCOBALAMIN				
	P	9048F	Injection 1mg in 1mL 3	20.00	UG	343,271	5,454,707
FOLIC ACID AND DERIVATIVES							
B03BB01			FOLIC ACID				
	P	1437P	Tablet 5mg	–	–	114,647	1,556,450
	P	2958Q	Tablet 500ug	0.40	MG	44,289	593,888

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
BLOOD AND BLOOD FORMING ORGANS							
ANTIANAEMIC PREPARATIONS							
OTHER ANTIANAEMIC PREPARATIONS							
OTHER ANTIANAEMIC PREPARATIONS							
B03XA02			DARBEPOETIN ALPHA				
	P	6320P	Injection 10ug in 0.4mL syringe 8	4.50	UG	222	54,205
	P	6321Q	Injection 20ug in 0.5mL syringe 8	4.50	UG	2,130	889,541
	P	6322R	Injection 30ug in 0.3mL syringe 8	4.50	UG	2,818	1,675,036
	P	6323T	Injection 40ug in 0.4mL syringe 8	4.50	UG	7,548	5,552,442
	P	6324W	Injection 50ug in 0.5mL syringe 8	4.50	UG	1,053	959,368
	P	6325X	Injection 60ug in 0.3mL syringe 8	4.50	UG	3,250	3,580,726
	P	6326Y	Injection 100ug in 0.5mL syringe 8	4.50	UG	1,915	3,455,951
	P	6365B	Injection 150ug in 0.3mL syringe 8	4.50	UG	882	2,304,137
	P	6438W	Injection 80ug in 0.4mL syringe 8	4.50	UG	1,440	2,089,712
	P	6488L	Injection 20ug in 0.5mL prefilled injection pen 8	4.50	UG	570	224,835
	P	6489M	Injection 40ug in 0.4mL prefilled injection pen 8	4.50	UG	1,943	1,361,946
	P	6490N	Injection 60ug in 0.3mL prefilled injection pen 8	4.50	UG	666	718,197
	P	6491P	Injection 80ug in 0.4mL prefilled injection pen 8	4.50	UG	374	525,160
	P	6492Q	Injection 100ug in 0.5mL prefilled injection pen 8	4.50	UG	379	657,909
	P	6493R	Injection 150ug in 0.3mL prefilled injection pen 8	4.50	UG	188	441,510
B03XA01			EPOETIN ALPHA				
	P	6205N	Injection 3,000 units in 0.3mL syringe 12	1.00	TE	112	62,679
	P	6206P	Injection 4,000 units in 0.4mL syringe 12	1.00	TE	509	311,753
	P	6207Q	Injection 10,000 units in 1mL syringe 12	1.00	TE	753	1,105,306
	P	6303R	Injection 6,000 units in 0.6mL syringe 12	1.00	TE	639	536,729
	P	6305W	Injection 8,000 units in 0.8mL syringe 12	1.00	TE	660	822,144
	P	6339P	Injection 40,000 units in 1mL syringe 2	1.00	TE	151	375,550
B03XA01			EPOETIN BETA				
	P	6482E	Injection 4,000 units in 0.3mL syringe 12	1.00	TE	784	453,765
	P	6483F	Injection 5,000 units in 0.3mL syringe 12	1.00	TE	156	136,525
	P	6484G	Injection 6,000 units in 0.3mL syringe 12	1.00	TE	838	737,458
	P	6485H	Injection 10,000 units in 0.6mL syringe 12	1.00	TE	1,103	1,453,460
	P	6486J	Injection 20,000 units in 0.6mL syringe 12	1.00	TE	191	572,309
B03XA03			METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA				
	P	9574X	Injection 30ug in 0.3mL prefilled syringe 1	4.00	UG	209	77,746
	P	9575Y	Injection 50ug in 0.3mL prefilled syringe 1	4.00	UG	353	238,397
	P	9576B	Injection 75ug in 0.3mL prefilled syringe 1	4.00	UG	218	209,204
	P	9577C	Injection 100ug in 0.3mL prefilled syringe 1	4.00	UG	301	357,982
	P	9578D	Injection 120ug in 0.3mL prefilled syringe 1	4.00	UG	251	335,277
	P	9579E	Injection 200ug in 0.3mL prefilled syringe 1	4.00	UG	238	479,835
	P	9580F	Injection 360ug in 0.3mL prefilled syringe 1	4.00	UG	166	558,225

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
BLOOD AND BLOOD FORMING ORGANS							
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS							
BLOOD AND RELATED PRODUCTS							
BLOOD SUBSTITUTES AND PLASMA PROTEIN FRACTIONS							
B05AA06	GELATIN	SUCCINYLATED					
P	8444K	I.V. infusion 20g per 500mL,500mL		-	-	1,892	67,030
B05AA07	HYDROXYETHYLSTARCH						
P	9487H	I.V. infusion 30g per 500mL, 500mL 3		-	-	1,377	49,039
<i>I.V. SOLUTIONS</i>							
SOLUTIONS FOR PARENTERAL NUTRITION							
B05BA03	GLUCOSE						
P	2245E	I.V. infusion 278mmol per l (5%) 1L		-	-	628	11,757
P	9444C	I.V. infusion 139mmol (anhydrous) per 500mL (5%) 500mL 5		-	-	267	3,186
SOLUTIONS AFFECTING THE ELECTROLYTE BALANCE							
B05BB01	SODIUM CHLORIDE						
P	2260Y	I.V. infusion 513mmol per l (3%) 1L		-	-	138	1,678
P	2264E	I.V. infusion 154mmol per l (0.9%) 1L		-	-	21,668	513,625
P	9392H	I.V. infusion 77mmol per 500mL (0.9%), 500mL 5		-	-	1,546	16,565
P	9473N	I.V. infusion 38.5mmol per 250mL (0.9%) 250mL 5		-	-	421	8,142
B05BB01	SODIUM CHLORIDE COMPOUND						
P	2266G	I.V. infusion 1L		-	-	395	11,425
B05BB02	SODIUM CHLORIDE with GLUCOSE						
P	2281C	I.V. infusion 31mmol-222mmol per l (0.18%-4%) 1L		-	-	2,898	66,608
B05BB01	SODIUM LACTATE COMPOUND						
P	2286H	I.V. infusion 1L		-	-	13,952	236,243
<i>IRRIGATING SOLUTIONS</i>							
SALT SOLUTIONS							
B05CB01	SODIUM CHLORIDE						
P	4460R	Irrigation solution 9mg per mL (0.9%) 500mL		-	-	422	4,921
P	4461T	Irrigation solution 9mg per mL (0.9%) 1L		-	-	296	3,234



ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
CARDIAC THERAPY							
CARDIAC GLYCOSIDES							
DIGITALIS GLYCOSIDES							
C01AA05 DIGOXIN							
	P	1322N	Tablet 250ug	0.25	MG	121,736	1,300,571
	P	2605D	Tablet 62.5ug	0.25	MG	286,148	2,971,072
	P	3164M	Oral solution for children 50ug per mL, 100mL	0.25	MG	466	12,693
<i>ANTIARRHYTHMICS CLASS I AND III</i>							
ANTIARRHYTHMICS CLASS IA							
C01BA03 DISOPYRAMIDE							
	P	2923W	Capsule 100mg	0.40	GM	4,378	128,978
	P	2924X	Capsule 150mg	0.40	GM	2,698	127,971
ANTIARRHYTHMICS CLASS IB							
C01BB01 LIGNOCAINE HYDROCHLORIDE							
	P	2875H	Injection 100mg in 5mL	3.00	GM	1,548	67,254
	P	2876J	Infusion 500mg in 5mL	3.00	GM	220	7,351
	P	3474W	Injection 100mg in 5mL	3.00	GM	9,151	341,011
ANTIARRHYTHMICS CLASS IC							
C01BC04 FLECAINIDE ACETATE							
	P	1088G	Tablet 50mg 60	0.20	GM	92,661	3,572,359
	P	1090J	Tablet 100mg	0.20	GM	129,724	5,975,876
ANTIARRHYTHMICS CLASS III							
C01BD01 AMIODARONE HYDROCHLORIDE							
	A	21775	Tablet 100mg 30	0.20	GM	114	–
	A	21776	Tablet 200mg 30	0.20	GM	4,864	–
	P	2343H	Tablet 200mg	0.20	GM	257,904	5,431,022
	P	2344J	Tablet 100mg	0.20	GM	119,601	1,755,282
<i>CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES</i>							
ADRENERGIC AGENTS							
C01CA24 ADRENALINE							
	P	1016L	Injection 1mg in 1mL (1 in 1,000)	0.50	MG	1,659	33,185
	P	3408J	I.M. injection 150ug in 0.3mL single dose auto-injector	0.50	MG	395	78,715
	P	3409K	I.M. injection 300ug in 0.3mL single dose auto-injector	0.50	MG	579	110,394
	P	3451P	Injection 1mg in 1mL (1 in 1,000)	0.50	MG	22,684	461,078
	P	8697R	I.M. injection 150mg in 0.3mL syringe	0.50	MG	22,186	4,330,695
	P	8698T	I.M. injection 300mg in 0.3mL syringe	0.50	MG	51,503	9,092,004

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
CARDIAC THERAPY							
VASODILATORS USED IN CARDIAC DISEASES							
ORGANIC NITRATES							
C01DA02 GLYCERYL TRINITRATE							
P	1459T		Tablets 600ug 100	2.50	MG	71,622	1,028,367
P	1515R		Td pad releasing approx. 5mg per 24 hours	5.00	MG	177,563	4,835,297
P	1516T		Td pad releasing approx. 10mg per 24 hours	5.00	MG	91,015	3,075,387
P	3475X		Buccal/sublingual spray (pump pack) 400ug per dose	2.50	MG	21,071	424,159
P	8010N		Td patch releasing approx. 5mg per 24 hours	5.00	MG	91,145	2,487,973
P	8011P		Td patch releasing approx. 10mg per 24 hours	5.00	MG	43,895	1,484,499
P	8026K		Td patch releasing approx. 1mg per 24 hours	5.00	MG	19,018	643,769
P	8027L		Td patch releasing approx. 5mg per 24 hours	5.00	MG	6,829	186,392
P	8028M		Td patch releasing approx. 10mg per 24 hours	5.00	MG	5,135	173,746
P	8119H		Td patch releasing approx. 15mg per 24 hours	5.00	MG	3,382	115,860
P	8171C		Buccal/sublingual spray (pump pack) 400ug per dose	2.50	MG	315,748	6,299,001
C01DA08 ISOSORBIDE DINITRATE							
P	2587E		Tablet 10mg	60.00	MG	9,601	107,063
P	2588F		Sublingual tablet 5mg	20.00	MG	6,153	87,246
C01DA14 ISOSORBIDE MONONITRATE							
P	1558B		Tablets sustained release 60mg 30	40.00	MG	675,389	8,565,007
P	8273K		Tablets sustained release 120mg 30	40.00	MG	251,126	5,291,262
OTHER VASODILATORS USED IN CARDIAC DISEASES							
C01DX16 NICORANDIL							
P	8228C		Tablet 10mg	40.00	MG	168,717	4,083,946
P	8229D		Tablet 20mg	40.00	MG	78,668	2,475,409
<i>OTHER CARDIAC PREPARATIONS</i>							
OTHER CARDIAC PREPARATIONS							
C01EB17 IVABRADINE							
A	19957		Tablets 5mg 56	10.00	MG	20,833	—
A	19958		Tablets 7.5mg 56	10.00	MG	6,754	—

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
ANTIHYPERTENSIVES							
ANTIADRENERGIC AGENTS CENTRALLY ACTING							
METHYLDOPA							
C02AB01	METHYLDOPA						
	P	1629R	Tablet 250mg	1.00	GM	156,857	2,182,266
IMIDAZOLINE RECEPTOR AGONISTS							
C02AC01	CLONIDINE						
	A	12786	Ampoule 150ug/mL 5	0.45	MG	112	—
	P	3141H	Tablet 150ug	0.45	MG	31,653	1,207,725
	P	3145M	Tablet 100ug	0.45	MG	113,406	3,275,392
C02AC05	MOXONIDINE						
	P	9019Q	Tablet 200mg 30	0.30	MG	252,848	5,210,259
	P	9020R	Tablet 400mg 30	0.30	MG	218,021	6,389,842
ANTIADRENERGIC AGENTS PERIPHERALLY ACTING							
ALPHA-ADRENOCEPTOR BLOCKING AGENTS							
C02CA01	PRAZOSIN HYDROCHLORIDE						
	P	1478T	Tablet 5mg (base)	5.00	MG	120,631	2,497,394
	P	1479W	Tablet 1mg (base)	5.00	MG	321,518	3,943,937
	P	1480X	Tablet 2mg (base)	5.00	MG	183,534	2,691,752
ARTERIOLAR SMOOTH MUSCLE AGENTS ACTING ON							
HYDRAZINOPHTHALAZINE DERIVATIVES							
C02DB02	HYDRALAZINE HYDROCHLORIDE						
	P	1639G	Tablet 50mg	0.10	GM	29,349	501,795
	P	1640H	Tablet 25mg	0.10	GM	35,243	535,508
PYRIMIDINE DERIVATIVES							
C02DC01	MINOXIDIL						
	P	2313R	Tablet 10mg	20.00	MG	5,085	281,628
OTHER ANTIHYPERTENSIVES							
OTHER ANTHIYPERTENSIVES							
C02KX02	AMBRISENTAN						
	P	9648T	Tablet 5mg 30	7.50	MG	201	820,365
	P	9649W	Tablet 10mg 30	7.50	MG	365	1,489,625
C02KX01	BOSENTAN						
	P	6429J	Tablet 62.5mg (base) 60	0.25	MG	152	608,151
	P	6430K	Tablet 125mg (base) 60	0.25	MG	2,526	10,307,832

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
DIURETICS							
<i>LOW-CEILING DIURETICS THIAZIDES</i>							
THIAZIDES PLAIN							
C03AA03			HYDROCHLOROTHIAZIDE				
	P	1484D	Tablet 25mg	25.00	MG	92,463	1,948,482
<i>LOW-CEILING DIURETICS EXCL. THIAZIDES</i>							
SULFONAMIDES PLAIN							
C03BA04			CHLORTHALIDONE				
	P	1585K	Tablet 25mg	25.00	MG	28,581	438,924
C03BA11			INDAPAMIDE				
	P	2436F	Tablet 2.5mg 90	2.50	MG	143,202	2,425,013
	P	8532C	Tablet 1.5mg (sustained release) 90	2.50	MG	344,322	6,430,822
<i>HIGH-CEILING DIURETICS</i>							
SULFONAMIDES PLAIN							
C03CA02			BUMETANIDE				
	A	17855	Tablet 1mg	1.00	MG	7,677	–
C03CA01			FRUSEMIDE				
	P	2411X	Oral solution 10mg per mL 30mL	40.00	MG	3,111	57,231
	P	2412Y	Tablet 40mg	40.00	MG	1,231,675	10,696,447
	P	2413B	Injection 20mg in 2mL	40.00	MG	7,798	88,345
	P	2414C	Tablet 20mg	40.00	MG	312,359	2,763,092
	P	2415D	Tablet 500mg	40.00	MG	13,878	245,282
	P	3466K	Injection 20mg in 2mL	40.00	MG	9,876	101,552
ARYLOXYACETIC ACID DERIVATIVES							
C03CC01			ETHACRYNIC ACID				
	P	8748K	Tablet 25mg	50.00	MG	2,551	471,898
<i>POTASSIUM-SPARING AGENTS</i>							
ALDOSTERONE ANTAGONISTS							
C03DA04			EPLERENONE				
	P	8879H	Tablet 25mg 30	50.00	MG	13,538	1,548,505
	P	8880J	Tablet 50mg 30	50.00	MG	2,809	329,441
C03DA01			SPIRONOLACTONE				
	P	2339D	Tablet 25mg	75.00	MG	343,328	4,171,369
	P	2340E	Tablet 100mg	75.00	MG	63,506	1,840,818
OTHER POTASSIUM-SPARING AGENTS							
C03DB01			AMILORIDE HYDROCHLORIDE				
	P	3109P	Tablet 5mg	10.00	MG	19,553	152,429
<i>DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB</i>							
LOW-CEILING DIURETICS AND POTASSIUM-SPARING AGENTS							
C03EA01			HYDROCHLOROTHIAZIDE with AMILORIDE HYDROCHLORIDE				
	P	1486F	Tablet 50mg–5mg	–	–	123,513	1,660,571
C03EA01			HYDROCHLOROTHIAZIDE with TRIAMTERENE				
	P	1280J	Tablet 25mg–50mg 100	–	–	26,932	346,548



ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
PERIPHERAL VASODILATORS							
PERIPHERAL VASODILATORS							
PURINE DERIVATIVES							
C04AD03 OXPENTIFYLLINE							
	A	17632	Tablet 400mg 50	1.00	GM	2,716	-
OTHER PERIPHERAL VASODILATORS							
C04AX02 PHENOXYBENZAMINE HYDROCHLORIDE							
	P	1862B	Capsule 10mg 30	30.00	MG	178	13,368
	P	9286R	Capsule 10mg 100	30.00	MG	1,685	2,159,563
VASOPROTECTIVES							
AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE							
CORTICOSTEROIDS							
C05AA01 HYDROCORTISONE with CINCHOCAINE HYDROCHLORIDE							
	P	4036K	Ointment 5mg-5mg per g (0.5%-0.5%) 30g	-	-	6,990	159,061
C05AA01 HYDROCORTISONE, CINCHOCAINE HYDROCHLORIDE							
	A	14345	Ointment 5mg-5mg-10mg per g (0.5%-0.5%-1%)	-	-	4,573	-
	P	4038M	Suppositories 5mg-5mg 12	-	-	7,550	171,000
C05AA01 HYDROCORTISONE, LIGNOCAINE BASE, ALUMINIUM SUBACETATE and ZINC OXIDE							
	A	14653	Ointment 2.5mg-50mg-35mg-180mg per g	-	-	2,604	-
C05AA04 PREDNISOLONE HEXANOATE, CINCHOCAINE HYDROCHLORIDE and CLEMIZOLE UNDECYLENATE							
	A	14656	Ointment 1.9mg-5mg-10mg per g (0.16-0.5%-1%)	-	-	16,820	-
	A	14657	Ointment 1.9mg-5mg-10mg per g (0.195-0.5%-1%)	-	-	16,010	-
	A	14658	Suppositories 1.3mg-1mg-5mg 12	-	-	10,581	-
LOCAL ANESTHETICS							
C05AD03 ADRENALINE EPHEDRINE BENZOCAINE ZINC OXIDE							
	A	13134	Ointment 50g 1	-	-	3,303	-
MUSCLE RELAXANTS							
C05AE01 GLYCERYL TRINITRATE							
	A	16349	Ointment 0.2% 30g 1	-	-	1,244	-
	A	20786	Ointment 0.2% 15g 1	-	-	447	-
OTHER AGENTS FOR TREATMENT HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE							
C05AX04 ZINC OXIDE							
	P	4039N	Compound ointment 50g	-	-	2,519	36,367
	P	4040P	Compound suppositories, 12	-	-	1,400	20,874
ANTIVARICOSE THERAPY							
HEPARINS OR HEPARINOIDS FOR TOPICAL USE							
C05BA01 HEPARINOID							
	A	12829	Cream 0.3%40g 1	-	-	848	-
	A	13774	Cream 0.3% 20g 1	-	-	1,095	-
CAPILLARY STABILIZING AGENTS							
BIOFLAVONOIDS							
C05CA02 HYDROXYETHYL RUTOSIDES							
	A	16101	Capsule 250mg 100	-	-	508	-

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
BETA BLOCKING AGENTS							
BETA BLOCKING AGENTS PLAIN							
BETA BLOCKING AGENTS PLAIN NON-SELECTIVE							
C07AA02			OXPRENOLOL HYDROCHLORIDE				
	P	2942W	Tablet 20mg	0.16	GM	1,679	19,854
	P	2961W	Tablet 40mg	0.16	GM	8,462	133,621
C07AA03			PINDOLOL				
	P	3062E	Tablet 5mg	15.00	MG	15,485	174,246
	P	3065H	Tablet 15mg	15.00	MG	17,191	233,293
C07AA05			PROPRANOLOL HYDROCHLORIDE				
	P	2565B	Tablet 10mg	0.16	GM	157,217	1,605,164
	P	2566C	Tablet 40mg	0.16	GM	301,035	3,190,267
	P	2899N	Tablet 160mg	0.16	GM	25,588	284,389
C07AA07			SOTALOL HYDROCHLORIDE				
	P	2043M	Tablet 160mg	0.16	GM	95,155	2,458,512
	P	8398B	Tablet 80mg 60	0.16	GM	388,242	5,996,520
BETA BLOCKING AGENTS PLAIN SELECTIVE							
C07AB03			ATENOLOL				
	P	1081X	Tablet 50mg	0.08	GM	3,867,794	38,650,746
C07AB07			BISOPROLOL				
	P	8604W	Tablet 2.5mg	10.00	MG	240,843	11,957,373
	P	8605X	Tablet 5mg	10.00	MG	231,087	13,890,184
	P	8606Y	Tablet 10mg	10.00	MG	194,890	13,902,969
C07AB02			METOPROLOL SUCCINATE				
	P	8732N	Tablet 23.75mg (controlled release) 15	150.00	MG	10,217	332,283
	P	8733P	Tablet 47.5mg (controlled release) 30	150.00	MG	41,964	3,134,857
	P	8734Q	Tablet 95mg (controlled release) 30	150.00	MG	41,009	3,749,505
	P	8735R	Tablet 190mg (controlled release) 30	150.00	MG	31,247	3,446,363
C07AB02			METOPROLOL TARTRATE				
	P	1324Q	Tablet 50mg	150.00	MG	1,375,891	14,574,845
	P	1325R	Tablet 100mg	150.00	MG	434,014	5,136,930
C07AB12			NEBIVOLOL				
	P	9310B	Tablet 1.25mg (as hydrochloride), 28	5.00	MG	5,286	174,739
	P	9311C	Tablet 5mg (as hydrochloride) 28	5.00	MG	14,082	873,666
	P	9312D	Tablet 10mg (as hydrochloride) 28	5.00	MG	6,891	469,386
	P	9316H	Tablet 1.25mg (as hydrochloride) 28	5.00	MG	4,672	197,151
ALPHA- AND BETA- ADRENOCEPTOR BLOCKING AGENTS							
C07AG02			CARVEDILOL				
	A	21656	Tablet 12.5mg 60	37.50	MG	128	–
	P	8255L	Tablet 3.125mg 30	37.50	MG	27,596	532,271
	P	8256M	Tablet 6.25mg	37.50	MG	115,505	5,262,477
	P	8257N	Tablet 12.5mg	37.50	MG	142,831	7,752,629
	P	8258P	Tablet 25mg	37.50	MG	258,276	17,571,323
C07AG01			LABETALOL HYDROCHLORIDE				
	P	1566K	Tablet 100mg	0.60	GM	19,499	297,330
	P	1567L	Tablet 200mg	0.60	GM	21,000	467,972



ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
CALCIUM CHANNEL BLOCKERS							
<i>SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS</i>							
DIHYDROPYRIDINE DERIVATIVES							
C08CA01 AMLODIPINE							
P	1343Q	Tablet 5mg (base) maleate salt 30	5.00	MG	231,616	3,751,969	
P	1345T	Tablet 10mg (base) maleate salt 30	5.00	MG	169,513	3,996,696	
P	2751T	Tablet 5mg (base) besylate salt 30	5.00	MG	1,429,246	23,266,376	
P	2752W	Tablet 10mg (base) besylate salt 30	5.00	MG	1,108,109	26,241,413	
C08CA02 FELODIPINE							
P	2361G	Tablet 2.5mg (extended release)	5.00	MG	178,805	2,269,700	
P	2366M	Tablet 5mg (extended release)	5.00	MG	421,515	6,515,374	
P	2367N	Tablet 10mg (extended release)	5.00	MG	512,676	12,150,398	
C08CA13 LERCANIPIDINE							
P	8534E	Tablet 10mg 30	10.00	MG	1,177,917	18,281,391	
P	8679T	Tablet 20mg 30	10.00	MG	1,039,096	22,203,753	
C08CA05 NIFEDIPINE							
P	1694E	Tablet 10mg 60	30.00	MG	35,448	542,043	
P	1695F	Tablet 20mg 60	30.00	MG	30,095	533,962	
P	1906H	Tablet 30mg (controlled release) 30	30.00	MG	301,024	5,616,714	
P	1907J	Tablet 60mg (controlled release) 30	30.00	MG	290,823	6,519,440	
P	8610E	Tablet 20mg (controlled release) 30	30.00	MG	119,439	2,130,646	
P	8938K	Tablet 20mg (controlled release) 30	30.00	MG	4,443	100,021	
<i>SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS</i>							
PHENYLALKYLAMINE DERIVATIVES							
C08DA01 VERAPAMIL HYDROCHLORIDE							
P	1241H	Tablet 240mg (sustained release)	0.24	GM	534,899	8,670,086	
P	1248Q	Tablet 40mg	0.24	GM	32,706	368,192	
P	1250T	Tablet 80mg	0.24	GM	29,262	438,530	
P	1253Y	Tablet 160mg	0.24	GM	11,609	210,300	
P	1254B	Tablet 120mg	0.24	GM	6,171	116,304	
P	2206D	Capsule 160mg (sustained release)	0.24	GM	55,835	701,034	
P	2207E	Capsule 240mg (sustained release)	0.24	GM	106,508	1,723,544	
P	2208F	Capsule 180mg (sustained release)	0.24	GM	213,254	2,940,710	
P	3494X	Injection 5mg in 2mL	0.24	GM	3,150	38,982	
BENZOTHAZEPINE DERIVATIVES							
C08DB01 DILTIAZEM HYDROCHLORIDE							
P	1312C	Capsule 180mg controlled delivery	0.24	GM	464,949	7,807,306	
P	1313D	Capsule 240mg controlled delivery	0.24	GM	438,848	8,961,909	
P	1335G	Tablet 60mg	0.24	GM	50,193	792,553	
P	8480H	Capsule 360mg controlled delivery 30	0.24	GM	300,890	7,433,076	
<i>NON-SELECTIVE CALCIUM CHANNEL BLOCKERS</i>							
OTHER NON-SELECTIVE CALCIUM CHANNEL BLOCKERS							
C08EX02 PERHEXILINE MALEATE							
P	1822X	Tablet 100mg	0.20	GM	30,025	1,881,938	

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM							
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, PLAIN							
CONVERTING ENZYME BLOCKERS							
C09AA01			CAPTOPRIL				
	P	1147J	Tablet 12.5mg	50.00	MG	4,894	78,869
	P	1148K	Tablet 25mg	50.00	MG	15,805	325,204
	P	1149L	Tablet 50mg	50.00	MG	25,739	900,493
	P	8760C	Oral solution 5mg per mL 95mL	50.00	MG	1,180	142,329
C09AA02			ENALAPRIL MALEATE				
	P	1368B	Tablet 10mg	10.00	MG	141,373	2,475,339
	P	1369C	Tablet 20mg	10.00	MG	271,790	6,087,737
	P	1370D	Tablet 5mg	10.00	MG	63,609	829,912
C09AA09			FOSINOPRIL				
	P	1182F	Tablet 10mg 30	15.00	MG	103,778	1,595,274
	P	1183G	Tablet 20mg	15.00	MG	197,569	4,143,110
C09AA03			LISINOPRIL				
	P	2456G	Tablet 5mg 30	10.00	MG	86,774	1,201,903
	P	2457H	Tablet 10mg 30	10.00	MG	165,265	2,915,320
	P	2458J	Tablet 20mg 30	10.00	MG	307,237	6,629,154
C09AA04			PERINDOPRIL				
	P	3050M	Tablet 2mg (erbumine) 30	4.00	MG	401,360	4,926,661
	P	3051N	Tablet 4mg (erbumine) 30	4.00	MG	752,035	13,085,090
	P	8704D	Tablet 8mg (erbumine) 30	4.00	MG	664,291	15,442,002
	P	9006B	Tablet 2.5mg (arginine) 30	4.00	MG	664,891	8,156,917
	P	9007C	Tablet 5mg (arginine) 30	4.00	MG	1,503,712	26,274,992
	P	9008D	Tablet 10mg (arginine) 30	4.00	MG	1,452,903	33,913,829
C09AA06			QUINAPRIL				
	P	1968N	Tablet 5mg (as hydrochloride) 30	15.00	MG	30,421	415,694
	P	1969P	Tablet 10mg (as hydrochloride) 30	15.00	MG	85,159	1,436,308
	P	1970Q	Tablet 20mg (as hydrochloride) 30	15.00	MG	185,703	3,839,635
C09AA05			RAMIPRIL				
	P	1316G	Tablet 10mg 30	2.50	MG	190,488	4,332,095
	P	1944H	Capsule 1.25mg 28	2.50	MG	163,028	1,851,158
	P	1945J	Capsule 2.5mg 28	2.50	MG	521,801	7,118,129
	P	1946K	Capsule 5.0mg 28	2.50	MG	954,040	14,993,941
	P	8470T	Capsule 10mg 30	2.50	MG	1,430,872	32,292,099
	P	8668F	Pack 7 Tabs 2.5mg 21 tabs 5mg and 10 caps 10mg	2.50	MG	985	20,985
	P	9120B	Capsule 1.25mg 30	2.50	MG	7,271	82,291
	P	9121C	Capsule 2.5mg 30	2.50	MG	28,146	371,431
	P	9122D	Capsule 5.0mg 30	2.50	MG	36,640	564,961
C09AA10			TRANDOLAPRIL				
	P	2791X	Capsule 500ug	2.00	MG	19,490	179,041
	P	2792Y	Capsule 1mg	2.00	MG	60,800	832,380
	P	2793B	Capsule 2mg	2.00	MG	134,510	2,085,062
	P	8758Y	Capsule 4mg 28	2.00	MG	146,861	3,392,489



ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM							
ACE INHIBITORS, COMBINATIONS							
ANGIOTENSIN-CONVERTING ENZYME BLOCKERS AND DIURETICS							
C09BA02	ENALAPRIL with HYDROCHLOROTHIAZIDE						
P	8477E	Tablet 20mg-6mg		-	-	124,585	3,511,520
C09BA09	FOSINOPRIL with HYDROCHLOROTHIAZIDE						
P	8400D	Tablet 10mg-12.5mg		-	-	55,107	1,179,601
P	8401E	Tablet 20mg-12.5mg		-	-	343,701	9,825,743
C09BA04	PERINDOPRIL with INDAPAMIDE						
P	2190G	Tablet 2.5mg (arginine)-0.625mg 30		-	-	47,004	758,766
P	2845R	Tablet 5mg (arginine)-1.25mg 30		-	-	1,165,611	33,816,555
P	8449Q	Tablet 4mg (erbumine)-1.25mg 30		-	-	450,325	12,748,542
C09BA06	QUINAPRIL with HYDROCHLOROTHIAZIDE						
P	8589C	Tablet 10mg(base) / 12.5mg 30		-	-	15,476	295,264
P	8590D	Tablet 20mg(base) / 12.5mg 30		-	-	83,617	1,799,529
ACE INHIBITORS AND CALCIUM CHANNEL BLOCKERS							
C09BB02	ENALAPRIL and LERCANIDIPINE						
P	9144G	Tablet 10mg-10mg 30		-	-	44,158	1,159,876
P	9145H	Tablet 10mg-20mg 30		-	-	97,471	2,767,349
C09BB04	PERINDOPRIL and AMLODIPINE						
P	9346X	Tablet 5mg-5mg 30		-	-	121,175	3,291,098
P	9347Y	Tablet 5mg-10mg 30		-	-	35,158	1,213,937
P	9348B	Tablet 10mg-5mg 30		-	-	203,867	6,724,555
P	9349C	Tablet 10mg-10mg 30		-	-	182,132	7,343,525
C09BB05	RAMIPRIL and FELODIPINE						
P	2626F	Tablet 2.5mg-2.5mg 30		-	-	9,356	187,922
P	2629J	Tablet 5mg-5mg 30		-	-	74,820	1,991,509
C09BB10	TRANDOLAPRIL and VERAPAMIL						
P	2857J	Tablet 4mg-240mg (sustained release) 28		-	-	60,809	1,925,171
P	9387C	Tablet 2mg-180mg (sustained release) 28		-	-	12,105	266,404

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM							
ANGIOTENSIN II ANTAGONISTS							
ANGIOTENSIN II ANTAGONISTS PLAIN							
C09CA06			CANDESARTAN				
	P	8295N	Tablet 4mg 30	8.00	MG	311,357	5,520,702
	P	8296P	Tablet 8mg 30	8.00	MG	865,083	18,177,091
	P	8297Q	Tablet 16mg 30	8.00	MG	1,057,118	30,761,877
	P	8889W	Tablet 32mg 30	8.00	MG	588,116	27,485,015
	P	8997M	Tablet 8mg 30	8.00	MG	6,588	152,202
	P	8998N	Tablet 16mg 30	8.00	MG	8,647	280,538
	P	8999P	Tablet 32mg 30	8.00	MG	4,543	223,861
C09CA02			EPROSARTAN				
	P	8397Y	Tablet 400mg (base) 56	0.60	GM	21,270	606,560
	P	8447N	Tablet 600mg (base) 28	0.60	GM	66,653	2,045,606
	P	8951D	Tablet 400mg (base) 56	0.60	GM	671	20,891
C09CA04			IRBESARTAN				
	P	8246B	Tablet 75mg	150.00	MG	589,293	12,093,515
	P	8247C	Tablet 150mg	150.00	MG	1,643,422	40,408,002
	P	8248D	Tablet 300mg	150.00	MG	1,894,898	57,458,272
C09CA01			LOSARTAN				
	A	16073	Tablet 50mg 30	0.05	GM	4,591	–
	P	8203R	Tablet 50mg	50.00	MG	131	3,511
C09CA08			OLMESARTAN MEDOXOMIL				
	P	2147B	Tablet 20mg 30	20.00	MG	289,623	7,250,896
	P	2148C	Tablet 40mg 30	20.00	MG	249,874	7,626,762
C09CA07			TELMISARTAN				
	P	8355R	Tablet 40mg	40.00	MG	1,313,692	28,510,929
	P	8356T	Tablet 80mg	40.00	MG	1,271,322	36,971,467
C09CA03			VALSARTAN				
	P	9368C	Tablet 40mg 28	80.00	MG	3,980	64,417
	P	9369D	Tablet 80mg 28	80.00	MG	53,517	1,079,558
	P	9370E	Tablet 160mg 28	80.00	MG	36,684	885,277
	P	9371F	Tablet 320mg 28	80.00	MG	12,919	369,595

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM							
ANGIOTENSIN II ANTAGONISTS COMBINATIONS							
ANGIOTENSIN II ANTAGONISTS AND DIURETICS							
C09DA06			CANDESARTAN with HYDROCHLOROTHIAZIDE				
	P	8504N	Tablet 16mg–12.5mg 30	–	–	932,420	29,120,255
	P	9314F	Tablet 32mg–12.5mg 30	–	–	218,425	10,594,131
	P	9315G	Tablet 32mg–25mg 30	–	–	105,414	5,321,860
C09DA02			EPROSARTAN with HYDROCHLOROTHIAZIDE				
	P	8624X	Tablet 600mg (base) –12.5mg 28	–	–	79,493	2,560,424
C09DA04			IRBESARTAN with HYDROCHLOROTHIAZIDE				
	P	2136K	Tablet 300mg–25mg 30	–	–	524,488	18,137,704
	P	8404H	Tablet 150mg–12.5mg 30	–	–	664,956	17,748,081
	P	8405J	Tablet 300mg–12.5mg 30	–	–	2,108,569	68,284,412
C09DA08			OLMESARTAN with HYDROCHLOROTHIAZIDE				
	P	2161R	Tablet 20mg 12.5mg 30	–	–	70,200	1,904,165
	P	2166B	Tablet 40mg 12.5mg 30	–	–	165,015	5,312,000
	P	2170F	Tablet 40mg 25mg 30	–	–	132,820	4,572,480
C09DA07			TELMISARTAN with HYDROCHLOROTHIAZIDE				
	P	8622T	Tablet 40mg–12.5mg 28	–	–	275,599	6,529,240
	P	8623W	Tablet 80mg–12.5mg 28	–	–	986,523	30,554,632
	P	9381R	Tablet 80mg–25mg 28	–	–	219,125	7,238,734
C09DA03			VALSARTAN with HYDROCHLOROTHIAZIDE				
	P	9372G	Tablet 80mg–12.5mg 28	–	–	8,286	183,297
	P	9373H	Tablet 160mg–12.5mg 28	–	–	14,800	384,375
	P	9374J	Tablet 160mg–25mg 28	–	–	7,069	198,195
	P	9481B	Tablet 320mg–12.5mg 28	–	–	7,534	230,850
	P	9482C	Tablet 320mg–25mg 28	–	–	6,610	216,147

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM							
ANGIOTENSIN II ANTAGONISTS COMBINATIONS							
ANGIOTENSIN II ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS							
C09DB01 AMLODIPINE and VALSARTAN							
P	5459H		Tablet 5mg as (besylate)-320mg 28	-	-	13,077	493,166
P	5460J		Tablet 10mg as (besylate)-320mg 28	-	-	18,595	819,565
P	9375K		Tablet 5mg as (besylate)-80mg 28	-	-	62,061	1,817,322
P	9376L		Tablet 5mg as (besylate)-160mg 28	-	-	122,506	4,063,429
P	9377M		Tablet 10mg as (besylate)-160mg 28	-	-	135,013	5,384,050
C09DB02 OLMESARTAN with AMLODIPINE							
P	5292M		Tablet containing olmesartan medoxomil 20mg with amlodipine 5mg (as besylate)	-	-	18,591	643,570
P	5293N		Tablet containing olmesartan medoxomil 40mg with amlodipine 5mg (as besylate)	-	-	33,662	1,334,845
P	5294P		Tablet containing olmesartan medoxomil 40mg with amlodipine 10mg (as besylate)	-	-	26,730	1,234,590
C09DB04 TELMISARTAN and AMLODIPINE							
P	8978M		Tablet 40mg-5mg (as besylate) 28	-	-	11,143	342,843
P	8979N		Tablet 40mg-10mg (as besylate) 28	-	-	2,415	90,728
P	8980P		Tablet 80mg-5mg (as besylate) 28	-	-	24,894	945,666
P	8981Q		Tablet 80mg-10mg (as besylate) 28	-	-	13,973	619,208
ANGIOTENSIN II ANTAGONISTS OTHER COMBINATIONS							
C09DX01 AMLODIPINE with VALSARTAN and HYDROCHLOROTHIAZIDE							
P	5285E		Tablet 5mg (as besylate)-160mg-12.5mg	-	-	32,022	1,124,529
P	5286F		Tablet 5mg (as besylate)-160mg-25mg	-	-	9,123	339,084
P	5287G		Tablet 10mg (as besylate)-160mg-12.5mg	-	-	28,295	1,181,947
P	5288H		Tablet 10mg (as besylate)-160mg-25mg	-	-	11,954	520,789
P	5289J		Tablet 10mg (as besylate)-320mg-25mg	-	-	23,186	1,104,845

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
LIPID MODIFYING AGENTS PLAIN							
LIPID MODIFYING AGENTS PLAIN							
HMG REDUCTASE INHIBITORS							
C10AA05 ATORVASTATIN							
P	8213G	Tablet 10mg (as calcium)	30	20.00	MG	1,618,265	68,969,500
P	8214H	Tablet 20mg (as calcium)	30	20.00	MG	3,612,371	209,258,444
P	8215J	Tablet 40mg (as calcium)	30	20.00	MG	4,022,296	317,721,039
P	8521L	Tablet 80mg (as calcium)	30	20.00	MG	1,466,799	161,477,124
P	9230T	Tablet 10mg (as calcium)	30	20.00	MG	57,541	2,453,519
P	9231W	Tablet 20mg (as calcium)	30	20.00	MG	129,380	7,501,427
P	9232X	Tablet 40mg (as calcium)	30	20.00	MG	149,959	11,861,390
P	9233Y	Tablet 80mg (as calcium)	30	20.00	MG	64,033	7,051,151
C10AA04 FLUVASTATIN							
P	2863Q	Tablet 80mg (as sodium) (prolonged release)	28	60.00	MG	21,972	997,815
P	8023G	Capsule 20mg (as sodium)	28	60.00	MG	22,565	575,671
P	8024H	Capsule 40mg (as sodium)	28	60.00	MG	32,294	989,328
P	9234B	Capsule 20mg (as sodium)	28	60.00	MG	912	23,267
P	9235C	Capsule 40mg (as sodium)	28	60.00	MG	1,355	43,337
P	9236D	Capsule 80mg (as sodium)	28	60.00	MG	1,216	55,261
C10AA03 PRAVASTATIN							
P	2833D	Tablet 10mg	30	30.00	MG	74,530	1,548,514
P	2834E	Tablet 20mg	30	30.00	MG	275,766	8,087,139
P	8197K	Tablet 40mg	30	30.00	MG	582,615	24,433,981
P	8829Q	Tablet 80mg	30	30.00	MG	127,986	7,536,160
P	9237E	Tablet 10mg	30	30.00	MG	3,198	66,499
P	9238F	Tablet 20mg	30	30.00	MG	10,835	317,851
P	9239G	Tablet 40mg	30	30.00	MG	20,778	869,750
P	9240H	Tablet 80mg	30	30.00	MG	7,482	440,495
C10AA07 ROSUVASTATIN							
P	3402C	Tablet 5mg (as calcium)	30	10.00	MG	33,628	1,517,306
P	3403D	Tablet 10mg (as calcium)	30	10.00	MG	66,962	4,127,460
P	3404E	Tablet 20mg (as calcium)	30	10.00	MG	37,640	3,201,555
P	3405F	Tablet 40mg (as calcium)	30	10.00	MG	19,526	2,316,372
P	9042X	Tablet 5mg (as calcium)	30	10.00	MG	1,103,734	49,868,015
P	9043Y	Tablet 10mg (as calcium)	30	10.00	MG	3,095,837	191,151,147
P	9044B	Tablet 20mg (as calcium)	30	10.00	MG	1,526,231	130,028,318
P	9045C	Tablet 40mg (as calcium)	30	10.00	MG	724,079	86,088,483
C10AA01 SIMVASTATIN							
P	2011W	Tablet 10mg	30	30.00	MG	428,380	10,337,801
P	2012X	Tablet 20mg	30	30.00	MG	1,357,650	43,330,446
P	2013Y	Tablet 5mg	30	30.00	MG	23,501	451,659
P	8173E	Tablet 40mg	30	30.00	MG	1,882,972	80,665,715
P	8313M	Tablet 80mg	30	30.00	MG	517,303	29,434,311
P	9241J	Tablet 5mg	30	30.00	MG	879	16,918
P	9242K	Tablet 10mg	30	30.00	MG	15,403	371,716
P	9243L	Tablet 20mg	30	30.00	MG	48,869	1,558,246
P	9244M	Tablet 40mg	30	30.00	MG	69,883	2,992,237
P	9245N	Tablet 80mg	30	30.00	MG	24,993	1,421,790

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
CARDIOVASCULAR SYSTEM							
LIPID MODIFYING AGENTS PLAIN							
LIPID MODIFYING AGENTS PLAIN							
FIBRATES							
C10AB05	FENOFIBRATE						
P	9022W	Tablet 48mg	60	0.20	GM	48,371	1,449,448
P	9023X	Tablet 145mg	30	0.20	GM	629,046	26,221,745
P	9246P	Tablet 48mg	60	0.20	GM	3,286	98,436
P	9247Q	Tablet 145mg	30	0.20	GM	26,218	1,093,519
C10AB04	GEMFIBROZIL						
P	1453L	Tablet 600mg		1.20	GM	165,466	4,732,962
P	9248R	Tablet 600mg	60	1.20	GM	5,081	145,353
BILE ACID SEQUESTRANTS							
C10AC02	COLESTIPOL HYDROCHLORIDE						
P	1224K	Sachets 5g	120	20.00	GM	940	79,881
C10AC01	COLESTYRAMINE						
P	2967E	Sachets 4.7g (equiv to 4g cholestyramine)		14.00	GM	33,525	2,362,895
P	9249T	Sachets 4.7g (equiv to 4g cholestyramine) 50, 2		14.00	GM	2,290	162,588
NICOTINIC ACID AND DERIVATIVES							
C10AD02	NICOTINIC ACID						
A	19191	Tablet 250mg		2.00	GM	4,508	—
OTHER LIPID MODIFYING AGENTS							
C10AX09	EZETIMIBE						
P	8757X	Tablet 10mg	30	10.00	MG	1,057,245	75,175,089
C10AX06	FISH OIL						
A	21434	Capsule 1000mg	28	—	—	1,281	—
LIPID MODIFYING AGENTS COMBINATIONS							
HMG COA REDUCTASE INHIBITORS IN COMBINATION WITH OTHER LIPID MOD AGENTS							
C10BA02	SIMVASTATIN and EZETIMIBE						
P	8881K	Tablet 40mg–10mg	30	—	—	375,579	40,478,393
P	8882L	Tablet 80mg–10mg	30	—	—	354,566	43,932,207
P	9483D	Tablet 10mg–10mg	30	—	—	24,271	2,154,379
P	9484E	Tablet 10mg–20mg	30	—	—	32,448	3,130,878
HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONS							
C10BX03	ATORVASTATIN and AMLODIPINE						
P	9049G	Tablet 10mg (base) 5mg (base)	30	—	—	88,719	4,537,185
P	9050H	Tablet 20mg (base) 5mg (base)	30	—	—	199,380	13,417,836
P	9051J	Tablet 40mg (base) 5mg (base)	30	—	—	212,957	18,817,326
P	9052K	Tablet 80mg (base) 5mg (base)	30	—	—	75,333	9,004,578
P	9053L	Tablet 10mg (base) 10mg (base)	30	—	—	66,380	3,831,127
P	9054M	Tablet 20mg (base) 10mg (base)	30	—	—	177,581	13,206,886
P	9055N	Tablet 40mg (base) 10mg (base)	30	—	—	233,066	22,240,079
P	9056P	Tablet 80mg (base) 10mg (base)	30	—	—	97,811	12,378,857

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
DERMATOLOGICALS							
ANTIFUNGALS FOR DERMATOLOGICAL USE							
ANTIFUNGALS FOR TOPICAL USE							
ANTIBIOTICS							
D01AA01			NYSTATIN				
	P	1698J	Cream 100,000 units per g 15g	–	–	697	12,824
	P	4001N	Cream 100,000 units per g 15g	–	–	649	8,292
IMIDAZOLE DERIVATIVES							
D01AC10			BIFONAZOLE				
	A	20955	Cream 1% 15 g	–	–	409	–
D01AC01			CLOTRIMAZOLE				
	P	1017M	Cream 10 mg per g (1%) 20g 2	–	–	3,257	36,546
	A	15576	Cream 10mg per g (1%) 50g	–	–	3,030	–
	A	15786	Cream 10mg per g (1%) 50g	–	–	14,338	–
	A	16585	Cream 10mg per g (1%) 20g	–	–	1,953	–
	A	17061	Cream (vaginal) 100 mg per g (10%)	–	–	1,007	–
	A	21214	Lotion 10mg per mL (1%) 20mL	–	–	445	–
	A	21737	Cream (vaginal) 10mg per g (1%), 20g	–	–	132	–
	P	4004R	Cream 10mg per g (1%) 20g	–	–	10,783	97,188
D01AC03			ECONAZOLE NITRATE				
	A	15470	Cream 10 mg per g (1%) 20g	–	–	355	–
D01AC08			KETOCONAZOLE				
	P	1574W	Shampoo 20mg per mL (2%) 60mL	–	–	1,784	32,923
	P	4007X	Shampoo 20mg per mL (2%) 100mL	–	–	180	3,608
	P	4008Y	Shampoo 20mg per mL (2%) 60mL	–	–	2,954	55,223
	P	9024Y	Shampoo 20mg per g (2%) 30g 1	–	–	5,457	127,694
	P	9025B	Shampoo 10mg per g (1%) 100mL	–	–	1,510	26,522
D01AC02			MICONAZOLE				
	A	17964	Cream 10mg per g (1%) 40g	–	–	503	–
	P	4341L	Tincture 20mg per mL (2%), 20mL	–	–	816	15,867
	P	9026C	Tincture 20mg per mL (2%), 15mL 2	–	–	1,307	20,686
	P	9027D	Cream 20mg per g (2%) 30g 1	–	–	1,788	26,487
	P	9028E	Cream 20mg per g (2%) 70g 1	–	–	1,940	32,869
	P	9029F	Powder 20mg per g (2%) 30g 1	–	–	456	7,075
	P	9030G	Lotion 20mg per mL (2%) 30g 1	–	–	540	9,105
	P	9031H	Tincture 20mg per mL (2%) 30mL 1	–	–	723	14,076
D01AC02			MICONAZOLE NITRATE				
	P	4454K	Cream 20mg per g (2%) 30g	–	–	2,688	39,924
D01AC52			MICONAZOLE and HYDROCORTISONE				
	A	17966	Cream 1% 1g/100g 30g	–	–	11,289	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
DERMATOLOGICALS							
ANTIFUNGALS FOR DERMATOLOGICAL USE							
ANTIFUNGALS FOR TOPICAL USE							
OTHER ANTIFUNGALS FOR TOPICAL USE							
D01AE16	AMOROLFINE						
P	4010C		Nail treatment kit containing 50mg (base) per mL	–	–	8,456	812,997
D01AE14	CICLOPIROX						
P	4106D		Shampoo 15mg per g (1.5%) 60mL	–	–	470	8,600
D01AE15	TERBINAFINE						
P	4463X		Gel 10mg per g (1%) 15g	–	–	890	21,182
P	4473K		Cream 10mg per g (1%) 15g	–	–	7,831	174,835
P	9160D		Cream 10mg per g (1%) 15g	–	–	5,928	223,457
D01AE18	TOLNAFTATE						
P	4481W		Spray aerosol 10mg per g (1%) 100g	–	–	370	5,624
ANTIFUNGALS FOR SYSTEMIC USE							
ANTIFUNGALS FOR SYSTEMIC USE							
D01BA01	GRISEOFULVIN						
P	1460W		Tablet 125mg	0.50	GM	6,757	173,968
P	2982Y		Tablet 500mg	0.50	GM	48,368	1,308,086
D01BA02	TERBINAFINE						
P	2285G		Tablet 250mg (base) 42	0.25	GM	7,362	720,153
P	2804N		Tablet 250mg (base)	0.25	GM	85,422	8,402,142
P	4011D		Tablet 250mg (base)	0.25	GM	2,003	197,446

D

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
DERMATOLOGICALS							
EMOLLIENTS AND PROTECTIVES							
<i>EMOLLIENTS AND PROTECTIVES</i>							
SILICONE PRODUCTS							
D02AA			DIMETHICONE and GLYCEROL				
	P	4551M	Cream 150mg–20mg per g (15%–2%) 600g	–	–	180	4,758
	P	4556T	Cream 150mg–20mg per g (15%–2%) 75g	–	–	209	2,611
SOFT PARAFFIN AND FAT PRODUCTS							
D02AC			PARAFFIN				
	P	4041Q	Ointment 100g	–	–	344	4,936
CARBAMIDE PRODUCTS							
D02AE01			UREA				
	P	4042R	Cream 100mg per g (10%) 100g	–	–	19,692	256,909
OTHER EMOLLIENTS AND PROTECTIVES							
D02AX			BATH EMOLLIENT				
	P	4122Y	Bath oil 500mL	–	–	5,928	116,406
D02AX			CARMELLOSE SODIUM with PECTIN and GELATIN				
	P	4518T	Paste 167mg–167mg–167mg per g	–	–	162	2,214
D02AX			DEWAXED OIL with LANOLIN				
	P	4107E	Lotion 500mL	–	–	4,631	81,285
<i>PROTECTIVES AGAINST UV-RADIATION</i>							
PROTECTIVES AGAINST UV-RADIATION FOR TOPICAL USE							
D02BA			SUNSCREENS				
	P	4543D	Solid stick 4.5g	–	–	794	9,728
	P	4544E	Cream 100g	–	–	3,384	54,571
	P	4546G	Lotion (non-alcoholic) 125mL	–	–	5,026	84,211

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
DERMATOLOGICALS							
PREPARATIONS FOR TREATMENT OF WOUNDS & ULCERS							
CICATRIZANTS							
OTHER CICATRIZANTS							
D03AX	VITAMIN A						
	A	16106	Ointment 50g	-	-	681	-

D

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
DERMATOLOGICALS							
ANTIPRURITICS, INCL ANTIHIST, ANESTHET, ETC.							
ANTIPRURITICS, INCL ANTIHIST, ANESTHET, ETC.							
ANAESTHETICS FOR TOPICAL USE							
D04AB01	LIGNOCAINE						
	A	12234	Gel 2% 15mL 1	-	-	589	-
	A	12239	Ointment 5% 15g 1	-	-	1,230	-
	A	12240	Ointment 5% 35g 1	-	-	546	-
D04AB01	LIGNOCAINE HYDROCHLORIDE and CARBOXYMETHYLCELLULOSE						
	P	4308R	Mucilage 20mg-25mg per mL (2%-2.5%), 200mL	-	-	2,636	224,434
OTHER ANTIPRURITICS							
D04AX	CROTAMITON						
	A	12933	Cream 10%20g 1	-	-	375	-
D04AX	PINE TAR and TRIETHANOLAMINE						
	P	4408B	Solution 23mg-60mg per mL (2.3%-6%) 500mL	-	-	1,701	39,172

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
DERMATOLOGICALS							
ANTIPSORIATICS							
ANTIPSORIATICS FOR TOPICAL USE							
TARS							
D05AA	TARS						
	P	8864M	Gel 10mg per g (1%) 100mL	–	–	3,192	126,466
OTHER ANTIPSORIATICS FOR TOPICAL USE							
D05AX02	CALCIPOTRIOL						
	P	2080L	Cream 50ug per g (0.005%) 30g 1	–	–	52,737	3,332,209
	P	9163G	Scalp solution 50ug per mL (0.005%) 30mL 1	–	–	12,502	491,449
D05AX52	CALCIPOTRIOL with BETAMETHASONE DIPROPIONATE						
	P	5276Q	Gel 50ug–500ug (base) per g (0.005%–0.05%) 30g	–	–	3,941	214,848
	P	9494Q	Ointment 50ug–500ug (base) per g (0.005%–0.05%), 30g	–	–	129,318	9,694,282
D05AX05	TAZAROTENE						
	A	19647	Cream 0.05% 30g 1	–	–	1,412	–
	A	19648	Cream 0.1% 30g 1	–	–	2,148	–
ANTIPSORIATICS FOR SYSTEMIC USE							
RETINOIDS FOR TREATMENT OF PSORIASIS							
D05BB02	ACITRETIN						
	P	2019G	Capsule 10mg	35.00	MG	11,282	2,314,958
	P	2020H	Capsule 25mg	35.00	MG	8,981	3,527,363

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
DERMATOLOGICALS							
ANTIBIOTICS AND CHEMOTHER. FOR DERMATOLOGICAL USE							
ANTIBIOTICS FOR TOPICAL USE							
OTHER ANTIBIOTICS FOR TOPICAL USE							
D06AX01			FUSIDIC ACID				
	A	13926	Ointment 2% 15mg 1	–	–	24,051	–
D06AX09			MUPIROCI				
	P	4348W	Cream 20mg (as calcium) per g (2%), 15g	–	–	253,339	4,163,457
	P	4350Y	Ointment 20mg per g (2%), 15g	–	–	263,313	4,312,431
CHEMOTHERAPEUTICS FOR TOPICAL USE							
SULFONAMIDES							
D06BA01			SILVER SULFADIAZINE				
	P	9479X	Cream 10mg per g (1%) 50g 1	–	–	72,521	1,537,868
ANTIVIRALS							
D06BB10			IMIQUIMOD				
	A	17990	Cream 5% sachets 6	–	–	21,310	–
	A	20128	Cream sachets 50mg per g (5%) 250mg 12	–	–	2,331	–
	P	2546B	Cream 50mg per g (5%) 250mg Sachet 12	–	–	27,893	4,470,141
	P	4134N	Cream sachets 50mg per g (5%) 250mg single use sachets 12	–	–	1,878	302,070
	P	4559Y	Cream sachets 50mg per g (5%) 250mg 12	–	–	1,494	239,078
D06BB04			PODOPHYLLOTOXIN				
	A	17402	Paint 5mg per mL (0.5%) 3mL (with applicators)	–	–	2,733	–
	P	4390C	Cream 1.5mg per g (0.15%) 5g	–	–	2,652	94,990
	P	4566H	Paint 5mg per mL (0.5%) 3.5mL (with 30 swabs)	–	–	3,780	32,156
OTHER CHEMOTHERAPEUTICS							
D06BX01			METRONIDAZOLE				
	A	17694	Gel 0.75% 30g 1	–	–	47,428	–
	A	20719	Gel 0.75% 40g	–	–	680	–
	A	20986	Gel 0.75% 50g	–	–	11,465	–
	A	20987	Gel 0.75% 30g	–	–	25,562	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH			2011	
				DDD	UNITS	SCRIPTS	COST(\$)
DERMATOLOGICALS							
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS							
CORTICOSTEROIDS, PLAIN							
CORTICOSTEROIDS, WEAK (GROUP I)							
D07AA02 HYDROCORTISONE							
A	10719		Cream 0.5% 30g 1	-	-	3,605	-
A	16625		Cream 1% 30g 1	-	-	14,381	-
A	16626		Cream 0.5% 30g 1	-	-	184	-
A	16627		Cream 1% 30g 1	-	-	4,149	-
A	21047		Cream 10mg per g (1%) 50g	-	-	276	-
P	2881P		Cream 10mg per g (1%) 50g	-	-	228,450	1,968,794
P	2882Q		Topical ointment 10mg per g (1%) 50g	-	-	62,512	541,581
P	2887Y		Cream 10mg per g (1%) 30g	-	-	112,861	1,003,426
P	2888B		Topical ointment 10mg per g (1%) 30g	-	-	34,148	304,254
CORTICOSTEROIDS, MODERATELY POTENT (GROUP II)							
D07AB08 DESONIDE							
A	17202		Lotion 0.05%60mg	-	-	5,139	-
D07AB09 TRIAMCINOLONE ACETONIDE							
P	2117K		Cream 200ug per g (0.02%) 100g	-	-	211,297	3,061,918
P	2118L		Ointment 200ug per g (0.02%) 100g	-	-	46,078	667,624
CORTICOSTEROIDS, POTENT (GROUP III)							
D07AC01 BETAMETHASONE							
A	10627		Ointment 30g 1	-	-	48,255	-
P	1115Q		Cream 500ug per g (0.05%) 15g	-	-	379,653	7,304,902
P	1119X		Ointment 500ug per g (0.05%) 15g	-	-	251,782	6,170,121
A	12881		Cream 30g 1	-	-	32,732	-
A	15271		Cream 500ug per g (0.05%) 50g	-	-	19,848	-
A	15272		Ointment 500ug per g (0.05%) 50g	-	-	16,175	-
A	17217		Scalp lotion 500ug per mL (0.05%) 30mL	-	-	28,271	-
P	2812B		Cream 200ug per g (0.02%) 100g	-	-	492,243	12,215,571
P	2813C		Cream 500ug per g (0.05%) 15g	-	-	75,359	659,657
P	2815E		Ointment 500ug per g (0.05%) 15g	-	-	29,292	260,759
P	2820K		Ointment 200ug per g (0.02%) 100g	-	-	106,463	2,732,610
P	4131K		Cream 1mg per g (0.1%) 30g	-	-	16,920	437,739
P	4132L		Ointment 1mg per g (0.1%) 30g	-	-	8,795	214,588
D07AC14 METHYLPREDNISOLONE ACEPONATE							
P	8054X		Cream 1mg per g (0.1%) 15g	-	-	210,528	4,337,303
P	8055Y		Ointment 1mg per g (0.1%) 15g	-	-	118,849	2,697,673
P	8128T		Ointment 1mg per g (0.1%) 15g	-	-	217,455	5,588,089
P	8618N		Lotion 1mg per g (0.1%) 20g	-	-	11,492	247,666
D07AC13 MOMETASONE							
P	1913Q		Cream 1mg per g (0.1%) 15g	-	-	510,913	9,865,242
P	1915T		Ointment 1mg per g (0.1%) 15g	-	-	287,132	7,199,381
A	20299		Cream 1mg per g (0.1%) 30g	-	-	4,096	-
A	20300		Ointment 1mg per g (0.1%) 30g	-	-	1,635	-
P	4342M		Cream 1mg per g (0.1%) 50g	-	-	37,757	1,368,728
P	4343N		Ointment 1mg per g (0.1%) 50g	-	-	25,844	1,077,770
P	8043H		Lotion 1mg per g (0.1% w/w) 30mL	-	-	288,471	7,539,239

D

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
DERMATOLOGICALS							
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS							
CORTICOSTEROIDS, COMB WITH ANTISEPTICS							
CORTICOSTEROIDS, WEAK, COMB WITH ANTISEPTICS							
D07BA04			HYDROCORTISONE and CLIOQUINOL				
	A	16100	Cream 1%–1% 30gm	–	–	7,023	–
	A	17035	Cream 1%–1% 60gm	–	–	4,054	–
CORTICOSTEROIDS, COMB WITH ANTIBIOTICS							
CORTICOSTEROIDS, WEAK, COMB WITH ANTIBIOTICS							
D07CA01			HYDROCORTISONE and CLOTRIMAZOLE				
	A	13540	Cream 1%30g 1	–	–	68,896	–
CORTICOSTEROIDS, MODERATELY POTENT, COMB. WITH ANTIBIOTICS							
D07CB01			TRIAMCINOLONE ACETONIDE with NEOMYCIN with GRAMICIDIN with NYSTATIN				
	A	11072	Ointment 30g 1	–	–	21,592	–
	P	4482X	Ointment 1mg–2.5mg (base)–250ug–100,000 units per g 15g	–	–	102,155	2,019,650
CORTICOSTEROIDS, OTHER COMBINATIONS							
CORTICOSTEROIDS, WEAK, OTHER COMBINATIONS							
D07XA01			HYDROCORTISONE with CLOTRIMAZOLE				
	A	16834	Cream 1% 50g 1	–	–	76,447	–
CORTICOSTEROIDS, POTENT, OTHER COMBINATIONS							
D07XC01			BETAMETHOSONE/CALCIPOTRIOL				
	A	18741	Ointment 500ug per g 15g	–	–	251	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
DERMATOLOGICALS							
ANTISEPTICS AND DISINFECTANTS							
ANTISEPTICS AND DISINFECTANTS							
PHENOL AND DERIVATIVES							
D08AE04			TRICLOSAN with ENTSUFON				
	A	11586	Lotion 200mL 1	-	-	199	-
	A	11587	Lotion 500mL 1	-	-	378	-
IODINE PRODUCTS							
D08AG02			POVIDONE IODINE				
	A	10226	Ointment 25g 1	-	-	897	-
	A	10230	Solution 15mL 1	-	-	509	-
	P	4411E	Solution 100mg per mL (10%) 100mL	-	-	3,292	72,976

D

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
DERMATOLOGICALS							
MEDICATED DRESSINGS							
<i>MEDICATED DRESSINGS</i>							
OINTMENT DRESSINGS WITH ANTIINFECTIVES							
D09AA		CADEXOMER IODINE					
	P	4932N	Tube 10g 4	-	-	798	82,753
	P	4933P	Tube 20g 2	-	-	298	31,018
ZINC BANDAGES							
D09AB01		BANDAGE ZINC PASTE					
	P	4750B	Bandage 7.5cm x 6m	-	-	667	60,563
SOFT PARAFFIN DRESSINGS							
D09AX		SOFT PARAFFIN DRESSING					
	P	4759L	Sterile sachets 10cm x 10cm 10	-	-	1,476	34,740
	P	4845B	Sterile sachets 10cm x 10cm 10	-	-	1,020	27,130

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
DERMATOLOGICALS							
ANTI-ACNE PREPARATIONS							
ANTI-ACNE PREPARATIONS FOR TOPICAL USE							
RETINOIDS FOR TOPICAL USE IN ACNE							
D10AD03 ADAPALENE							
	A	15680	Gel 0.1% 30g 1	–	–	27,833	–
	A	16348	Cream 0.1% 30g 1	–	–	27,508	–
D10AD53 ADAPALENE COMBINATIONS							
	P	8954G	Gel 1mg–25mg per g, (0.1%–2.5%) 30g 1	–	–	40,668	1,433,170
	P	8955H	Gel 1mg–25mg per g, (0.1%–2.5%) 30g 1	–	–	38,174	1,419,588
D10AD04 ISOTRETINOIN							
	A	14786	Gel 0.05% 30g	–	–	5,915	–
D10AD01 TRETINOIN							
	A	11780	Cream 0.05%20g 1	–	–	693	–
	A	14354	Cream .025% 25g 1	–	–	5,639	–
	A	14355	Cream 0.05% 25g 1	–	–	8,175	–
	A	14356	Cream 0.1% 25g 1	–	–	3,788	–
	A	14512	Cream 0.05% 50g 1	–	–	54,557	–
	A	17039	Gel 0.01%30g 1	–	–	135	–
	A	20524	Cream 0.05%10g 1	–	–	453	–
PEROXIDES							
D10AE51 CLINDAMYCIN with BENZYLPEROXIDE							
	A	19649	Gel 1%–5% 25g 1	–	–	95,304	–
ANTIINFECTIVES FOR TREATMENT OF ACNE							
D10AF01 CLINDAMYCIN							
	A	13816	Topical solution 1% 100mL 1	–	–	22,769	–
	A	16422	Topical solution 1% 50mL 1	–	–	17,489	–
	A	16520	Lotion 10mg per mL 60mL	–	–	3,738	–
	A	19646	Gel 1% 30g 1	–	–	3,230	–
D10AF02 ERYTHROMYCIN							
	A	15129	Gel 2% 30g 1	–	–	70,191	–
ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE							
RETINOIDS FOR TREATMENT OF ACNE							
D10BA01 ISOTRETINOIN							
	P	2549E	Capsule 40mg 30	30.00	MG	1,803	206,804
	P	2591J	Capsule 10mg	30.00	MG	13,044	1,031,710
	P	2592K	Capsule 20mg	30.00	MG	157,056	18,867,964

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
DERMATOLOGICALS							
OTHER DERMATOLOGICAL PREPARATIONS							
OTHER DERMATOLOGICAL PREPARATIONS							
ANTIHDROTICS							
D11AA	DIPHEMANIL METHYLSULPHATE						
	P 4191N		Dusting powder 20mg per g (2%) 50g	-	-	3,441	64,421
MEDICATED SHAMPOOS							
D11AC30	OTHERS						
	P 4405W		Scalp cleanser 3mg-3mg-1mg-3mg-10mg per mL	-	-	770	16,173
D11AC30	SALICYLIC ACID with COAL TAR SOLUTION						
	P 4560B		Scalp cleanser 20mg-50mg per mL (2%-5%) 200mL	-	-	2,912	60,970
D11AC30	SALICYLIC ACID, COAL TAR SOLUTION, PINE TAR and UNDECYLENAMIDE						
	P 4447C		Scalp cleanser 20mg-10mg-10mg-10mg per mL	-	-	1,131	21,316
D11AC03	SELENIUM SULFIDE						
	P 4452H		Shampoo 25mg per mL (2.5%) 125mL	-	-	1,077	15,971
WART AND ANTI-CORN PREPARATIONS							
D11AF	LACTIC ACID with SALICYLIC ACID						
	P 4386W		Liquid 167mg per g (16.7%-16.7%),15mL 1	-	-	401	5,837
D11AF	SALICYLIC ACID						
	P 4389B		Gel 270mg per g (27%), 15g	-	-	315	5,352
AGENTS FOR DERMATITIS, EXCL CORTICOSTEROIDS							
D11AH02	PIMECROLIMUS						
	A 18308		Cream 1% 30g, 1	-	-	5,078	-
	P 8802G		Cream 10mg per g (1%) 15g	-	-	38,851	1,317,138
OTHER DERMATOLOGICALS							
D11AX	ALLANTOIN, GLYCEROL and ICHTHAMMOL						
	P 4281H		Cream 5mg-10mg-10mg per g (0.5%-1%-1%) 50g	-	-	624	13,281
D11AX	CATIONIC CONDITIONER with PANTHENOL						
	P 4510J		Cream 200g	-	-	343	4,997
D11AX18	DICLOFENAC						
	P 4046Y		Gel 30mg per g (3%), 25g	-	-	17,279	1,012,032
D11AX16	EFLORNITHINE						
	A 19662		Cream 11.5%, 30g, 1	-	-	4,291	-
D11AX	SKIN CLEANSER						
	P 4549K		Lotion 500mL	-	-	12,080	253,855
D11AX	ZINC OXIDE, STARCH and CHLORPHENESIN						
	P 4497Q		Dusting powder 100g	-	-	659	8,644

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENITO URINARY SYSTEM AND SEX HORMONES							
GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS							
ANTIINFECTIVES/ANTISEPT.,EXCL. COMB. WITH CORTICOSTEROIDS							
ANTIBIOTICS							
G01AA10			CLINDAMYCIN				
	A	15081	Vaginal cream 2% 40gm	0.10	GM	22,102	–
G01AA01			NYSTATIN				
	P	4013F	Vaginal cream 100,000 units per dose, 15 doses, 75g	100.00	TE	6,805	93,827
ORGANIC ACIDS							
G01AD02			RICINOLEIC ACID, ACETIC ACID and HYDROXYQUINOLINE SULPHATE				
	P	4434J	Vaginal jelly 7mg–9.4mg–250ug per g	–	–	311	10,257
IMIDAZOLE DERIVATIVES							
G01AF02			CLOTRIMAZOLE				
	A	15913	Pessary 500mg	0.10	GM	2,364	–
	A	19067	Vaginal cream 50mg per 5g (1%) 35g	0.10	GM	394	–
	A	20605	Pessaries 100mg 6	0.10	GM	4,622	–
	A	20606	Pessary 500mg	0.10	GM	3,022	–
	A	20607	Vaginal cream 50mg per 5g (1%) 35g	0.10	GM	8,137	–
	A	20608	Vaginal cream 100mg per 5g (2%) 20g	0.10	GM	7,249	–
	P	4016J	Vaginal cream 50mg per 5g (1%) 35g	0.10	GM	658	9,932
	P	4017K	Vaginal cream 100mg per 5g (2%) 20g	0.10	GM	404	6,164
G01AF20			CLOTRIMAZOLE and FLUCONAZOLE				
	A	20144	Vaginal Cream 1% 10g and capsule 150mg 1	–	–	1,491	–
G01AF05			ECONAZOLE NITRATE				
	A	12661	Foam-sol 1%10g 3	0.10	GM	1,625	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENITO URINARY SYSTEM AND SEX HORMONES							
OTHER GYNAECOLOGICALS							
CONTRACEPTIVES FOR TOPICAL USE							
INTRAUTERINE CONTRACEPTIVES							
G02BA03	LEVONORGESTREL						
	P	8633J	Intrauterine drug 52mg releasing 20ug per 24 hours	-	-	89,088	21,869,307
G02BA02	POLYETHYLENE COPPER						
	A	13296	Intrauterine device 1	-	-	1,804	-
OTHER GYNAECOLOGICALS							
PROLACTIN INHIBITORS							
G02CB01	BROMOCRIPTINE MESYLATE						
	P	1444B	Tablet 2.5mg	5.00	MG	3,765	73,971
G02CB03	CABERGOLINE						
	P	8114C	Tablet 0.5mg	0.50	MG	32,903	2,512,297
	P	8115D	Tablet 0.5mg	0.50	MG	2,148	69,986
G02CB04	QUINAGOLIDE						
	P	8822H	Tablet 75ug (base)	75.00	UG	846	57,928

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
GENITO URINARY SYSTEM AND SEX HORMONES							
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM							
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE							
PROGESTOGENS AND ESTROGENS, FIXED COMBINATIONS							
G03AA09			DESOGESTREL with ETHINYLOESTRADIOL				
	A	14249	Tablet 28 1 150 ug/30ug	-	-	60,128	-
G03AA			DIENOGEST with ETHINYLOESTRADIOL				
	A	19955	Tablet 2mg-30ug + 7 inert 28	-	-	2,965	-
	A	19956	Tablet 2mg-30ug + 7 inert 28x3	-	-	25,183	-
	A	21042	Tablet 2mg-30ug + 7 inert 28	-	-	216	-
	A	21043	Tablet 2mg-30ug + 7 inert 28x3	-	-	5,145	-
G03AA			ETHINYLOESTRADIOL and ETONOGESTREL				
	A	19917	Ethinylloest 11.7mg & Etonog 2.7mg vaginal ring 1	-	-	12,395	-
	A	19918	Ethinylloest 11.7mg & Etonog 2.7mg vaginal ring 3	-	-	34,481	-
G03AA12			ETHINYLOESTRADIOL with DROSPIRENONE				
	A	17645	Tablet 3mg-30ug 21 + 7 inert	-	-	101,506	-
	A	17646	Tablet 3mg-30ug 21 + 7 inert 28x3	-	-	463,617	-
	A	20451	Tablet 3mg-20ug 24+4	-	-	53,594	-
	A	20452	Tablet 3mg-20ug 24+4 28x3	-	-	256,778	-
G03AA10			ETHINYLOESTRADIOL with GESTODENE				
	A	15082	Tablets 75ug/30ug, 21 + 7	-	-	123	-
G03AA07			LEVONORGESTREL with ETHINYLOESTRADIOL				
	P	1394J	Tablets 150ug-30ug 21 + 7 inert 28	-	-	1,560,035	26,489,624
	P	1456P	Tablets 125ug-50ug 21 + 7 inert	-	-	84,499	1,435,511
	A	16212	Tablets 100ug-50ug 28	-	-	128,351	-
	A	16217	Tablets 100ug-20ug + 7 inert 28	-	-	15,837	-
	A	16970	Tablets 100ug-20ug 21 + 7 inert	-	-	111,383	-
	A	17708	Tablets 100ug 20ug + 7 inert 28x3	-	-	9,880	-
G03AA05			NORETHISTERONE with ETHINYLOESTRADIOL				
	P	2772X	Tablets 500ug-35ug 21	-	-	137	2,043
	P	2773Y	Tablets 1mg-35ug, 21	-	-	233	2,892
	P	2774B	Tablets 500ug-35ug 21 + 7 inert 28	-	-	114,210	1,877,945
	P	2775C	Pack containing 21 tablets 1mg-35ug	-	-	90,679	1,491,579
G03AA05			NORETHISTERONE with MESTRANOL				
	P	3176E	Tablets 1mg-50ug 21	-	-	1,368	22,562
	P	3179H	Tablets 1mg-50ug 21 + 7 inert 28	-	-	14,175	233,296
G03AA12			OESTRADIOL with DROSPIRENONE				
	A	19550	Tablet 1mg-2mg 28	-	-	43,578	-
PROGESTOGENS AND ESTROGENS, SEQUENTIAL PREPARATIONS							
G03AB06			ETHINYLOESTRADIOL with GESTODENE				
	A	18555	Tablet 30ug/75ug 28x3	-	-	19,183	-
G03AB03			LEVONORGESTREL with ETHINYLOESTRADIOL				
	P	1392G	Pack containing 6 tablets 50ug	-	-	360,338	6,124,859
G03AB04			NORETHISTERONE with ETHINYLOESTRADIOL				
	A	21514	Norethisterone 0.5mg and ethinylloestradiol 35 mcg 21 active tablets	-	-	171	-
	P	2776D	Tablets 500/35ug 12,1000/35ug 9 + 7 inert	-	-	4,003	65,942

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENITO URINARY SYSTEM AND SEX HORMONES							
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM							
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE							
PROGESTOGENS							
G03AC08	ETONOGESTREL						
	P	8487Q	Subcutaneous implant 68mg	0.07	MG	87,744	18,920,108
G03AC06	MEDROXYPROGESTERONE						
	P	3118D	Injection 150mg in 1mL	1.67	MG	220,018	4,700,987
G03AC01	NORETHISTERONE						
	P	1967M	Tablets 350ug 28	--	--	36,991	607,970
EMERGENCY CONTRACEPTIVES							
G03AD01	LEVONORGESTREL						
	A	19549	Tablet 0.75mg 2	--	--	14,649	--
	A	20453	Tablet 1.5mg 1	--	--	2,724	--
	A	20617	Tablet 1.5mg 1	--	--	16,609	--
	A	21159	Tablet 1.5mg 1	--	--	8,175	--
	P	2913H	Tablets 30ug 28	0.03	MG	124,534	2,149,461
ANDROGENS							
3-OXOANDROSTEN (4) DERIVATIVES							
G03BA03	TESTOSTERONE						
	A	16153	Cream 2% 50g	--	--	147	--
	A	17178	Cream 5% 50g	--	--	133	--
	P	2101N	Injection 250mg	18.00	MG	34,392	1,166,156
	P	2114G	Injection 250mg in 1mL	18.00	MG	17,631	598,786
	P	2115H	Capsule 40mg	120.00	MG	29,683	1,520,481
	A	21420	Injection 100mg in 1mL	18.00	MG	431	--
	P	8098F	Subcutaneous implant 100mg	18.00	MG	2,457	412,963
	P	8099G	Subcutaneous implant 200mg	18.00	MG	2,089	535,722
	P	8460G	Transdermal patch 12.2mg (2.5mg per 24 hr) 60	3.00	MG	2,841	285,083
	P	8619P	Transdermal patch 24.3mg (5mg per 24 hr) 30	3.00	MG	7,463	771,479
	P	8830R	Transdermal gel 50mg in 5mg sachet 30	50.00	MG	63,758	7,011,327
	P	9004X	Injection 1000 mg in 4mL	18.00	MG	55,195	8,148,459
5-ANDROSTANON (3) DERIVATIVES							
G03BB01	MESTEROLONE						
	A	11642	Tablet 25mg 50	50.00	MG	722	--

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENITO URINARY SYSTEM AND SEX HORMONES							
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM							
ESTROGENS							
NATURAL AND SEMISYNTHETIC ESTROGENS, PLAIN							
G03CA03 OESTRADIOL							
A	16209		Tablet 1mg 28	2.00	MG	11,210	–
A	16210		Tablet 2mg 28	2.00	MG	11,571	–
P	1742Q		Vaginal tablets 25ug	0.03	MG	571,857	13,280,605
P	1743R		Transdermal patches 2mg 8	0.05	MG	55,911	961,546
P	1745W		Transdermal patches 8mg 8	0.05	MG	17,220	331,232
A	21759		Implant 50mg 1	1.00	MG	117	–
A	21760		Implant 100mg 1	1.00	MG	632	–
P	8125P		Transdermal patches 3.9mg (releasing 50ug/24hrs)	0.05	MG	41,923	716,562
P	8126Q		Transdermal patches 7.8mg (releasing 100ug/24hrs)	0.05	MG	12,326	241,166
P	8140K		Transdermal patches 1.5mg (releasing 50ug/24hrs)	0.05	MG	36,877	630,560
P	8286D		Transdermal gel 1mg in 1g sachet 28	1.00	MG	71,454	1,270,506
P	8311K		Transdermal pat 750ug (rel 25ug/24 hrs)	0.05	MG	14,060	240,271
P	8312L		Transdermal patch 3mg (rel 100ug/24 hrs)	0.05	MG	7,012	137,278
P	8485N		Transdermal patches 2mg (releasing 25ug/24hrs)	0.05	MG	21,640	369,238
P	8486P		Transdermal patches 5.7mg (releasing 75ug/24hrs)	0.05	MG	10,421	199,853
P	8761D		Transdermal patches 3.9mg (releasing 25ug/24hrs)	0.05	MG	20,352	347,038
P	8762E		Transdermal patches 5.85mg (releasing 37.5ug/24hrs)	0.05	MG	25,435	433,984
P	8763F		Transdermal patches 7.8mg (releasing 500ug/24hrs)	0.05	MG	71,470	1,220,443
P	8764G		Transdermal patches 1.17mg (releasing 75ug/24hrs)	0.05	MG	25,905	495,742
P	8765H		Transdermal patches 1.56mg (releasing 100ug/24hrs)	0.05	MG	25,944	513,256
G03CA03 OESTRADIOL VALERATE							
P	1663M		Tablets 1mg 28	2.00	MG	96,040	1,120,074
P	1664N		Tablets 2mg 28	2.00	MG	99,746	1,407,039
P	4365R		Implant 50mg 1	–	–	310	15,040
P	4366T		Implant 100mg 1	–	–	1,602	194,757
P	8274L		Tablets 2mg 56	2.00	MG	12,082	164,847
G03CA04 OESTRIOL							
P	1771F		Pessaries 500ug 15	0.20	MG	18,366	390,088
P	1781R		Vaginal cream 1mg per g (0.1%) 15g	0.20	MG	259,641	4,969,938
A	19732		Tablets 1mg 30	2.00	MG	2,697	–
G03CA57 OESTROGENS CONJUGATED							
A	20689		Tablets 300ug 28	0.63	MG	123,117	–
A	20690		Tablets 625ug 28	0.63	MG	193,374	–
OTHER ESTROGENS							
G03CX01 TIBOLONE							
A	16835		Tablet 2.5mg 28	2.50	MG	105,645	–
A	20242		Tablet 2.5mg 28	2.50	MG	144,631	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENITO URINARY SYSTEM AND SEX HORMONES							
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM							
PROGESTOGENS							
PREGNEN (4) DERIVATIVES							
G03DA02			MEDROXYPROGESTERONE				
	A	14247	Tablet 2.5mg	5.00	MG	2,443	–
	P	2321E	Tablet 10mg	5.00	MG	33,027	528,928
	P	2323G	Tablet 5mg 56	5.00	MG	77,600	1,139,770
	P	2722G	Tablet 10mg	5.00	MG	16,499	514,321
G03DA04			PROGESTERONE				
	A	18750	Pessaries 200mg 15	90.00	MG	3,167	–
	P	6366C	Gel Vaginal (prolonged release) 90mg single dose	90.00	MG	332	–
PREGNADIEN DERIVATIVES							
G03DB01			DYDROGESTERONE				
	P	1350C	Tablet 10mg	10.00	MG	880	13,289
ESTREN DERIVATIVES							
PROGESTOGENS							
G03DC02			NORETHISTERONE				
	P	2993M	Tablet 5mg	5.00	MG	122,856	4,601,305
PROGESTOGENS AND ESTROGENS IN COMBINATION							
PROGESTOGENS AND ESTROGENS, FIXED COMBINATIONS							
G03FA12			MEDROXYPROGESTERONE and ESTROGEN				
	A	20691	Tablet 625ug 2.5mg 28	–	–	72,403	–
	A	20692	Tablet 625ug 5mg 28	–	–	87,737	–
G03FA01			NORETHISTERONE and ESTROGEN				
	A	20742	Tablets 1mg–500ug, 28	–	–	117,141	–
	A	20743	Pack containing 28 tablets 2mg–1mg	–	–	74,358	–
PROGESTOGENS AND ESTROGENS, SEQUENTIAL PREPARATIONS							
G03FB08			DYDROGESTERONE and ESTROGEN				
	P	8244X	Tabs estradiol 2mg+est/dydro 2mg/10mg, 28mg(14/14)	–	–	16,058	301,477
G03FB06			MEDROXYPROGESTERONE and ESTROGEN				
	A	19194	Pack 14 tablets oestrogens 625ug	–	–	242	–
G03FB05			OESTRADIOL with NORETHISTERONE ACETATE				
	A	20741	Tablets sequential pack 2mg–1mg	–	–	52,039	–
	P	8425K	Transdermal patch 4 4.33mg, 4 620ug/2.7mg	–	–	15,294	292,633
	P	8426L	Transdermal patch 4 4.33mg, 4 510ug/4.8mg	–	–	9,951	191,137
	P	8427M	Transdermal patch 620ug/2.7mg, 8 50ug/day	–	–	68,297	1,304,882
	P	8428N	Transdermal patch 510ug/4.8mg, 8	–	–	27,779	530,985

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENITO URINARY SYSTEM AND SEX HORMONES							
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM							
GONADOTROPHINS AND OTHER OVULATION STIMULANTS							
GONADOTROPHINS							
G03GA05 FOLLITROPIN ALFA							
P	8713N		Injection 300iu in 0.5mL multi-dose cartridge	75.00	IE	438	297,229
P	8714P		Injection 450iu in 0.75mL multi-dose cartridge	75.00	IE	568	424,396
P	8715Q		Injection 900iu in 1.5mL multi-dose cartridge	75.00	IE	1,673	1,713,871
G03GA06 FOLLITROPIN BETA							
P	8565T		Soln for injection 300iu in 0.36mL mult-dose cart	75.00	IE	1,336	675,034
P	8566W		Soln for injection 600iu in 0.75mL mult-dose cart	75.00	IE	1,743	1,219,683
P	8871X		Soln for injection 900iu in 1.08mL mult-dose cart	75.00	IE	1,269	1,172,176
G03GA01 HUMAN CHORIONIC GONADOTROPHIN							
P	1581F		Ampoules pdr for inj. 1500units and 1mL solvent 3/3	250.00	IE	3,423	281,302
P	6181H		Powder for inj. 5000units with solvent	250.00	IE	7,988	–
OVULATION STIMULANTS, SYNTHETIC							
G03GB02 CLOMIPHENE CITRATE							
P	1211R		Tablet 50mg	9.00	MG	41,287	1,432,531
ANTIANDROGENS							
ANTIANDROGENS, PLAIN PREPARATIONS							
G03HA01 CYPROTERONE ACETATE							
P	1269T		Tablet 50mg	0.10	GM	21,000	1,205,473
P	1270W		Tablet 50mg	0.10	GM	13,087	2,434,548
P	8019C		Tablet 100mg	0.10	GM	30,394	5,515,440
ANTIANDROGENS AND ESTROGENS							
G03HB01 CYPROTERONE and ETHINYLOESTRADIOL							
A	20836		Tablet 35ug/2mg 28 3	–	–	206,249	–
G03HB01 CYPROTERONE and OESTROGEN							
A	14126		Tablet 35ug/2mg 28 1	–	–	7,363	–
A	14127		Tablet 35ug/2mg 28 3	–	–	45,675	–
A	15418		Tablet 35ug/2mg 28 1	–	–	6,842	–
A	15419		Tablet 35ug/2mg 28 3	–	–	151,095	–
A	17090		Tablet 35ug/2mg 28 1	–	–	3,912	–
A	17091		Tablet 35ug/2mg 28 3	–	–	67,874	–
A	18070		Tablet 35ug/2mg 28 1	–	–	7,329	–
A	18071		Tablet 35ug/2mg 28 3	–	–	142,842	–
OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM							
ANTIGONADOTROPINS AND SIMILAR AGENTS							
G03XA01 DANAZOL							
P	1285P		Capsule 100mg	0.60	GM	683	40,147
P	1287R		Capsule 200mg	0.60	GM	1,325	116,355
G03XA02 GESTRINONE							
P	8015W		Capsule 2.5mg	0.70	MG	182	14,857
ANTIGONADOTROPINS AND SIMILAR AGENTS							
G03XC01 RALOXIFENE							
P	8363E		Tablet 60mg 28	60.00	MG	224,491	12,981,751

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENITO URINARY SYSTEM AND SEX HORMONES							
UROLOGICALS							
<i>OTHER UROLOGICALS, INCL. ANTISPASMODICS</i>							
URINARY ANTISPASMODICS							
G04BD10			DARIFENACIN				
	A	19785	Tablet modified release 7.5 mg (H B r salt) 28	7.50	MG	3,930	–
	A	19786	Tablet modified release 15mg (H B r salt) 28	7.50	MG	4,567	–
G04BD04			OXYBUTYNIN				
	P	8039D	Tablet 5mg	15.00	MG	255,511	3,920,696
	P	9454N	Transdermal patches 36mg (releasing approx. 3.9mg per 24 hrs) 8, 1	3.90	MG	74,079	2,615,181
G04BD08			SOLIFENACIN				
	A	19781	Tablet 5mg 30	5.00	MG	86,792	–
	A	19782	Tablet 10mg 30	5.00	MG	50,884	–
G04BD07			TOLTERODINE				
	A	18891	Tablet 1mg 56	4.00	MG	2,153	–
	A	18892	Tablet 2mg 56	4.00	MG	8,828	–
DRUGS USED IN ERECTILE DYSFUNCTION							
G04BE01			ALPROSTADIL				
	P	4579B	Intracavernosal injection 10ug in single syringe	0.02	MG	8,952	736,074
	P	4580C	Intracavernosal injection 20 ug in single syringe	0.02	MG	16,761	1,747,377
G04BE03			SILDENAFIL				
	A	20993	Tablet 100mg 12	50.00	MG	4,000	–
	P	4584G	Tablet 25mg 4	50.00	MG	4,044	712,492
	P	4585H	Tablet 50mg 4	50.00	MG	39,292	3,272,608
	P	4586J	Tablet 100mg 4	50.00	MG	323,114	26,162,306
	P	9605M	Tablet 20mg 90	50.00	MG	1,173	1,109,415
G04BE08			TADALAFIL				
	A	18863	Tablet 20mg 8	10.00	MG	65,963	–
	A	20367	Tablet 5mg 28	10.00	MG	29,623	–
	P	4596X	Tablet 10mg 4	10.00	MG	17,019	1,355,515
	P	4597Y	Tablet 20mg 4	10.00	MG	231,454	19,261,955
G04BE09			WARDENAFIL				
	A	17959	Tablet 5mg 4	10.00	MG	257	–
	A	17961	Tablet 10mg 4	10.00	MG	2,304	–
	A	17962	Tablet 20mg 2	10.00	MG	114	–
	A	17963	Tablet 20mg 2	10.00	MG	35,381	–
	A	20239	Tablet 20mg 8	10.00	MG	12,256	–
OTHER UROLOGICALS							
G04BX			SODIUM BICARBONATE				
	P	9470K	Capsule 840mg 100	–	–	45,743	650,142
G04BX			SODIUM CITRO-TARTRATE				
	P	4049D	Sachets cont. oral effervescent powder 4g 28	–	–	26,070	358,811

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENITO URINARY SYSTEM AND SEX HORMONES							
UROLOGICALS							
<i>DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY</i>							
ALPHA-ADRENORECEPTOR ANTAGONISTS							
G04CA01 ALFUZOSIN							
	A	20995	Tablet 10mg 30	7.50	MG	5,172	–
	A	20996	Tablet 10mg 60	7.50	MG	489	–
G04CA02 TAMSULOSIN							
	P	4070F	Tablet 400ug (prolonged release) 30	0.40	MG	328,518	20,815,466
G04CA52 TAMSULOSIN and DUTASTERIDE							
	A	21496	Capsule containing dutasteride 500ug with tamsulosin hydrochloride 400ug 30	–	–	122	–
	P	5490Y	Capsule containing dutasteride 500ug with tamsulosin hydrochloride 400ug 30	–	–	35,544	1,241,396
G04CA03 TERAZOSIN							
	P	4397K	Tablet 2mg	5.00	MG	2,115	99,676
	P	4398L	Tablet 5mg	5.00	MG	1,633	105,120
	P	4399M	Tablet 10mg	5.00	MG	1,286	110,559
TESTOSTERONE-5-ALPHA REDUCTASE INHIBITORS							
G04CB02 DUTASTERIDE							
	P	5468T	Capsule 500ug 30	0.50	MG	42,910	1,258,078
G04CB01 FINASTERIDE							
	A	16113	Tablet 1mg 28	–	–	64,578	–
	A	20715	Tablet 5mg 30	5.00	MG	6,285	–
	A	21366	Tablet 5mg 30	5.00	MG	197	–
	A	21407	Tablet 5mg 30	5.00	MG	416	–
	P	4233T	Tablet 5mg	5.00	MG	59,899	6,529,916

				2011			
ATC	ITEM TYPE	CODE	FORM AND STRENGTH	DDD	UNITS	SCRIPTS	COST(\$)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES							
PITUITARY, HYPOTHALAMIC HORMONES AND ANALOGUES							
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES							
ACTH							
H01AA02			TETRACOSACTRIN				
	P	2832C	Injection 1mg in 1mL	0.25	MG	112	7,498
THYROTROPHIN							
H01AB01			THYROTROPIN				
	P	2700D	Powder for injection 0.9mg 2	–	–	661	1,271,031
SOMATROPIN AND ANALOGUES							
H01AC01			SOMATROPIN				
	A	20165	Injection 4mg (diluent provided) 1	2.00	IE	134	–
POSTERIOR PITUITARY LOBE HORMONES							
VASOPRESSIN AND ANALOGUES							
H01BA02			DESMOPRESSIN				
	P	2129C	Intranasal solution 100ug per mL 2.5mL	25.00	UG	3,199	543,093
	P	8662X	Tablet 200mg 90	400.00	UG	7,822	1,601,689
	P	8663Y	Tablet 200mg 30	400.00	UG	15,278	1,152,212
	P	8711L	Nasal spray (pump pack) 10ug per mL 6mL	25.00	UG	15,366	2,485,888
	P	8712M	Nasal spray (pump pack) 10ug per mL 6mL	25.00	UG	21,302	1,816,833
	P	8975J	Wafer 240ug (base) 30	240.00	UG	571	66,202
	P	9398P	Wafer 120ug 30	240.00	UG	10,626	889,043
HYPOTHALAMIC HORMONES							
GONADOTROPHIN-RELEASING HORMONES							
H01CA02			NAFARELIN				
	P	2962X	Nasal spray (pump pack) 200ug base per dose 60	0.40	MG	3,165	308,829
SOMATOSTATIN AND ANALOGUES							
H01CB03			LANREOTIDE				
	P	6423C	Injection 60mg (base) single dose syringe 2	3.00	MG	802	1,221,338
	P	6424D	Injection 90mg (base) single dose syringe 2	3.00	MG	576	1,218,208
	P	6425E	Injection 120mg (base) single dose syringe 2	3.00	MG	817	2,111,430
H01CB02			OCTREOTIDE				
	P	6228T	Injection 100ug (as acetate) in 1mL 90	0.70	MG	246	235,323
	P	6426F	Inj (mod release) 10mg (as acetate) vial + diluent syringe	0.70	MG	400	554,558
	P	6427G	Inj (mod release) 20mg (as acetate) vial + diluent syringe	0.70	MG	1,135	2,399,157
	P	6428H	Inj (mod release) 30mg (as acetate) vial + diluent syringe	0.70	MG	1,612	4,038,418

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES							
CORTICOSTEROIDS FOR SYSTEMIC USE							
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN							
MINERALOCORTICIDS							
H02AA02			FLUDROCORTISONE ACETATE				
	P	1433K	Tablet 100ug	0.10	MG	30,521	1,359,152
GLUCOCORTICIDS							
H02AB01			BETAMETHASONE				
	P	2694T	Injection 3mg–3.9mg (equiv.to 5.7 mg) in 1ml	1.50	MG	39,605	988,378
H02AB16			BUDESONIDE				
	A	16038	Capsule 3mg 90	9.00	MG	3,115	–
H02AB10			CORTISONE				
	P	1246N	Tablet 5mg	37.50	MG	10,943	242,845
	P	1247P	Tablet 25mg	37.50	MG	32,794	584,197
H02AB02			DEXAMETHASONE				
	P	1291Y	Injection 8mg in 2mL	1.50	MG	14,801	353,934
	P	1292B	Tablet 500ug	1.50	MG	28,987	258,390
	P	2507Y	Tablet 4mg	1.50	MG	96,867	1,181,551
	P	2509C	Injection 4mg in 1mL	1.50	MG	12,736	224,485
	P	3472R	Injection 4mg in 1mL	1.50	MG	8,599	154,139
H02AB09			HYDROCORTISONE				
	P	1499X	Tablet 4mg	30.00	MG	28,160	394,362
	P	1500Y	Tablet 20mg	30.00	MG	20,275	290,224
	P	1501B	Injection equivalent to 100mg with 2mL solvent	30.00	MG	3,336	54,835
	P	1510L	Injection equivalent to 100mg with 2mL solvent	30.00	MG	8,177	278,177
	P	1511M	Injection equivalent to 250mg with 2mL solvent	30.00	MG	522	28,097
	P	3096Y	Injection equivalent to 250mg with 2mL solvent	30.00	MG	556	10,192
	P	3470P	Injection equivalent to 100mg with 2mL solvent	30.00	MG	9,719	152,171
	P	3471Q	Injection equivalent to 250mg with 2mL solvent	30.00	MG	8,169	127,054
H02AB04			METHYLPREDNISOLONE				
	P	1928L	Injection 40mg in 1mL	20.00	MG	52,609	1,193,356
	P	2981X	Injection equiv to 40mg methylprednisolone	20.00	MG	1,495	47,952
	P	5264C	Powder for injection 1g (as sodium succinate) 1	20.00	MG	247	20,413
	P	8834Y	Injection equiv to 1g methylprednisolone with diluent	20.00	MG	4,436	542,994
H02AB06			PREDNISOLONE				
	A	17393	Tablet 5mg 30	10.00	MG	117	–
	P	1916W	Tablet 25mg	10.00	MG	694,737	6,931,252
	P	1917X	Tablet 5mg	10.00	MG	714,944	6,026,206
	P	3152X	Tablet 1mg	10.00	MG	222,482	1,850,816
	P	8285C	Oral solution equiv to 5mg prednisolone per mL	10.00	MG	501,281	7,446,761
H02AB07			PREDNISONE				
	P	1934T	Tablet 1mg	10.00	MG	106,073	940,129
	P	1935W	Tablet 5mg	10.00	MG	304,053	2,788,518
	P	1936X	Tablet 25mg	10.00	MG	261,861	2,956,343
H02AB08			TRIAMCINOLONE ACETONIDE				
	A	11073	Ampoule 40mg per mL 5	7.50	MG	1,473	–
	P	2990J	Injection 10mg in 1mL	7.50	MG	25,068	625,945

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES							
THYROID THERAPY							
THYROID PREPARATIONS							
THYROID HORMONES							
H03AA01			LEVOTHYROXINE SODIUM				
	P	2173J	Tablet equivalent to 200ug anhydrous thyroxine sodium	0.15	MG	52,483	1,414,037
	P	2174K	Tablet equivalent to 50ug anhydrous thyroxine sodium	0.15	MG	557,496	12,980,902
	P	2175L	Tablet equivalent to 100ug anhydrous thyroxine sodium	0.15	MG	558,324	13,338,396
	P	9287T	Tablet equivalent to 75ug anhydrous thyroxine sodium	0.15	MG	117,564	2,814,552
H03AA02			LIOTHYRONINE				
	P	2318B	Tablet 20ug	60.00	UG	13,480	1,152,578
ANTITHYROID PREPARATIONS							
THIOURACILS							
H03BA02			PROPYLTHIOURACIL				
	P	1955X	Tablet 50mg	0.10	GM	15,636	773,258
SULPHUR-CONTAINING IMIDAZOLE DERIVATIVES							
H03BB01			CARBIMAZOLE				
	P	1153Q	Tablet 5mg	15.00	MG	94,686	2,883,076

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES							
PANCREATIC HORMONES							
GLYCOGENOLYTIC HORMONES							
GLYCOGENOLYTIC HORMONES							
H04AA01			GLUCAGON HYDROCHLORIDE				
	P	1449G	Injection set containing 1mg (1iu)	1.00	MG	37,602	1,745,491
	P	3467L	Injection set containing 1mg (1iu)	1.00	MG	15,144	691,021

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES							
CALCIUM HOMEOSTASIS							
PARATHYROID HORMONES AND ANALOGUES							
PARATHYROID HORMONES AND ANALOGUES							
H05AA02 TERIPARATIDE (RBE)							
	P	9411H	Multidose injection pen 250ug per 1mL 2.4mL in multi dose pre filled pen	0.02	MG	6,842	2,999,277
ANTI-PARATHYROID AGENTS							
CALCITONIN PREPARATIONS							
H05BA01 CALCITONIN (SALMON SYNTHETIC)							
	P	2997R	Injection (salmon) 100iu in 1mL ampoule	100.00	IE	174	36,689
OTHER ANTI-PARATHYROID AGENTS							
H05BX01 CINACALCET							
	P	9157Y	Tablets 30mg (base) 28	60.00	MG	8,391	3,087,146
	P	9158B	Tablets 60mg (base) 28	60.00	MG	3,981	2,909,901
	P	9159C	Tablets 90mg (base) 28	60.00	MG	1,735	1,883,274
	P	9625N	Tablets 30mg (base) 56	60.00	MG	482	256,240
	P	9626P	Tablets 60mg (base) 56	60.00	MG	239	280,777

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIBACTERIALS FOR SYSTEMIC USE							
TETRACYCLINES							
TETRACYCLINES							
J01AA02			DOXYCYCLINE				
	A	18810	Capsule 100mg 7	0.10	GM	142	–
	P	2702F	Tablet 100mg (HCl salt after 1 Oct 2007) 28	0.10	GM	69,109	969,936
	P	2703G	Capsule 100mg (as HCl salt after 1 Oct 2007)	0.10	GM	47,580	667,404
	P	2707L	Capsule 50mg (as HCl salt after 1 Oct 2007)	0.10	GM	261,401	2,617,307
	P	2708M	Capsule 100mg (as HCl salt after 1 Oct 2007)	0.10	GM	274,132	2,373,449
	P	2709N	Tablet 100mg (as HCl salt after 1 Oct 2007)	0.10	GM	267,509	2,353,294
	P	2711Q	Tablet 50mg (as HCl salt after 1 Oct 2007) 25	0.10	GM	237,551	2,388,587
	P	2714W	Tablet 100mg (as HCl salt after 1 Oct 2007) 21	0.10	GM	42,079	505,148
	P	2715X	Capsule 100mg (as HCl salt after 1 Oct 2007)	0.10	GM	42,569	516,608
	P	3321T	Tablet 100mg	0.10	GM	1,359	11,351
	P	3322W	Capsule 100mg	0.10	GM	551	4,602
	P	5082L	Tablet 100mg (monohydrate) 7	0.10	GM	8,039	67,201
	P	9105F	Tablet 100mg (monohydrate) 7	0.10	GM	157,068	1,323,223
	P	9106G	Tablet 50mg (as monohydrate) 25	0.10	GM	215,207	2,135,908
	P	9107H	Tablet 100mg (monohydrate) 28	0.10	GM	30,949	432,929
	P	9108J	Tablet 100mg (as monohydrate) 21	0.10	GM	17,848	215,455
J01AA08			MINOCYCLINE				
	P	1616C	Tablet 50mg	0.20	GM	375,942	5,649,836
	P	3037W	Capsule 100mg	0.20	GM	2,726	20,772
BETA-LACTAM ANTIBACTERIALS, PENICILLINS							
PENICILLINS WITH EXTENDED SPECTRUM							
J01CA04			AMOXYCILLIN				
	P	1878W	Sachet containing oral powder 3g	1.00	GM	13,230	125,991
	P	1884E	Capsule 250mg	1.00	GM	324,160	2,767,974
	P	1886G	Powder for syrup 125mg per 5mL 100mL	1.00	GM	601,956	6,492,721
	P	1887H	Powder for syrup 250mg per 5mL 100mL	1.00	GM	1,117,188	12,986,280
	P	1888J	Powder paediatric oral drops 100mg per mL 20mL	1.00	GM	210,519	2,782,081
	P	1889K	Capsule 500mg	1.00	GM	3,226,606	34,158,818
	P	3300Q	Capsule 500mg	1.00	GM	478,202	4,976,019
	P	3301R	Capsule 250mg	1.00	GM	40,044	338,221
	P	3302T	Powder for syrup 125mg per 5mL 100mL	1.00	GM	9,725	104,921
	P	3309E	Sachet containing oral powder 3g	1.00	GM	23,228	208,547
	P	3393N	Powder for syrup 250mg per 5mL 100mL	1.00	GM	8,039	93,146
	P	5225B	Powder for oral suspension 500mg per 5mL 100mL	1.00	GM	226	3,264
	P	8581P	Tablet 1g 14	1.00	GM	166,347	1,769,181
	P	8705E	Powder for oral suspension 500mg per 5mL 100mL	1.00	GM	42,696	622,590
	P	9714G	Powder paediatric oral drops 100mg per mL 20mL	1.00	GM	337	2,797
J01CA01			AMPICILLIN				
	P	2390T	Injection 500mg (solvent required)	2.00	GM	154	1,635
	P	2977Q	Injection 1g (solvent required)	2.00	GM	7,130	127,121

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIBACTERIALS FOR SYSTEMIC USE							
BETA-LACTAM ANTIBACTERIALS, PENICILLINS							
BETA-LACTAMASE SENSITIVE PENICILLINS							
J01CE08			BENZATHINE PENICILLIN				
	P	2267H	Injection 900mg in 2.3mL cartridge–needle unit	3.60	GM	1,887	498,088
J01CE10			BENZATHINE PHENOXYMETHYLPENICILLIN				
	P	5012T	Oral suspension 150mg per 5mL 100mL	2.00	GM	230	4,187
	P	9143F	Oral suspension 150mg per 5mL 100mL	2.00	GM	150,708	3,179,461
J01CE01			BENZYL PENICILLIN				
	P	1775K	Injection 600mg (solvent required)	3.60	GM	4,369	406,302
	P	2647H	Injection 3g (solvent required)	3.60	GM	1,512	154,203
	P	3486L	Injection 600mg (with sterilised water)	3.60	GM	2,011	74,308
	P	3487M	Injection 3g (solvent supplied)	3.60	GM	1,709	21,790
J01CE02			PHENOXYMETHYLPENICILLIN				
	P	1703P	Tablet 250mg	2.00	GM	9,716	110,475
	P	1705R	Capsule 250mg	2.00	GM	28,862	322,375
	P	1787C	Tablet 250mg	2.00	GM	19,906	220,474
	P	1789E	Capsule 250mg	2.00	GM	26,100	289,681
	P	2965C	Capsule 500mg	2.00	GM	257,137	3,479,267
	P	3028J	Tablet 500mg	2.00	GM	112,408	1,500,770
	P	3360W	Tablet 250mg	2.00	GM	689	6,430
	P	3361X	Tablet 500mg	2.00	GM	2,868	29,685
	P	3363B	Capsule 250mg	2.00	GM	1,206	12,396
	P	3364C	Capsule 500mg	2.00	GM	6,730	78,328
	P	8976K	Powder for oral liquid 125mg (as potassium) per 5mL, 100mL 2	2.00	GM	1,527	24,043
	P	8977L	Powder for oral liquid 250mg (as potassium) per 5mL, 100mL 2	2.00	GM	5,888	107,532
J01CE09			PROCAINE PENICILLIN				
	P	1794K	Injection 1.5g	0.60	GM	6,247	576,313
	P	3485K	Injection 1.5g	3.60	GM	19,257	1,774,134
BETA-LACTAMASE RESISTANT PENICILLINS							
J01CF01			DICLOXACILLIN				
	P	8121K	Capsule 250mg	2.00	GM	23,261	267,741
	P	8122L	Capsule 500mg	2.00	GM	293,180	5,491,987
J01CF05			FLUCLOXACILLIN				
	P	1524F	Injection 500mg (solvent required)	2.00	GM	178	3,495
	P	1525G	Injection 1g (solvent required)	2.00	GM	14,578	745,116
	P	1526H	Capsule 250mg	2.00	GM	61,050	705,800
	P	1527J	Capsule 500mg	2.00	GM	421,024	7,849,229
	A	20345	Powder for syrup 250mg per 5mL 100mL	2.00	GM	168	–
	A	20436	Powder for syrup 250mg per 5mL 100mL	2.00	GM	208	–
	P	5091Y	Capsule 500mg	2.00	GM	283	4,595
	P	9149M	Powder for oral liquid 125mg per 5mL 100mL	2.00	GM	24,280	392,923
	P	9150N	Powder for oral liquid 250mg per 5mL 100mL	2.00	GM	53,073	1,178,172

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIBACTERIALS FOR SYSTEMIC USE							
BETA-LACTAM ANTIBACTERIALS, PENICILLINS							
COMBINATIONS OF PENICILLINS, INCL. BETA-LACTAMASE INHIBITORS							
J01CR02			AMOXYCILLIN with CLAVULANIC ACID				
	P	1891M	Tablet 500mg–125mg	1.00	GM	483,302	5,839,410
	P	1892N	Powder for syrup 125mg–31.25mg per 5mL 75mL	1.00	GM	74,965	933,641
	P	5006L	Tablet 875mg–125mg	1.00	GM	69,866	991,919
	P	5008N	Tablet 500mg–125mg	1.00	GM	11,785	140,164
	P	5011R	Powder for syrup 400mg–57mg per 5mL 50mL	1.00	GM	250	3,426
	P	8254K	Tablet 875mg–125mg	1.00	GM	3,248,923	47,085,252
	P	8319W	Powder for syrup 400mg–57mg per 5mL 50mL	1.00	GM	502,172	7,277,634
J01CR03			TICARCILLIN with CLAVULANIC ACID				
	P	2179Q	Injection 3g–100mg (solvent required)	15.00	GM	25,452	4,317,889
	P	6884H	Injection 3g–100mg 10mL and NS	15.00	GM	8,489	1,399,832
OTHER BETA-LACTAM ANTIBACTERIALS							
FIRST-GENERATION CEPHALOSPORINS							
J01DB01			CEFALEXIN				
	A	20843	Capsule 250mg 20	2.00	GM	1,547	–
	P	3058Y	Capsule 250mg	2.00	GM	326,812	2,930,052
	P	3094W	Granules for syrup 125mg per 5mL 100mL	2.00	GM	157,600	1,850,234
	P	3095X	Granules for syrup 250mg per 5mL 100mL	2.00	GM	475,688	6,387,137
	P	3119E	Capsule 500mg	2.00	GM	4,131,708	44,259,027
	P	3317N	Capsule 250mg	2.00	GM	3,001	26,187
	P	3318P	Capsule 500mg	2.00	GM	24,389	257,108
	P	3320R	Granules for syrup 250mg per 5mL 100mL	2.00	GM	215	2,798
J01DB03			CEFALOTHIN				
	P	2964B	Injection 1g (solvent required)	4.00	GM	20,138	488,345
J01DB04			CEPHAZOLIN				
	P	1257E	Injection 1g (solvent required)	3.00	GM	14,978	871,632
	P	5478H	Powder for injection 1g 10	3.00	GM	22,520	1,139,995
	P	5479J	Powder for injection 2g 10	3.00	GM	832	91,495
	P	9326W	Powder for injection 2g 10	3.00	GM	726	122,922
SECOND-GENERATION CEPHALOSPORINS							
J01DC04			CEFACLOR				
	P	1169M	Tablet 375mg (sustained release)	1.00	GM	565,032	7,209,149
	P	2460L	Powder for oral susp 125mg per 5mL 100mL	1.00	GM	109,618	1,458,038
	P	2461M	Powder for oral susp 250mg per 5mL 75mL	1.00	GM	254,172	3,480,641
	P	5045M	Tablet 375mg (sustained release)	1.00	GM	430	5,390
J01DC02			CEFUROXIME				
	P	8292K	Tablet 250mg 14	0.50	GM	117,985	2,288,367

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIBACTERIALS FOR SYSTEMIC USE							
OTHER BETA-LACTAM ANTIBACTERIALS							
THIRD-GENERATION CEPHALOSPORINS							
J01DD01			CEFOTAXIME				
	P	1085D	Injection 1g (solvent required)	4.00	GM	1,194	27,334
	P	1086E	Injection 2g (solvent required)	4.00	GM	284	11,501
J01DD04			CEFTRIAXONE				
	P	1784X	Injection 1g (solvent required)	2.00	GM	49,014	1,722,862
	P	1785Y	Injection 2g (solvent required)	2.00	GM	6,172	387,864
	P	9058R	Injection 500mg (solvent required)	2.00	GM	2,457	25,194
FOURTH-GENERATION CEPHALOSPORINS							
J01DE01			CEFEPIME				
	P	8315P	Injection 1g (solvent required)	2.00	GM	463	91,562
	P	8316Q	Injection 2g (solvent required)	2.00	GM	493	215,242
<i>SULFONAMIDES AND TRIMETHOPRIM</i>							
TRIMETHOPRIM AND DERIVATIVES							
J01EA01			TRIMETHOPRIM				
	P	2922T	Tablet 300mg	0.40	GM	818,423	6,986,733
COMBINATIONS OF SULFONAMIDES AND TRIMETHOPRIM, INCL. DERIVATIVES							
J01EE01			TRIMETHOPRIM with SULPHAMETHOXAZOLE				
	P	2949F	Tablet 80mg–400mg	–	–	4,401	36,799
	P	2951H	Tablet 160mg–800mg	–	–	352,312	3,570,458
	P	3103H	Oral suspension 40mg–200mg per 5mL 100mL	–	–	113,266	1,036,517
	P	3390K	Tablet 160mg–800mg	–	–	821	7,575

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIBACTERIALS FOR SYSTEMIC USE							
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS							
MACROLIDES							
J01FA10			AZITHROMYCIN				
	A	19032	Tablet 500mg 3	0.30	GM	110,785	–
	A	20776	Tablet 500mg 3	0.30	GM	18,722	–
	A	21494	Tablet 500mg 3	0.30	GM	282	–
	P	4115N	Tablet 500mg	0.30	GM	10,332	505,825
	P	6221K	Tablet 600mg 16	0.30	GM	252	14,773
	P	8200N	Tablet 500mg	0.30	GM	63,310	1,348,144
	P	8201P	Powder for oral suspension 200mg per 5mL 15mL	0.30	GM	11,635	248,771
	P	8336R	Tablet 500mg 2	0.30	GM	70,901	1,483,631
J01FA09			CLARITHROMYCIN				
	P	6151R	Tablet 250mg 100	0.50	GM	274	11,893
	P	6152T	Tablet 500mg 100	0.50	GM	352	25,823
	P	8318T	Tablet 250mg 14	0.50	GM	1,086,817	13,802,295
	P	9192T	Powder for oral liquid 250mg per 5mL 50mL	0.50	GM	54,143	1,988,345
J01FA01			ERYTHROMYCIN				
	P	1397M	I.V. infusion 1g (base)	1.00	GM	793	66,721
	P	1404X	Capsule 250mg	1.00	GM	176,131	1,692,223
	P	2424N	Granules for paediatric oral susp 200mg	1.00	GM	202,961	2,507,452
	P	2428T	Granules for oral susp 400mg (base) per 5mL 10	1.00	GM	238,354	3,208,986
	P	2750R	Tablet 400mg (base)	1.00	GM	484,646	5,313,899
	P	3325B	Capsule 250mg	1.00	GM	12,317	114,309
	P	3334L	Granules for paediatric oral suspension 200mg	1.00	GM	367	4,479
	P	3336N	Tablet 400mg (base)	1.00	GM	5,807	61,810
	P	3337P	Granules for oral suspension 400mg(base) per 5mL	1.00	GM	260	3,484
J01FA06			ROXITHROMYCIN				
	P	1760P	Tablet 150mg 10	0.30	GM	912,765	10,667,189
	P	5260W	Tablet 150mg 10	0.30	GM	658	7,559
	P	5261X	Tablet 300mg 5	0.30	GM	751	8,624
	P	8016X	Tablet 300mg 5	0.30	GM	1,258,607	14,851,275
	P	8129W	Tablet for oral suspension 50mg 10	0.30	GM	80,393	1,082,506
LINCOSAMIDES							
J01FF01			CLINDAMYCIN				
	A	16644	Capsule 150mg 100	1.20	GM	233	–
	P	3138E	Capsule 150mg	1.20	GM	158,155	5,254,016
	P	5057E	Capsule 150mg	1.20	GM	38,075	730,302
J01FF02			LINCOMYCIN				
	P	2530E	Injection 600mg in 2mL	1.80	GM	3,628	133,291

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIBACTERIALS FOR SYSTEMIC USE							
AMINOGLYCOSIDE ANTIBACTERIALS							
OTHER AMINOGLYCOSIDES							
J01GB03			GENTAMICIN SULPHATE				
	P	2824P	Injection 80mg (base) in 2mL	0.24	GM	19,524	391,212
J01GB01			TOBRAMYCIN				
	P	1356J	Injection 80mg (base)	0.24	GM	2,204	241,556
	P	5442K	Solution for inhalation 300mg in 5mL 56	0.30	GM	444	958,039
	P	8872Y	Injection 80mg (base) in 2mL (without preserv)	0.24	GM	1,786	234,695
QUINOLONE ANTIBACTERIALS							
FLUOROQUINOLONES							
J01MA02			CIPROFLOXACIN				
	P	1208N	Tablet 250mg	1.00	GM	19,696	741,039
	P	1209P	Tablet 500mg	1.00	GM	155,443	10,036,845
	P	1210Q	Tablet 750mg	1.00	GM	41,891	4,249,645
	A	21046	Tablet 250mg 2	1.00	GM	554	–
J01MA14			MOXIFLOXACIN				
	A	20350	Tablet 400mg 5	0.40	GM	7,313	–
J01MA06			NORFLOXACIN				
	A	13660	Tablet 400mg 6	0.80	GM	49,459	–
	P	3010K	Tablet 400mg	0.80	GM	230,530	4,602,026
OTHER ANTIBACTERIALS							
GLYCOPEPTIDE ANTIBACTERIALS							
J01XA01			VANCOMYCIN				
	P	2269K	Powder for injection 1gm (1000000iu) 1	2.00	GM	686	25,315
	P	2270L	Powder for injection 1gm (1000000iu) 3	2.00	GM	18,738	924,390
	P	3130R	Injection 500mg (500000iu) (solvent required)	2.00	GM	219	4,585
	P	3131T	Injection 500mg (500000iu) (solvent required)	2.00	GM	7,639	347,918
STEROID ANTIBACTERIALS							
J01XC01			FUSIDIC ACID				
	P	2312Q	Tablet (sodium salt) 250mg (enteric coated)	1.50	GM	20,488	4,034,300
IMIDAZOLE DERIVATIVES							
J01XD01			METRONIDAZOLE				
	P	1638F	I.V. infusion 500mg in 100mL	1.50	GM	15,142	434,942
NITROFURAN DERIVATIVES							
J01XE01			NITROFURANTOIN				
	P	1692C	Capsule 50mg	0.20	GM	67,317	1,375,796
	P	1693D	Capsule 100mg	0.20	GM	97,626	2,580,472
OTHER ANTIBACTERIALS							
J01XX05			HEXAMINE HIPPURATE				
	P	3124K	Tablet 1g	2.00	GM	98,389	4,172,489

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIMYCOTICS FOR SYSTEMIC USE							
ANTIMYCOTICS FOR SYSTEMIC USE							
IMIDAZOLE DERIVATIVES							
J02AB02			KETOCONAZOLE				
	P	1572R	Tablet 200mg	0.20	GM	22,422	965,873
	P	1573T	Tablet 200mg	0.20	GM	29,945	606,042
TRIAZOLE DERIVATIVES							
J02AC01			FLUCONAZOLE				
	A	14171	Capsule 150mg 1	0.20	GM	5,103	–
	P	1471K	Capsule 50mg 28	0.20	GM	8,380	432,455
	P	1472L	Capsule 100mg 28	0.20	GM	11,978	1,148,705
	P	1474N	Solution for IV infusion 200mg in 100mL 7	0.20	GM	840	266,622
	P	1475P	Capsule 200mg	0.20	GM	14,760	2,843,759
	A	19776	Capsule 150mg 1	0.20	GM	242	–
	A	19901	Capsule 150mg 1	0.20	GM	1,392	–
	A	19919	Capsule 150mg 1	0.20	GM	473	–
	A	20146	Capsule 150mg 1	0.20	GM	315	–
	A	20244	Capsule 150mg 1	0.20	GM	959	–
	A	20490	Capsule 150mg 1	0.20	GM	178	–
	A	20517	Capsule 150mg 1	0.20	GM	756	–
	A	20660	Capsule 150mg 1	0.20	GM	4,249	–
	A	20799	Capsule 150mg 1	0.20	GM	1,734	–
J02AC02			ITRACONAZOLE				
	A	14810	Capsule 100mg	0.20	GM	2,975	–
	A	16227	Capsule 100mg 28	0.20	GM	3,495	–
	P	8196J	Capsule 100mg	0.20	GM	7,185	2,273,030
J02AC04			POSACONAZOLE				
	P	9360P	Oral suspension 40mg/mL 105, 1	0.80	GM	2,548	6,860,165
J02AC03			VORICONAZOLE				
	P	9363T	Tablet 50mg 56	0.40	GM	741	937,022
	P	9364W	Tablet 200mg 56	0.40	GM	3,127	8,650,917

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIMYCOBACTERIALS							
DRUGS FOR TREATMENT OF TUBERCULOSIS							
ANTIBIOTICS							
J04AB04	RIFABUTIN						
	P	6195C	Capsule 150mg 120	0.15	GM	152	6,177
J04AB02	RIFAMPICIN						
	P	1981G	Capsule 150mg	0.60	GM	1,007	18,677
	P	1982H	Capsule 150mg	0.60	GM	486	14,688
	P	1983J	Capsule 300mg	0.60	GM	1,953	122,192
	P	1984K	Capsule 300mg	0.60	GM	6,682	123,115
	P	8025J	Syrup 100mg per 5mL 60mL	0.60	GM	314	11,915
HYDRAZIDES							
J04AC01	ISONIAZID						
	P	1554T	Tablet 100mg	0.30	GM	1,912	22,496
DRUGS FOR TREATMENT OF LEPROSY							
DRUGS FOR TREATMENT OF LEPROSY							
J04BA02	DAPSONE						
	P	1272Y	Tablet 100mg	50.00	MG	3,439	380,868
	P	8801F	Tablet 25mg	50.00	MG	2,364	237,502

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIVIRALS FOR SYSTEMIC USE							
DIRECT ACTING ANTIVIRALS							
NUCLEOSIDES AND NUCLEOTIDES EXCL. REVERSE TRANSCRIPTASE INHIBITORS							
J05AB01			ACICLOVIR				
	P	1003T	Tablet 200mg	4.00	GM	5,017	329,258
	P	1007B	Tablets 200mg 90	4.00	GM	30,499	3,571,167
	P	1052J	Tablets 800mg 35	4.00	GM	9,847	1,378,135
	P	8234J	Tablets 800mg 120	4.00	GM	179	70,556
J05AB09			FAMCICLOVIR				
	A	19696	Tablet 250mg 14	0.75	GM	129	—
	A	19996	Tablet 500mg 3	0.75	GM	45,335	—
	A	21238	Tablet 500mg 3	0.75	GM	29,107	—
	A	21347	Tablet 500mg 3	0.75	GM	1,374	—
	P	2274Q	Tablet 250mg 20	0.75	GM	16,255	2,167,806
	P	8002E	Tablet 250mg	0.75	GM	60,711	8,405,831
	P	8092X	Tablet 125mg	0.75	GM	7,826	1,032,150
	P	8217L	Tablet 250mg	0.75	GM	83,780	28,955,342
	P	8896F	Tablet 500mg 56	0.75	GM	6,540	2,236,191
	P	8897G	Tablet 500mg 30	0.75	GM	4,103	791,740
J05AB11			VALACICLOVIR				
	A	20467	Tablet 1000mg 4	3.00	GM	13,735	—
	P	5480K	Tablet 500mg (as hydrochloride) 30	3.00	GM	104,930	17,533,761
	P	8064K	Tablet 500mg 42	3.00	GM	42,891	9,159,804
	P	8133C	Tablet 500mg 20	3.00	GM	16,952	1,790,019
	P	8134D	Tablet 500mg 30	3.00	GM	269,995	44,680,140
J05AB14			VALGANCICLOVIR				
	P	6357N	Tablet 450mg (base) 120	0.90	GM	157	490,270
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS							
J05AF08			ADEFOVIR DIPIVOXIL				
	P	6450L	Tablet 30mg 60	10.00	MG	2,103	2,496,121
J05AF02			DIDANOSINE				
	P	6300N	Capsule 250mg (enteric coated beads) 60	0.40	GM	211	—
J05AF10			ENTECAVIR				
	P	9602J	Tablet 0.5mg 60	0.50	MG	12,115	9,308,463
	P	9603K	Tablet 1mg 60	0.50	MG	1,920	2,335,174
J05AF05			LAMIVUDINE				
	P	6193Y	Tablet 150mg 120	0.30	GM	333	134,940
	P	6257H	Tablet 100mg 56	0.30	GM	4,237	1,233,369
	P	6435Q	Tablet 300mg 60	0.30	GM	638	27,932
J05AF04			STAVUDINE				
	P	6190T	Capsule 40mg 120	80.00	MG	207	—
J05AF07			TENOFOVIR				
	P	6358P	Tablet containing tenofovir disoproxil fumarate 300mg 60	0.25	GM	8,468	8,009,432
J05AF01			ZIDOVUDINE				
	P	6154X	Capsule 250mg 240	0.60	GM	183	—

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
ANTIVIRALS FOR SYSTEMIC USE							
DIRECT ACTING ANTIVIRALS							
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS							
J05AG03	EFAVIRENZ						
	P	6356M	Tablet 600mg 60	0.60	GM	121	71,860
J05AG01	NEVIRAPINE						
	P	6215D	Tablet 200mg 120	0.40	GM	5,490	2,454,544
NEURAMINIDASE INHIBITORS							
J05AH02	OSELTAMIVIR						
	A	17034	Capsule 75mg 10	–	–	42,756	–
	A	20830	Capsule 30mg 10	0.15	GM	127	–
J05AH01	ZANAMIVIR						
	A	16327	Rotadisk 5mg 20	20.00	MG	3,818	–
ANTIVIRALS FOR TREATMENT OF HIV INFECTION, COMBINATIONS							
J05AR	LOPINAVIR with RITONAVIR						
	P	6495W	Tablet 200mg–50mg 240	–	–	4,789	5,555,288
J05AR03	TENOFOVIR with EMTRICITABINE						
	P	6468K	Tablet containing tenofovir disoproxil fumarate 300mg with emtricitabine 200mg 60	–	–	225	280,123
J05AR06	TENOFOVIR with EMTRICITABINE and EFAVIRENZ						
	P	9650X	Tablet containing tenofovir disoproxil fumarate 300mg with emtricitabine 200mg and efavirenz 600mg 60	–	–	217	476,461
J05AR01	ZIDOVUDINE and LAMIVUDINE						
	P	6234D	Tablet 150mg–300mg 120	–	–	1,594	1,160,527
J05AR04	ZIDOVUDINE with LAMIVUDINE with ABACAVIR						
	P	6327B	Tablet 300mg–150mg–300mg (as sulfate) 120	–	–	530	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
VACCINES							
BACTERIAL VACCINES							
CHOLERA VACCINES							
J07AE01	CHOLERA						
	A	20362	Oral granules inactivated choleme 2	-	-	27,194	-
J07AE02	CHOLERA, LIVE ATTENUATED						
	A	18382	Oral granules Cholera, inactivated 14	-	-	21,849	-
MENINGOCOCCAL VACCINES							
J07AH04	MENINGOCOCCAL						
	A	14507	Vial 0.5mL 1	-	-	7,189	-
	A	15130	Vial 0.5mL 1	-	-	223	-
J07AH07	MENINGOCOCCAL C						
	A	17637	Syringe 10ug per 0.5mL conjugated 1	-	-	510	-
PERTUSSIS VACCINES							
J07AJ52	DIPHTHERIA with TETANUS with PERTUSSIS PURIFIED ANTIGEN						
	A	17092	Injection 0.5mL 1	-	-	86,387	-
J07AJ51	DIPHTHERIA, TETANUS and PERTUSSIS VACCINE, ADSORBED						
	A	19778	Injection 0.5mL	-	-	17,112	-
PNEUMOCOCCAL VACCINES							
J07AL01	PNEUMOCOCCAL						
	P	1903E	Injection 0.5mL (23 valent)	-	-	13,339	611,310
TETANUS VACCINES							
J07AM51	TETANUS TOXOID, COMBINATIONS with DIPHTHERIA						
	P	3463G	Injection 0.5mL in pre-filled syringe	-	-	25,705	5,540,788
	P	8783G	Injection 0.5mL in pre-filled syringe	-	-	7,129	448,393
TYPHOID,VACCINES							
J07AP01	SALMONELLA-TYPHI						
	A	19176	Oral live attenuated capsule Typhoid	-	-	9,097	-
J07AP01	TYPHOID ORAL LIVE ATTENUATED						
	A	13158	Cap-ec 3 1	-	-	150	-
J07AP03	TYPHOID PURIFIED POLYSACCHARIDE ANTIGEN						
	A	14718	Syringe 0.5mL	-	-	137,341	-
	A	16719	Injection 25ug	-	-	23,659	-
VIRAL VACCINES							
ENCEPHALITIS VACCINES							
J07BA02	JAPANESE ENCEPHALITIS VACCINE						
	A	20716	Pre-filled syringe 0.5mL	-	-	436	-
INFLUENZA VACCINES							
J07BB02	INFLUENZA VACCINE						
	A	20292	Injection 0.5mL	-	-	1,231	-
	A	20834	Injection 0.1mL	-	-	8,703	-
	A	21010	Injection (trivalent) 0.5mL	-	-	147,561	-
	A	21012	Injection (trivalent) 0.5mL	-	-	121,930	-
	A	21013	Injection (trivalent) 0.5mL	-	-	9,027	-
	A	21473	Pre-filled syringe 0.5mL 1	-	-	2,085	-

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE							
VACCINES							
VIRAL VACCINES							
HEPATITIS VACCINES							
J07BC02			HEPATITIS A				
	A	15677	Syringe 720u/0.5mL	-	-	28,418	-
	A	15687	Syringe 144u 1	-	-	98,639	-
	A	15770	Syringe 25u 1	-	-	381	-
	A	17617	Vial 0.5mL 1	-	-	321	-
J07BC20			HEPATITIS A\HEPATITIS B				
	A	15760	Syringe 1mL	-	-	107,763	-
	A	15917	Syringe 0.5mL	-	-	2,175	-
	A	17055	Syringe 0.5mL	-	-	6,835	-
J07BC01			HEPATITIS B				
	A	13026	Ampoule 20ug per mL 1	-	-	67,965	-
	A	13473	Ampoule 10ug per 0.5mL 1	-	-	1,577	-
	A	20760	Pre-filled syringe 20ug per mL 1	-	-	19,830	-
	A	20833	Pre-filled syringe 10ug per 0.5mL 1	-	-	505	-
J07BC20			SALMONELLA and HEPATITIS A				
	A	17818	Prefilled syringe 25ug and 160 Elisa units	-	-	80,159	-
MEASLES VACCINES							
J07BD52			MEASLES with MUMPS with RUBELLA				
	A	18509	Injection 0.5mL 1	-	-	12,044	-
POLIOMYELITIS VACCINES							
J07BF03			POLIOMYELITIS				
	A	16235	Injection 0.5mL	-	-	8,066	-
RABIES VACCINES							
J07BG01			RABIES INACTIVATED				
	A	14107	Injection 1mL 1	-	-	4,738	-
	A	19166	Injection 2.5ug 1	-	-	6,207	-
VARICELLA VACCINES							
J07BK01			VARICELLA LIVE ATTENUATED				
	A	16723	Vaccine 0.5mL	-	-	9,947	-
PAPILLOMAVIRUS VACCINES							
J07BM02			VACCINE PAPILLOMAVIRUS (HUMAN TYPES 16 and 18)				
	A	20142	Injection 0.5mL prefilled syringe 1	-	-	615	-
J07BM01			VACCINE PAPILLOMAVIRUS (HUMAN TYPES 6, 11, 16 and 18)				
	A	10756	Injection 0.5mL prefilled syringe 1	-	-	12,064	-
BACTERIAL AND VIRAL VACCINES, COMBINED							
BACTERIAL AND VIRAL VACCINES, COMBINED							
J07CA02			DIPHThERIA-PERTUSSIS-POLIOMYELITIS--TETANUS				
	A	18391	Injection 0.5mL 1	-	-	209	-
	A	19175	Injection 0.5mL, 1	-	-	30,759	-
	A	20236	Injection 0.5mL syringe	-	-	4,060	-

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
ALKYLATING AGENTS							
NITROGEN MUSTARD ANALOGUES							
L01AA02			CHLORAMBUCIL				
	P	1163F	Tablet 2mg	--	--	3,068	372,900
L01AA01			CYCLOPHOSPHAMIDE				
	P	1031G	Injection 2g (solvent required)	--	--	10,305	595,376
	P	1079T	Injection 500mg (solvent required)	--	--	4,971	201,630
	P	1080W	Injection 1g (solvent required)	--	--	5,709	192,735
	P	1266P	Tablet 50mg	--	--	9,464	283,840
	P	5914G	Injection 500mg (solvent required)	--	--	3,419	56,188
	P	5915H	Injection 1g (solvent required)	--	--	5,570	118,352
	P	5916J	Injection 2g (solvent required)	--	--	2,201	93,473
	P	6704W	Injection 500 mg 10mL and NS	--	--	735	32,919
	P	6710E	Injection 1g 10mL and NS	--	--	1,483	54,623
	P	7055H	Injection 2g 10mL and NS	--	--	1,311	78,212
L01AA06			IFOSFAMIDE				
	P	5943T	Powder for I.V. injection 1g	--	--	290	52,229
	P	5944W	Powder for I.V. injection 2g	--	--	228	78,973
	P	8076C	Powder for I.V. injection 1g	--	--	465	168,874
	P	8077D	Powder for I.V. injection 2g	--	--	1,042	658,563
L01AA03			MELPHALAN				
	P	2547C	Tablet 2mg	--	--	3,036	146,900
ALKYL SULPHONATES							
L01AB01			BUSULPHAN				
	P	1128J	Tablet 2mg	--	--	386	33,004
NITROSOUREAS							
L01AD05			FOTEMUSTINE				
	P	5900M	Powder for injection 208mg with solvent	--	--	193	209,276
	P	8786K	Powder for injection 208mg with solvent	--	--	619	910,890
OTHER ALKYLATING AGENTS							
L01AX03			TEMOZOLOMIDE				
	P	8378Y	Capsule 5mg	--	--	226	64,760
	P	8379B	Capsule 20mg 5	--	--	1,051	724,208
	P	8380C	Capsule 100mg 5	--	--	4,612	11,289,113
	P	8381D	Capsule 250mg 5	--	--	1,517	2,820,846
	P	8819E	Capsule 5mg 15	--	--	318	126,903
	P	8820F	Capsule 20mg 15	--	--	425	294,492
	P	8821G	Capsule 100mg 15	--	--	658	1,665,408
	P	9361Q	Capsule 140mg 15	--	--	1,103	3,719,077
	P	9362R	Capsule 140mg 5	--	--	1,516	3,978,846

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
ANTIMETABOLITES							
FOLIC ACID ANALOGUES							
L01BA01			METHOTREXATE				
	P	1622J	Tablet 2.5mg	–	–	62,435	814,485
	P	1623K	Tablet 10mg	–	–	117,068	5,254,740
	P	2272N	Tablet 10mg 15	–	–	38,236	831,937
	P	2395C	Injection 50mg in 2mL	–	–	18,046	641,138
	P	2396D	Injection 5mg in 2mL	–	–	1,620	118,413
	P	5875F	Solution concentrate I.V. infusion 1000mg in 10mL	–	–	202	19,090
	P	5962T	Injection 5mg in 2mL	–	–	793	12,486
	P	5963W	Injection 50mg in 2mL	–	–	312	5,320
	P	8851W	Solution concentrate I.V. infusion 1000mg in 10mL	–	–	410	93,989
	P	8852X	Solution concentrate I.V. infusion 5000mg in 50mL	–	–	249	150,647
	P	8863L	Solution concentrate I.V. infusion 500mg in 20mL	–	–	173	14,399
L01BA04			PEMETREXED				
	P	5834C	Powder for I.V. infusion 500mg (base) 2	–	–	3,699	5,801,119
	P	5835D	Powder for I.V. infusion 100mg (base) 1	–	–	2,205	1,272,526
	P	9130M	Powder for I.V. infusion 500mg (base) 2	–	–	5,173	9,553,207
	P	9131N	Powder for I.V. infusion 100mg (base) 1	–	–	6,000	11,872,504
L01BA03			RALTITREXED				
	P	8284B	Powder for I.V. infusion 2mg	–	–	248	209,443
PURINE ANALOGUES							
L01BB05			FLUDARABINE				
	P	5840J	Powder for I.V. injection 50mg 5	–	–	255	135,186
	P	5841K	Solution for I.V. injection 50mg in 2mL 5	–	–	227	114,624
	P	9184J	Tablet 10mg 20	–	–	807	773,506
	P	9185K	Powder for I.V. injection 50mg 5	–	–	493	644,120
	P	9207N	Solution for I.V. injection 50mg in 2mL 5	–	–	256	320,852
L01BB02			MERCAPTOPYRINE				
	P	1598D	Tablet 50mg	–	–	20,884	5,112,990
L01BB03			THIOGUANINE				
	P	1233X	Tablet 40mg	–	–	648	172,405

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011		COST(\$)
				DDD	UNITS	
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS						
ANTINEOPLASTIC AGENTS						
ANTIMETABOLITES						
PYRIMIDINE ANALOGUES						
L01BC07		AZACITIDINE				
	P	6100C	Powder for injection 100mg	–	–	379 2,924,159
	P	6138C	Powder for injection 100mg	–	–	290 2,193,399
L01BC06		CAPECITABINE				
	P	8361C	Tablet 150mg	–	–	1,732 240,190
	P	8362D	Tablet 500mg 120	–	–	29,034 20,599,474
L01BC01		CYTARABINE				
	P	2884T	Injection set containing 100mg and 5mL solvent	–	–	1,516 946,122
	P	5918L	Injection set containing 100mg and 5mL solvent	–	–	643 46,978
L01BC02		FLUOROURACIL				
	P	2528C	Injection 500mg in 10mL	–	–	35,672 1,947,236
	P	4222F	Cream 50mg per g (5%) 20g	–	–	101,789 5,685,649
	P	5808Q	Injection 5000mg in 100mL 1	–	–	169 5,863
	P	5872C	Injection 1000mg in 20mL 5	–	–	9,548 248,202
	P	5935J	Injection 500mg in 10mL	–	–	11,697 337,206
	P	8995K	Injection 2500mg in 50mL 2	–	–	151 6,719
	P	8996L	Injection 5000mg in 100mL 1	–	–	238 11,656
	P	9005Y	Injection 1000mg in 20mL 5	–	–	12,363 602,946
L01BC05		GEMCITABINE				
	P	5843M	Solution concentrate for I.V. infusion 200mg (base) in 20mL	–	–	164 16,786
	P	5844N	Solution concentrate for I.V. infusion 1000mg (base) in 100mL	–	–	635 141,110
	P	5845P	Solution concentrate for I.V. infusion 2gm (base)	–	–	854 280,144
	P	5852B	Solution concentrate for I.V. infusion 500mg (base) in 50mL 4	–	–	290 35,756
	P	5936K	Powder for I.V. infusion 200mg (base)	–	–	4,803 463,119
	P	5937L	Powder for I.V. infusion 1gm (base)	–	–	7,388 1,636,951
	P	8049P	Powder for I.V. infusion 200mg (base)	–	–	4,735 1,611,400
	P	8050Q	Powder for I.V. infusion 1gm (base)	–	–	10,584 6,093,187
	P	9401T	Solution concentrate for I.V. infusion 200mg (base) in 20mL	–	–	1,056 334,105
	P	9402W	Solution concentrate for I.V. infusion 1000mg (base) in 100mL	–	–	1,232 657,100
	P	9414L	Solution concentrate for I.V. infusion 2gm (base)	–	–	3,428 2,683,005
	P	9463C	Solution concentrate for I.V. infusion 500mg (base) in 50mL 4	–	–	770 342,068

ATC	ITEM TYPE	CODE	FORM AND STRENGTH			2011	
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS							
VINCA ALKALOIDS AND ANALOGUES							
L01CA01	VINBLASTINE	SULPHATE					
	P	2199R	Injection set containing 10mg and 10mL solvent	–	–	1,270	173,963
	P	5989F	Injection set containing 10mg and 10mL solvent	–	–	1,407	71,519
L01CA02	INCRISTINE	SULPHATE					
	P	2374Y	Injection set containing 1mg and 1mL solvent	–	–	5,097	585,586
	P	5991H	Injection set containing 1mg and 1mL solvent	–	–	4,301	116,439
L01CA04	VINORELBINE						
	P	5992J	Solution for I.V. infusion 10mg (base) in 1mL	–	–	497	105,778
	P	5993K	Solution for I.V. infusion 50mg (base) in 5mL	–	–	1,599	505,211
	P	8280T	Solution for I.V. infusion 10mg (base) in 1mL	–	–	812	697,460
	P	8281W	Solution for I.V. infusion 50mg (base) in 5mL	–	–	1,799	1,592,442
	P	9009E	Capsule 20mg (base) 20	–	–	135	205,332
PODOPHYLLOTOXIN DERIVATIVES							
L01CB01	ETOPOSIDE						
	P	1389D	Capsule 100mg	–	–	504	178,884
	P	1390E	Solution for I.V. infusion 100mg in 5mL	–	–	2,980	470,522
	P	1396L	Capsule 50mg	–	–	700	286,551
	P	5931E	Solution for I.V. infusion 100mg in 5mL	–	–	801	67,685
	P	5932F	Powder for I.V. infusion 100mg (as phosphate)	–	–	4,751	379,865
	P	5933G	Powder for I.V. infusion 1g (as phosphate)	–	–	177	48,404
	P	8120J	Powder for I.V. infusion 100mg (as phosphate)	–	–	3,237	493,597
	P	8515E	Powder for I.V. infusion 1g (as phosphate)	–	–	1,958	617,475
	P	9010F	Capsule 30mg, 16	–	–	313	638,713

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS							
TAXANES							
L01CD02	DOCETAXEL						
P	5270J		Solution concentrate for I.V. infusion 20mg in 1mL 2	–	–	296	440,170
P	5271K		Injection set containing 1 single use vial concentrate for I.V. infusion 20mg (anhydrous) 2	–	–	370	481,515
P	5272L		Solution concentrate for I.V. infusion 80mg in 4mL 1	–	–	252	528,738
P	5273M		Injection set containing 1 single use vial concentrate for I.V. infusion 80mg (anhydrous) 1	–	–	516	1,066,166
P	5274N		Solution concentrate for I.V. infusion 140mg in 7mL	–	–	179	397,324
P	5428Q		Solution concentrate for I.V. infusion 20mg in 1mL 1	–	–	175	320,397
P	5429R		Solution concentrate for I.V. infusion 20mg in 2mL 1	–	–	122	200,002
P	5430T		Injection set containing 1 single use vial concentrate for I.V. infusion 20mg (anhydrous) 2	–	–	241	411,206
P	5431W		Solution concentrate for I.V. infusion 80mg in 4mL 1	–	–	151	333,820
P	5433Y		Injection set containing 1 single use vial concentrate for I.V. infusion 80mg (anhydrous) 1	–	–	213	478,311
P	5463M		Solution concentrate for I.V. infusion 20mg in 1mL 2	–	–	2,380	3,464,919
P	5464N		Solution concentrate for I.V. infusion 80mg in 4mL	–	–	3,452	7,308,555
P	5486R		Solution concentrate for I.V. infusion 20mg in 2mL 2	–	–	771	1,304,260
P	5487T		Solution concentrate for I.V. infusion 80mg in 8mL 1	–	–	546	1,298,446
P	5595L		Injection set containing 1 single use vial concentrate for I.V. infusion 20mg (anhydrous) 2	–	–	114	57,081
P	5596M		Solution concentrate for I.V. infusion 80mg in 4mL 1	–	–	122	169,851
P	5811W		Solution concentrate for I.V. infusion 20mg in 1mL 2	–	–	227	137,803
P	5812X		Injection set containing 1 single use vial concentrate for I.V. infusion 20mg (anhydrous) 2	–	–	163	89,946
P	5813Y		Solution concentrate for I.V. infusion 80mg in 4mL 1	–	–	258	333,925
P	5814B		Injection set containing 1 single use vial concentrate for I.V. infusion 80mg (anhydrous) 1	–	–	211	309,661
P	5855E		Solution concentrate for I.V. infusion 20mg in 1mL 2	–	–	360	206,127
P	5856F		Solution concentrate for I.V. infusion 80mg in 4mL 1	–	–	663	980,977
P	5860K		Solution concentrate for I.V. infusion 20mg in 2mL 2	–	–	181	88,793
P	5861L		Solution concentrate for I.V. infusion 80mg in 8mL 1	–	–	301	406,718
P	5862M		Solution concentrate for I.V. infusion 160mg in 16mL 1	–	–	252	582,347
P	5864P		Solution concentrate for I.V. infusion 20mg in 1mL 2	–	–	206	107,532
P	5866R		Injection set containing 1 single use vial concentrate for I.V. infusion 20mg (anhydrous) 2	–	–	270	158,848
P	5867T		Solution concentrate for I.V. infusion 80mg in 4mL 1	–	–	318	427,517
P	5869X		Injection set containing 1 single use vial concentrate for I.V. infusion 80mg (anhydrous)	–	–	258	332,770
P	5921P		Injection set containing I.V. infusion 20mg	–	–	3,011	1,718,497
P	5922Q		Injection set containing I.V. infusion 80mg	–	–	4,294	5,851,199

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS							
TAXANES							
	P	8071T	Injection set containing I.V. infusion 20mg	–	–	6,524	10,835,714
	P	8074Y	Injection set containing I.V. infusion 80mg	–	–	7,415	16,431,278
	P	8967Y	Solution concentrate for I.V. infusion 160mg in 16mL	–	–	268	686,621
	P	8986Y	Solution concentrate for I.V. infusion 20mg in 1mL 2	–	–	253	391,632
	P	8988C	Injection set containing 1 single use vial concentrate for I.V. infusion 20mg (anhydrous) 2	–	–	424	667,458
	P	8989D	Solution concentrate for I.V. infusion 80mg in 4mL	–	–	278	578,351
	P	8991F	Injection set containing 1 single use vial concentrate for I.V. infusion 80mg (anhydrous) 1	–	–	448	881,602
	P	9291B	Injection set containing 1 single use vial concentrate for I.V. infusion 20mg (anhydrous)	–	–	291	447,416
L01CD01	PACLITAXEL						
	P	3017T	Solution for I.V. infusion 150mg in 25mL	–	–	5,000	6,925,701
	P	3026G	Solution for I.V. infusion 30mg in 5mL	–	–	6,231	4,339,159
	P	5847R	Solution for I.V. infusion 100mg (base) 1	–	–	5,287	3,572,771
	P	5973J	Solution for I.V. infusion 30mg in 5mL	–	–	2,424	499,172
	P	5974K	Solution for I.V. infusion 100mg in 16.7mL	–	–	1,783	776,244
	P	5975L	Solution for I.V. infusion 150mg in 25mL	–	–	1,843	1,014,326
	P	5976M	Solution for I.V. infusion 300mg in 50mL	–	–	1,685	1,671,398
	P	8018B	Solution for I.V. infusion 100mg in 16.7mL	–	–	3,936	4,273,009
	P	8360B	Solution for I.V. infusion 300mg in 50mL	–	–	3,647	4,495,121
	P	9415M	Solution for I.V. infusion 100mg (base) 1	–	–	6,464	12,920,905

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES							
ANTHRACYCLINES AND RELATED SUBSTANCES							
L01DB01			DOXORUBICIN HYDROCHLORIDE				
	P	1336H	Solution for I.V. or intravesical 10mg	–	–	702	22,382
	P	1340M	Solution for I.V. or intravesical 20mg	–	–	532	34,556
	P	1342P	Solution for I.V. or intravesical 50mg	–	–	7,919	772,057
	P	5879K	Solution for I.V. or intravesical 100mg in 50mL	–	–	2,967	172,501
	P	5880L	Solution for I.V. or intravesical 200mg in 100mL	–	–	489	56,856
	P	5891C	Solution for I.V. infusion 20mg in 10mL	–	–	746	656,631
	P	5892D	Suspension for IV infusion 50mg in 25mL	–	–	701	1,078,359
	P	5925W	Solution for I.V. or intravesical 10mg	–	–	532	6,474
	P	5926X	Solution for I.V. or intravesical 20mg	–	–	857	23,948
	P	5927Y	Solution for I.V. or intravesical 50mg	–	–	3,197	154,885
	P	8569B	Suspension for IV infusion 20mg in 10mL	–	–	1,799	3,692,437
	P	8570C	Suspension for IV infusion 50mg in 25mL	–	–	1,315	2,828,627
	P	8827N	Solution for I.V. or intravesical 100mg in 50mL	–	–	5,550	424,184
	P	8828P	Solution for I.V. or intravesical 200mg in 100mL	–	–	638	90,398
L01DB03			EPIRUBICIN HYDROCHLORIDE				
	P	1375J	Solution for I.V. injection 10mg in 5mL 4	–	–	424	58,785
	P	1376K	Solution for I.V. injection 20mg in 10mL 4	–	–	189	50,231
	P	1377L	Solution for I.V. injection 50mg in 25mL 3	–	–	4,298	3,184,855
	P	5884Q	Solution for injection 200mg in 100mL	–	–	1,256	872,559
	P	5885R	Solution for injection 100mg in 50mL 2	–	–	1,651	799,767
	P	5928B	Solution for I.V. injection 10mg in 5mL 4	–	–	527	35,020
	P	5929C	Solution for I.V. injection 20mg in 10mL 4	–	–	526	62,062
	P	5930D	Solution for I.V. injection 50mg in 25mL 3	–	–	1,394	569,320
	P	8817C	Solution for injection 100mg in 50mL 2	–	–	2,045	1,396,197
	P	8858F	Solution for injection 200mg in 100mL	–	–	1,519	1,219,574
L01DB06			IDARUBICIN HYDROCHLORIDE				
	P	8531B	Solution for I.V. injection 10mg in 10mL	–	–	135	247,595
L01DB07			MITOZANTRONE				
	P	1929M	Injection 20mg in 10mL	–	–	586	105,481
	P	1930N	Injection 25mg in 12.5mL	–	–	495	105,274
	P	5965Y	Injection 20mg in 10mL	–	–	136	18,973
OTHER CYTOTOXIC ANTIBIOTICS							
L01DC01			BLEOMYCIN				
	P	2315W	Injection 15,000 units (solvent required)	–	–	1,189	373,523
	P	5903Q	Injection 15,000 units (solvent required)	–	–	2,094	180,191

ATC	ITEM TYPE	CODE	FORM AND STRENGTH			2011	
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
OTHER ANTINEOPLASTIC AGENTS							
PLATINUM COMPOUNDS							
L01XA02		CARBOPLATIN					
	P	1160C	Solution for I.V. injection 50mg in 5mL	–	–	1,869	102,413
	P	1161D	Solution for I.V. injection 150mg in 15mL	–	–	13,906	4,958,238
	P	1162E	Solution for I.V. injection 450mg in 45mL	–	–	8,119	1,871,220
	P	5906W	Solution for I.V. injection 50mg in 5mL	–	–	2,634	99,908
	P	5907X	Solution for I.V. injection 150mg in 15mL	–	–	6,917	1,005,410
	P	5908Y	Solution for I.V. injection 450mg in 45mL	–	–	6,952	974,981
L01XA01		CISPLATIN					
	P	2578Q	I.V. injection 10mg in 10mL	–	–	216	3,656
	P	2579R	I.V. injection 50mg in 50mL	–	–	4,307	144,242
	P	2580T	I.V. injection 100mg in 100mL	–	–	10,813	521,828
	P	5909B	I.V. injection 10mg in 10mL	–	–	138	782
	P	5910C	I.V. injection 50mg in 50mL	–	–	1,962	24,024
	P	5911D	I.V. injection 100mg in 100mL	–	–	4,198	138,816
L01XA03		OXALIPLATIN					
	P	2310N	Powder for I.V. infusion 200mg in 40mL	–	–	3,997	4,976,199
	P	5877H	Solution for I.V. infusion 50mg in 10mL	–	–	2,318	547,035
	P	5878J	Solution for I.V. infusion 100mg in 20mL	–	–	3,481	1,676,669
	P	5994L	Powder for I.V. infusion 50mg	–	–	1,477	415,028
	P	5995M	Powder for I.V. infusion 100mg	–	–	2,624	1,824,874
	P	5999R	Powder for I.V. infusion 200mg in 40mL	–	–	2,401	1,917,171
	P	8539K	Powder for I.V. infusion 50mg	–	–	5,828	4,932,837
	P	8540L	Powder for I.V. infusion 100mg	–	–	6,071	7,586,004
	P	8847P	Solution for I.V. infusion 50mg in 10mL	–	–	2,924	2,366,717
	P	8848Q	Solution for I.V. infusion 100mg in 20mL	–	–	3,013	3,262,456

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
OTHER ANTINEOPLASTIC AGENTS							
MONOCLONAL ANTIBODIES							
L01XC07		BEVACIZUMAB					
	P	5849W	Soln for IV infusion 100mg/4mL	-	-	5,330	2,987,618
	P	5850X	Soln for IV infusion 400mg/16mL	-	-	6,019	10,916,840
	P	9442Y	Soln for IV infusion 100mg/4mL	-	-	10,531	19,089,552
	P	9443B	Soln for IV infusion 400mg/16mL	-	-	12,730	33,671,465
L01XC06		CETUXIMAB					
	P	5447Q	Solution for IV infusion 100mg in 20mL 1	-	-	878	2,162,802
	P	5448R	Solution for IV infusion 500mg in 100mL 1	-	-	1,357	5,547,879
	P	5599Q	Solution for IV infusion 100mg in 20mL 1	-	-	424	231,198
	P	5600R	Solution for IV infusion 500mg in 100mL 1	-	-	742	1,370,820
	P	5836E	Solution for IV infusion 100mg in 20mL 1	-	-	329	145,607
	P	5837F	Solution for IV infusion 500mg in 100mL 1	-	-	223	395,560
	P	5838G	Solution for IV infusion 100mg in 20mL 1	-	-	140	73,656
	P	5839H	Solution for IV infusion 500mg in 100mL 1	-	-	367	671,770
	P	9136W	Solution for IV infusion 100mg in 20mL 1	-	-	119	167,225
	P	9137X	Solution for IV infusion 500mg in 100mL 1	-	-	151	363,311
	P	9138Y	Solution for IV infusion 100mg in 20mL 1	-	-	270	459,407
	P	9139B	Solution for IV infusion 500mg in 100mL 1	-	-	391	927,042
L01XC02		RITUXIMAB					
	P	5896H	Solution for IV infusion 100mg\10mL	-	-	5,803	4,496,375
	P	5897J	Solution for IV infusion 500mg\50mL	-	-	4,580	10,455,430
	P	5978P	Solution for IV infusion 100mg\10mL	-	-	5,078	4,106,134
	P	5979Q	Solution for IV infusion 500mg\50mL	-	-	4,538	10,317,352
	P	8293L	Solution for IV infusion 100mg\10mL	-	-	12,908	16,269,769
	P	8294M	Solution for IV infusion 500mg\50mL	-	-	13,316	33,726,683
	P	8665C	Solution for IV infusion 100mg\10mL	-	-	11,019	14,375,934
	P	8666D	Solution for IV infusion 500mg\50mL	-	-	10,752	26,820,525
	P	9611W	Solution for IV infusion 500mg\50mL	-	-	738	3,360,435
L01XC03		TRASTUZUMAB					
	P	6497Y	Powder for IV infusion 150mg	-	-	9,762	33,220,609
	P	9691C	Powder for IV infusion 60mg	-	-	3,750	7,950,331

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
OTHER ANTINEOPLASTIC AGENTS							
PROTEIN KINASE INHIBITORS							
L01XE06	DASATINIB						
	P	2482P	Tablet 50mg 60	-	-	483	2,569,222
	P	2485T	Tablet 70mg 60	-	-	227	1,454,307
	P	9283N	Tablet 50mg 60	-	-	183	966,843
	P	9341P	Tablet 100mg 60	-	-	434	2,306,718
	P	9342Q	Tablet 100mg 60	-	-	486	2,559,750
L01XE03	ERLOTINIB						
	P	9166K	Tablet 25mg (as hydrochloride) 30	-	-	426	575,934
	P	9167L	Tablet 100mg (as hydrochloride) 30	-	-	1,553	4,224,266
	P	9168M	Tablet 150mg (as hydrochloride) 30	-	-	4,704	15,790,000
L01XE02	GEFITINIB						
	P	8769M	Tablet 250mg 30	-	-	383	1,492,942
L01XE01	IMATINIB						
	P	5444M	Tablet 400mg (as mesylate) 30	-	-	135	529,574
	P	9111M	Tablet 100mg (base) 60	-	-	718	2,091,988
	P	9112N	Tablet 400mg (base) 30	-	-	2,901	11,516,541
	P	9113P	Tablet 100mg (base) 60	-	-	5,381	20,245,598
	P	9114Q	Tablet 400mg (base) 30	-	-	13,733	57,487,362
	P	9115R	Tablet 100mg (base) 60	-	-	502	2,126,859
	P	9116T	Tablet 400mg (base) 30	-	-	892	4,402,203
	P	9123E	Tablet 100mg (base) 60	-	-	247	725,124
	P	9124F	Tablet 400mg (base) 30	-	-	214	878,778
L01XE07	LAPATINIB						
	P	9148L	Tablet 250mg 140	-	-	1,615	5,444,098
L01XE08	NILOTINIB						
	P	9171Q	Capsule 200mg (as hydrochloride monohydrate) 112	-	-	1,031	5,656,562
	P	9285Q	Capsule 200mg (as hydrochloride monohydrate) 112	-	-	608	3,343,816
L01XE05	SORAFENIB						
	P	9380Q	Tablet 200mg (as tosylate) 120	-	-	1,377	8,889,156
L01XE04	SUNITINIB						
	P	9417P	Capsule 12.5mg (as malate) 28	-	-	170	322,837
	P	9418Q	Capsule 25mg (as malate) 28	-	-	280	1,010,356
	P	9419R	Capsule 50mg (as malate) 28	-	-	542	3,822,448
	P	9420T	Capsule 12.5mg (as malate) 28	-	-	1,332	2,702,163
	P	9421W	Capsule 25mg (as malate) 28	-	-	2,125	7,574,434
	P	9422X	Capsule 50mg (as malate) 28	-	-	1,119	7,796,750
	P	9489K	Capsule 25mg (as malate) 28	-	-	154	548,232
	P	9490L	Capsule 50mg (as malate) 28	-	-	121	842,049

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ANTINEOPLASTIC AGENTS							
OTHER ANTINEOPLASTIC AGENTS							
OTHER ANTINEOPLASTIC AGENTS							
L01XX27			ARSENIC TRIOXIDE				
	P	5851Y	Injection concentrate 10mg in 10mL 60	-	-	113	133,475
L01XX32			BORTEZOMIB				
	P	5488W	Powder for inject 3.5mg (solvent required) 4	-	-	186	1,348,180
	P	9117W	Powder for injection 3.5mg (solvent required) 4	-	-	1,961	14,223,459
	P	9118X	Powder for injection 3.5mg (solvent required) 4	-	-	149	1,072,305
L01XX05			HYDROXYUREA				
	P	3093T	Capsule 500mg	-	-	36,148	2,783,999
L01XX19			IRINOTECAN				
	P	5833B	IV injection 500mg in 25mL	-	-	796	598,920
	P	5846Q	IV injection 300mg in 15mL	-	-	1,376	688,605
	P	5958N	IV injection 40mg in 2mL	-	-	1,968	149,229
	P	5959P	IV injection 100mg in 5mL	-	-	3,438	1,021,147
	P	8414W	IV injection 40mg in 2mL	-	-	2,054	517,565
	P	8415X	IV injection 100mg in 5mL	-	-	4,780	3,010,911
	P	9119Y	IV injection 500mg in 25mL	-	-	1,751	1,589,124
	P	9410G	IV injection 300mg in 15mL	-	-	4,825	2,964,728
L01XX17			TOPOTECAN				
	P	5985B	Powder for I.V. infusion 4mg (base)	-	-	127	135,036
	P	8199M	Powder for I.V. infusion 4mg (base)	-	-	311	629,204

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ENDOCRINE THERAPY							
HORMONES AND RELATED AGENTS							
PROGESTOGENS							
L02AB02			MEDROXYPROGESTERONE				
	P	2316X	Tablet 200mg	1000.00	MG	1,575	159,597
	P	2725K	Tablet 100mg	1000.00	MG	1,982	179,175
	P	2727M	Tablet 250mg	1000.00	MG	169	21,212
	P	2728N	Tablet 500mg	1000.00	MG	650	81,771
L02AB01			MEGESTROL				
	P	2734X	Tablet 160mg	160.00	MG	1,271	106,074
GONADOTROPHIN RELEASING HORMONE ANALOGUES							
L02AE03			GOSERELIN				
	P	1454M	Subcutaneous implant 3.6mg	0.13	MG	20,890	6,939,702
	P	8093Y	Subcutaneous implant 10.8mg (base) in prefilled injection syringe	0.13	MG	47,349	52,496,206
	P	9064C	Subcutaneous implant 3.6mg (base) in prefilled injection syringe and 28 tabs 50mg	0.13	MG	381	181,975
	P	9065D	Subcutaneous implant 10.8mg (base) in prefilled injection syringe and 28 tabs 50mg	0.13	MG	819	1,025,021
	P	9066E	Subcutaneous implant 10.8mg (base) in prefilled injection syringe and 84 tabs 50mg	0.13	MG	3,455	5,280,311
L02AE02			LEUPRORELIN ACETATE				
	A	14727	Injection 5mg	0.13	MG	2,684	—
	P	8707G	Suspns subcutaneous inj (mod rel) 7.5mg inj set	0.13	MG	637	267,649
	P	8708H	Suspns subcutaneous inj (mod rel) 22.5mg inj set	0.13	MG	4,109	4,554,956
	P	8709J	Suspns subcutaneous inj (mod rel) 30mg inj set	0.13	MG	1,012	1,468,872
	P	8859G	Suspns subcutaneous inj (mod rel) 45mg inj set	0.13	MG	3,236	6,890,624
	P	8875D	I.M. injection (modified release) 7.5mg diluent	0.13	MG	3,457	1,452,363
	P	8876E	I.M. injection (modified release) 22.5mg diluent	0.13	MG	14,271	15,821,745
	P	8877F	I.M. injection (modified release) 30mg diluent	0.13	MG	9,171	13,318,173
L02AE04			TRIPTORELIN				
	P	9379P	Powder for I.M. injection (prolonged release) 11.25mg (as embonate) with solvent, syringe and needles	0.13	MG	363	402,478

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
ENDOCRINE THERAPY							
HORMONE ANTAGONISTS AND RELATED AGENTS							
ANTI-ESTROGENS							
L02BA01	TAMOXIFEN						
	P	2109B	Tablet 10mg (base) 60	20.00	MG	2,570	95,355
	P	2110C	Tablet 20mg (base) 60	20.00	MG	123,685	7,108,053
L02BA02	TOREMIFENE						
	P	8216K	Tablet 60mg (base)	60.00	MG	1,550	114,201
ANTI-ANDROGENS							
L02BB03	BICALUTAMIDE						
	P	8094B	Tablet 50mg	50.00	MG	39,147	6,268,681
L02BB01	FLUTAMIDE						
	P	1417N	Tablet 250mg	750.00	MG	1,987	399,937
L02BB02	NILUTAMIDE						
	P	8131Y	Tablet 150mg	30.00	MG	4,693	1,124,014
AROMATASE INHIBITORS							
L02BG03	ANASTROZOLE						
	P	8179L	Tablet 1mg	1.00	MG	215,668	38,827,728
L02BG06	EXEMESTANE						
	P	8506Q	Tablet 25mg 30	25.00	MG	24,287	4,067,637
L02BG04	LETROZOLE						
	P	8245Y	Tablet 2.5mg	2.50	MG	139,035	25,025,780
OTHER HORMONE ANTAGONISTS AND RELATED AGENTS							
L02BX02	DEGARELIX						
	P	5455D	Powder for injection 80mg (as acetate) with solvent, syringe and needles 2 1	2.70	MG	707	298,666
	P	5456E	Powder for injection 120mg (as acetate) with solvent, syringe and needles 2 1	2.70	MG	171	75,439

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
IMMUNOSTIMULANTS							
CYTOKINES AND IMMUNOMODULATORS							
COLONY STIMULATING FACTORS							
L03AA02	FILGRASTIM						
	P	6126K	Injection 300ug in 1mL 20	0.35	MG	135	211,380
	P	6291D	Injection 300ug in 0.5mL 20	0.35	MG	2,014	3,726,573
	P	6292E	Injection 480ug in 0.5mL 20	0.35	MG	812	3,407,194
L03AA13	PEGFILGRASTIM						
	P	6363X	Injection 6mg in 0.6mL single use syringe	0.30	MG	17,242	35,310,849
INTERFERONS							
L03AB07	INTERFERON BETA-1a						
	P	8289G	Inj. set 1 vial powder dose 30ug (6,000,000iu)	4.30	UG	1,937	2,046,761
	P	8403G	Injection 44ug (12,000,000iu) in 0.5mL single syringe	4.30	UG	12,004	12,679,048
	P	8805K	Injection 30ug (6,000,000iu) in 0.5mL single syringe	4.30	UG	18,843	19,912,194
	P	8968B	Injection 44ug (12,000,000iu) in 0.5mL syringe dose auto injector	4.30	UG	599	629,949
	P	9332E	Solution for injection 132ug in 1.5mL multidose cartridge 4	4.30	UG	6,511	7,026,974
L03AB08	INTERFERON BETA-1b						
	P	8101J	Injection set 1 vial powder dose 8,000,000iu	4.00	ME	28,972	34,195,002
L03AB04	INTERFERON ALFA-2a						
	P	8180M	Solution for injection 3,000,000iu in 0.5mL 15	2.00	ME	1,441	791,336
	P	8181N	Solution for injection 3,000,000iu in 0.5mL 15	2.00	ME	173	90,955
	P	8551C	Injection 45,000,000iu in 0.5mL syringe 5	2.00	ME	170	113,228
L03AB05	INTERFERON ALFA-2b						
	P	8348J	Solution for injection 18,000,000iu in 1.2mL multi-dose pen 3	2.00	ME	227	143,433
L03AB11	PEGINTERFERON ALFA-2a						
	P	6449K	Prefilled syringe 180ug/0.5mL 8	26.00	UG	499	839,165
L03AB61	RIBAVIRIN and PEGINTERFERON ALFA-2a						
	P	6394M	112 ribavirin 200mg/4 syringes peg-interf alfa-2a 180mcg 2	-	-	366	658,626
	P	6395N	140 ribavirin 200mg/4 syringes peg-interf alfa-2a 180mcg 2	-	-	702	1,438,690
	P	6396P	168 ribavirin 200mg/4 syringes peg-interf alfa-2a 180mcg 2	-	-	729	1,636,500
L03AB60	RIBAVIRIN and PEGINTERFERON ALFA-2b						
	P	6405D	112 ribavirin 200mg/4 single use injection pens 2	-	-	186	321,435
	P	6407F	140 ribavirin 200mg/4 single use injection pens 2	-	-	311	565,284
	P	6410J	168 ribavirin 200mg/4 single use injection pens 2	-	-	120	270,599
OTHER IMMUNOSTIMULANTS							
L03AX03	BCG VACCINE						
	P	1131M	Vial powder for intravesical admin. 5x10 ⁸ CFU	-	-	1,846	1,007,333
	P	1140B	Injection set 1 vial Powder	-	-	1,627	561,047
	P	5901N	Injection set 1 vial Powder	-	-	1,086	227,070
	P	5902P	Ampoule containing powder 5x10 ⁸ CFU	-	-	274	54,920
L03AX13	GLATIRAMER ACETATE						
	P	8726G	Inj 20mg in 1mL single dose prefilled syringe	20.00	MG	26,389	28,830,836

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
IMMUNOSUPPRESSANTS							
IMMUNOSUPPRESSANTS							
SELECTIVE IMMUNOSUPPRESSANTS							
L04AA24	ABATACEPT						
	P	9621J	Powder for I.V. infusion 250mg	27.00	MG	4,187	6,761,459
L04AA18	EVEROLIMUS						
	P	8840G	Tablet 0.25mg 60	1.50	MG	200	61,174
	P	8841H	Tablet 0.5mg 60	1.50	MG	767	556,187
	P	8842J	Tablet 0.75mg 120	1.50	MG	420	647,017
	P	9352F	Tablet 1mg 120	1.50	MG	129	283,404
L04AA27	FINGOLIMOD						
	P	5262Y	Capsule 500ug (as hydrochloride) 28	0.50	MG	5,189	12,013,373
L04AA13	LEFLUNOMIDE						
	P	5449T	Tablet 10mg 30	20.00	MG	4,347	334,388
	P	5450W	Tablet 20mg 30	20.00	MG	8,257	938,025
	P	8374R	Tablet 10mg 30	20.00	MG	52,418	4,488,435
	P	8375T	Tablet 20mg 30	20.00	MG	117,464	14,856,128
L04AA06	MYCOPHENOLIC ACID						
	P	6208R	Capsule 250mg 600	2.00	GM	277	113,944
	P	6209T	Tablet 500mg 300	2.00	GM	1,238	960,706
	P	6370G	Tablet (enteric coated) 360mg 240	2.00	GM	246	168,452
	P	8649F	Capsule 250mg 300	2.00	GM	1,495	888,473
	P	8650G	Capsule 500mg 150	2.00	GM	10,106	6,512,489
	P	8652J	Tablet (enteric coated) 180mg 120	2.00	GM	364	103,515
	P	8653K	Tablet (enteric coated) 360mg 120	2.00	GM	1,832	934,495
L04AA23	NATALIZUMAB						
	P	9624M	Sol.concentrate for I.V. infusion 300mg in 15mL	10.00	MG	4,756	9,967,651
L04AA10	SIROLIMUS						
	P	8724E	Tablet 1mg 100	3.00	MG	449	383,651
	P	8833X	Tablet 2mg 100	3.00	MG	199	324,800

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
IMMUNOSUPPRESSANTS							
IMMUNOSUPPRESSANTS							
TUMOR NECROSIS FACTOR ALPHA INHIBITORS							
L04AB04			ADALIMUMAB				
P	8737W		Injection 40mg in 0.8mL prefilled syringe	2.90	MG	1,323	2,344,912
P	8741C		Injection 40mg in 0.8mL prefilled syringe	2.90	MG	12,063	21,386,484
P	8963R		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	119	211,400
P	8964T		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	119	210,847
P	8965W		Injection 40mg in 0.8mL prefilled pen 2	2.90	MG	250	442,106
P	8966X		Injection 40mg in 0.8mL prefilled pen 2	2.90	MG	368	651,801
P	9033K		Injection 40mg in 0.8mL prefilled syringe	2.90	MG	351	622,874
P	9034L		Injection 40mg in 0.8mL prefilled syringe	2.90	MG	2,697	4,785,378
P	9077R		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	332	589,088
P	9078T		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	2,901	5,141,488
P	9099X		Injection 40mg in 0.8mL prefilled syringe	2.90	MG	4,799	8,516,055
P	9100Y		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	30,176	53,528,847
P	9101B		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	1,522	2,697,221
P	9102C		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	9,370	16,624,137
P	9103D		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	1,763	3,129,872
P	9104E		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	10,140	17,990,941
P	9186L		Injection 40mg in 0.8mL prefilled syringe 6	2.90	MG	203	1,033,332
P	9187M		Injection 40mg in 0.8mL prefilled pen 6	2.90	MG	557	2,833,101
P	9188N		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	539	954,746
P	9189P		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	4,019	7,133,256
P	9190Q		Injection 40mg in 0.8mL prefilled pen 2	2.90	MG	1,679	2,980,579
P	9191R		Injection 40mg in 0.8mL prefilled pen 2	2.90	MG	11,212	19,900,161
P	9425C		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	728	1,291,356
P	9426D		Injection 40mg in 0.8mL prefilled pen 2	2.90	MG	875	1,552,187
P	9427E		Injection 40mg in 0.8mL prefilled syringe 2	2.90	MG	3,634	6,443,237
P	9428F		Injection 40mg in 0.8mL prefilled pen 2	2.90	MG	4,439	7,871,173
P	9680L		Injection 40mg in 0.8mL prefilled pen 2	2.90	MG	127	212,905
L04AB05			CERTOLIZUMAB PEGOL				
P	3425G		Injection 200mg in 1mL single use prefilled syringe 1	14.00	MG	4,286	7,320,227

				2011			
ATC	ITEM TYPE	CODE	FORM AND STRENGTH	DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
IMMUNOSUPPRESSANTS							
IMMUNOSUPPRESSANTS							
TUMOR NECROSIS FACTOR ALPHA INHIBITORS							
L04AB01	ETANERCEPT						
P	3449M	Injection 50mg in 1 mL single use prefilled syringes 4 1		7.00	MG	240	425,849
P	6367D	Injection set 4 vial pdr 25mg and 4 syringe solvent		7.00	MG	469	793,614
P	8637N	Injection set 4 vial pdr 25mg and 4 syringe solvent		7.00	MG	112	204,848
P	8638P	Injection set 4 vial pdr 25mg and 4 syringe solvent		7.00	MG	2,547	4,697,721
P	8779C	Injection set 4 vial pdr 25mg and 4 syringe solvent		7.00	MG	743	1,348,012
P	9036N	Injection set 4 vial pdr 25mg and 4 syringe solvent		7.00	MG	345	637,320
P	9085E	Injection 50mg in 1mL single use prefilled syr, 4		7.00	MG	375	666,395
P	9086F	Injection 50mg in 1mL single use prefilled syr, 4		7.00	MG	4,839	8,586,405
P	9087G	Injection 50mg in 1mL single use prefilled syr, 4		7.00	MG	276	489,763
P	9088H	Injection 50mg in 1mL single use prefilled syr, 4		7.00	MG	3,083	5,470,293
P	9089J	Injection 50mg in 1mL single use prefilled syr, 4		7.00	MG	1,080	1,916,576
P	9090K	Injection 50mg in 1mL single use prefilled syr, 4		7.00	MG	19,164	34,020,613
P	9091L	Injection 50mg in 1mL single use prefilled syr, 4		7.00	MG	123	218,394
P	9431J	Injection 50mg in 1mL single use prefilled syr, 4		7.00	MG	2,364	4,195,387
P	9455P	Injection 50mg in 1mL single use auto injector, 4		7.00	MG	922	1,636,115
P	9456Q	Injection 50mg in 1mL single use auto injector, 4		7.00	MG	5,097	9,044,217
P	9457R	Injection 50mg in 1mL single use auto injector, 4		7.00	MG	901	1,609,315
P	9458T	Injection 50mg in 1mL single use auto injector, 4		7.00	MG	4,133	7,338,944
P	9459W	Injection 50mg in 1mL single use auto injector, 4		7.00	MG	3,669	6,522,988
P	9460X	Injection 50mg in 1mL single use auto injector, 4		7.00	MG	19,266	34,216,717
P	9461Y	Injection 50mg in 1mL single use auto injector, 4		7.00	MG	286	507,580
P	9462B	Injection 50mg in 1mL single use auto injector, 4		7.00	MG	1,311	2,326,309
L04AB06	GOLIMUMAB						
P	3426H	Injection 50mg in 0.5mL single use prefilled syringe 1		1.66	MG	1,933	3,439,093
P	3427J	Injection 50mg in 0.5mL single use prefilled pen 1		1.66	MG	814	1,446,714
P	3428K	Injection 50mg in 0.5mL single use prefilled syringe 1		1.66	MG	4,999	8,886,932
P	3429L	Injection 50mg in 0.5mL single use prefilled pen 1		1.66	MG	1,094	1,944,975
P	3430M	Injection 50mg in 0.5mL single use prefilled syringe 1		1.66	MG	811	1,441,488
P	3431N	Injection 50mg in 0.5mL single use prefilled pen 1		1.66	MG	338	600,724
P	3432P	Injection 50mg in 0.5mL single use prefilled syringe 1		1.66	MG	1,884	3,348,316
P	3433Q	Injection 50mg in 0.5mL single use prefilled pen 1		1.66	MG	395	702,004
P	3434R	Injection 50mg in 0.5mL single use prefilled syringe 1		1.66	MG	857	1,523,376
P	3435T	Injection 50mg in 0.5mL single use prefilled pen 1		1.66	MG	337	598,984
P	3436W	Injection 50mg in 0.5mL single use prefilled syringe 1		1.66	MG	2,235	3,972,129
P	3437X	Injection 50mg in 0.5mL single use prefilled pen 1		1.66	MG	662	1,176,644
L04AB02	INFLIXIMAB						
P	6397Q	Powder for I.V. infusion 100mg 1		3.75	MG	762	1,815,776
P	6448J	Powder for I.V. infusion 100mg 1		3.75	MG	1,700	5,963,451
P	6496X	Powder for I.V. infusion 100mg 1		3.75	MG	469	1,738,274
P	9612X	Powder for I.V. infusion 100mg 1		3.75	MG	146	365,897
P	9613Y	Powder for I.V. infusion 100mg 1		3.75	MG	2,145	6,830,885
P	9617E	Powder for I.V. infusion 100mg 1		3.75	MG	237	907,593
P	9674E	Powder for I.V. infusion 100mg 1		3.75	MG	409	1,309,432

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS							
IMMUNOSUPPRESSANTS							
<i>IMMUNOSUPPRESSANTS</i>							
INTERLEUKIN INHIBITORS							
L04AC07			TOCILIZUMAB				
	P	9671B	Concentrate for injection 80mg in 4mL 1	20.00	MG	4,177	1,842,260
	P	9672C	Concentrate for injection 200mg in 10mL 1	20.00	MG	1,907	1,089,461
	P	9673D	Concentrate for injection 400mg in 20mL 1	20.00	MG	5,785	6,953,210
L04AC05			USTEKINUMAB				
	P	9304Q	Injection 45mg in 0.5mL	0.54	MG	1,177	7,168,538
	P	9305R	Injection 45mg in 0.5mL	0.54	MG	1,677	10,973,299
CALCINEURIN INHIBITORS							
L04AD01			CYCLOSPORIN				
	P	6232B	Capsule 10mg (with microemulsion pre-concentrate) 120	0.25	GM	300	24,462
	P	6352H	Capsule 25mg 120	0.25	GM	1,316	225,401
	P	6353J	Capsule 50mg 120	0.25	GM	1,129	341,608
	P	6354K	Capsule 100mg 120	0.25	GM	1,479	790,970
	P	8657P	Capsule 10mg 120	0.25	GM	1,375	157,800
	P	8658Q	Capsule 25mg 60	0.25	GM	8,495	1,133,815
	P	8659R	Capsule 50mg 60	0.25	GM	12,520	2,712,630
	P	8660T	Capsule 100mg 60	0.25	GM	11,810	4,946,983
	P	8661W	Oral liquid 100mg per mL	0.25	GM	277	172,128
L04AD02			TACROLIMUS				
	P	5299X	Capsule 0.5mg 30	5.00	MG	279	22,491
	P	5300Y	Capsule 1mg (once daily prolonged release) 60	5.00	MG	598	192,468
	P	5451X	Capsule 5mg (once daily prolonged release) 30	5.00	MG	181	131,977
	P	6216E	Capsule 1mg 200	5.00	MG	849	612,132
	P	6328C	Capsule 500ug 200	5.00	MG	208	48,202
	P	8646C	Capsule 500ug 100	5.00	MG	3,956	795,524
	P	8647D	Capsule 1mg 100	5.00	MG	11,221	6,242,627
	P	8648E	Capsule 5mg 100	5.00	MG	528	754,499
OTHER IMMUNOSUPPRESSANTS							
L04AX01			AZATHIOPRINE				
	P	2687K	Tablet 50mg	0.15	GM	148,416	8,179,191
	P	2688L	Tablet 25mg	0.15	GM	17,053	604,414
L04AX04			LENALIDOMIDE				
	P	9643M	Capsule 10mg 21	10.00	MG	494	2,907,307
	P	9644N	Capsule 15mg 21	10.00	MG	586	3,883,781
	P	9645P	Capsule 25mg 21	10.00	MG	1,234	8,613,410
L04AX02			THALIDOMIDE				
	P	6469L	Capsules 50mg 112	0.10	GM	2,820	3,103,418
	P	9684Q	Capsules 100mg 56	0.10	GM	1,129	1,571,458

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
MUSCULO-SKELETAL SYSTEM							
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS							
ANTIINFLAMMATORY/ANTIRHEUMATIC PRODDUCTS, NON-STEROIDS							
ACETIC ACID DERIVATIVES AND RELATED SUBSTANCES							
M01AB05 DICLOFENAC							
P	1299J		Tablet 25mg (enteric coated)	0.10	GM	71,607	891,172
P	1300K		Tablet 50mg (enteric coated) 50	0.10	GM	807,472	8,730,212
P	1302M		Suppository 100mg 40	0.10	GM	13,903	334,612
A	16918		Tablet 25mg 20	0.10	GM	9,695	–
A	16971		Tablet 25mg 10	0.10	GM	1,565	–
A	17454		Tablet 25mg 30	0.10	GM	11,486	–
A	18567		Tablet 50mg 20	0.10	GM	142,621	–
A	18726		Suppository 50mg 10	0.10	GM	1,430	–
A	20662		Tablet 25mg (enteric coated) 30	0.10	GM	2,281	–
A	20718		Tablet 25mg 30	0.10	GM	1,721	–
P	5077F		Tablet 50mg (enteric coated)	0.10	GM	1,630	16,158
P	5361E		Tablet 25mg (enteric coated) 100	0.10	GM	113	1,441
P	5362F		Tablet 50mg (enteric coated) 50	0.10	GM	1,175	14,593
P	5365J		Tablet 50mg (enteric coated) 50	0.10	GM	847	9,779
M01AB55 DICLOFENAC with MISOPROSTOL							
P	4190M		Tablet 50mg 200ug 60	–	–	1,018	39,744
M01AB01 INDOMETHACIN							
P	2454E		Capsule 25mg	0.10	GM	293,848	3,432,413
P	2757D		Suppository 100mg	0.10	GM	51,720	1,125,151
P	5377B		Capsule 25mg 100	0.10	GM	342	4,001
P	5379D		Capsule 25mg 100	0.10	GM	292	3,428
M01AB15 KETOROLAC							
A	13986		Ampoule 30mg per 1mL 5	30.00	MG	2,400	–
A	14188		Tablet 10mg 30	30.00	MG	1,985	–
A	14950		Ampoule 10mg per 1mL	30.00	MG	119	–
M01AB02 SULINDAC							
P	2047R		Tablet 100mg	0.40	GM	1,737	27,812
P	2048T		Tablet 200mg	0.40	GM	4,981	76,119
P	5217N		Tablet 100mg	0.40	GM	819	–
P	5218P		Tablet 200mg	0.40	GM	2,199	15

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
MUSCULO-SKELETAL SYSTEM							
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS							
ANTIINFLAMMATORY/ANTIRHEUMATIC PRODDUCTS, NON-STEROIDS							
OXICAMS							
M01AC06 MELOXICAM							
P	8561N		Tablet 7.5mg	15.00	MG	295,834	5,418,563
P	8562P		Tablet 15mg	15.00	MG	833,659	19,808,926
P	8887R		Capsule 7.5mg 30	15.00	MG	373,397	6,851,257
P	8888T		Capsule 15mg 30	15.00	MG	822,119	19,547,982
M01AC01 PIROXICAM							
P	1895R		Dispersible tablet 10mg 50	20.00	MG	3,298	40,014
P	1896T		Dispersible tablet 20mg 25	20.00	MG	50,143	597,909
P	1897W		Capsule 10mg	20.00	MG	22,410	273,518
P	1898X		Capsule 20mg	20.00	MG	108,078	1,287,711
P	5203W		Capsule 10mg	20.00	MG	262	2,958
P	5204X		Capsule 20mg	20.00	MG	206	2,454
PROPIONIC ACID DERIVATIVES							
M01AE01 IBUPROFEN							
A	13267		Tablet 200mg 12	1.20	GM	267	—
A	13268		Tablet 200mg 24	1.20	GM	3,636	—
A	13372		Tablet 200mg 48	1.20	GM	2,384	—
A	15401		Susp 0.1/5mL 100mL	1.20	GM	420	—
A	21048		Tablet 200mg 50	1.20	GM	3,002	—
A	21412		Tablet 400mg 12	1.20	GM	259	—
A	21413		Tablet 400mg 24	1.20	GM	962	—
A	21414		Tablet 400mg 10	1.20	GM	203	—
P	3190X		Tablet 400mg	1.20	GM	183,869	2,652,488
P	3192B		Tablet 400mg 30	1.20	GM	224,118	2,061,146
P	5123P		Tablet 400mg	1.20	GM	399	4,311
P	5124Q		Tablet 400mg 30	1.20	GM	8,218	74,808
P	5368M		Tablet 400mg 100	1.20	GM	475	8,619

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
MUSCULO-SKELETAL SYSTEM							
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS							
ANTIINFLAMMATORY/ANTIRHEUMATIC PRODDUCTS, NON-STEROIDS							
PROPIONIC ACID DERIVATIVES							
M01AE51 IBUPROFEN with CODEINE							
A	17716		Tablet 200mg/12.8mg 48	–	–	1,699	–
A	18882		Tablet 200mg/12.8mg 48	–	–	324	–
A	18887		Tablet 200mg/12.8mg 48	–	–	275	–
A	19136		Tablet 200mg/12.5mg 12	–	–	5,141	–
A	19137		Tablet 200mg/12.5mg 12	–	–	18,233	–
A	19138		Tablet 200mg/12.5mg 12	–	–	3,014	–
A	19795		Tablet 200mg/12.8mg 75	–	–	1,231	–
A	20613		Tablet 200mg/12.8mg 48	–	–	258	–
A	21001		Tablet 200mg/12.5mg 15	–	–	1,761	–
A	21002		Tablet 200mg/12.5mg 30	–	–	42,944	–
A	21099		Tablet 200mg/12.8mg 30	–	–	50,265	–
A	21114		Tablet 200mg/12.8mg 30	–	–	19,505	–
A	21115		Tablet 200mg/12.8mg 24	–	–	174	–
A	21127		Tablet 200mg/12.8mg 24	–	–	390	–
A	21135		Tablet 200mg/12.8mg 24	–	–	381	–
A	21376		Tablet 200mg/12.8mg 24	–	–	403	–
M01AE03 KETOPROFEN							
P	1588N		Suppository 100mg	0.15	GM	1,709	43,097
P	1590Q		Capsules 200mg (sustained release) 28	0.15	GM	124,545	2,382,717
P	5136H		Capsule 200mg (sustained release)	0.15	GM	236	4,283
M01AE02 NAPROXEN							
A	11401		Tablet 275mg 12	0.50	GM	958	–
P	1614Y		Tablet 750mg (sustained release) 28	0.50	GM	101,532	1,225,225
P	1615B		Tablet 1g (sustained release) 28	0.50	GM	215,496	3,006,352
P	1658G		Oral suspension 125mg per 5mL 474mL	0.50	GM	773	63,802
P	1659H		Tablet 500mg	0.50	GM	169,968	2,135,301
P	1674D		Tablet 250mg	0.50	GM	47,622	608,562
P	1795L		Tablet 550mg 50	0.50	GM	37,543	478,248
P	5176K		Tablet 250mg	0.50	GM	140	1,357
P	5177L		Tablet 500mg	0.50	GM	291	3,559
P	5346J		Tablet 500mg 50	0.50	GM	249	3,166
P	5347K		Tablet 750mg (sustained release) 28	0.50	GM	340	4,224
P	5348L		Tablet 1g (sustained release) 28	0.50	GM	213	3,229
P	5349M		Tablet 250mg 100	0.50	GM	152	1,446
P	5350N		Tablet 500mg 50	0.50	GM	111	1,380
P	5397C		Oral suspension 125mg per 5mL 474mL	0.50	GM	272	21,210
M01AE11 TIAPROFENIC ACID							
P	2103Q		Tablet 300mg	600.00	MG	8,140	142,779

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
MUSCULO-SKELETAL SYSTEM							
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS							
ANTIINFLAMMATORY/ANTIRHEUMATIC PRODDUCTS, NON-STEROIDS							
FENAMATES							
M01AG01 MEFENAMIC ACID							
	A	11611	Capsule 250mg 20	1.00	GM	1,079	–
	P	1824B	Capsule 250mg	1.00	GM	46,048	833,514
COXIBS							
M01AH01 CELECOXIB							
	A	17093	Capsule 200mg 10	0.20	GM	5,064	–
	P	8439E	Capsule 100mg 60	0.20	GM	238,573	7,659,158
	P	8440F	Capsule 200mg 60	0.20	GM	1,256,674	41,439,420
M01AH05 ETORICOXIB							
	A	20525	Tablet 30mg 30	60.00	MG	4,188	–
	A	20526	Tablet 60mg 30	60.00	MG	7,797	–
	A	20527	Tablet 120mg 10	60.00	MG	5,414	–
OTHER ANTIINFL./ANTIRHEUMATIC AGENTS, NON-STEROIDS							
M01AX12 PENTOSAN-POLY SULFATE SODIUM							
	A	14955	Capsule 100mg 100	–	–	393	–
SPECIFIC ANTIRHEUMATIC AGENTS							
GOLD PREPARATIONS							
M01CB03 AURANOFIN							
	P	1095P	Tablet 3mg	6.00	MG	2,269	147,883
M01CB01 SODIUM AUROTHIOMALATE							
	P	2016D	Injection 10mg	2.40	MG	115	7,599
	P	2017E	Injection 20mg	2.40	MG	222	22,757
	P	2018F	Injection 50mg	2.40	MG	1,377	209,816
PENICILLAMINE							
M01CC01 PENICILLAMINE							
	P	2721F	Tablet 125mg	0.50	GM	353	12,589
	P	2838J	Tablet 250mg	0.50	GM	3,748	196,267

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
MUSCULO-SKELETAL SYSTEM							
TOPICAL PRODUCTS FOR JOINT and MUSCULAR PAIN							
<i>TOPICAL PRODUCTS FOR JOINT and MUSCULAR PAIN</i>							
ANTIINFL. PREP., NON-STERIODS FOR TOPICAL USE							
M02AA15 DICLOFENAC							
	A	14860	Gel 50g 1	-	-	3,417	-
	A	14861	Gel 100g 1	-	-	11,872	-
	A	14979	Gel 20g 1	-	-	1,164	-
M02AA07 PIROXICAM							
	A	15090	Gel 0.5% 25g 1	-	-	344	-
	A	15091	Gel 0.5% 50g 1	-	-	876	-
CAPSAICIN and SIMILAR AGENTS							
M02AB CAPSAICIN							
	A	15579	Cream 0.025% 45g	-	-	153	-
PREPARATIONS with SALICYLIC ACID DERIVATIVES							
M02AC METHYL SALICYLATE							
	A	12931	Cream 100g 1	-	-	425	-
	P	4022Q	Compound Cream APF 100gm	-	-	2,083	29,888
	P	4023R	Ointment BP 100gm	-	-	1,011	12,424
	P	4026X	Liniment APF 100gm	-	-	1,155	11,532
M02AC METHYL SALICYLATE with MENTHOL with EUCALYPTUS OIL							
	A	11224	Cream 125g 1	-	-	6,971	-
	A	12943	Cream 50g 1	-	-	263	-

M

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
MUSCULO-SKELETAL SYSTEM							
MUSCLE RELAXANTS							
<i>MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS</i>							
ETHERS, CHEMICALLY CLOSE TO ANTIHISTAMINES							
M03BC01			ORPHENADRINE CITRATE				
	A	11353	Tablet 100mg 100	0.12	GM	9,503	–
M03BC51			ORPHENADRINE CITRATE with PARACETAMOL				
	A	11354	Tablet 35mg–450mg 100	0.12	GM	7,732	–
	A	21041	Tablet 35mg–450mg 24	0.12	GM	12,154	–
OTHER CENTRALLY ACTING AGENTS							
M03BX01			BACLOFEN				
	P	2729P	Tablet 10mg	50.00	MG	107,146	3,543,243
	P	2730Q	Tablet 25mg	50.00	MG	54,536	3,311,190
	P	6284R	Intrathecal injection 10mg in 5mL 10	0.55	MG	167	107,805
<i>MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS</i>							
DANTROLENE AND DERIVATIVES							
M03CA01			DANTROLENE SODIUM				
	P	1779P	Capsule 25mg	0.10	GM	5,447	407,647
	P	1780Q	Capsule 50mg	0.10	GM	2,524	211,939

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
MUSCULO-SKELETAL SYSTEM							
ANTIGOUT PREPARATIONS							
ANTIGOUT PREPARATIONS							
PREPARATIONS INHIBITING URIC ACID PRODUCTION							
M04AA01 ALLOPURINOL							
	P	2600W	Tablet 100mg	0.40	GM	298,779	3,807,654
	P	2604C	Tablet 300mg	0.40	GM	814,169	8,305,863
PREPARATIONS INCREASING URIC ACID EXCRETION							
M04AB01 PROBENECID							
	P	1940D	Tablet 500mg	1.00	GM	18,928	1,417,819
PREPARATIONS WITH NO EFFECT ON URIC ACID METABOLISM							
M04AC01 COLCHICINE							
	P	3410L	Tablet 500ug 30	1.00	MG	407,860	4,579,764

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
MUSCULO-SKELETAL SYSTEM							
DRUGS FOR TREATMENT OF BONE DISEASES							
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION							
BISPHOSPHONATES							
M05BA04			ALENDRONIC ACID				
	P	8090T	Tablet 40mg	10.00	MG	11,133	1,233,712
	P	8511Y	Tablet 70mg alendronic acid 4	10.00	MG	566,106	22,273,005
M05BA02			CLODRONIC ACID				
	P	8132B	Capsule equivalent to 400mg sodium clodronate	1.60	GM	635	218,040
	P	8265B	Capsule equivalent to 800mg sodium clodronate	1.60	GM	10,289	4,023,804
M05BA01			DISODIUM ETIDRONATE				
	P	2920Q	Tablet 200mg	0.40	GM	335	49,567
M05BA03			DISODIUM PAMIDRONATE				
	P	6223M	Vial pdr for IV infuse 90mg amp solvent 10mL	60.00	MG	2,566	1,041,142
	P	6289B	Concentrated injection 90mg in 10mL	60.00	MG	403	156,364
	P	8209C	2 Vials pdr for IV infuse 30mg 2 amp solvent 10mL	60.00	MG	222	57,725
	P	8462J	Concentrated injection 30mg in 10mL	60.00	MG	192	42,125
	P	8463K	Concentrated injection 60mg in 10mL	60.00	MG	122	34,100
M05BA06			IBANDRONIC ACID				
	P	9357L	Tablet 50mg (as ibandronate sodium monohydrate) 28	5.00	MG	7,179	2,458,694
	P	9619G	Inj for I.V. infusion equiv 6mg (as ibandronate sodium monohydrate) in 6mL	6.00	MG	1,399	519,486
M05BA07			RISEDRONIC ACID				
	P	4444X	Tablet 35mg 4	5.00	MG	1,670	80,649
	P	8481J	Tablet 5mg 28	5.00	MG	7,967	383,500
	P	8482K	Tablet 30mg 28	5.00	MG	2,914	789,281
	P	8621R	Tablet 35mg	5.00	MG	307,687	14,821,966
	P	8972F	Tablet 35mg (enteric coated) 4	5.00	MG	35,478	1,647,400
	P	9391G	Tablet 150mg 1	5.00	MG	331,281	16,932,501
M05BA05			TILUDRONIC ACID				
	P	8267D	Tablet 200mg	0.40	MG	488	148,655
M05BA08			ZOLEDRONIC ACID				
	P	6371H	Injection concentrate I.V. infusion 4mg (as monohydrate) in 5mL	4.00	MG	22,355	11,521,908
	P	9288W	Solution for I.V. infusion 5mg (as monohydrate) in 100mL	0.01	MG	27,537	16,213,056
	P	9350D	Solution for I.V. infusion 5mg (as monohydrate) in 100mL	0.01	MG	880	517,607

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
MUSCULO-SKELETAL SYSTEM							
DRUGS FOR TREATMENT OF BONE DISEASES							
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION							
BISPHOSPHONATES, COMBINATIONS							
M05BB05			ALENDRONATE SODIUM with COLECALCIFEROL and CALCIUM CARBONATE				
	P	9351E	Pack 4 tablets equiv 70mg alendronic acid with 140ug colecalciferol, 48 tablets calcium carbonate 1.25g	10.00	MG	235,622	10,631,507
M05BB03			ALENDRONIC ACID and COLECALCIFEROL				
	P	9012H	Tablet equiv to 70mg alendronic with 70ug Colecal	-	-	312,243	14,100,363
	P	9183H	Tablet equiv to 70mg alendronic with 140ug Colecal	-	-	439,522	19,843,357
M05BB01			ETIDRONIC ACID AND CALCIUM				
	P	8056B	28 tabs 200mg and 76 tabs calcium (equiv 500mg)	-	-	6,222	439,148
M05BB04			RISEDRONIC ACID and CALCIUM CARBONATE with COLECALCIFEROL				
	P	4380M	4 tablets 35mg and 24 sachets granules 2.5g-22ug	-	-	1,297	62,728
	P	8974H	4 tablets 35mg and 24 sachets granules 2.5g-22ug	-	-	39,378	1,829,574
	P	9147K	4 tablets 35mg and 24 sachets granules 2.5g-22ug	-	-	275,632	13,313,619
M05BB02			RISEDRONIC SODIUM with CALCIUM CARBONATE				
	P	4059P	Pack containing 4 tablets 35mg and 24 tabs 1.25g	-	-	1,628	79,698
	P	8899J	Pack containing 4 tablets 35mg and 24 tabs 1.25g	-	-	373,806	18,053,356
	P	8973G	Pack containing 4 tablets 35mg and 24 tabs 1.25g	-	-	36,324	1,687,086
OTHER DRUGS AFFECTING BONE STRUCTURE							
M05BX04			DENOSUMAB				
	P	5110Y	Injection 120mg in 1.7ml 1	0.33	MG	302	160,374
	P	5457F	Injection 60mg in 1 ml prefilled syringe	0.33	MG	13,454	4,103,294
M05BX03			STRONTIUM RANELATE				
	P	3036T	Granules for oral suspension 2g, 28 Sachets	2.00	GM	336,269	17,904,218

N

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANAESTHETICS							
ANAESTHETICS, GENERAL							
OPIOID ANAESTHETICS							
N01AH01 FENTANYL							
	A	14186	Ampoule 100ug/2.5	-	-	274	-
OTHER GENERAL ANAESTHETICS							
N01AX03 KETAMINE HYDROCHLORIDE							
	A	11084	Ampoule 200mg/2mL	-	-	232	-
ANAESTHETICS, LOCAL							
AMIDES							
N01BB02 LIGNOCAINE HYDROCHLORIDE							
	A	15896	Ampoule 1% 2mL	-	-	709	-
N01BB52 PRILOCAINE with LIGNOCAINE							
	A	14984	Patch 1g	-	-	342	-

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANALGESICS							
OPIOIDS							
NATURAL OPIUM ALKALOIDS							
N02AA55 OXYCODONE COMBINATIONS							
	P	8000C	Tablet 5mg–2.5mg 28	75.00	MG	835	25,680
	P	8934F	Tablet 10mg–5mg (controlled release) 28	75.00	MG	1,018	33,047
	P	8935G	Tablet 20mg–10mg (controlled release) 28	75.00	MG	585	30,887
	P	8936H	Tablet 40mg–20mg (controlled release) 28	75.00	MG	229	21,873
N02AA55 OXYCODONE with NALOXONE							
	A	21342	Tablet 5mg–2.5mg 20	75.00	MG	367	–
	A	21343	Tablet 10mg–5mg 20	75.00	MG	417	–
	A	21344	Tablet 20mg–10mg 20	75.00	MG	1,136	–
N02AA59 CODEINE with ASPIRIN							
	A	10090	Tablet soluble 8mg–300mg 20	–	–	5,885	–
	A	10466	Tablet soluble 8mg–500mg 24	–	–	1,253	–
	A	21158	Tablet soluble 9.5mg–500mg 24	–	–	330	–
	A	21174	Tablet soluble 8mg–300mg 40	–	–	1,484	–
	P	4061R	Tablet soluble 8mg–300mg 50	–	–	781	12,129
N02AA59 CODEINE with PARACETAMOL							
	A	11705	Capsule 8mg–500mg 50	–	–	1,119	–
	A	11706	Tablet 8mg–500mg 100	–	–	7,663	–
	A	11755	Tablet soluble 8mg–500mg 24	–	–	2,111	–
	P	1215Y	Tablet 30mg–500mg 20	–	–	2,475,701	19,831,389
	A	12670	Tablet 8mg–500mg 20	–	–	132	–
	A	12736	Tablet 30mg–500mg 50	–	–	3,611	–
	A	17212	Tablet 9.6mg–500mg 48	–	–	941	–
	A	17267	Caplet 8mg–500mg 48	–	–	735	–
	A	17819	Tablet 8mg–500mg 24	–	–	5,056	–
	A	17820	Tablet 8mg–500mg 48	–	–	1,691	–
	A	18373	Tablet 8mg–500mg 24	–	–	10,468	–
	A	18376	Tablet 8mg–500mg 96	–	–	368	–
	A	18377	Tablet 8mg–500mg 100	–	–	350	–
	A	18378	Tabsole 8mg–500mg 24	–	–	731	–
	A	18734	Tablet 15mg–500mg 12	–	–	21,426	–
	A	19039	Caplet 8mg–500mg 24	–	–	10,577	–
	A	19041	Tablet 8mg–500mg 24	–	–	14,432	–

N

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANALGESICS							
OPIOIDS							
NATURAL OPIUM ALKALOIDS							
A	21096		Tablet 9.6mg–500mg 36	–	–	1,737	–
A	21097		Tablet 9.6mg–500mg 24	–	–	12,471	–
A	21098		Tablet 9.6mg–500mg 12	–	–	509	–
A	21111		Tablet 10mg–500mg 40	–	–	12,495	–
A	21112		Tabsole 10mg–500mg 40	–	–	1,092	–
A	21113		Tablet 10mg–500mg 40	–	–	5,709	–
A	21142		Tablet 10mg–500mg 24	–	–	144	–
A	21146		Tablet 10mg–500mg 40	–	–	732	–
A	21168		Tablet 8mg–500mg 40	–	–	636	–
A	21173		Tablet 8mg–500mg 40	–	–	561	–
A	21224		Tablet 10mg–500mg 40	–	–	557	–
A	21225		Caplet 8mg–500mg 40	–	–	8,175	–
A	21226		Tablet 8mg–500mg 40	–	–	20,842	–
A	21227		Caplet 15mg–500mg 24	–	–	23,010	–
A	21240		Tablet 10mg–500mg 24	–	–	207	–
A	21241		Tablet 10mg–500mg 40	–	–	691	–
A	21243		Tablet 10mg–500mg 96	–	–	119	–
P	3316M		Tablet 30mg–500mg 20	–	–	141,767	1,133,893
P	4170L		Tablet 15mg–500mg 20	–	–	10,935	154,993
P	4171M		Tablet 8mg–500mg	–	–	15,806	209,846
P	8785J		Tablet 30mg–500mg 60	–	–	1,050,145	17,869,798
N02AA08 DIHYDROCODEINE							
A	11785		Linctus 200mL 1	–	–	9,955	–
A	12825		Linctus 100mL 1	–	–	6,440	–
N02AA03 HYDROMORPHONE							
P	8420E		Injection 2mg in 1mL 5	4.00	MG	3,944	158,850
P	8421F		Injection 10mg in 1mL 5	4.00	MG	2,913	288,791
P	8422G		Injection 50mg in 5mL 5	4.00	MG	2,348	337,966
P	8424J		Oral liquid 1mg per mL 473mL	20.00	MG	5,575	422,358
P	8541M		Tablet 2mg 20	20.00	MG	3,410	87,527
P	8542N		Tablet 4mg	20.00	MG	3,432	115,934
P	8543P		Tablet 8mg	20.00	MG	3,527	304,873
P	9299K		Tablet 4mg (modified release) 10	20.00	MG	19,439	745,959
P	9406C		Tablet 8mg (modified release) 10	20.00	MG	23,892	1,150,623
P	9407D		Tablet 16mg (modified release) 10	20.00	MG	19,714	1,448,684
P	9408E		Tablet 32mg (modified release) 10	20.00	MG	10,665	1,358,237
P	9409F		Tablet 64mg (modified release) 10	20.00	MG	4,957	1,403,245

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANALGESICS							
OPIOIDS							
NATURAL OPIUM ALKALOIDS							
NO2AA01 MORPHINE							
A		13087	Ampoule 5mg/mL 5	30.00	MG	3,787	–
A		15415	Mixture 200mL 1mg per mL	100.00	MG	794	–
P		1607N	Injection 120mg in 1.5mL	30.00	MG	2,679	343,553
P		1644M	Injection 10mg in 1mL	30.00	MG	76,146	1,272,024
P		1645N	Injection 15mg in 1mL	30.00	MG	12,715	290,500
P		1646P	Tablet 30mg	100.00	MG	11,586	253,471
P		1647Q	Injection 30mg in 1mL	30.00	MG	23,606	851,017
P		1653B	Tablet 10mg (controlled release)	100.00	MG	69,215	1,927,806
P		1654C	Tablet 30mg (controlled release)	100.00	MG	72,447	3,814,326
P		1655D	Tablet 60mg (controlled release)	100.00	MG	56,387	4,734,512
P		1656E	Tablet 100mg (controlled release)	100.00	MG	50,333	6,163,096
A		19608	Injection 10mg in 1mL	30.00	MG	212	–
P		2122Q	Oral solution 2mg per mL 200mL	100.00	MG	18,514	333,115
P		2123R	Oral solution 5mg per mL 200mL	100.00	MG	26,812	573,941
P		2124T	Oral solution 10mg per mL 200mL	100.00	MG	28,215	886,845
P		2839K	Capsule 20mg (sustained release)	100.00	MG	47,801	1,864,586
P		2840L	Capsule 50mg (sustained release)	100.00	MG	37,064	2,338,360
P		2841M	Capsule 100mg (sustained release)	100.00	MG	27,224	3,283,132
P		3479D	Injection 15mg in 1mL	30.00	MG	8,463	121,442
P		3480E	Injection 30mg in 1mL	30.00	MG	3,270	51,580
P		5393W	Tablet 10mg 20	100.00	MG	177	5,338
P		5394X	Tablet 20mg 20	100.00	MG	153	3,483
P		8035X	Tablet 5mg (controlled release)	100.00	MG	27,819	543,884
P		8146R	Sachet 30mg (controlled release)	100.00	MG	1,063	89,874
P		8305D	Sachet 60mg granules for oral suspn	100.00	MG	646	69,018
P		8306E	Sachet 100mg granules for oral suspn	100.00	MG	406	66,225
P		8349K	Capsule 10mg (sustained release) 20	100.00	MG	21,366	524,431
P		8453X	Tablet 200mg (controlled release)	100.00	MG	713	235,613
P		8489T	Tablet 15mg (controlled release) 20	100.00	MG	35,340	1,106,383
P		8490W	Sachet 20mg granules for oral suspn 20	100.00	MG	2,891	230,630
P		8491X	Capsule 30mg (controlled release) 10	100.00	MG	2,420	79,262
P		8492Y	Capsule 60mg (controlled release) 10	100.00	MG	2,669	148,457
P		8493B	Capsule 90mg (controlled release) 10	100.00	MG	2,597	189,452
P		8494C	Capsule 120mg (controlled release) 10	100.00	MG	3,433	387,200
P		8669G	Tablet 10mg 20	100.00	MG	1,180	18,286
P		8670H	Tablet 20mg 20	100.00	MG	915	18,183

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANALGESICS							
OPIOIDS							
NATURAL OPIUM ALKALOIDS							
N02AA05 OXYCODONE							
A	16416		Tablet 20mg (controlled release) 60	75.00	MG	180	—
A	16420		Tablet 80mg (controlled release) 60	75.00	MG	248	—
P	2481N		Suppository 30mg	30.00	MG	8,392	783,553
P	2622B		Tablet 5mg	75.00	MG	1,251,453	17,812,723
P	5195K		Tablet 5mg	75.00	MG	1,754	21,460
P	8385H		Tablet 10mg (controlled release) 20	75.00	MG	396,552	12,638,793
P	8386J		Tablet 20mg (controlled release) 20	75.00	MG	328,654	17,860,449
P	8387K		Tablet 40mg (controlled release) 20	75.00	MG	213,048	19,232,764
P	8388L		Tablet 80mg (controlled release) 20	75.00	MG	121,866	17,950,960
P	8464L		Capsule 5mg 20	75.00	MG	87,644	1,223,375
P	8501K		Capsule 10mg 20	75.00	MG	117,738	2,556,469
P	8502L		Capsule 20mg 20	75.00	MG	78,035	3,005,102
P	8644Y		Oral solution 5mg per 5mL 250mL	75.00	MG	11,012	304,426
P	8681X		Tablet 5mg (controlled release) 20	75.00	MG	220,409	6,313,132
P	9399Q		Tablet 15mg (controlled release) 20	75.00	MG	83,210	3,555,379
P	9400R		Tablet 30mg (controlled release) 20	75.00	MG	103,992	7,679,206
PHENYLPIPERIDINE DERIVATIVES							
N02AB03 FENTANYL							
P	5265D		Transdermal patch 1.28mg (releasing approx. 12ug per hour) 5	1.20	MG	7,319	306,211
P	5277R		Transdermal patch 2.55mg (releasing approx. 25ug per hour) 5	1.20	MG	10,249	518,218
P	5278T		Transdermal patch 5.10mg (releasing approx. 50ug per hour) 5	1.20	MG	5,695	479,435
P	5279W		Transdermal patch 7.65mg (releasing approx. 75ug per hour) 5	1.20	MG	2,318	257,150
P	5280X		Transdermal patch 10.20mg (releasing approx. 100ug per hour) 5	1.20	MG	2,081	285,175
P	5401G		Lozenge 200ug 3	0.60	MG	829	255,007
P	5402H		Lozenge 400ug 3	0.60	MG	328	112,528
P	5407N		Lozenges 200ug (as citrate) 3 20	0.60	MG	624	474,843
P	5408P		Lozenges 400ug (as citrate) 3 20	0.60	MG	555	506,407
P	5409Q		Lozenges 600ug (as citrate) 20	0.60	MG	208	230,786
P	5410R		Lozenge 800ug 3	0.60	MG	188	319,193
P	5437E		Transdermal patch 2.063mg (releasing approx. 12ug per hour)	1.20	MG	421	17,687
P	5438F		Transdermal patch 4.125mg (releasing approx. 25ug per hour)	1.20	MG	766	38,038
P	5439G		Transdermal patch 8.25mg (releasing approx. 50ug per hour)	1.20	MG	427	35,035
P	5440H		Transdermal patch 12.375mg (releasing approx. 75ug per hour)	1.20	MG	175	19,659
P	5441J		Transdermal patch 16.5mg (releasing approx. 100ug per hour)	1.20	MG	177	24,649
P	8878G		Transdermal patch 2.1mg (12ug per hour) 5	1.20	MG	162,994	8,783,710
P	8891Y		Transdermal patch 4.2mg (25ug per hour) 5	1.20	MG	184,584	12,438,347
P	8892B		Transdermal patch 8.4mg (50ug per hour) 5	1.20	MG	116,492	13,651,042
P	8893C		Transdermal patch 12.6mg (75ug per hour) 5	1.20	MG	58,406	9,320,207
P	8894D		Transdermal patch 16.8mg (100ug per hour) 5	1.20	MG	57,500	12,451,401

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANALGESICS							
OPIOIDS							
PHENYLPIPERIDINE DERIVATIVES							
N02AB02			PETHIDINE HYDROCHLORIDE				
	A	15888	Injection 100mg in 2mL 10	0.40	GM	2,906	–
	A	18990	Injection 100mg in 2mL	0.40	GM	11,289	–
	A	19593	Injection 50mg in 1mL	0.40	GM	145	–
	A	19982	Injection 100mg in 2mL 5	0.40	GM	12,568	–
DIPHENYLPROPYLAMINE DERIVATIVES							
N02AC04			DEXTROPROPOXYPHENE NAPSYLATE				
	P	4081T	Capsule 100mg	0.30	GM	18,343	535,309
N02AC54			DEXTROPROPOXYPHENE with PARACETAMOL				
	A	16347	Capsule 32.5mg 325mg 20	–	–	98,242	–
	A	16444	Tablet 32.5mg 325mg 20	–	–	323,012	–
	A	16650	Tablet 32.5mg 325mg 20	–	–	16,476	–
ORIPAVINE DERIVATIVES							
N02AE01			BUPRENORPHINE				
	A	15207	Tablets 2mg (slow release)	1.20	MG	1,523	–
	P	8865N	Trans patch 5mg (release approx 5ug per hour) 2	1.20	MG	467,380	14,792,664
	P	8866P	Trans patch 10mg (release approx 10ug per hour)	1.20	MG	446,297	23,271,444
	P	8867Q	Trans patch 20mg (release approx 20ug per hour)	1.20	MG	259,463	21,013,189
OTHER OPIOIDS							
N02AX02			TRAMADOL				
	P	2527B	Tablet 50mg (twice daily sustained release) 20	0.30	GM	142,685	2,284,094
	P	3484J	Injection 100mg in 2mL 5	0.30	GM	15,406	214,703
	P	5232J	Capsule 50mg 20	0.30	GM	2,062	18,542
	P	8455B	Capsule 50mg 20	0.30	GM	134,916	1,232,696
	P	8523N	Tablet 100mg (twice daily sustained release) 20	0.30	GM	442,246	8,966,330
	P	8524P	Tablet 150mg (twice daily sustained release) 20	0.30	GM	214,772	5,871,293
	P	8525Q	Tablet 200mg (twice daily sustained release) 20	0.30	GM	382,770	12,436,081
	P	8582Q	Injection 100mg in 2mL 5	0.30	GM	10,840	148,291
	P	8611F	Capsule 50mg 20	0.30	GM	853,616	7,713,802
	P	8843K	Oral drops 100mg per mL 10mL	0.30	GM	3,322	75,806
	P	9199E	Tablet 100mg (once a day extended release)	0.30	GM	24,918	499,673
	P	9200F	Tablet 200mg (once a day extended release) 10	0.30	GM	28,062	829,298
	P	9201G	Tablet 300mg (once a day extended release) 10	0.30	GM	17,632	658,925
OTHER ANALGESICS AND ANTIPYRETICS							
SALICYLIC ACID DERIVATIVES							
N02BA01			ASPIRIN				
	P	1010E	Tablet 300mg (dispersible)	3.00	GM	83,613	708,114

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANALGESICS							
OTHER ANALGESICS AND ANTIPYRETICS							
ANILIDES							
N02BE51			METOCLOPRAMIDE and PARACETAMOL				
A	19053		Tablet 5mg/500mg 8	—	—	2,212	—
A	19053		Tablet 5mg/500mg 8	—	—	2,212	—
A	19575		Capsule 5mg/500mg 10	—	—	513	—
A	19575		Capsule 5mg/500mg 10	—	—	513	—
N02BE01			PARACETAMOL				
A	11515		Tablet 500mg 50	3.00	GM	2,213	—
A	11516		Tablet 500mg 100	3.00	GM	398	—
A	11517		Tab-sol 500mg 24	3.00	GM	375	—
A	11519		Drop 20mL 1	3.00	GM	144	—
P	1746X		Tablet 500mg	3.00	GM	451,660	3,725,378
P	1747Y		Mixture 120mg per 5mL 100mL	3.00	GM	10,786	101,149
P	1770E		Elixir 240mg per 5mL 200mL	3.00	GM	102,913	1,338,542
P	5196L		Tablet 500mg	3.00	GM	324	2,668
P	5319Y		Suppositories 500mg 24	3.00	GM	2,157	152,084
P	5320B		Suppositories 500mg 24	3.00	GM	746	57,054
P	5343F		Tablet 665mg (modified release) 9 6	3.00	GM	5,293	87,262
P	5344G		Tablet 665mg (modified release) 9 6	3.00	GM	1,384	22,881
P	8784H		Tablet 500mg 300	3.00	GM	1,118,241	13,418,866
P	8814X		Tablet 665mg (modified release) 1 92	3.00	GM	3,761,261	62,237,213
N02BE51			PARACETAMOL with CODEINE with DOXYLAMINE				
A	10870		Tablet 24	—	—	3,800	—
A	10870		Tablet 24	—	—	3,800	—
A	12600		Tablet 20	—	—	35,858	—
A	12600		Tablet 20	—	—	35,858	—
A	12932		Capsule 24	—	—	1,649	—
A	12932		Capsule 24	—	—	1,649	—
A	13102		Tablet 20	—	—	157,742	—
A	13102		Tablet 20	—	—	157,742	—
A	13823		Capsule 20	—	—	567	—
A	13823		Capsule 20	—	—	567	—
A	14177		Tablet 20	—	—	23,072	—
A	14177		Tablet 20	—	—	23,072	—
A	15650		Caplet 500mg—8mg—5mg	—	—	10,867	—
A	15650		Caplet 500mg—8mg—5mg	—	—	10,867	—
A	17268		Tablet 500mg—9.6mg—5.1mg 20	—	—	1,740	—
A	17268		Tablet 500mg—9.6mg—5.1mg 20	—	—	1,740	—
A	20267		Caplet 450mg 9.75mg 5mg 20	—	—	160	—
A	20267		Caplet 450mg 9.75mg 5mg 20	—	—	160	—
A	21244		Tablet 450mg 9.75mg 5mg 24	—	—	491	—
A	21244		Tablet 450mg 9.75mg 5mg 24	—	—	491	—
A	21453		Tablet 450mg 9.75mg 5mg 20	—	—	5,097	—
A	21453		Tablet 450mg 9.75mg 5mg 20	—	—	5,097	—

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANALGESICS							
OTHER ANALGESICS AND ANTIPYRETICS							
ANILIDES							
N02BE51			PARACETAMOL with PROMETHAZINE with CODEINE				
A	14779		Syrup 200mL 1	–	–	2,785	–
A	14779		Syrup 200mL 1	–	–	2,785	–
A	18358		Syrup 120mg–6.5mg–5mg in 5mL 100mL	–	–	2,260	–
A	18358		Syrup 120mg–6.5mg–5mg in 5mL 100mL	–	–	2,260	–
OTHERS ANALGESICS AND ANTIPYRETICS							
N02BG09			METHOXYFLURANE				
P	3489P		Liquid for inhalation 999.9mg per g, 3mL (with inhaler)	–	–	11,478	513,965
ANTIMIGRAINE PREPARATIONS							
ERGOT ALKALOIDS							
N02CA01			DIHYDROERGOTAMINE				
P	1323P		Injection 1mg in 1mL	4.00	MG	1,731	44,899
P	3460D		Injection 1mg in 1mL	4.00	MG	4,650	79,251
N02CA52			ERGOTAMINE TARTRATE with CAFFEINE				
A	18569		Suppositories 2mg–100mg 5	–	–	7,877	–
N02CA52			ERGOTAMINE with CAFFEINE				
A	13550		Tablet 1mg–100mg 20	–	–	239	–
N02CA04			METHYSERGIDE				
P	2826R		Tablet 1mg	4.00	MG	6,855	320,756
SELECTIVE 5HT RECEPTOR AGONISTS							
N02CC06			ELETRIPTAN				
P	5290K		Tablet 40mg (as hydrobromide) 4	40.00	MG	25,265	622,005
P	5291L		Tablet 80mg (as hydrobromide) 4	40.00	MG	12,802	312,206
N02CC02			NARATRIPTAN				
P	8298R		Tablet 2.5mg (as hydrochloride) 4 (2 upto Feb06)	2.50	MG	78,811	2,035,724
P	9734H		Tablet 2.5mg (as hydrochloride) 4	2.50	MG	4,896	138,207
N02CC04			RIZATRIPTAN				
P	9313E		Wafer 10mg (as benzoate)	10.00	MG	105,779	2,638,386
N02CC01			SUMATRIPTAN				
A	14181		Tablet 100mg	50.00	MG	10,490	–
A	15987		Nasal Spray 10mg per dose 2	20.00	MG	2,399	–
A	16720		Injection 6mg in 0.5mL refill	6.00	MG	1,003	–
P	8144P		Tablet 50mg (base) 4 (2 upto Feb06)	50.00	MG	366,801	8,884,831
P	8341B		Nasal Spray 20mg per dose 2	20.00	MG	81,151	1,549,625
P	8885P		Tablet (fast disintegrating) 50mg (as succinate) 4	50.00	MG	46,818	1,130,671
N02CC03			ZOLMITRIPTAN				
P	8266C		Tablet 2.5mg 4 (2 upto Feb06)	2.50	MG	125,427	3,233,348
P	9736K		Tablet 2.5mg 4	2.50	MG	10,526	289,867
OTHER ANTIMIGRAINE PREPARATIONS							
N02CX01			PIZOTIFEN MALATE				
P	3074T		Tablet 500ug (base)	1.50	MG	131,140	2,972,315

N

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANTIEPILEPTICS							
ANTIEPILEPTICS							
BARBITURATES AND DERIVATIVES							
N03AA02			PHENOBARBITONE				
	P	1850J	Tablet 30mg	0.10	GM	14,328	237,623
	P	1853M	Injection 200mg in 1mL	0.10	GM	144	8,901
N03AA03			PRIMIDONE				
	P	1939C	Tablet 250mg	1.25	GM	15,540	1,292,104
HYDANTOIN DERIVATIVES							
N03AB02			PHENYTOIN				
	P	1249R	Tablet 50mg	0.30	GM	6,300	245,146
	P	1873N	Capsule 30mg	0.30	GM	18,888	547,893
	P	1874P	Capsule 100mg	0.30	GM	138,302	4,144,770
	P	2692Q	Paediatric oral suspension 30mg per 5mL 500mL	0.30	GM	8,646	300,879
SUCCINIMIDE DERIVATIVES							
N03AD01			ETHOSUXIMIDE				
	P	1413J	Capsule 250mg	1.25	GM	3,351	181,352
	P	1414K	Paediatric syrup 250mg per 5mL 250mL	1.25	GM	3,894	129,231
BENZODIAZEPINE DERIVATIVES							
N03AE01			CLONAZEPAM				
	P	1805B	Tablet 500ug	8.00	MG	32,983	635,716
	P	1806C	Tablet 2mg	8.00	MG	30,591	936,529
	P	1807D	Injection 1mg in 2mL (set containing solution)	8.00	MG	2,738	69,025
	P	1808E	Paediatric oral drops 2.5mg in 1mL 10mL	8.00	MG	7,061	124,212
	P	3478C	Oral liquid 2.5mg per mL 10mL	8.00	MG	2,046	21,954
	P	5337X	Tablet 500ug	8.00	MG	30,827	449,821
	P	5338Y	Tablet 2mg	8.00	MG	6,232	136,292
	P	5339B	Oral liquid 2.5mg per mL 10mL	8.00	MG	8,483	126,752
	P	5340C	Tablet 500ug	8.00	MG	16,508	227,557
	P	5341D	Tablet 2mg	8.00	MG	7,352	157,444
	P	5342E	Oral liquid 2.5mg per mL 10mL	8.00	MG	978	16,270
CARBOXAMIDE DERIVATIVES							
N03AF01			CARBAMAZEPINE				
	P	2419H	Tablet 200mg	1.00	GM	119,020	3,450,906
	P	2422L	Tablet 100mg	1.00	GM	51,704	948,125
	P	2426Q	Tablet 200mg (controlled release)	1.00	GM	74,686	2,202,593
	P	2427R	Oral suspension 100mg per 5mL 300mL	1.00	GM	24,317	694,782
	P	2431Y	Tablet 400mg (controlled release)	1.00	GM	55,989	2,744,927
N03AF02			OXCARBAZEPINE				
	P	8584T	Tablet 150mg 100	1.00	GM	1,953	147,114
	P	8585W	Tablet 300mg 100	1.00	GM	7,298	919,852
	P	8586X	Tablet 600mg 100	1.00	GM	5,000	983,017
	P	8588B	Oral suspension 60mg per mL 250mL	1.00	GM	1,388	194,152

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANTIEPILEPTICS							
ANTIEPILEPTICS							
FATTY ACID DERIVATIVES							
N03AG01 SODIUM VALPROATE							
P	2289L	Tablet 200mg (enteric coated) 200		1.50	GM	278,767	8,603,955
P	2290M	Tablet 500mg (enteric coated) 200		1.50	GM	328,216	17,327,767
P	2293Q	Oral liquid 200mg per 5mL 300 mL		1.50	GM	57,659	2,261,630
P	2294R	Crushable tablet 100mg		1.50	GM	59,894	2,031,168
P	2295T	Syrup 200mg per 5mL 300mL		1.50	GM	16,446	642,937
N03AG06 TIAGABINE							
P	8221Q	Tablet 5mg (base)		30.00	MG	562	45,220
P	8222R	Tablet 10mg (base)		30.00	MG	902	142,057
P	8223T	Tablet 15mg (base)		30.00	MG	381	77,169
N03AG04 VIGABATRIN							
P	2667J	Tablet 500mg 120		2.00	GM	7,283	990,075
P	2668K	Oral powder sachet 500mg		2.00	GM	2,331	225,441
OTHER ANTIEPILEPTICS							
N03AX12 GABAPENTIN							
P	1834M	Capsule 300mg 100		1.80	GM	86,460	5,685,899
P	1835N	Capsule 400mg 100		1.80	GM	19,583	1,892,305
P	4591P	Capsule 100mg 100		1.80	GM	11,704	308,508
P	4592Q	Capsule 300mg 100		1.80	GM	9,512	679,474
P	4593R	Capsule 400mg 100		1.80	GM	1,424	124,336
P	4594T	Tablet 600mg 100		1.80	GM	1,666	243,845
P	4595W	Tablet 800mg 100		1.80	GM	952	177,937
P	8389M	Tablet 800mg 100		1.80	GM	11,623	2,045,893
P	8505P	Capsule 100mg 100		1.80	GM	34,660	823,182
P	8559L	Tablet 600mg 100		1.80	GM	18,435	2,418,321
N03AX18 LACOSAMIDE							
P	9333F	Tablet 50mg 14		0.30	GM	2,192	212,382
P	9335H	Tablet 100mg 56		0.30	GM	6,817	1,447,805
P	9337K	Tablet 150mg 56		0.30	GM	1,870	508,825
P	9338L	Tablet 200mg 56		0.30	GM	3,750	1,336,658
N03AX09 LAMOTRIGINE							
P	2848X	Tablet 25mg		0.30	GM	46,052	1,515,944
P	2849Y	Tablet 50mg		0.30	GM	81,188	3,816,756
P	2850B	Tablet 100mg		0.30	GM	136,481	9,808,318
P	2851C	Tablet 200mg		0.30	GM	99,348	11,357,051
P	8063J	Tablet 5mg		0.30	GM	4,959	108,225
N03AX14 LEVETIRACETAM							
P	8654L	Tablet 250mg 60		1.50	GM	46,806	2,879,855
P	8655M	Tablet 500mg 60		1.50	GM	141,243	14,634,332
P	8656N	Tablet 1gm 60		1.50	GM	75,039	11,872,180
P	9169N	Oral solution 100mg per mL 300mL		1.50	GM	9,045	1,149,798

N

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANTIEPILEPTICS							
ANTIEPILEPTICS							
OTHER ANTIEPILEPTICS							
N03AX16 PREGABALIN							
	P	4320J	Capsules 25mg 56	0.30	GM	18,591	876,351
	P	4322L	Capsules 75mg 56	0.30	GM	131,360	11,865,695
	P	4323M	Capsules 150mg 56	0.30	GM	69,237	9,144,276
	P	4324N	Capsules 300mg 56	0.30	GM	22,659	4,270,073
N03AX03 SULTHIAME							
	P	2099L	Tablet 50mg	0.40	GM	1,156	86,046
	P	2100M	Tablet 200mg	0.40	GM	1,449	262,982
N03AX11 TOPIRAMATE							
	P	8163P	Tablet 25mg	0.30	GM	68,216	2,999,244
	P	8164Q	Tablet 50mg	0.30	GM	85,203	5,610,006
	P	8165R	Tablet 100mg	0.30	GM	47,040	4,571,366
	P	8166T	Tablet 200mg	0.30	GM	23,248	3,920,413
	P	8371N	Capsule 15mg	0.30	GM	1,537	65,808
	P	8372P	Capsule 25mg	0.30	GM	1,762	82,994
	P	8520K	Capsule 50mg	0.30	GM	2,593	225,757
N03AX15 ZONISAMIDE							
	P	9388D	Capsule 25mg 56	0.20	GM	868	20,695
	P	9389E	Capsule 50mg 56	0.20	GM	968	39,088
	P	9390F	Capsule 100mg 112	0.20	GM	1,090	89,305

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANTI-PARKINSON DRUGS							
ANTICHOLINERGIC AGENTS							
TERTIARY AMINES WITH CARBON CHAIN							
N04AA01			BENZHEXOL HYDROCHLORIDE				
	P	1109J	Tablet 2mg	10.00	MG	11,676	176,530
	P	1110K	Tablet 5mg	10.00	MG	4,787	105,019
N04AA02			BIPERIDEN HYDROCHLORIDE				
	P	2544X	Tablet 2mg	10.00	MG	12,076	246,901
ETHERS OF TROPINE OR TROPINE DERIVATIVES							
N04AC01			BENZTROPINE MESYLATE				
	P	2362H	Tablet 2mg 60	2.00	MG	56,121	710,095
	P	3038X	Injection 2mg in 2mL	2.00	MG	583	102,834
	P	3457Y	Injection 2mg in 2mL	2.00	MG	3,894	402,628
DOPAMINERGIC AGENTS							
DOPA AND DOPA DERIVATIVES							
N04BA02			LEVODOPA and DECARBOXYLASE INHIBITOR				
	P	8970D	Intestinal gel 20mg–5mg (as monohydrate) per mL, 100mL 56	0.60	GM	201	1,746,840
N04BA02			LEVODOPA with BENSERAZIDE				
	P	2225D	Capsule 100mg–25mg	0.60	GM	37,177	1,514,751
	P	2226E	Capsule 200mg–50mg	0.60	GM	21,261	1,136,124
	P	2227F	Capsule 50mg–12.5mg	0.60	GM	21,588	506,084
	P	2228G	Tablet 200mg–50mg	0.60	GM	43,490	2,402,757
	P	2229H	Tablet 100mg–25mg	0.60	GM	63,774	2,664,947
	P	2231K	Capsule 100mg–25mg (sustained release)	0.60	GM	21,610	976,032
	P	8218M	Dispersible tablet 50mg–12.5mg	0.60	GM	7,884	197,939
	P	8219N	Dispersible tablet 100mg–12.5mg	0.60	GM	9,393	425,736
N04BA02			LEVODOPA with CARBIDOPA				
	P	1242J	Tablet 100mg–25mg	0.60	GM	202,997	8,534,396
	P	1245M	Tablet 250mg–25mg	0.60	GM	46,410	2,197,615
	P	1255C	Tablet 200mg–50mg 100	0.60	GM	13,327	977,877
N04BA03			LEVODOPA with CARBIDOPA and ENTACAPONE				
	P	9344T	Tablet 75mg–18.75mg–200mg 200	0.45	GM	1,129	358,429
	P	9345W	Tablet 125mg–31.25mg–200mg 200	0.45	GM	2,788	975,787
N04BA03			LEVODOPA, DECARBOXYLASE INHIBITOR and COMT INHIBITOR				
	P	8797B	Tablet 50mg–12.5mg–200mg	0.45	GM	1,936	598,769
	P	8798C	Tablet 100mg–25mg–200mg	0.45	GM	12,745	4,298,077
	P	8799D	Tablet 150mg–37.5mg–200mg	0.45	GM	12,376	4,563,375
	P	9292C	Tablet 200mg–50mg–200mg 200	0.45	GM	8,149	3,205,722
ADAMANTANE DERIVATIVES							
N04BB01			AMANTADINE HYDROCHLORIDE				
	P	3016R	Capsule 100mg	0.20	GM	15,441	682,776

N

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
ANTI-PARKINSON DRUGS							
DOPAMINERGIC AGENTS							
DOPAMINE AGONISTS							
N04BC07	APOMORPHINE						
	P	9607P	Injection 20mg in 2mL 5	20.00	MG	757	1,524,606
N04BC01	BROMOCRIPTINE MESYLATE						
	P	1443Y	Capsule 2.5mg (base)	40.00	MG	7,223	250,789
	P	1445C	Capsule 10mg	40.00	MG	511	76,347
	P	1446D	Capsule 5mg	40.00	MG	2,738	146,082
N04BC06	CABERGOLINE						
	P	8393R	Tablet 1mg 30	3.00	MG	11,601	748,019
	P	8394T	Tablet 2mg 30	3.00	MG	11,288	1,041,131
N04BC02	PERGOLIDE						
	P	2808T	Tablet 50ug (base)	3.00	MG	454	29,493
	P	2809W	Tablet 250ug (base)	3.00	MG	1,528	104,551
	P	2810X	Tablet 1mg (base)	3.00	MG	732	179,414
N04BC05	PRAMIPEXOLE						
	P	3418X	Tablet 0.375mg	2.50	MG	7,428	166,209
	P	3419Y	Tablet 0.75mg 30	2.50	MG	20,155	765,166
	P	3420B	Tablet 1.5mg 30	2.50	MG	18,441	1,227,600
	P	3421C	Tablet 3mg 30	2.50	MG	10,880	1,495,765
	P	3422D	Tablet 4.5mg (extended release) 30	2.50	MG	5,109	1,043,138
	P	9151P	Tablet 125ug 30	2.50	MG	6,565	90,676
	P	9152Q	Tablet 250ug 100	2.50	MG	39,421	1,683,280
	P	9153R	Tablet 1mg 100	2.50	MG	19,894	3,084,106
	P	9393J	Tablet 125ug 30	2.50	MG	53,623	629,630
	P	9394K	Tablet 250ug 100	2.50	MG	25,740	1,059,322
N04BC04	ROPINIROLE						
	A	18889	Tablet 0.5mg 28	6.00	MG	6,079	—
	A	18890	Tablet 2mg 28	6.00	MG	2,087	—
	A	20645	Tablet 0.5mg 28	6.00	MG	113	—
MONOAMINE OXIDASE TYPE B INHIBITORS							
N04BD01	SELEGILINE HYDROCHLORIDE						
	P	1973W	Tablet 5mg 100	5.00	MG	6,144	325,748
OTHER DOPAMINERGIC AGENTS							
N04BX02	ENTACAPONE						
	P	8367J	Tablet 200mg	1.00	GM	12,846	3,604,065

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
NERVOUS SYSTEM							
PSYCHOLEPTICS							
ANTIPSYCHOTICS							
PHENOTHIAZINE WITH DIMETHYLAMINOPROPYL GROUP							
N05AA01			CHLORPROMAZINE HYDROCHLORIDE				
P	1195X		Injection 50mg in 2mL	0.10	GM	528	10,629
P	1196Y		Tablet 10mg	0.30	GM	8,866	92,791
P	1197B		Tablet 25mg	0.30	GM	35,122	390,808
P	1199D		Tablet 100mg	0.30	GM	23,926	422,059
P	1201F		Mixture 25mg per 5mL 100mL	0.30	GM	4,466	88,025
P	3455W		Injection 50mg in 2mL	0.10	GM	4,638	94,494
PHENOTHIAZINE WITH PIPERAZINE STRUCTURE							
N05AB02			FLUPHENAZINE DECANOATE				
P	1001Q		Injection 50mg in 2mL	1.00	MG	3,666	138,138
P	1046C		Injection 12.5mg in 0.5mL	1.00	MG	1,915	36,743
P	3098C		Injection 25mg in 1mL	1.00	MG	3,703	97,126
N05AB04			PROCHLORPERAZINE				
A	21180		Suppositories 5mg 10	100.00	MG	1,571	—
P	2369Q		Injection 12.5mg in 1mL	50.00	MG	6,415	123,322
P	2893G		Tablet 5mg	100.00	MG	794,785	8,003,439
P	2895J		Suppositories 25mg 5	100.00	MG	17,071	407,083
P	3477B		Injection 12.5mg in 1mL	50.00	MG	10,077	168,938
P	5205Y		Tablet 5mg	100.00	MG	146	1,352
N05AB06			TRIFLUOPERAZINE HYDROCHLORIDE				
P	2185B		Tablet 1mg (base)	20.00	MG	10,696	142,436
P	2186C		Tablet 5mg (base)	20.00	MG	12,624	181,623
P	2386N		Tablet 2mg (base)	20.00	MG	7,090	96,138
PHENOTHIAZINE WITH PIPERIDINE STRUCTURE							
N05AC01			PERICYAZINE				
P	3052P		Tablet 2.5mg	50.00	MG	32,502	338,637
P	3053Q		Tablet 10mg	50.00	MG	15,662	227,104
BUTYROPHENONE DERIVATIVES							
N05AD01			HALOPERIDOL				
P	2761H		Tablet 500ug 100	8.00	MG	42,684	429,485
P	2763K		Oral liquid 2mg per mL 100 mL	8.00	MG	1,690	30,119
P	2765M		I.M. injection equivalent to 50mg haloperidol	3.30	MG	2,178	57,606
P	2766N		I.M. injection equivalent to 150mg haloperidol	3.30	MG	1,824	83,358
P	2767P		Tablet 1.5mg	8.00	MG	12,565	132,619
P	2768Q		Injection 5mg in 1mL	8.00	MG	9,624	220,735
P	2770T		Tablet 5mg	8.00	MG	16,951	191,691
P	3456X		Injection 5mg in 1mL	8.00	MG	3,582	79,053

N

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOLEPTICS							
ANTIPSYCHOTICS							
INDOLE DERIVATIVES							
N05AE04 ZIPRASIDONE							
	A	19954	Capsule 20mg 60	80.00	MG	26,109	–
	P	9070J	Capsule 20mg 60	80.00	MG	6,724	630,865
	P	9071K	Capsule 40mg 60	80.00	MG	12,516	2,272,802
	P	9072L	Capsule 60mg 60	80.00	MG	5,708	1,505,320
	P	9073M	Capsule 80mg 60	80.00	MG	14,631	5,018,012
THIOXANTHENE DERIVATIVES							
N05AF01 FLUPENTHIXOL							
	A	21510	Injection 40mg in 2mL 5	4.00	MG	1,200	–
	A	21511	Injection 20mg in 1mL 5	4.00	MG	485	–
	P	2255Q	Injection oily I.M. 20mg in 1mL	4.00	MG	3,197	50,283
	P	2256R	Injection oily I.M. 40mg in 1mL	4.00	MG	1,203	24,529
	P	2257T	Injection oily I.M. 100mg in 1mL	4.00	MG	7,055	321,274
N05AF05 ZUCLOPENTHIXOL							
	A	15616	Tablet 10mg 100	30.00	MG	1,406	–
	A	21527	Depot injection 200mg/mL 5	15.00	MG	2,548	–
	P	8097E	Oily I.M. injection 200mg in 1mL 5	15.00	MG	19,744	418,658

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOLEPTICS							
ANTIPSYCHOTICS							
DIAZEPINES, OXAZEPINES, THIAZEPINES AND OXEPINES							
N05AH05 ASENAPINE							
P	5140M		Sublingual wafer 5mg (as maleate)	20.00	MG	331	51,915
P	5141N		Sublingual wafer 10mg (as maleate) 60	20.00	MG	291	73,436
N05AH02 CLOZAPINE							
P	6101D		Tablet 25mg 100	0.30	GM	8,269	487,946
P	6102E		Tablet 100mg 100	0.30	GM	35,424	10,448,829
P	6417R		Tablet 50mg 100	0.30	GM	8,285	641,977
P	6418T		Tablet 200mg 100	0.30	GM	19,956	7,405,668
N05AH03 OLANZAPINE							
P	8170B		Tablet 2.5mg 30	10.00	MG	164,105	9,415,570
P	8185T		Tablet 5mg 30	10.00	MG	260,841	28,712,518
P	8186W		Tablet 7.5mg 30	10.00	MG	65,495	11,753,061
P	8187X		Tablet 10mg 30	10.00	MG	345,218	94,811,608
P	8433W		Wafer 5mg 28	10.00	MG	62,025	6,850,997
P	8434X		Wafer 10mg 28	10.00	MG	75,840	20,828,539
P	8952E		Wafer 15mg 28	10.00	MG	2,990	957,566
P	8953F		Wafer 20mg 28	10.00	MG	5,419	2,105,908
P	9294E		Powder for injection 210mg (as pamoate monohydrate) with diluent 2	10.00	MG	158	74,618
P	9295F		Powder for injection 300mg (as pamoate monohydrate) with diluent 2	10.00	MG	644	439,526
P	9303P		Powder for injection 405mg (as pamoate monohydrate) with diluent 2	10.00	MG	757	393,609
N05AH04 QUETIAPINE							
P	5458G		Tablet (modified release) 150mg (as fumarate)	0.40	GM	8,229	1,152,937
P	8456C		Tablet 25mg (base) 60	0.40	GM	294,062	16,819,606
P	8457D		Tablet 100mg (base) 90	0.40	GM	155,111	21,661,838
P	8458E		Tablet 200mg (base) 60	0.40	GM	126,773	27,429,662
P	8580N		Tablet 300mg (base) 60	0.40	GM	96,133	29,326,089
P	9202H		Tablet (modified release) equivalent to 50mg	0.40	GM	73,052	7,573,655
P	9203J		Tablet (modified release) equivalent to 200mg 60	0.40	GM	32,984	6,366,432
P	9204K		Tablet (modified release) equivalent to 300mg 60	0.40	GM	33,636	9,411,655
P	9205L		Tablet (modified release) equivalent to 400mg 60	0.40	GM	27,958	10,288,013
BENZAMIDES							
N05AL05 AMISULPRIDE							
P	8594H		Tablet 100mg 30	0.40	GM	21,524	855,296
P	8595J		Tablet 200mg 60	0.40	GM	29,326	3,549,923
P	8596K		Tablet 400mg 60	0.40	GM	33,229	7,238,870
P	8736T		Oral solution 100mg per mL 60mL 2	0.40	GM	383	64,949
LITHIUM							
N05AN01 LITHIUM CARBONATE							
P	3059B		Tablet 250mg 200	889.00	MG	99,633	1,671,132
P	8290H		Tablet 450mg (slow release) 200	889.00	MG	43,730	1,441,984

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOLEPTICS							
ANTIPSYCHOTICS							
OTHER ANTIPSYCHOTICS							
N05AX12 ARIPIPRAZOLE							
	A	19165	Tablet 5mg 30	15.00	MG	1,141	—
	P	8717T	Tablet 10mg 30	15.00	MG	56,114	8,884,340
	P	8718W	Tablet 15mg 30	15.00	MG	32,499	7,419,502
	P	8719X	Tablet 20mg 30	15.00	MG	24,056	6,573,768
	P	8720Y	Tablet 30mg 30	15.00	MG	27,748	9,128,115
N05AX13 PALIPERIDONE							
	P	5102M	I.M. injection (modified release) 50mg (as palmitate) in pre filled syringe 1	2.50	MG	235	66,397
	P	5103N	I.M. injection (modified release) 75mg (as palmitate) in pre filled syringe 1	2.50	MG	417	151,154
	P	5107T	I.M. injection (modified release) 100mg (as palmitate) in pre filled syringe 1	2.50	MG	623	274,073
	P	5109X	I.M. injection (modified release) 150mg (as palmitate) in pre filled syringe 1	2.50	MG	455	199,683
	P	9140C	Tablet 3mg (prolonged release) 28	6.00	MG	10,883	1,854,780
	P	9141D	Tablet 6mg (prolonged release) 28	6.00	MG	14,964	2,869,584
	P	9142E	Tablet 9mg (prolonged release) 28	6.00	MG	5,404	1,234,288
N05AX08 RISPERIDONE							
	P	3169T	Tablet 1mg	5.00	MG	75,656	3,586,614
	P	3170W	Tablet 2mg	5.00	MG	54,620	5,328,427
	P	3171X	Tablet 3mg	5.00	MG	33,760	4,875,156
	P	3172Y	Tablet 4mg	5.00	MG	28,754	5,586,615
	P	8100H	Oral solution 1mg per mL 100mL	5.00	MG	5,386	666,483
	P	8780D	Pdr for I.M. injection 25mg/2mL diluent syringe	2.70	MG	41,239	12,241,549
	P	8781E	Pdr for I.M. injection 37.5mg/2mL diluent syringe	2.70	MG	42,135	16,812,778
	P	8782F	Pdr for I.M. injection 50mg/2mL diluent syringe	2.70	MG	53,612	25,032,880
	P	8787L	Tablet 0.5mg 60	5.00	MG	110,187	3,038,205
	P	8788M	Tablet 0.5mg (orally disintegrating) 56	5.00	MG	26,291	791,627
	P	8789N	Tablet 1mg 60	5.00	MG	67,983	3,215,787
	P	8790P	Tablet 1mg (orally disintegrating) 56	5.00	MG	9,600	500,367
	P	8792R	Tablet 1mg (orally disintegrating) 56	5.00	MG	8,425	432,708
	P	8794W	Tablet 2mg (orally disintegrating) 56	5.00	MG	6,926	631,942
	P	8869T	Tablet 0.5mg 60	5.00	MG	72,667	2,000,563
	P	8870W	Tablet 0.5mg (orally disintegrating) 56	5.00	MG	13,520	403,697
	P	9075P	Tablet 3mg (orally disintegrating) 56	5.00	MG	3,130	396,832
	P	9076Q	Tablet 4mg (orally disintegrating) 56	5.00	MG	2,580	421,876
	P	9079W	Tablet 2mg 60	5.00	MG	22,426	2,152,917
	P	9080X	Tablet 2mg (orally disintegrating) 56	5.00	MG	2,412	224,058
	P	9293D	Oral solution 1mg per mL 100mL 1	5.00	MG	8,086	981,582

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOLEPTICS							
ANXIOLYTICS							
BENZODIAZEPINE DERIVATIVES							
N05BA12			ALPRAZOLAM				
	P	2130D	Tablet 250ug	1.00	MG	86,873	875,791
	P	2131E	Tablet 500ug	1.00	MG	184,514	2,343,919
	P	2132F	Tablet 1mg	1.00	MG	217,567	3,899,525
	P	8118G	Tablet 2mg	1.00	MG	202,627	4,951,757
N05BA08			BROMAZEPAM				
	P	4150K	Tablet 3mg	10.00	MG	12,162	341,117
	P	4151L	Tablet 6mg	10.00	MG	23,828	790,600
N05BA09			CLOBAZAM				
	A	10898	Tablet 10mg 50	20.00	MG	25,758	—
N05BA01			DIAZEPAM				
	A	15450	Elixir 0.1% 100mL	10.00	MG	1,001	—
	A	20925	Tablet 2mg 50	10.00	MG	137	—
	P	2558P	Injection 10mg in 2mL	10.00	MG	3,954	53,516
	P	3161J	Tablet 2mg	10.00	MG	260,645	2,011,938
	P	3162K	Tablet 5mg	10.00	MG	1,977,635	15,533,180
	P	3458B	Injection 10mg in 2mL	10.00	MG	9,488	116,546
	P	5071X	Tablet 2mg	10.00	MG	401	3,033
	P	5072Y	Tablet 5mg	10.00	MG	3,689	27,834
	P	5355W	Tablet 2mg 50	10.00	MG	201	1,776
	P	5356X	Tablet 5mg 50	10.00	MG	1,225	11,073
	P	5357Y	Tablet 2mg 50	10.00	MG	182	1,478
	P	5358B	Tablet 5mg 50	10.00	MG	817	7,614
N05BA06			LORAZEPAM				
	A	13807	Tablet 1mg 50	2.50	MG	82,486	—
	A	13808	Tablet 2.5mg 50	2.50	MG	31,383	—
	A	21539	Tablet 50mg 1	2.50	MG	537	—
	A	21540	Tablet 2.5mg 50	2.50	MG	358	—
N05BA04			OXAZEPAM				
	P	3132W	Tablet 15mg	50.00	MG	249,039	1,863,758
	P	3133X	Tablet 30mg	50.00	MG	941,786	7,205,180
	P	3134Y	Tablet 15mg	50.00	MG	10,837	97,577
	P	3135B	Tablet 30mg	50.00	MG	11,046	102,166
	P	5193H	Tablet 30mg	50.00	MG	170	1,284
	P	5371Q	Tablet 15mg 50	50.00	MG	449	3,881
	P	5372R	Tablet 30mg 50	50.00	MG	586	5,326
	P	5373T	Tablet 15mg 50	50.00	MG	150	1,355
	P	5374W	Tablet 30mg 50	50.00	MG	1,285	12,402
AZASPIRODECANEDIONE DERIVATIVES							
N05BE01			BUSPIRONE HYDROCHLORIDE				
	P	4144D	Tablet 5mg 50	30.00	MG	2,160	120,233
	P	4145E	Tablet 10mg 50	30.00	MG	2,611	249,323

N

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOLEPTICS							
HYPNOTICS AND SEDATIVES							
ALDEHYDES AND DERIVATIVES							
N05CC01			CHLORAL HYDRATE				
	A	18744	Syrup 1g/10mL 200mL	1.00	GM	114	–
BENZODIAZEPINE DERIVATIVES							
N05CD03			FLUNITRAZEPAM				
	P	4216X	Tablet 1mg 30	1.00	MG	35,949	630,213
N05CD08			MIDAZOLAM				
	A	11021	Ampoule 15mg/3mL 5	15.00	MG	414	–
	A	12645	Ampoule 5mg/mL 10	15.00	MG	20,953	–
	A	13771	Ampoule 5mg/mL 10	15.00	MG	132	–
	A	17973	Ampoule 5mg/mL 5	15.00	MG	145	–
	A	18505	Ampoule 5mg/mL 10	15.00	MG	4,602	–
N05CD02			NITRAZEPAM				
	P	2723H	Tablet 5mg 25	5.00	MG	489,294	3,827,846
	P	2732T	Tablet 5mg 50	5.00	MG	9,425	92,386
	P	5359C	Tablet 5mg 50	5.00	MG	395	3,727
	P	5360D	Tablet 5mg 50	5.00	MG	679	6,466
N05CD07			TEMAZEPAM				
	A	18587	Capsule 10mg 25	20.00	MG	207	–
	P	2088X	Tablet 10mg	20.00	MG	58,139	524,118
	P	2089Y	Tablet 10mg 25	20.00	MG	2,458,466	18,784,739
	P	5221T	Tablet 10mg	20.00	MG	849	6,397
	P	5375X	Tablet 10mg 50	20.00	MG	2,651	23,963
	P	5376Y	Tablet 10mg 50	20.00	MG	2,280	20,843
N05CD05			TRIAZOLAM				
	A	13374	Tablet 0.125mg 50	0.25	MG	8,976	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOLEPTICS							
HYPNOTICS AND SEDATIVES							
BENZODIAZEPINE RELATED DRUGS							
N05CF02 ZOLPIDEM							
A	16809		Tablet 10mg 7	10.00	MG	9,611	—
A	19763		Tablet 6.25mg 21	10.00	MG	189	—
A	19765		Tablet 12.5mg 21	10.00	MG	115	—
A	19797		Tablet 10mg 7	10.00	MG	1,662	—
A	19803		Tablet 10mg 7	10.00	MG	11,850	—
A	19817		Tablet 10mg 7	10.00	MG	4,698	—
A	20286		Tablet 10mg 14	10.00	MG	19,098	—
A	20288		Tablet 10mg 14	10.00	MG	33,941	—
A	20289		Tablet 10mg 14	10.00	MG	108,024	—
A	20290		Tablet controlled release 6.25mg 14	10.00	MG	10,659	—
A	20291		Tablet controlled release 12.5mg 14	10.00	MG	81,443	—
A	20305		Tablet 10mg 14	10.00	MG	131,329	—
A	20311		Tablet 10mg 14	10.00	MG	9,274	—
A	20393		Tablet 10mg 14	10.00	MG	11,443	—
A	20454		Tablet 10mg 14	10.00	MG	1,764	—
A	20466		Tablet 10mg 14	10.00	MG	18,886	—
N05CF01 ZOPICLONE							
A	14925		Tablet 7.5mg 10	7.50	MG	17,981	—
P	4522B		Tablet 7.5mg	7.50	MG	143,438	3,794,697
BENZODIAZEPINE RELATED DRUGS							
N05CH01 MELATONIN							
A	21037		Tablet prolonged release 2mg 21	2.00	MG	68,145	—
A	21801		Tablet 2mg 30	2.00	MG	530	—

N

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOANALEPTICS							
ANTIDEPRESSANTS							
NON SELECTIVE MONOAMINE REUPTAKE INHIBITORS							
N06AA09			AMITRIPTYLINE HYDROCHLORIDE				
	P	2417F	Tablet 10mg 50	75.00	MG	555,169	4,692,995
	P	2418G	Tablet 25mg 50	75.00	MG	591,252	5,098,700
	P	2429W	Tablet 50mg 50	75.00	MG	480,780	4,459,350
N06AA04			CLOMIPRAMINE HYDROCHLORIDE				
	P	1561E	Tablet 25mg 50	100.00	MG	64,117	2,028,214
N06AA16			DOTHIEPIN HYDROCHLORIDE				
	P	1357K	Capsule 25mg 50	150.00	MG	195,612	1,771,069
	P	1358L	Tablet 75mg 50	150.00	MG	289,133	2,881,440
	A	21791	Capsule 25mg 50	150.00	MG	7,407	—
N06AA12			DOXEPIN HYDROCHLORIDE				
	P	1011F	Capsule 10mg (base) 50	100.00	MG	58,253	524,900
	P	1012G	Tablet 50mg (base) 50	100.00	MG	114,530	1,213,161
	P	1013H	Capsule 25mg (base) 50	100.00	MG	120,266	1,184,418
N06AA02			IMIPRAMINE HYDROCHLORIDE				
	P	2420J	Tablet 10mg 50	100.00	MG	32,846	282,344
	P	2421K	Tablet 25mg 50	100.00	MG	91,454	950,733
N06AA10			NORTRIPTYLINE HYDROCHLORIDE				
	P	2522R	Tablet 10mg (base) 50	75.00	MG	28,009	387,307
	P	2523T	Tablet 25mg (base) 50	75.00	MG	78,686	1,620,517
N06AA06			TRIMIPRAMINE MALEATE				
	A	16468	Capsule 50mg 50	150.00	MG	7,865	—

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOANALEPTICS							
ANTIDEPRESSANTS							
SELECTIVE SEROTONIN REUPTAKE INHIBITORS							
N06AB04 CITALOPRAM							
	P	8220P	Tablet 20mg (base) 28	20.00	MG	1,350,309	36,621,786
	P	8702B	Tablet 10mg (base) 28	20.00	MG	68,293	1,154,627
	P	8703C	Tablet 40mg (base) 28	20.00	MG	165,095	5,823,236
N06AB10 ESCITALOPRAM							
	P	8700X	Tablet 10mg (base) 28	10.00	MG	1,184,154	30,688,137
	P	8701Y	Tablet 20mg (base) 28	10.00	MG	1,022,027	29,949,485
	P	8849R	Oral solution 10mg (base) per mL 28mL	10.00	MG	5,574	212,415
	P	9432K	Tablet 10mg (base) 28	10.00	MG	9,250	269,684
	P	9433L	Tablet 20mg (base) 28	10.00	MG	8,440	292,191
N06AB03 FLUOXETINE HYDROCHLORIDE							
	P	1434L	Capsule 20mg (base) 28	20.00	MG	917,809	25,656,162
	P	8270G	Tablet 20mg (base) (dispersible) 28	20.00	MG	279,534	6,962,990
N06AB08 FLUVOXAMINE							
	P	8174F	Tablet 100mg 30	0.10	GM	276,403	10,271,608
	P	8512B	Tablet 50mg 30	0.10	GM	120,996	2,536,787
N06AB05 PAROXETINE							
	P	2242B	Tablet 20mg (base) 30	20.00	MG	964,825	30,444,185
	P	9197C	Tablet 20mg (as mesilate) 30	20.00	MG	4,259	109,027
N06AB06 SERTRALINE							
	P	2236Q	Tablet 50mg (base) 30	50.00	MG	1,286,942	31,905,893
	P	2237R	Tablet 100mg (base) 30	50.00	MG	1,375,400	39,731,172
	P	8836C	Tablet 50mg (base) 30	50.00	MG	48,971	1,230,461
	P	8837D	Tablet 100mg (base) 30	50.00	MG	63,524	1,830,799
MONOAMINE OXIDASE INHIBITORS, NON-SELECTIVE							
N06AF03 PHENELZINE SULPHATE							
	P	2856H	Tablet 15mg (base) 100	60.00	MG	7,150	956,184
N06AF04 TRANYLCYPROMINE SULPHATE							
	P	2444P	Tablet 10mg (base) 50	10.00	MG	17,296	1,294,127
MONOAMINE OXIDASE TYPE A INHIBITORS							
N06AG02 MOCLOBEMIDE							
	P	1900B	Tablet 150mg 60	0.30	GM	37,871	705,208
	P	8003F	Tablet 300mg 60	0.30	GM	97,926	3,182,516

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOANALEPTICS							
ANTIDEPRESSANTS							
OTHER ANTIDEPRESSANTS							
N06AX22			AGOMELATINE				
	A	21346	Tablet 25mg 28	25.00	MG	38,726	—
N06AX12			BUPROPION				
	P	8465M	Tablet 150mg (sustained release)	0.30	GM	12,008	885,829
	P	8710K	Tablet 150mg (sustained release) 90	0.30	GM	9,062	1,435,851
N06AX23			DESVENLAFAXINE				
	P	9366Y	Tablet 50mg (base) (extended release) 28	50.00	MG	642,603	28,846,549
	P	9367B	Tablet 100mg (base) (extended release) 28	50.00	MG	472,898	27,326,178
N06AX21			DULOXETINE				
	P	9155W	Capsule 30mg 28	60.00	MG	210,967	9,089,602
	P	9156X	Capsule 60mg 28	60.00	MG	790,570	44,108,158
N06AX03			MIANSERIN HYDROCHLORIDE				
	P	1627P	Tablet 10mg 50	60.00	MG	18,744	297,444
	P	1628Q	Tablet 20mg 50	60.00	MG	37,209	1,339,671
N06AX11			MIRTAZAPINE				
	P	8513C	Tablet 30mg 30	30.00	MG	887,107	26,442,341
	P	8855C	Tablet 15mg (orally disintegrating) 30	30.00	MG	93,895	2,503,961
	P	8856D	Tablet 30mg (orally disintegrating) 30	30.00	MG	89,522	3,371,330
	P	8857E	Tablet 45mg (orally disintegrating) 30	30.00	MG	37,144	1,870,537
	P	8883M	Tablet 45mg 30	30.00	MG	244,891	10,104,316
	P	9365X	Tablet 15mg 30	30.00	MG	98,766	1,942,642
N06AX18			REBOXETINE				
	P	8583R	Tablet 4mg (base) 60	8.00	MG	57,828	2,432,181
N06AX16			VENLAFAXINE				
	P	8301X	Capsule 75mg (base) (modified release) 28	100.00	MG	1,166,438	55,183,036
	P	8302Y	Capsule 150mg (base) (modified release) 28	100.00	MG	1,358,592	83,340,681
	P	8868R	Capsule 37.5mg (base) (modified release) 28	100.00	MG	155,814	4,488,277

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOANALEPTICS							
PSYCHOSTIMULANTS AND NOOTROPICS							
CENTRALLY ACTING SYMPATHOMIMETICS							
N06BA09 ATOMOXETINE							
	P	9092M	Capsule 10mg base 56	80.00	MG	3,911	868,469
	P	9093N	Capsule 18mg base 56	80.00	MG	4,180	916,240
	P	9094P	Capsule 25mg base 56	80.00	MG	7,921	1,747,898
	P	9095Q	Capsule 40mg base 56	80.00	MG	9,315	2,050,442
	P	9096R	Capsule 60mg base 56	80.00	MG	6,659	1,463,341
	P	9289X	Capsule 80mg base 28	80.00	MG	2,931	443,948
	P	9290Y	Capsule 100mg base 28	80.00	MG	1,093	164,334
N06BA02 DEXAMPHETAMINE SULPHATE							
	P	1165H	Tablet 5mg	15.00	MG	213,988	5,641,138
N06BA04 METHYLPHENIDATE							
	P	2172H	Tablet (extended release) 27mg 30	30.00	MG	44,637	2,491,921
	P	2276T	Capsule controlled release 20mg	30.00	MG	36,132	1,653,373
	P	2280B	Capsule controlled release 30mg	30.00	MG	35,849	1,966,128
	P	2283E	Capsule controlled release 40mg	30.00	MG	29,776	1,675,737
	P	2387P	Tablet (extended release) 18mg 30	30.00	MG	24,871	1,295,310
	P	2388Q	Tablet (extended release) 36mg 30	30.00	MG	85,460	5,444,649
	P	2432B	Tablet (extended release) 54mg 30	30.00	MG	86,483	6,087,502
	P	3440C	Capsule 10mg (modified release) 30	30.00	MG	7,310	269,126
	P	8839F	Tablet 10mg 100	30.00	MG	122,523	2,248,389
N06BA07 MODAFINIL							
	A	17624	Tablet 100mg 30	0.30	GM	2,930	—
	P	8816B	Tablet 100mg 120	0.30	GM	10,930	3,399,631

N

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
PSYCHOANALEPTICS							
ANTI-DEMENTIA DRUGS							
ANTICHOLINESTERASES							
N06DA02 DONEPEZIL							
	P	8495D	Tablet 5mg 28	7.50	MG	61,221	9,742,851
	P	8496E	Tablet 10mg 28	7.50	MG	197,711	30,791,291
N06DA04 GALANTAMINE							
	P	8770N	Tablet 8mg (base) (prolonged release) 28	16.00	MG	18,052	2,113,984
	P	8771P	Tablet 16mg (base) (prolonged release) 28	16.00	MG	68,076	9,342,944
	P	8772Q	Tablet 24mg (base) (prolonged release) 28	16.00	MG	18,981	3,078,483
N06DA03 RIVASTIGMINE							
	P	8497F	Capsule 1.5mg 56	9.00	MG	1,601	261,957
	P	8498G	Capsule 3mg 56	9.00	MG	2,836	450,057
	P	8499H	Capsule 4.5mg 56	9.00	MG	1,472	231,238
	P	8500J	Capsule 6mg 56	9.00	MG	1,674	260,109
	P	8563Q	Oral solution 2mg (base) per mL 120mL	9.00	MG	145	26,862
	P	9161E	TD patch 9mg (release approx. 4.6mg per 24hrs) 30	9.50	MG	11,305	1,879,658
	P	9162F	TD patch 18mg (release approx. 9.5mg per 24hrs) 30	9.50	MG	24,289	4,033,599
OTHER ANTI-DEMENTIA DRUGS							
N06DX01 MEMANTINE HYDROCHLORIDE							
	P	1956Y	Tablet 10mg 56	20.00	MG	20,875	2,235,591
	P	2059J	Oral drops 10mg per g 50g	20.00	MG	155	15,768
	P	9306T	Tablet 20mg 28	20.00	MG	9,216	997,050

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
OTHER NERVOUS SYSTEM DRUGS							
PARASYMPATHOMIMETICS							
ANTICHOLINESTERASES							
N07AA02			PYRIDOSTIGMINE BROMIDE				
	P	1959D	Tablet 60mg	180.00	MG	12,926	855,569
	P	2608G	Tablet 180mg (sustained release)	180.00	MG	2,642	336,611
	P	2724J	Tablet 10mg	180.00	MG	3,796	103,793
CHOLINE ESTERS							
N07AB02			BETHANECHOL CHLORIDE				
	P	1062X	Tablet 10mg	45.00	MG	6,301	154,852
DRUGS USED IN ADDICTIVE DISORDERS							
DRUGS USED IN NICOTINE DEPENDENCE							
N07BA01			NICOTINE				
	P	3414Q	Transdermal patch (releasing 21mg/24hr) 28	14.00	MG	52,033	2,870,563
	P	4572P	Transdermal patch 14cm (releasing 14mg/24hr) 7	14.00	MG	736	50,166
	P	4573Q	Transdermal patch 21cm (releasing 21mg/24hr) 7	14.00	MG	1,171	80,789
	P	4576W	Transdermal patch releasing 5mg/16hr 7	14.00	MG	959	49,174
	P	4577X	Transdermal patch releasing 10mg/16hr 7	14.00	MG	430	23,955
	P	4578Y	Transdermal patch releasing 15mg/16hr 7	14.00	MG	655	43,813
	P	5465P	Transdermal patch (releasing 21mg/24hr) 28	14.00	MG	111,619	6,152,034
	P	9198D	Transdermal patch releasing 15mg/16hr 28	14.00	MG	83,160	4,586,929
N07BA03			VARENICLINE				
	P	5469W	Tablet 1mg (as tartrate)	2.00	MG	33,105	4,088,164
	P	9128K	Pack tabs 0.5mg;tabs 1mg 14;tabs 1mg 28 (tartrate)	2.00	MG	265,459	27,420,568
	P	9129L	Tablet 1mg (as tartrate) 112	2.00	MG	141,344	32,234,730
DRUGS USED IN ALCOHOL DEPENDENCE							
N07BB03			ACAMPROSATE				
	P	8357W	Tablet 333mg (enteric coated)	2.00	GM	32,864	5,441,031
N07BB01			DISULFIRAM				
	A	16345	Effervescent Tablet 200mg 30	—	—	9,071	—
N07BB04			NALTREXONE				
	P	8370M	Tablet 50mg 30	50.00	MG	26,138	3,536,691

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
NERVOUS SYSTEM							
OTHER NERVOUS SYSTEM DRUGS							
DRUGS USED IN ADDICTIVE DISORDERS							
DRUGS USED IN OPIOID DEPENDENCE							
N07BC01			BUPRENORPHINE				
	P	6307Y	Tablet (sublingual) 400ug (as hydrochloride)	8.00	MG	4,319	–
	P	6308B	Tablet (sublingual) 2mg (as hydrochloride)	8.00	MG	20,359	–
	P	6309C	Sublingual tablet 8mg (base)	8.00	MG	24,568	–
N07BC51			BUPRENORPHINE with NALOXONE				
	P	6470M	Tablet (sublingual) 2mg (as hydrochloride)–0.5mg (as hydrochloride) 28	–	–	37,043	–
	P	6471N	Tablet (sublingual) 8mg (as hydrochloride)–2mg (as hydrochloride) 28	–	–	34,104	–
N07BC02			METHADONE HYDROCHLORIDE				
	P	1606M	Injection 10mg in 1mL	25.00	MG	893	178,343
	P	1609Q	Tablet 10mg	25.00	MG	93,915	3,481,070
	A	17513	Syrup 25mg per 5mL 200mL	25.00	MG	18,943	–
	P	5399E	Syrup 25mg per 5mL 200mL	25.00	MG	431	8,564
	P	5400F	Syrup 25mg per 5mL 200mL	25.00	MG	274	7,806
	P	6171T	Syrup 25mg per 5mL 200mL	25.00	MG	30,303	–
	P	6172W	Syrup 25mg per 5mL 1L	25.00	MG	6,404	–
<i>ANTIVERTIGO PREPARATIONS</i>							
ANTIVERTIGO PREPARATIONS							
N07CA01			BETAHISTINE				
	A	16064	Tablet 16mg 25	24.00	MG	176,638	–
	A	21679	Tablet 16mg 25	24.00	MG	2,881	–
<i>OTHER NERVOUS SYSTEM DRUGS</i>							
OTHER NERVOUS SYSTEM DRUGS							
N07XX02			RILUZOLE				
	P	8664B	Tablet 50mg 56	0.10	GM	7,548	5,142,867
N07XX06			TETRABENAZINE				
	P	1330B	Tablet 25mg	0.10	GM	6,438	2,297,998

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS							
ANTIPROTOZOALS							
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES							
NITROIMIDAZOLE DERIVATIVES							
P01AB01			METRONIDAZOLE				
	P	1621H	Tablet 400mg	2.00	GM	437,043	4,307,355
	P	1626N	Tablet 400mg	2.00	GM	1,737	11,068
	P	1630T	Oral suspension 320mg per 5mL	2.00	GM	33,530	656,060
	P	1636D	Tablet 200mg	2.00	GM	123,106	974,020
	P	1642K	Suppositories 500mg 10	2.00	GM	1,533	41,016
	P	3339R	Tablet 200mg	2.00	GM	54,454	429,258
	P	3341W	Oral suspension 320mg per 5mL	2.00	GM	534	9,979
	P	5155H	Tablet 400mg	2.00	GM	71,316	698,789
P01AB02			TINIDAZOLE				
	P	1465D	Tablet 500mg	2.00	GM	145,373	1,652,836
OTHER AGENTS AGAINST AMOEBIASIS							
P01AX06			ATOVAQUONE				
	P	8300W	Oral suspension 750mg per 5mL 210mL	2.25	GM	173	219,231
ANTIMALARIALS							
QUINOLINE DERIVATIVES							
P01BA02			HYDROXYCHLOROQUINE SULPHATE				
	P	1512N	Tablet 200mg	0.52	GM	207,537	7,789,133
BIGUANIDES							
P01BB51			ATOVAQUONE with PROGUANIL				
	A	18864	Tablet 12	-	-	2,676	-
	P	9439T	Tablet 250mg 100mg 12	-	-	33,389	3,452,041
METHANOLQUINOLINES							
P01BC02			MEFLOQUINE				
	A	14495	Tablet 250mg 8	1.00	GM	17,009	-
P01BC01			QUININE				
	P	1975Y	Tablet 300mg	1.50	GM	75,195	1,067,527
	A	20898	Tablet 300mg 50	1.50	GM	1,319	-
	A	21305	Tablet 300mg 50	-	-	35,433	-
DIAMINOPYRIMIDINES							
P01BD01			PYRIMETHAMINE				
	P	1966L	Tablet 25mg	-	-	215	3,529

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS							
ANTHELMINTICS							
ANTITREMATODALS							
QUINOLINE DERIVATIVES							
P02BA01		PRAZIQUANTEL					
	P	9447F	Tablet 600mg 8	3.00	GM	1,385	54,683
ANTINEMATODAL AGENTS							
BENZIMIDAZOLE DERIVATIVES							
P02CA03		ALBENDAZOLE					
	P	8459F	Tablet 400mg	4.00	GM	387	71,315
	P	8503M	Tablet 200mg 6	0.40	GM	2,076	80,246
	P	9047E	Tablet 200mg 6	0.40	GM	929	31,008
P02CA01		MEBENDAZOLE					
	P	4325P	Tablet 100mg	0.20	GM	444	6,586
TETRAHYDROPYRIMIDINE DERIVATIVES							
P02CC01		PYRANTEL EMBONATE					
	P	3047J	Tablet 125mg (base)	0.75	GM	429	3,858
	P	3048K	Tablet 250mg (base)	0.75	GM	2,424	25,169
AVERMECTINES							
P02CF01		IVERMECTIN					
	P	8359Y	Tablet 3mg 4	12.00	MG	7,020	281,986

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS							
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLANTS							
ECTOPARASITICIDES, INCL. SCABICIDES							
PYRETHRINES, INCL. SYNTHETIC COMPOUNDS							
P03AC04 PERMETHRIN							
	P	3054R	Cream 50mg per g (5%) 30g	-	-	92,726	1,562,870
OTHER ECTOPARASITICIDES, INCL. SCABICIDES							
P03AX01 BENZYL BENZOATE							
	A	13227	Lotion 25% 200mL 1	-	-	647	-
	A	19826	Lotion 25% 200mL 1	-	-	437	-

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
RESPIRATORY SYSTEM							
NASAL PREPARATIONS							
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE							
SYMPATHOMIMETICS, PLAIN							
R01AA05			OXYMETAZOLINE				
	P	4378K	Nasal spray 500ug per mL (0.05%) 15mL	0.40	MG	1,519	26,123
	P	4379L	Nasal spray 500ug per mL (0.05%) 18mL	0.40	MG	311	5,226
R01AA07			XYLOMETAZOLINE				
	A	11436	Nasal spray 15mL 1	0.80	MG	531	–
ANTIALLERGIC AGENTS, EXCL. CORTICOSTEROIDS							
R01AC02			LEVOCABASTINE				
	P	4311X	Nasal spray 500ug per mL (0.05) 10mL	0.60	MG	1,797	32,677
R01AC08			OLOPATADINE				
	A	17620	Eye drop 0.10% 1	–	–	71,116	–
R01AC01			SODIUM CROMOGLYCATE				
	P	4468E	Nasal spray metered dose pump 20mg per mL (2%)	40.00	MG	653	14,905
CORTICOSTEROIDS							
R01AD01			BECLOMETHASONE DIPROPIONATE				
	A	17056	Aqueous nasal spray 50ug per dose 200 dose	0.40	MG	2,922	–
R01AD05			BUDESONIDE				
	A	17200	Nasal spray aqueous (pump) 32ug per dose 60 doses	0.30	MG	998	–
	A	17201	Nasal spray aqueous (pump) 32ug per dose 120 doses	0.30	MG	1,313	–
	A	17850	Nasal spray aqueous (pump) 64ug per dose 240 doses	0.30	MG	64,559	–
	A	17952	Nasal spray aqueous (pump) 64ug per dose 120 doses	0.30	MG	127,089	–
	P	4092J	Nasal spray aqueous (pump) 64ug per dose 120 doses	0.30	MG	53,071	1,692,035
R01AD08			FLUTICASONE				
	A	17840	Aqueous Nasal unit dose instillation 400ug 28	0.20	MG	5,539	–
R01AD12			FLUTICASONE FUROATE				
	A	20423	Nasal spray 27.5ug per spray 120	0.11	MG	33,488	–
R01AD09			MOMETASONE FUROATE				
	A	16441	Aqueous Nasal spray 50ug per dose	0.20	MG	566,360	–
	A	18043	Aqueous Nasal spray 50ug per dose 65 doses	0.20	MG	44,551	–
OTHER NASAL PREPARATIONS							
R01AX03			IPRATROPIUM BROMIDE				
	A	16829	Aqueous nasal spray (pump pack) 42ug per dose 10mL	0.24	MG	129	–
	P	4089F	Aqueous nasal spray (pump pack) 21ug per dose	0.24	MG	7,080	166,723
	P	4090G	Aqueous nasal spray (pump pack) 42ug per dose	0.24	MG	9,483	289,444
R01AX06			MUPIROCIN				
	P	9440W	Nasal ointment 20mg (as calcium) per g (2%) 3g 1	–	–	67,411	1,395,527

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
RESPIRATORY SYSTEM							
NASAL PREPARATIONS							
NASAL DECONGESTANTS FOR SYSTEMIC USE							
SYMPATHOMIMETICS							
R01BA52			BROMHEXINE with GUAIPHENESIN with PSEUDOEPHEDRINE				
	A	19678	Liquid 100mL 1	-	-	131	-
R01BA52			BROMHEXINE with PSEUDOEPHEDRINE				
	A	19485	Liquid 200mL	-	-	380	-
R01BA52			CHLORPHENIRAMINE with PARACETAMOL with CODEINE PSEUDOEPHERINE				
	A	19971	Tab 2mg chlor/500mg para/30mg pseud 8+/9mg codeine	-	-	2,123	-
R01BA52			CHLORPHENIRAMINE with PARACETAMOL with CODEINE with PSEUDOEPHERINE				
	A	21325	Tablet 24 ??	-	-	886	-
R01BA52			CHLORPHENIRAMINE with PSEUDOEPHEDRINE with PARACETEMOL				
	A	19538	Tablet 24	-	-	496	-
R01BA52			CODEINE with PARACETAMOL with PSEUDOEPHEDRINE				
	A	21324	Tablet 6mg-500mg-30mg 24	-	-	340	-
	A	21327	Tablet 2mg-500mg-30mg 24	-	-	381	-
R01BA52			CODEINE with PARRACETAMOL with PSEUDOEPHEDRINE with TRIPROLIDINE				
	A	19481	Tablet 24	-	-	28,460	-
R01BA52			DEXTROMETHORPHAN with DOXYLAMINE with PARACETAMOL with PSEUDOEPHEDRINE				
	A	19483	Capsule 24	-	-	4,818	-
	A	19484	Capsule 20	-	-	425	-
R01BA52			DEXTROMETHORPHAN with PARACETAMOL with PSEUDOEPHEDRINE				
	A	19482	Capsule 24	-	-	606	-
	A	19503	Tablet 24	-	-	437	-
R01BA52			DEXTROMETHORPHAN with PARACETAMOLE with PSEUDOEPHEDRINE				
	A	19541	Tablet 24	-	-	958	-
R01BA52			IBUPROFEN with PSEUDOEPHEDRINE				
	A	19513	Tablet 24	-	-	1,027	-
R01BA52			IBUPROFEN with PSEUDOEPHEDRINE with PSEUDOEPHEDRINE				
	A	19492	Tablet 24	-	-	1,804	-
R01BA52			LORATADINE with PSEUDOEPHEDRINE				
	A	19534	Tablet 6	-	-	10,205	-

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
RESPIRATORY SYSTEM							
NASAL PREPARATIONS							
NASAL DECONGESTANTS FOR SYSTEMIC USE							
SYMPATHOMIMETICS							
R01BA52			PARACETAMOL with PSEUDEPHEDRINE with CHLORPHENIRAMINE				
	A	20670	Tablet 500mg-30mg-2mg 12	-	-	529	-
	A	20671	Tablet 500mg-30mg-2mg 24	-	-	496	-
R01BA52			PARACETAMOL with PSEUDOEPHEDRINE				
	A	11894	Tablet 10	-	-	193	-
	A	19478	Tablet 24	-	-	2,121	-
	A	19504	Tablet 24	-	-	2,031	-
	A	19515	Tablet 24	-	-	3,018	-
	A	21326	Tablet 500mg/30mg 24	-	-	474	-
R01BA52			PARACETAMOL with PSEUDOEPHEDRINE with TRIPROLIDINE				
	A	19514	Tablet 24	-	-	3,276	-
	A	19516	Tablet 20	-	-	1,608	-
R01BA52			PSEUDEPHEDRINE with FEXOFENADINE				
	A	19644	Tablet 120mg-60mg 6	-	-	12,101	-
R01BA02			PSEUDOEPHEDRINE				
	A	19683	Tablets 60mg 12	0.24	GM	5,237	-
	A	19962	Tablets substaained release 120mg 6	0.24	GM	11,171	-
	A	20491	Tablet 60mg 30	0.24	GM	149	-
	P	4029C	Tablet 60mg 12	0.24	GM	504	8,825

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
RESPIRATORY SYSTEM							
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES							
ADRENERGICS, INHALANTS							
SELECTIVE BETA-2-ADRENOCEPTOR AGONISTS							
R03AC13			EFORMOTEROL				
	P	8136F	Capsule contain powder oral inhalation 12ug	24.00	UG	9,828	385,319
	P	8239P	Powder oral inhalation breath actuated 6ug	24.00	UG	8,840	235,412
	P	8240Q	Powder oral inhalation breath actuated 12ug	24.00	UG	47,204	1,828,721
R03AC18			INDACATEROL				
	P	5134F	Capsule containing powder for oral inhalation 150ug (as maleate) 30	0.15	MG	1,711	123,574
	P	5137J	Capsule containing powder for oral inhalation 300ug (as maleate) 30	0.15	MG	476	34,944
R03AC02			SALBUTAMOL				
	P	1099W	Capsule 200ug (base) (oral inhalation)	0.80	MG	2,019	34,346
	P	2000G	Nebuliser solution single dose 2.5mg (base)	10.00	MG	89,107	1,608,250
	P	2001H	Nebuliser solution single dose 5mg (base)	10.00	MG	400,163	7,625,015
	P	3495Y	Oral pressurised inhalant 100ug (base) CFC-free 200 doses	0.80	MG	21,263	233,052
	P	3496B	Nebuliser solution single dose 2.5mg (base)	10.00	MG	5,478	69,627
	P	3497C	Nebuliser solution single dose 5mg (base)	10.00	MG	9,050	118,286
	P	8288F	Oral pressurised inhalant 100ug (base) CFC-free	0.80	MG	3,042,584	44,108,589
	P	8354Q	Oral pressurised inhalant breath actuated 100ug	0.80	MG	62,924	2,415,119
R03AC12			SALMETEROL				
	P	8141L	Powder inhal in breath actu dev 50ug/dose 60 doses	0.10	MG	34,956	1,336,762
R03AC03			TERBUTALINE SULPHATE				
	P	1252X	Pdr for inhalation in breath actu dev 500ug/dose	2.00	MG	234,494	4,172,355
ADRENERGICS AND OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES							
R03AK07			EFORMOTEROL with BUDESONIDE				
	P	8625Y	Pdr oral inhal in breath actu dev 200ug-6ug/dose 120	-	-	1,077,617	63,318,178
	P	8750M	Pdr oral inhal in breath actu dev 400ug-12ug/dose 60	-	-	414,457	36,192,570
	P	8796Y	Pdr oral inhal in breath actu dev 6ug-100ug/dose 120	-	-	44,273	2,409,843
R03AK06			SALMETEROL and FLUTICASONE				
	P	8430Q	Pdr oral inhal in breath actu dev 50ug/100ug 60	-	-	65,326	3,082,528
	P	8431R	Pdr oral inhal in breath actu dev 50ug/250ug 60	-	-	693,059	41,163,347
	P	8432T	Pdr oral inhal in breath actu dev 50ug/500ug 60	-	-	627,099	49,870,399
	P	8517G	Oral Press inhal 25ug-50ug 120	-	-	105,712	4,985,171
	P	8518H	Oral Press inhal 25ug-125ug 120	-	-	311,442	18,453,851
	P	8519J	Oral Press inhal 25ug-250ug 120	-	-	1,329,927	104,637,968

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
RESPIRATORY SYSTEM							
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES							
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS							
GLUCOCORTICOIDS							
R03BA01			BECLOMETHASONE DIPROPIONATE				
	P	8406K	Oral press inhal 50ug/dose (200 doses) CFC free	0.80	MG	8,610	165,199
	P	8407L	Oral press inhal 100ug/dose (200 doses) CFC free	0.80	MG	47,435	1,587,027
	P	8408M	Oral press inhal in breath actv dev 50ug CFC free	0.80	MG	1,645	45,795
	P	8409N	Oral press inhal in breath actu dev 100ug CFC free	0.80	MG	17,531	686,103
R03BA02			BUDESONIDE				
	P	2065Q	Nebuliser suspn single dose units 500ug in 2mL 30	1.50	MG	8,708	376,632
	P	2066R	Nebuliser suspn single dose units 1mg in 2mL 30	1.50	MG	22,579	1,318,947
	P	2070Y	Pder for oral inhal in breath actu dev 100ug/dose	0.80	MG	6,299	146,639
	P	2071B	Pder oral inhal in breath actu dev 200ug/dose	0.80	MG	53,998	1,674,883
	P	2072C	Pder oral inhal in breath actu dev 400ug/dose	0.80	MG	84,979	3,889,578
R03BA08			CICLESONIDE				
	P	8853Y	Oral pressurised inhalation 80ug/dose 120 doses	0.16	MG	15,146	395,635
	P	8854B	Oral pressurised inhalation 160ug/dose 120 doses	0.16	MG	83,307	3,518,442
R03BA05			FLUTICASONE				
	P	8147T	Powder for oral inhalation 100ug/dose 60 doses	0.60	MG	10,876	185,342
	P	8148W	Powder for oral inhalation 250ug/dose 60 doses	0.60	MG	39,414	1,213,861
	P	8149X	Powder for oral inhalation 500ug/dose 60 doses	0.60	MG	13,274	683,967
	P	8345F	Oral pressurised inhalation 125ug/dose 120 doses	0.60	MG	112,119	3,432,008
	P	8346G	Oral pressurised inhalation 250ug/dose 120 doses	0.60	MG	108,102	5,393,519
	P	8516F	Oral pressurised inhalation 50ug/dose 120 doses	0.60	MG	174,594	2,974,952
ANTICHOLINERGICS							
R03BB01			IPRATROPIUM BROMIDE				
	P	1542E	Nebuliser solution single dose 250ug/mL 30	0.30	MG	32,806	1,165,608
	A	20312	Inhalation solution 250ug per mL 20mL 1	0.30	MG	195	–
	P	8238N	Nebuliser solution single dose 500ug in 1mL 30	0.30	MG	173,477	7,164,070
	P	8671J	Oral pressurised inhalation 21ug/dose 200 doses	0.12	MG	94,889	3,157,229
R03BB04			TIOTROPIUM BROMIDE				
	P	8626B	Capsule 18ug (base)(oral inhalation) 30	18.00	UG	1,811,763	139,262,047
ANTIALLERGIC AGENTS, EXCL. CORTICOSTEROIDS							
R03BC03			NEDOCROMIL				
	P	8365G	Oral pressurised inhalation 2mg (112 doses)	8.00	MG	60,829	2,309,230
R03BC01			SODIUM CROMOGLYCAT				
	P	2878L	Capsule 20mg (oral inhalation)	80.00	MG	1,933	61,923
	P	8334P	Oral pressurised inhalation 5mg/dose 112 doses	40.00	MG	24,479	896,134
	P	8767K	Oral pressurised inhalation 1mg/dose 200 doses	40.00	MG	3,787	114,588
ADRENERGICS FOR SYSTEMIC USE							
SELECTIVE BETA-2-ADRENOCEPTOR AGONISTS							
R03CC02			SALBUTAMOL				
	P	1103C	Syrup 2mg (base) per 5mL 300mL	12.00	MG	36,534	792,578
R03CC03			TERBUTALINE SULPHATE				
	P	1034K	Injection 500ug in 1mL	15.00	MG	175	72,767
	A	17236	Elixir 0.3mg/mL 300mL	2.00	MG	18,713	–
	P	3491R	Injection 500ug in 1mL	15.00	MG	3,791	115,739

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
RESPIRATORY SYSTEM							
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES							
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES							
XANTHINES							
R03DA04 THEOPHYLLINE							
	P	2614N	Syrup 80mg per 15mL 500mL	0.40	GM	12,318	151,912
	P	2634P	Tablet 250mg (sustained release)	0.40	GM	15,983	212,060
	P	8230E	Tablet 200mg (sustained release)	0.20	GM	14,371	173,855
	P	8231F	Tablet 300mg (sustained release)	0.40	GM	11,705	171,395
LEUKOTRIENERECEPTOR ANTAGONISTS							
R03DC03 MONTELUKAST							
	A	16115	Chewable tablet 10mg 28	10.00	MG	45,610	–
	P	8627C	Chewable tablet 4mg (base) 28	10.00	MG	95,883	4,592,136
	P	8628D	Chewable tablet 5mg (base) 28	10.00	MG	132,023	6,029,685

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
RESPIRATORY SYSTEM							
COUGH AND COLD PREPARATIONS							
<i>EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES</i>							
EXPECTORANTS							
R05CA10			GUAIPHENESIN with PSEUDOEPHEDRINE				
	A	13545	Syrup sf100mL	–	–	535	–
R05CA10			SENEGA and AMMONIA				
	A	13810	Mixture 200mL	–	–	341	–
	A	19447	Mixture 200mL	–	–	889	–
	P	4074K	Mixture 200mL	–	–	9,436	87,498
MUCOLYTICS							
R05CB02			BROMHEXINE HYDROCHLORIDE				
	A	10212	Elx 4mg/5mL 1	24.00	MG	7,356	–
	A	13662	Tablet 8mg 100	24.00	MG	3,365	–
<i>COUGH SUPPRESSANTS, EXCL.COMBINATIONS WITH EXPECTORANTS</i>							
OPIUM ALKALOIDS AND DERIVATIVES							
R05DA04			CODEINE				
	P	1214X	Tablet 30mg	100.00	MG	68,675	2,348,124
	A	12817	Linctus 0.5% 100mL 1	100.00	MG	585	–
	A	20268	Linctus 5mg per mL 100mL	100.00	MG	724	–
R05DA20			CODEINE with PARACETAMOL with PSEUDOEPHEDRINE				
	A	10584	Tablet 24	–	–	12,102	–
	A	19469	Tablet 24	–	–	6,411	–
R05DA20			DEXTROMETHORPHAN with BROMPHENIRAMINE with PHENYLEPHRINE				
	A	14751	Elixir sugar free 200mL	–	–	127	–
	A	14785	Elixir sugar free 100mL	–	–	648	–
R05DA20			DEXTROMETHORPHAN with DIPHENHDRAMINE				
	A	18877	Linctus 100mL 1	–	–	142	–
R05DA08			PHOLCODINE				
	A	10723	Linctus 200mL 1	50.00	MG	2,059	–
	A	12611	Linctus 200mL 1	50.00	MG	1,072	–
	A	12921	Expectorant 200mL 1	50.00	MG	466	–
	A	13809	Linctus 1mg per mL (0.1%) 100mL	50.00	MG	203	–
	P	4071G	Linctus 1mg per mL (0.1%) 100mL	50.00	MG	3,984	57,505
R05DA20			PHOLCODINE with PSEUDOEPHEDRINE				
	A	13367	Mixture 200mL 1	50.00	MG	268	–

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
RESPIRATORY SYSTEM							
ANTIHISTAMINES FOR SYSTEMIC USE							
ANTIHISTAMINES FOR SYSTEMIC USE							
AMINOALKYL ETHERS							
R06AA02			DIPHENHYDRAMINE				
	A	20792	Tablet 50mg 10	0.20	GM	372	-
R06AA52			DIPHENHYDRAMINE with AMMONIUM CHLORIDE				
	A	10194	Mixture 100mL 1	-	-	925	-
	A	13099	Mixture 200mL 1	-	-	1,765	-
	A	18879	Linctus 200mL 1	-	-	113	-
R06AA52			DIPHENHYDRAMINE with PHENYLEPH				
	A	11694	200mL 1	-	-	627	-
R06AA09			DOXYLAMINE				
	A	13003	Tablet 25mg 20	-	-	13,488	-
	A	14123	Capsule 25mg 20	-	-	2,702	-
	A	20365	Tablet 25mg 20	-	-	1,005	-
SUBSTITUTED ALKYLAMINES							
R06AB51			BROMPHENIRAMINE COMBINATIONS				
	A	10663	Elixir 100mL 1	24.00	MG	515	-
R06AB54			CHLORPHENIRAMINE with CODEINE with PARACETAMOL with PSEUDOEPHEDRINE				
	A	19479	Tablet 24	-	-	1,344	-
	A	19480	Capsule 24	-	-	5,027	-
R06AB54			CHLORPHENIRAMINE with CODEINE with PARACETAMOL with PSEUDOEPHRINE				
	A	19679	Tablets 24	-	-	38,211	-
R06AB54			CHLORPHENIRAMINE with PARACETAMOL				
	A	18516	Tablets 2mg/500mg 24	-	-	1,606	-
R06AB54			CHLORPHENIRAMINE with PARACETAMOL with PSEUDOEPHEDRINE				
	A	19475	Tablet 24	-	-	2,702	-
	A	19506	Tablets 24	-	-	934	-
R06AB54			CHLORPHENIRAMINE with PHENYLEPHRINE				
	A	10604	Syrup 100mL 1	-	-	1,549	-
	A	16069	Syrup 100mL 1	-	-	1,043	-
R06AB54			CHLORPHENIRAMINE with PHOLCODEINE with PSEUDOEPHRINE				
	A	19542	Syrup 100mL	-	-	255	-
R06AB54			CHLORPHENIRAMINE with PSEUDOEPHREDINE with PARACETAMOL				
	A	20838	Tablet 24	-	-	153	-
R06AB54			CHLORPHENIRAMINE with PSEUDOEPHRINE				
	A	19532	Tablets 12	-	-	31,479	-
R06AB02			DEXCHLORPHENIRAMINE				
	A	11602	Syrup 2mg/5mL 1	6.00	MG	3,532	-
	A	20724	Tablet 2mg 20	6.00	MG	7,642	-
	A	20725	Tablet 2mg 40	6.00	MG	5,761	-
R06AB05			PHENIRAMINE				
	A	13917	Tablet 50mg	75.00	MG	1,344	-

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
RESPIRATORY SYSTEM							
ANTIHISTAMINES FOR SYSTEMIC USE							
ANTIHISTAMINES FOR SYSTEMIC USE							
PHENOTHIAZINE DERIVATIVES							
R06AD02			PROMETHAZINE				
	A	15810	Tablet 25mg 30	25.00	MG	2,536	–
	P	1948M	Injection 50mg in 2mL	25.00	MG	8,838	215,917
	A	20215	Tablet 10mg 50	25.00	MG	256	–
	A	20216	Tablet 25mg 50	25.00	MG	268	–
	A	20858	Tablet 10mg 50	25.00	MG	186	–
	A	20859	Tablet 25mg 50	25.00	MG	601	–
	P	3488N	Injection 50mg in 2mL	25.00	MG	11,791	242,822
	P	4072H	Tablet 10mg	25.00	MG	13,541	198,562
	P	4073J	Tablet 25mg	25.00	MG	18,446	309,836
	P	5325G	Tablet 10mg 50	25.00	MG	5,819	89,411
	P	5326H	Tablet 25mg 50	25.00	MG	7,119	125,385
	P	5327J	Oral liquid 5mg per 5mL 100mL	25.00	MG	8,243	219,059
	P	5328K	Tablet 10mg 50	25.00	MG	1,466	24,221
	P	5329L	Tablet 25mg 50	25.00	MG	2,357	39,388
	P	5330M	Oral liquid 5mg per 5mL 100mL	25.00	MG	6,119	162,805
R06AD01			TRIMEPRAZINE				
	A	12156	Syrup 7.5mg/5 l	30.00	MG	959	–
	A	12157	Syrup 30mg/5 l	30.00	MG	2,053	–
PIPERAZINE DERIVATIVES							
R06AE07			CETIRIZINE				
	A	14363	Tablet 10mg	10.00	MG	4,110	–
	A	16121	Oral drops 10mg per mL 20mL	10.00	MG	681	–
	A	16122	Oral solution 1mg/mL 75mL	10.00	MG	1,276	–
	A	16123	Oral solution 1mg/mL 200mL	10.00	MG	204	–
	P	4175R	Tablet 10mg 30	10.00	MG	17,415	683,947
OTHER ANTIHISTAMINES FOR SYSTEMIC USE							
R06AX02			CYPROHEPTADINE HYDROCHLORIDE				
	P	1798P	Tablet 4mg	12.00	MG	74,577	1,050,928
R06AX27			DESLORATADINE				
	A	18721	Tablet 5mg 7	5.00	MG	130	–
R06AX26			FEXOFENADINE				
	A	16142	Tablet 180mg 10	0.12	GM	204	–
	A	16266	Tablet 180mg 30	0.12	GM	155	–
	A	18895	Tablet 180mg 30	0.12	GM	145	–
	P	4237B	Capsule 60mg	0.12	GM	3,048	164,517
	P	4238C	Tablet 120mg	0.12	GM	10,748	494,347
R06AX13			LORATADINE				
	A	13978	Tablet 10mg	10.00	MG	4,161	–
	A	14513	Syrup 100mL	10.00	MG	320	–
	A	19685	Tablet 10mg	10.00	MG	1,412	–
	P	4313B	Tablet 10mg	10.00	MG	36,640	1,657,456

ATC	ITEM TYPE	CODE	FORM AND STRENGTH			2011	
				DDD	UNITS	SCRIPTS	COST(\$)
SENSORY ORGANS							
OPHTHALMOLOGICALS							
ANTIINFECTIVES							
ANTIBIOTICS							
S01AA01			CHLORAMPHENICOL				
	P	1171P	Eye ointment 10mg per g (1%) 4g	–	–	465,568	4,557,234
	A	14670	Eye drops Minims 0.5% 20	–	–	519	–
	P	2360F	Eye drops 5mg per mL (0.5%) 10mL	–	–	971,268	10,659,333
	P	5511C	Eye ointment 10mg per g (1%) 4g	–	–	3,314	32,376
	P	5512D	Eye drops 5mg per mL (0.5%) 10mL	–	–	6,841	75,247
S01AA11			GENTAMICIN SULPHATE				
	P	1441W	Eye drops 3mg (base) per mL (0.3%) 5mL	–	–	9,877	180,597
S01AA12			TOBRAMYCIN				
	P	2328M	Eye drops 3mg per mL (0.3%) 5mL	–	–	72,918	1,397,356
	P	2329N	Eye ointment 3mg per g (0.3%) 3.5g	–	–	20,250	454,444
	P	5569D	Eye drops 3mg per mL (0.3%) 5mL	–	–	366	7,059
SULFONAMIDES							
S01AB04			SULPHACETAMIDE				
	P	2063N	Eye drops 100mg per mL (10%) 15mL	–	–	3,554	39,210
ANTIVIRALS							
S01AD03			ACICLOVIR				
	P	1002R	Eye ointment 30mg per g (3%) 4.5g	–	–	42,185	1,435,305
	P	5501M	Eye ointment 30mg per g (3%) 4.5g	–	–	850	28,682
OTHER ANTIINFECTIVES							
S01AX13			CIPROFLOXACIN				
	P	1217C	Eye drops 3mg per mL (0.3%) 5mL	–	–	17,506	477,403
	A	17303	Eye drops 3mg per mL (0.3%) 5mL	–	–	120	–
	P	5564W	Eye drops 3mg per mL (0.3%) 5mL 2	–	–	444	8,842
	P	5565X	Eye drops 1mg per mL (0.1%) 5mL 1	–	–	380	4,028
S01AX11			OFLOXACIN				
	A	17320	Eye drops 3mg per mL (0.3%) 5mL	–	–	211	–
	P	8383F	Eye drops 3mg per mL (0.3%) 5mL	–	–	17,812	532,582
S01AX20			POLYETHYLENE GLYCOL 400				
	P	5559N	Eye drops 2.5mg per mL (0.25%), 15mL	–	–	861	9,118
	P	9491M	Eye drops 2.5mg per mL (0.25%), 15mL	–	–	8,075	85,854
	P	9492N	Eye drops 2.5mg per mL (0.25%), 15mL	–	–	950	10,061
	P	9493P	Eye drops 2.5mg per mL (0.25%), single dose units 0.4mL, 20 5	–	–	1,659	63,560

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
SENSORY ORGANS							
OPHTHALMOLOGICALS							
ANTIINFLAMMATORY AGENTS							
CORTICOSTEROIDS, PLAIN							
S01BA01			DEXAMETHASONE				
	P	1288T	Eye drops 1mg per mL (0.1%) 5mL	-	-	213,715	2,266,908
S01BA07			FLUOROMETHOLONE				
	P	1204J	Eye drops 1mg per mL (0.1%) 5mL	-	-	251,312	2,663,698
	P	1438Q	Eye drops 1mg per mL (0.1%) 5mL	-	-	66,799	707,757
	P	5513E	Eye drops 1mg per mL (0.1%) 5mL	-	-	10,364	109,952
	P	5533F	Eye drops 1mg per mL (0.1%) 5mL	-	-	4,981	52,835
S01BA02			HYDROCORTISONE				
	P	2441L	Eye ointment 10mg per g (1%) 5g	-	-	68,785	874,126
	P	5516H	Eye ointment 10mg per g (1%) 5g	-	-	1,055	13,406
S01BA04			PREDNISOLONE				
	A	14678	Minims 0.5% 20	-	-	4,360	-
CORTICOSTEROIDS AND SYMPATHOMIMETICS IN COMB							
S01BB02			PREDNISOLONE ACETATE with PHENYLEPHRINE HYDROCHLORIDE				
	P	3112T	Eye drops 10mg-1.2mg per mL (1%-0.12%) 10mL	-	-	305,340	7,098,877
S01BB02			PREDNISOLONE and MYDRIATICS				
	P	5568C	Eye drops 10mg-1.2mg per mL (1%-0.12%) 10mL	-	-	752	17,843
ANTIINFLAMMATORY AGENTS, NON-STERIODS							
S01BC03			DICLOFENAC				
	A	15226	Eye drops 0.1%	-	-	988	-
	A	19829	Eye drops 5mg/5mL (0.1%)	-	-	22,783	-
S01BC04			FLURBIPROFEN				
	P	8699W	Eye drops 300ug per mL(0.03%) single dose 0.4mL 5	-	-	1,743	28,057
S01BC05			KETOROLAC TROMETAMOL				
	A	16800	Eye drops 0.5% 5mL	-	-	68,870	-
ANTIGLAUCOMA PREPARATIONS AND MIOTICS							
SYMPATHOMIMETICS IN GLAUCOMA THERAPY							
S01EA03			APRACLONIDINE				
	P	8083K	Eye drops 5mg (base) per mL (0.5%) 10mL	1.50	MG	6,799	282,566
S01EA05			BRIMONIDINE				
	P	5298W	Eye drops 1.5mg per mL (0.15%) 5mL	0.30	MG	46,119	925,986
	P	5534G	Eye drops 2mg per mL (0.2%) 5mL	0.40	MG	707	14,251
	P	5563T	Eye drops 1.5mg per mL (0.15%) 5mL	0.30	MG	153	3,077
	P	8351M	Eye drops 2mg per mL (0.2%) 5mL	0.40	MG	181,159	3,644,231
PARASYMPATHOMIMETICS							
S01EB01			PILOCARPINE				
	A	14676	Eye drops Minims 2% 20	-	-	413	-
	P	2595N	Eye drops 10mg per mL (1%) 15mL	4.00	MG	11,740	146,741
	P	2596P	Eye drops 20mg per mL (2%) 15mL	8.00	MG	25,410	349,356
	P	2598R	Eye drops 40mg per mL (4%) 15mL	16.00	MG	16,984	282,118

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
SENSORY ORGANS							
OPHTHALMOLOGICALS							
ANTIGLAUCOMA PREPARATIONS AND MIOTICS							
CARBONIC ANHYDRASE INHIBITORS							
S01EC01		ACETAZOLAMIDE					
	P	1004W	Tablet 250mg	0.75	GM	33,418	742,233
S01EC04		BRINZOLAMIDE					
	P	5540N	Eye drops 10mg per mL (1%) 5mL	2.00	MG	1,067	24,315
	P	8483L	Eye drops 10mg per mL (1%) 5mL	2.00	MG	256,070	5,837,363
S01EC03		DORZOLAMIDE					
	P	5541P	Eye drops 20mg per mL (2%) 5mL	6.00	MG	863	18,387
	P	8488R	Eye drops 20mg per mL (2%) 5mL	6.00	MG	58,831	1,255,392
BETA BLOCKING AGENTS							
S01ED02		BETAXOLOL HYDROCHLORIDE					
	P	2811Y	Eye drops 2.5mg (base) per mL(0.25%) 5mL	0.50	MG	56,017	827,202
	P	2825Q	Eye drops 5mg (base) per mL (0.5%) 5mL	1.00	MG	27,648	408,944
S01ED51		BIMATOPROST with TIMOLOL MALEATE					
	P	3438Y	Eye drops 10ug–5mg (base) per mL (1%–0.5%) 5mL	–	–	27,912	750,762
	P	5558M	Eye drops 300ug–5mg (base) per mL (0.03%–0.5%) 3mL	–	–	581	27,074
	P	9464D	Eye drops 300ug–5mg (base) per mL (0.03%–0.5%) 3mL	–	–	100,747	4,695,267
S01ED51		BRIMONIDINE TARTRATE with TIMOLOL MALEATE					
	P	5535H	Eye drops 2mg–5mg (base) per mL (0.2–0.5%) 5mL	–	–	619	16,141
	P	8826M	Eye drops 2mg–5mg (base) per mL (0.2–0.5%) 5mL	–	–	138,421	3,602,513
S01ED51		LATANOPROST with TIMOLOL MALEATE					
	P	8895E	Eye drops 50ug–5mg per mL (0.005%–0.5%) 2.5 mL	–	–	449,972	20,977,908
S01ED01		TIMOLOL MALEATE					
	P	1278G	Eye drops 2.5mg (base) per mL (0.25%) 5mL	0.50	MG	31,799	366,670
	P	1279H	Eye drops 5mg (base) per mL (0.5%) 5mL	1.00	MG	182,289	2,243,417
	P	1925H	Eye drops (gellan gum solution) 2.5mg (base)	0.25	MG	17,357	200,508
	P	1926J	Eye drops (gellan gum solution) 5mg (base)	0.50	MG	94,188	1,161,061
	P	5548B	Eye drops 5mg (base) per mL (0.5%) 5mL	1.00	MG	427	5,265
	P	5550D	Eye drops (gellan gum solution) 5mg (base) per mL (0.5%) 2.5mL	0.50	MG	429	5,292
	P	8803H	Eye gel 1mg (base) per g (0.1%) 5g	–	–	48,099	620,606
S01ED51		TIMOLOL MALEATE with PILOCARPINE HYDROCHLORIDE					
	P	8567X	Eye drops 5mg–20mg per mL (0.5%– 2%) 5mL	–	–	223,011	6,073,977
S01ED51		TIMOLOL with DORZOLAMIDE					
	P	5542Q	Eye drops 20mg–5mg (base) per mL (2–0.5%) 5mL	–	–	469	12,750
S01ED51		TIMOLOL with LATANOPROST					
	P	5553G	Eye drops 50ug–5mg (base) per mL (0.005–0.5%) 2.5mL	–	–	2,031	94,649
S01ED51		TIMOLOL with TRAVOPROST					
	P	5555J	Eye drops 40ug–5mg (base) per mL (0.004–0.5%) 2.5mL	–	–	531	24,745
S01ED51		TRAVAPROST with TIMOLOL					
	P	9057Q	Eye drops 40ug–5mg (base) per mL (0.004–0.5%) 2.5mL	–	–	142,099	6,621,230

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
SENSORY ORGANS							
OPHTHALMOLOGICALS							
ANTIGLAUCOMA PREPARATIONS AND MIOTICS							
PROSTAGLANDIN ANALOGUES							
S01EE03			BIMATOPROST				
	P	5551E	Eye drops 300ug per mL (0.03%) 3mL	30.00	UG	1,364	57,479
	P	8620Q	Eye drops 300ug per mL (0.03%) 3mL	30.00	UG	271,353	11,434,920
S01EE01			LATANOPROST				
	P	5552F	Eye drops 50ug per mL (0.005%) 2.5mL	5.00	UG	8,021	337,999
	P	8243W	Eye drops 50ug per mL (0.005%) 2.5mL	5.00	UG	1,535,210	64,676,637
S01EE04			TRAVOPROST				
	P	5554H	Eye drops 40ug per mL (0.004%) 2.5mL	4.00	UG	984	41,466
	P	8597L	Eye drops 40ug per mL (0.004%)	4.00	UG	151,647	6,389,027
MYDRIATICS AND CYCLOPLEGICS							
ANTICHOLINERGICS							
S01FA01			ATROPINE SULPHATE				
	P	1093M	Eye drops 10mg per mL (1%) 15mL	–	–	18,535	392,517
S01FA05			HOMATROPINE HYDROBROMIDE				
	P	2541R	Eye drops 20mg per mL (2%) 15mL	–	–	15,532	272,448
SYMPATHOMIMETICS EXCL. ANTIGLAUCOMA PREPARATIONS							
S01FB01			PHENYLEPHRINE				
	A	14674	Minims 10 % 20	–	–	218	–
DECONGESTANTS AND ANTIALLERGICS							
SYMPATHOMIMETICS USED AS DECONGESTANTS							
S01GA51			ANTAZOLINE with NAPHAZOLINE				
	P	4031E	Eye drops 5mg (sulphate)–250ug (nitrate) per mL 10mL	–	–	1,031	14,278
	P	4032F	Eye drops 5mg (phosphate)–500ug per mL 15mL	–	–	891	13,176
S01GA01			NAPHAZOLINE				
	P	4035J	Eye drops 1mg per mL (0.1%) 15mL	–	–	1,134	17,105
S01GA51			NAPHAZOLINE with PHENIRAMINE				
	A	21030	Eye drops 250ug–3mg per mL (0.025%–0.3%) 15mL	–	–	1,371	–
OTHER ANTIALLERGICS							
S01GX07			AZELASTINE				
	A	20633	Eye drops 0.5mg/mL 6mL	–	–	275	–
S01GX08			KETOTIFEN				
	A	18722	Eye drops 250mg (base) per mL 2.5mL	–	–	260	–
	A	18723	Eye drops 250mg (base) per mL 5mL	–	–	3,386	–
	A	19792	Eye drops 250mg (base) per mL 2.5mL	–	–	262	–
S01GX02			LEVOCABASTINE				
	P	4310W	Eye drops 500ug per mL (0.05%) 4mL	–	–	3,419	62,545
S01GX05			LODOXAMIDE				
	A	19726	Eye drops 0.1% 10mL	–	–	457	–
S01GX01			SODIUM CROMOGLYCATE				
	P	1127H	Eye drops 20mg per mL (2%) 10mL	–	–	42,741	606,608
	P	5529B	Eye drops 20mg per mL (2%) 10mL	–	–	201	2,866

ATC	ITEM TYPE	CODE	FORM AND STRENGTH			2011	
				DDD	UNITS	SCRIPTS	COST(\$)
SENSORY ORGANS							
OPHTHALMOLOGICALS							
OCULAR VASCULAR DISORDER AGENTS							
ANTINEOVASCULARISATION AGENTS							
S01LA04	RANIBIZUMAB						
	P	1382R	Solution for intravitreal injection 2.3mg in 0.23mL	–	–	160,826	342,907,018
S01LA01	VERTEPORFIN						
	P	1349B	Powder for I.V. infusion 15mg	–	–	147	336,935
OTHER OPHTHALMOLOGICALS							
OTHER OPHTHALMOLOGICALS							
S01XA20	CARBOMER						
	P	9210R	Eye gel 2mg per g (0.2%) 10g	–	–	10,617	109,791
S01XA20	CARBOMER 940						
	P	5502N	Ocular lubricating gel 3mg per g (0.3%) 30	–	–	385	13,369
	P	5503P	Eye gel 2mg per g (0.2%) 10g	–	–	464	4,826
	P	8384G	Eye gel 2mg per g (0.2%) 10g	–	–	114,556	1,193,847
	P	8514D	Ocular lubricating gel 3mg per g (0.3%) 30	–	–	23,705	863,200
S01XA20	CARBOMER 980						
	P	8578L	Eye gel 2mg per g (0.2%) single dose units 0.6mL 30	–	–	6,163	225,554
S01XA20	CARMELLOSE SODIUM						
	P	2324H	Eye drops 10mg per mL (1%) single dose units 30	–	–	25,397	937,271
	P	2338C	Eye drops 5mg per mL (0.5%) single dose units 30	–	–	117,089	4,307,684
	P	5505R	Eye drops 10mg per mL (1%) single dose units 30	–	–	191	6,532
	P	5506T	Eye drops 5mg per mL (0.5%) single dose units 30	–	–	440	14,760
	P	5507W	Eye drops 5mg per mL (0.5%) 15mL	–	–	1,206	12,772
	P	5508X	Eye drops 10mg per mL (1%) 15mL	–	–	1,505	15,938
	P	5509Y	Eye drops 2.5mg per mL (0.25%) single dose 0.6mL 24	–	–	283	10,389
	P	5510B	Ocular lub gel 10mg per mL (1%) single unit 0.6mL	–	–	122	3,734
	P	8548X	Eye drops 5mg per mL (0.5%) 15mL	–	–	344,263	3,645,518
	P	8593G	Eye drops 10mg per mL (1%) 15mL	–	–	100,591	1,064,587
	P	8823J	Eye drops 2.5mg per mL (0.25%) single dose 0.6mL 24	–	–	13,520	547,401
	P	8824K	Ocular lub gel 10mg per mL (1%) single unit 0.6mL	–	–	4,473	154,671
	P	9211T	Eye drops 5mg per mL (0.5%) 15mL	–	–	21,664	229,256
	P	9212W	Eye drops 10mg per mL (1%) 15mL	–	–	9,730	102,812
S01XA20	CARMELLOSE SODIUM with GLYCERIN						
	P	5556K	Eye drops 5mg–9mg per mL (0.5%–0.9%) 15mL	–	–	1,288	13,700
	P	9307W	Eye drops 5mg–9mg per mL (0.5%–0.9%) single dose units 0.4mL, 30 3	–	–	6,998	248,898
	P	9355J	Eye drops 5mg–9mg per mL (0.5%–0.9%) 15mL	–	–	47,181	498,197
	P	9356K	Eye drops 5mg–9mg per mL (0.5%–0.9%) 15mL	–	–	45,836	484,497

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
SENSORY ORGANS							
OPHTHALMOLOGICALS							
OTHER OPHTHALMOLOGICALS							
OTHER OPHTHALMOLOGICALS							
S01XA20			HYPROMELLOSE				
	P	1509K	Eye drops 3mg–1mg per mL (0.3%–0.1%) 15mL	–	–	350,240	3,680,359
	P	2956N	Eye drops 5mg per mL (0.5%) 15mL	–	–	12,156	124,529
	P	5518K	Eye drops 3mg–1mg per mL (0.3%) 15mL	–	–	2,251	23,129
	P	5520M	Eye drops 3mg–1mg per mL (0.3%–0.1%) 15mL	–	–	324	3,398
	P	8287E	Eye drops 3mg–1mg per mL (0.3%) 15mL	–	–	171,343	1,757,754
	P	9213X	Eye drops 3mg per mL (0.3%) 15mL (contains sodium perborate as preservatives)	–	–	11,434	117,275
	P	9214Y	Eye drops 5mg per mL (0.5%) 15mL	–	–	1,116	11,459
S01XA20			HYPROMELLOSE with CARBOMER 980				
	P	5519L	Ocular lubricating gel 2mg–3mg per g (0.2%–0.3%)	–	–	2,086	21,603
	P	8564R	Ocular lubricating gel 3mg–2mg per g (0.3%–0.2%)	–	–	122,031	1,260,563
	P	9215B	Ocular lubricating gel 3mg–2mg per g (0.3%–0.2%) 10g	–	–	11,102	114,343
S01XA20			HYPROMELLOSE with DEXTRAN				
	P	5521N	Eye drops (0.3%–0.1%) single dose 0.4mL 28	–	–	482	16,010
	P	8299T	Eye drops (0.3%–0.1%) single dose 0.4mL 28	–	–	76,403	2,760,935
	P	9216C	Eye drops 3mg–1mg per mL (0.3%–0.1%) 15mL	–	–	31,249	327,929
S01XA20			PARAFFIN				
	A	10757	Eye ointment 3.5g 1	–	–	534	–
	P	1750D	Compound eye ointment 7g	–	–	135,252	2,863,394
	P	1754H	Compound eye ointment 3.5g	–	–	28,660	617,397
	P	5522P	Compound eye ointment 7g	–	–	1,488	30,771
	P	5523Q	Compound eye ointment 3.5g	–	–	318	5,438
	P	9217D	Compound eye ointment 3.5g	–	–	1,587	33,264
	P	9218E	Pack containing 2 tubes compound eye ointment 3.5g	–	–	12,238	252,227
S01XA20			POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL				
	P	5524R	Eye drops 4mg–3mg per mL (0.4%–0.3%) 15mL	–	–	7,451	78,980
	P	5532E	Eye drops 4mg–3mg per mL single dose units 0.8mL 28	–	–	467	16,005
	P	8676P	Eye drops 4mg–3mg per mL (0.4%–0.3%) 15mL	–	–	437,948	4,629,976
	P	9170P	Eye drops 4mg–3mg per mL single dose units 0.8mL 28	–	–	27,127	945,371
	P	9219F	Eye drops 4mg–3mg per mL (0.4%–0.3%) 15mL	–	–	33,049	349,373
S01XA20			POLYVINYL ALCOHOL				
	P	2681D	Eye drops 30mg per mL (3%) 15mL	–	–	17,240	177,220
	P	2682E	Eye drops 14mg per mL (1.4%) 15mL	–	–	64,241	660,124
	P	8831T	Eye drops 14mg per mL (1.4%) 15mL	–	–	1,638	16,430
	P	8832W	Eye drops 30mg per mL (3%) 15mL	–	–	784	8,010
	P	9220G	Eye drops 14mg per mL (1.4%) 15mL	–	–	6,343	65,218
	P	9221H	Eye drops 14mg per mL (1.4%) 15mL (contains sodium chlorite/hydrogen peroxide as preservative)	–	–	241	2,476
	P	9222J	Eye drops 30mg per mL (3%) 15mL	–	–	1,653	16,916
S01XA20			SOY LECITHIN				
	P	9448G	Eye spray 10mg per mL (1%) 10mL 2	–	–	6,312	216,599

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			COST(\$)
				DDD	UNITS	SCRIPTS	
SENSORY ORGANS							
OTOLOGICALS							
ANTIINFECTIVES							
ANTIINFECTIVES							
S02AA01			CHLORAMPHENICOL				
	P	1172Q	Ear drops (aqueous) 5mg per mL (0.5%) 5mL	-	-	16,249	179,565
S02AA15			CIPROFLOXACIN				
	P	2480M	Ear drops 3mg per mL (0.3%) 5mL	-	-	56,231	1,099,281
S02AA30			NEOMYCIN UNDECENOATE with BACITRACIN ZINC				
	P	2296W	Ear ointment 12mg (3.5mg base)-400 units per g	-	-	27,512	238,408
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION							
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION							
S02CA06			DEXAMETHASONE with FRAMYCETIN SULPHATE and GRAMICIDIN				
	P	2781J	Ear drops 500ug-5mg-50ug per mL	-	-	540,782	5,079,781
S02CA02			FLUMETHASONE PIVALATE with CLIOQUINOL				
	A	15097	Ear drops 200ug-10mg per mL (0.02%-1%)	-	-	63,113	-
S02CA03			HYDROCORTISONE with CIPROFLOXACIN				
	A	21026	Ear drops 10 mL	-	-	120,562	-
S02CA04			TRIAMCINOLONE ACETONIDE with NEOMYCIN SULPHATE GRAMICIDIN and NYSTATIN				
	P	2971J	Ear drops 1mg-2.5mg (base)-250ug per mL	-	-	142,811	1,584,698
	P	2974M	Ear ointment 1mg-2.5mg (base)-250ug per mL	-	-	397,870	3,252,776
OTHER OTOLOGICALS							
ANALGESICS AND ANESTHETICS							
S02DA			PHENAZONE with BENZOCAINE				
	A	10094	Ear drops 10mL 1	-	-	640	-
INDIFFERENT PREPARATIONS							
S02DC			CARBAMIDE PEROXIDE				
	P	4176T	Ear drops 65mg per mL (6.5%) 10mL	-	-	3,449	55,455
S02DC			DICHLOROBENZENE CHLORBUTOL and TURPENTINE OIL				
	P	4180B	Ear drops 20mg-50mg-0.1mL per mL (2%-5%-10%) 11mL	-	-	5,470	77,002
S02DC			DOCUSATE SODIUM				
	P	4199B	Ear drops 50mg per mL (5%) 10mL	-	-	13,061	188,960

<i>ATC</i>	<i>ITEM TYPE</i>	<i>CODE</i>	<i>FORM AND STRENGTH</i>	<i>2011</i>			
				<i>DDD</i>	<i>UNITS</i>	<i>SCRIPTS</i>	<i>COST(\$)</i>
SENSORY ORGANS							
OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS							
<i>ANTIINFECTIVES</i>							
ANTIINFECTIVES							
S03AA			FRAMYCETIN SULPHATE				
	P	1440T	Eye and ear drops 5mg per mL (0.5%) 8mL	-	-	56,099	567,012

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
VARIOUS							
ALLERGENS							
ALLERGENS							
ALLERGEN EXTRACTS							
V01AA07			INSECT ALLERGEN EXTRACT—HONEY BEE VENOM				
	P	2886X	Injection set containing 550ug	-	-	2,593	613,113
V01AA07			INSECT ALLERGEN EXTRACT—PAPER WASP VENOM				
	P	2918N	Injection set containing 550ug	-	-	477	113,230

ATC	ITEM TYPE	CODE	FORM AND STRENGTH	2011			
				DDD	UNITS	SCRIPTS	COST(\$)
VARIOUS							
ALL OTHER THERAPEUTIC PRODUCTS							
ALL OTHER THERAPEUTIC PRODUCTS							
ANTIDOTES							
V03AB15			NALOXONE HYDROCHLORIDE				
	A	16982	Injection 400ug/mL	–	–	305	–
	P	3482G	Injection 2mg in 5mL	–	–	8,533	608,182
IRON CHELATING AGENTS							
V03AC03			DEFERASIROX				
	P	6500D	Tablet 250mg (dispersible) 168	–	–	242	320,231
	P	9600G	Tablet 500mg (dispersible) 168	–	–	1,811	5,294,872
DRUGS FOR TREATMENT OF HYPERKALEMIA AND HYPERPHOSPHATEMIA							
V03AE03			LANTHANUM CARBONATE				
	P	9403X	Chewable tablet 500mg (base) 90	2.25	GM	1,612	526,736
	P	9404Y	Chewable tablet 750mg (base) 90	2.25	GM	1,141	553,103
	P	9405B	Chewable tablet 1000mg (base) 90	2.25	GM	2,005	1,063,850
V03AE02			SEVELAMER				
	P	2142R	Sevelamer hydrochloride tablet 800mg 180	6.40	GM	18,826	7,264,815
	P	9620H	Sevelamer hydrochloride tablet 800mg 360	6.40	GM	460	262,217
V03AE01			SODIUM POLYSTYRENE SULPHONATE				
	P	4470G	Oral powder 454g	–	–	4,759	343,756
DETOXIFYING AGENTS FOR CYTOSTATIC TREATMENT							
V03AF03			CALCIUM FOLINATE				
	P	2308L	Tablet 15mg	60.00	MG	9,984	1,016,068
	P	5870Y	Injection equiv to 300mg folinic acid in 30mL	60.00	MG	686	74,975
	P	5886T	Injection equiv to 100mg folinic acid in 10mL	60.00	MG	3,040	334,384
	P	5890B	Injection equiv to 50mg folinic acid in 5mL	60.00	MG	7,339	367,356
	P	8740B	Injection equiv to 50mg folinic acid in 5mL	60.00	MG	11,465	1,416,627
	P	8812T	Injection equiv to 100mg folinic acid in 10mL	60.00	MG	7,127	1,783,856
	P	9041W	Injection equiv to 300mg folinic acid in 30mL	60.00	MG	938	235,844
V03AF01			MESNA				
	P	5960Q	Solution for I.V. injection 400mg in 4mL	–	–	139	5,170
	P	5961R	Solution for I.V. injection 1g in 10mL	–	–	353	20,176
	P	8078E	Solution for I.V. injection 400mg in 4mL	–	–	187	15,157
	P	8079F	Solution for I.V. injection 1g in 10mL	–	–	1,551	304,275
DRUGS FOR TREATMENT OF HYPERCALCEMIA							
V03AG			SODIUM ACID PHOSPHATE				
	P	2946C	Tablet containing 500mgP–469mgNa–123mgK	–	–	6,109	514,877
OTHER THERAPEUTIC PRODUCTS							
V03AX			POLY L LACTIC ACID				
	P	9475Q	Powder for injection 150mg 2	–	–	1,300	579,156

TABLE 2

COMMUNITY PRESCRIPTION DRUG USE, IN DDD/1000/DAY, FOR 2009 TO 2011

Table 2 lists most drugs on the Australian market by defined daily dose (DDD) per 1000 of the population per day from 2009 to 2011. To be listed in Table 2 the drugs need to have an assigned DDD. Items are arranged on the ATC code by generic name and the DDD/1000/day is given for both the subsidised 'PBS/RPBS' and the non-subsidised 'survey' components.

DDDs/1000 population/day for combination products are reported in terms of the DDD for each constituent where appropriate, ie, the ASM accounts for drugs in combination products as if they were administered as plain products. In editions prior to 2008, DDDs for combination products were not accounted for. For instance in atorvastatin and amlodipine combination product, the DDD component will be reported in 2 separate locations: the contribution to C10AA05—Atorvastatin and C08CA01—Amlodipine. DDDs entry for these drugs as a combination product is flagged as “combination” where the DDDs are part of a single product then the entry will be flagged as “plain”.

Note that not all combination products are included in table 2. Combination drugs will only be reported in terms of DDD of each constituent where:

- the constituent drugs were also available as plain drugs on the PBS;
- the combination was one of the usual forms of these drugs prescribed;
- the constituent drugs had independent actions ; and
- the WHO Defined Daily Dose was consistent across the various forms of the constituent drugs.

In addition, Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDD) 2012 is used in all statistics published in this edition (refer to WHO collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2012).

An index by the second level of the ATC classification follows:

ALIMENTARY TRACT AND METABOLISM	194
A01 STOMATOLOGICAL PREPARATIONS	194
A02 DRUGS FOR ACID RELATED DISORDERS	195
A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	196
A04 ANTIEMETICS AND ANTINAUSEANTS	197
A05 BILE AND LIVER THERAPY	198
A06 LAXATIVES	199
A07 ANTIDIARR. INTEST. ANTIINFL./ANTIINFECT. AGENTS	200
A08 ANTI OBESITY PREPARATIONS EXCL DIET PRODUCTS	201
A10 ANTIDIABETIC THERAPY	202
A11 VITAMINS	205
A12 MINERAL SUPPLEMENTS	206
A14 ANABOLIC AGENTS FOR SYSTEMIC USE	207

BLOOD AND BLOOD FORMING ORGANS	208
B01 ANTITHROMBOTIC AGENTS	208
B02 ANTIHAEMORRHAGICS	211
B03 ANTIANAEMIC PREPARATIONS	212
CARDIOVASCULAR SYSTEM	213
C01 CARDIAC THERAPY	213
C02 ANTIHYPERTENSIVES	215
C03 DIURETICS	216
C04 PERIPHERAL VASODILATORS	217
C07 BETA BLOCKING AGENTS	218
C08 CALCIUM CHANNEL BLOCKERS	219
C09 AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM	220
C10 LIPID MODIFYING AGENTS PLAIN	223
DERMATOLOGICALS	225
D01 ANTIFUNGALS FOR DERMATOLOGICAL USE	225
D05 ANTIPSORIATICS	226
D10 ANTI-ACNE PREPARATIONS	227
GENITO URINARY SYSTEM AND SEX HORMONES	228
G01 GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS	228
G02 OTHER GYNAECOLOGICALS	229
G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	230
G04 UROLOGICALS	233
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES	235
H01 PITUITARY, HYPOTHALAMIC HORMONES AND ANALOGUES	235
H02 CORTICOSTEROIDS FOR SYSTEMIC USE	236
H03 THYROID THERAPY	237
H04 PANCREATIC HORMONES	238
H05 CALCIUM HOMEOSTASIS	239
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE	240
J01 ANTIBACTERIALS FOR SYSTEMIC USE	240
J02 ANTIMYCOTICS FOR SYSTEMIC USE	244
J04 ANTIMYCOBACTERIALS	245
J05 ANTIVIRALS FOR SYSTEMIC USE	246
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	249
L02 ENDOCRINE THERAPY	249
L03 IMMUNOSTIMULANTS	251
L04 IMMUNOSUPPRESSANTS	252

MUSCULO-SKELETAL SYSTEM	254
M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	254
M03 MUSCLE RELAXANTS	256
M04 ANTIGOUT PREPARATIONS	257
M05 DRUGS FOR TREATMENT OF BONE DISEASES	258
M09 OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST.	260
NERVOUS SYSTEM	261
N02 ANALGESICS	262
N03 ANTIEPILEPTICS	263
N04 ANTI-PARKINSON DRUGS	265
N05 PSYCHOLEPTICS	267
N06 PSYCHOANALEPTICS	271
N07 OTHER NERVOUS SYSTEM DRUGS	274
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	276
P01 ANTIPROTOZOALS	276
P02 ANTHELMINTICS	277
RESPIRATORY SYSTEM	278
R01 NASAL PREPARATIONS	278
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	279
R05 COUGH AND COLD PREPARATIONS	282
R06 ANTIHISTAMINES FOR SYSTEMIC USE	283
SENSORY ORGANS	284
S01 OPHTHALMOLOGICALS	284
VARIOUS	285
V03 ALL OTHER THERAPEUTIC PRODUCTS	285

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
<i>ALIMENTARY TRACT AND METABOLISM</i>					
<i>STOMATOLOGICAL PREPARATIONS</i>					
<i>STOMATOLOGICAL PREPARATIONS</i>					
<i>ANTIINFECTIVES FOR LOCAL ORAL TREATMENT</i>					
<i>AMPHOTERICIN</i>					
A01AB04	PBS/RPBS	Plain	0.076	0.072	0.074
	SURVEY	Plain	0.027	0.025	0.026
<i>CHLORHEXIDINE</i>					
A01AB03	PBS/RPBS	Plain	0.003	0.003	0.003
	SURVEY	Plain	0.002	0.002	0.003
<i>MICONAZOLE</i>					
A01AB09	SURVEY	Plain	0.002	0.002	0.002
<i>NYSTATIN</i>					
A01AB11	PBS/RPBS	Plain	0.024	0.024	0.025
	SURVEY	Plain	0.006	0.005	0.006

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
ALIMENTARY TRACT AND METABOLISM					
DRUGS FOR ACID RELATED DISORDERS					
DRUGS FOR PEPTIC ULCER AND GORD					
H2-RECEPTOR ANTAGONISTS					
CIMETIDINE					
A02BA01	PBS/RPBS	Plain	0.075	0.044	0.011
	SURVEY	Plain	0.030	0.026	0.011
FAMOTIDINE					
A02BA03	PBS/RPBS	Plain	0.368	0.326	0.290
	SURVEY	Plain	0.075	0.059	0.057
NIZATIDINE					
A02BA04	PBS/RPBS	Plain	0.401	0.434	0.472
	SURVEY	Plain	0.105	0.108	0.118
RANITIDINE HYDROCHLORIDE					
A02BA02	PBS/RPBS	Plain	3.090	2.902	2.725
	SURVEY	Plain	0.577	0.558	0.549
PROSTAGLANDINS					
MISOPROSTOL					
A02BB01	PBS/RPBS	Plain	0.007	0.006	0.006
	PBS/RPBS	Combination	0.001	0.001	0.001
	PBS/RPBS	Total	0.008	0.007	0.007
	SURVEY	Plain	0.001	0.002	0.002
	SURVEY	Combination	0.001	0.002	0.001
	SURVEY	Total	0.002	0.004	0.003
PROTON PUMP INHIBITORS					
ESOMEPRAZOLE					
A02BC05	PBS/RPBS	Plain	21.650	22.390	21.455
	SURVEY	Plain	0.073	0.097	2.700
LANSOPRAZOLE					
A02BC03	PBS/RPBS	Plain	2.947	1.972	1.751
	SURVEY	Plain	0.027	0.328	0.529
OMEPRAZOLE					
A02BC01	PBS/RPBS	Plain	12.420	11.615	10.872
	SURVEY	Plain	2.623	2.309	2.195
	SURVEY	Combination	0.000	0.000	0.000
	SURVEY	Total	2.623	2.309	2.195
PANTOPRAZOLE					
A02BC02	PBS/RPBS	Plain	14.691	13.996	14.068
	SURVEY	Plain	0.206	2.358	3.168
RABEPRAZOLE					
A02BC04	PBS/RPBS	Plain	9.327	9.950	10.396
	SURVEY	Plain	0.029	0.038	0.048
OTHER DRUGS FOR PEPTIC ULCER AND GORD					
SUCRALFATE					
A02BX02	PBS/RPBS	Plain	0.044	0.047	0.050
	SURVEY	Plain	0.011	0.011	0.011

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
ALIMENTARY TRACT AND METABOLISM					
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS					
DRUGS FOR FUNCTIONAL BOWEL DISORDERS					
SYNT ANTICHOLIN,ESTERS WITH TERTIARY AMINO GROUP					
MEBEVERINE HYDROCHLORIDE					
A03AA04	PBS/RPBS	Plain	0.041	0.037	0.034
	SURVEY	Plain	0.304	0.310	0.313
SYNT ANTICHOLINERGICS,ESTERS,QUATER AMMONIUM COMPOUND					
GLYCOPYRROLATE					
A03AB02	SURVEY	Plain	0.000	0.000	0.000
PROPANTHELINE					
A03AB05	PBS/RPBS	Plain	0.097	0.088	0.077
	SURVEY	Plain	0.020	0.018	0.016
PAPAVERINE AND DERIVATIVES					
PAPAVERINE					
A03AD01	SURVEY	Plain	0.021	0.000	0.000
BELLADONNA AND DERIVATIVES PLAIN					
BELLADONNA ALKALOIDS TERTIARY AMINES					
ATROPINE					
A03BA01	PBS/RPBS	Plain	0.006	0.006	0.004
	SURVEY	Plain	0.000	0.000	0.000
HYOSCYAMINE SULPHATE with ATROPINE SULPHATE with HYOSCINE HYDROBROMIDE					
A03BA04	SURVEY	Plain	0.000	0.000	0.000
BELLADONNA ALKALOIDS SEMISYNT QUATER AMMONIUM COMPOUND					
BUTYLSCOPOLAMINE					
A03BB01	PBS/RPBS	Plain	0.002	0.002	0.003
	SURVEY	Plain	0.034	0.031	0.028
PROPULSIVES					
PROPULSIVES					
DOMPERIDONE					
A03FA03	PBS/RPBS	Plain	0.612	0.660	0.708
	SURVEY	Plain	0.228	0.253	0.275
METOCLOPRAMIDE HYDROCHLORIDE					
A03FA01	PBS/RPBS	Plain	0.679	0.690	0.706
	SURVEY	Plain	0.407	0.384	0.400
	SURVEY	Combination	0.000	0.000	0.000
	SURVEY	Total	0.407	0.384	0.400

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ALIMENTARY TRACT AND METABOLISM					
ANTIEMETICS AND ANTINAUSEANTS					
ANTIEMETICS AND ANTINAUSEANTS					
SEROTONIN (5HT3) ANTAGONISTS					
DOLASETRON MESYLATE					
A04AA04	PBS/RPBS	Plain	0.005	0.004	0.001
	SURVEY	Plain	0.000	0.000	0.000
GRANISETRON					
A04AA02	PBS/RPBS	Plain	0.026	0.028	0.020
	SURVEY	Plain	0.000	0.000	0.000
ONDANSETRON					
A04AA01	PBS/RPBS	Plain	0.039	0.043	0.045
	SURVEY	Plain	0.011	0.013	0.018
PALONOSETRON					
A04AA05	PBS/RPBS	Plain	0.000	0.000	0.005
TROPISETRON					
A04AA03	PBS/RPBS	Plain	0.011	0.010	0.009
	SURVEY	Plain	0.000	0.000	0.000
VARIOUS ANTIEMETICS					
APREPITANT					
A04AD12	PBS/RPBS	Plain	0.013	0.015	0.018
	SURVEY	Plain	0.000	0.000	0.000
SCOPOLAMINE					
A04AD01	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ALIMENTARY TRACT AND METABOLISM					
BILE AND LIVER THERAPY					
<i>BILE THERAPY</i>					
BILE ACID PREPARATIONS					
URSODEOXYCHOLIC ACID					
A05AA02	PBS/RPBS	Plain	0.189	0.200	0.210
	SURVEY	Plain	0.005	0.006	0.009

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
ALIMENTARY TRACT AND METABOLISM					
LAXATIVES					
LAXATIVES					
SOFTENERS EMOLLIENTS					
DOCUSATE SODIUM					
A06AA02	PBS/RPBS	Plain	0.018	0.018	0.017
	SURVEY	Plain	0.081	0.109	0.129
LIQUID PARAFFIN					
A06AA01	SURVEY	Plain	0.000	0.000	0.000
CONTACT LAXATIVES					
BISACODYL					
A06AB02	PBS/RPBS	Plain	0.476	0.446	0.436
	SURVEY	Plain	0.028	0.024	0.027
BULK PRODUCERS					
PSYLLIUM HYDROPHILIC MUCILLOID					
A06AC01	PBS/RPBS	Plain	0.237	0.205	0.181
	SURVEY	Plain	0.026	0.031	0.034
OSMOTICALLY ACTING LAXATIVES					
LACTULOSE					
A06AD11	PBS/RPBS	Plain	2.059	2.041	2.038
	SURVEY	Plain	0.239	0.263	0.270
LACTULOSE with GALACTOSE with LACTOSE with EPILACTOSE					
A06AD11	SURVEY	Plain	0.000	0.001	0.001
MACROGOL					
A06AD15	PBS/RPBS	Plain	2.722	3.669	4.518
	SURVEY	Plain	0.191	0.197	0.259
SODIUM PHOSPHATE					
A06AD17	SURVEY	Plain	0.000	0.000	0.000
ENEMAS					
BISACODYL					
A06AG02	PBS/RPBS	Plain	0.002	0.002	0.001
	SURVEY	Plain	0.000	0.000	0.000
PERIPHERAL OPIOID RECEPTOR ANTAGONISTS					
METHYLNALTREXONE BROMIDE					
A06AH01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
OTHER LAXATIVES					
GLYCEROL					
A06AX01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
ALIMENTARY TRACT AND METABOLISM					
ANTIDIARR. INTEST. ANTIINFL./ANTIINFECT. AGENTS					
INTESTINAL ANTIINFECTIVES					
ANTIBIOTICS					
NEOMYCIN SULPHATE					
A07AA01	PBS/RPBS	Plain	0.001	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
NYSTATIN					
A07AA02	PBS/RPBS	Plain	0.075	0.073	0.070
	SURVEY	Plain	0.069	0.068	0.061
VANCOMYCIN					
A07AA09	PBS/RPBS	Plain	0.000	0.000	0.001
	SURVEY	Plain	0.000	0.000	0.000
ANTIPROPULSIVES					
ANTIPROPULSIVES					
DIPHENOXYLATE HYDROCHLORIDE with ATROPINE SULPHATE					
A07DA01	PBS/RPBS	Plain	0.128	0.122	0.116
	SURVEY	Plain	0.060	0.052	0.050
LOPERAMIDE HYDROCHLORIDE					
A07DA03	PBS/RPBS	Plain	0.296	0.304	0.309
	SURVEY	Plain	0.060	0.053	0.054
INTESTINAL ANTIINFLAMMATORY AGENTS					
AMINOSALICYLIC ACID AND SIMILAR AGENTS					
BALSALAZIDE					
A07EC04	PBS/RPBS	Plain	0.061	0.065	0.064
	SURVEY	Plain	0.000	0.000	0.000
MESALAZINE					
A07EC02	PBS/RPBS	Plain	1.081	1.195	1.347
	SURVEY	Plain	0.006	0.008	0.012
OLSALAZINE SODIUM					
A07EC03	PBS/RPBS	Plain	0.140	0.130	0.118
	SURVEY	Plain	0.001	0.000	0.000
SULPHASALAZINE					
A07EC01	PBS/RPBS	Plain	1.399	1.389	1.375
	SURVEY	Plain	0.018	0.017	0.015

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ALIMENTARY TRACT AND METABOLISM					
ANTIOBESITY PREPARATIONS EXCL DIET PRODUCTS					
<i>ANTIOBESITY PREPARATIONS EXCL DIET PRODUCTS</i>					
CENTRALLY ACTING ANTI OBESITY PRODUCTS					
PHENTERMINE					
A08AA01	SURVEY	Plain	1.772	1.689	2.002
SIBUTRAMINE					
A08AA10	SURVEY	Plain	0.796	0.401	0.000
PERIPHERALLY ACTING ANTI OBESITY PRODUCTS					
ORLISTAT					
A08AB01	PBS/RPBS	Plain	0.002	0.001	0.001
	SURVEY	Plain	0.016	0.008	0.009

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ALIMENTARY TRACT AND METABOLISM					
ANTIDIABETIC THERAPY					
INSULINS AND ANALOGUES					
INSULINS AND ANALOGUES FAST-ACTING					
INSULIN (BEEF)					
A10AB02	PBS/RPBS	Plain	0.007	0.006	0.005
INSULIN (HUMAN)					
A10AB01	PBS/RPBS	Plain	0.687	0.605	0.538
	SURVEY	Plain	0.006	0.005	0.009
INSULIN ASPART					
A10AB05	PBS/RPBS	Plain	3.393	3.734	4.079
	SURVEY	Plain	0.030	0.029	0.021
INSULIN GLULISINE					
A10AB06	PBS/RPBS	Plain	0.229	0.274	0.298
	SURVEY	Plain	0.001	0.002	0.004
INSULIN LISPRO					
A10AB04	PBS/RPBS	Plain	0.869	0.873	0.899
	SURVEY	Plain	0.008	0.014	0.009
INSULINS AND ANALOGUES INTERMEDIATE-ACTING					
INSULIN (BEEF)					
A10AC02	PBS/RPBS	Plain	0.010	0.008	0.007
	SURVEY	Plain	0.004	0.002	0.002
INSULIN (HUMAN)					
A10AC01	PBS/RPBS	Plain	1.405	1.192	1.029
	SURVEY	Plain	0.028	0.025	0.031
INSULINS AND ANALOGUES INTERMEDIATE ACTING COMBINED WITH FAST-ACTING					
INSULIN (HUMAN)					
A10AD01	PBS/RPBS	Plain	2.293	2.069	1.821
	SURVEY	Plain	0.042	0.026	0.038
INSULIN ASPART/PROTAMINE ASPART					
A10AD30	PBS/RPBS	Plain	2.869	3.217	3.516
	SURVEY	Plain	0.026	0.015	0.009
INSULIN LISPRO					
A10AD04	PBS/RPBS	Plain	0.416	0.492	0.539
	SURVEY	Plain	0.001	0.001	0.003
INSULINS AND ANALOGUES LONG-ACTING					
INSULIN DETEMIR					
A10AE05	PBS/RPBS	Plain	0.699	0.763	0.813
	SURVEY	Plain	0.009	0.007	0.003
INSULIN GLARGINE					
A10AE04	PBS/RPBS	Plain	4.430	5.103	5.777
	SURVEY	Plain	0.043	0.046	0.049

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ALIMENTARY TRACT AND METABOLISM					
ANTIDIABETIC THERAPY					
ORAL BLOOD GLUCOSE LOWERING DRUGS					
BIGUANIDES					
METFORMIN HYDROCHLORIDE					
A10BA02	PBS/RPBS	Plain	12.724	13.338	13.636
	PBS/RPBS	Combination	0.531	0.795	1.325
	PBS/RPBS	Total	13.255	14.133	14.961
	SURVEY	Plain	4.341	4.306	4.357
	SURVEY	Combination	0.099	0.098	0.101
	SURVEY	Total	4.440	4.404	4.458
SULFONAMIDES UREA DERIVATIVES					
GLIBENCLAMIDE					
A10BB01	PBS/RPBS	Plain	0.631	0.536	0.445
	PBS/RPBS	Combination	0.437	0.434	0.412
	PBS/RPBS	Total	1.068	0.970	0.857
	SURVEY	Plain	0.122	0.101	0.078
	SURVEY	Combination	0.158	0.157	0.157
	SURVEY	Total	0.280	0.258	0.235
GLICLAZIDE					
A10BB09	PBS/RPBS	Plain	13.516	12.832	12.763
	SURVEY	Plain	3.012	2.717	2.722
GLIMEPIRIDE					
A10BB12	PBS/RPBS	Plain	2.051	1.896	1.684
	SURVEY	Plain	0.568	0.486	0.418
GLIPIZIDE					
A10BB07	PBS/RPBS	Plain	0.414	0.364	0.308
	SURVEY	Plain	0.070	0.067	0.064
ALPHA GLUCOSIDASE INHIBITORS					
ACARBOSE					
A10BF01	PBS/RPBS	Plain	0.147	0.140	0.137
	SURVEY	Plain	0.006	0.003	0.004
THIAZOLIDINEDIONES					
PIOGLITAZONE HYDROCHLORIDE					
A10BG03	PBS/RPBS	Plain	1.686	1.807	1.654
	SURVEY	Plain	0.008	0.008	0.006
ROSIGLITAZONE					
A10BG02	PBS/RPBS	Plain	0.473	0.282	0.139
	PBS/RPBS	Combination	0.273	0.219	0.138
	PBS/RPBS	Total	0.746	0.501	0.277
	SURVEY	Plain	0.003	0.002	0.002
	SURVEY	Combination	0.001	0.001	0.002
	SURVEY	Total	0.004	0.003	0.004

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ALIMENTARY TRACT AND METABOLISM					
ANTIDIABETIC THERAPY					
ORAL BLOOD GLUCOSE LOWERING DRUGS					
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS					
SAXAGLIPTIN					
A10BH03	PBS/RPBS	Plain	0.000	0.000	0.045
	SURVEY	Plain	0.000	0.000	0.001
SITAGLIPTIN					
A10BH01	PBS/RPBS	Plain	0.678	0.898	1.051
	PBS/RPBS	Combination	0.044	0.402	0.940
	PBS/RPBS	Total	0.722	1.300	1.991
	SURVEY	Plain	0.016	0.014	0.015
	SURVEY	Combination	0.000	0.002	0.007
	SURVEY	Total	0.016	0.016	0.022
VILDAGLIPTIN					
A10BH02	PBS/RPBS	Plain	0.000	0.048	0.218
	PBS/RPBS	Combination	0.000	0.000	0.149
	PBS/RPBS	Total	0.000	0.048	0.367
	SURVEY	Plain	0.000	0.001	0.002
	SURVEY	Combination	0.000	0.000	0.000
	SURVEY	Total	0.000	0.001	0.002
OTHER BLOOD GLUCOSE LOWERING DRUGS					
EXENATIDE					
A10BX04	PBS/RPBS	Plain	0.000	0.037	0.231
	SURVEY	Plain	0.007	0.007	0.007
REPAGLINIDE					
A10BX02	SURVEY	Plain	0.001	0.001	0.004

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ALIMENTARY TRACT AND METABOLISM					
VITAMINS					
VITAMIN A AND D INCL COMBINATIONS OF THE TWO					
VITAMIN A PLAIN					
VITAMIN A					
A11CA01	SURVEY	Plain	0.005	0.003	0.006
VITAMIN D AND ANALOGUES					
CALCITRIOL					
A11CC04	PBS/RPBS	Plain	0.493	0.479	0.456
	SURVEY	Plain	0.010	0.010	0.010
VITAMIN B1,PLAIN AND IN COMB. WITH VITAMIN B6 AND B12					
THIAMINE (VITAMIN B1) PLAIN					
THIAMINE HYDROCHLORIDE					
A11DA01	PBS/RPBS	Plain	0.427	0.444	0.486
	SURVEY	Plain	0.892	1.007	1.010
OTHER PLAIN VITAMIN PREPARATIONS					
OTHER PLAIN VITAMIN PREPARATIONS					
PYRIDOXINE HYDROCHLORIDE					
A11HA02	SURVEY	Plain	0.009	0.007	0.009

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ALIMENTARY TRACT AND METABOLISM					
MINERAL SUPPLEMENTS					
<i>CALCIUM</i>					
CALCIUM					
CALCIUM (DIFFERENT SALTS IN COMBINATION)					
A12AA20	SURVEY	Plain	0.000	0.000	0.000
CALCIUM CARBONATE					
A12AA04	PBS/RPBS	Plain	0.094	0.113	0.124
	PBS/RPBS	Combination	1.532	1.515	1.851
	PBS/RPBS	Total	1.626	1.628	1.975
	SURVEY	Plain	0.198	0.189	0.151
	SURVEY	Combination	0.044	0.030	0.033
	SURVEY	Total	0.242	0.219	0.184
CALCIUM, COMBINATIONS WITH VITAMIN D AND/OR OTHER DRUGS					
CALCIUM CARBONATE with CHOLECALCIFEROL					
A12AX	SURVEY	Plain	0.018	0.017	0.020
<i>POTASSIUM</i>					
POTASSIUM					
POTASSIUM CHLORIDE					
A12BA01	PBS/RPBS	Plain	1.447	1.387	1.366
	SURVEY	Plain	0.155	0.145	0.143
<i>OTHER MINERAL SUPPLEMENTS</i>					
ZINC					
ZINC SULPHATE					
A12CB01	SURVEY	Plain	0.000	0.000	0.000
SELENIUM					
SELENIUM					
A12CE01	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ALIMENTARY TRACT AND METABOLISM					
ANABOLIC AGENTS FOR SYSTEMIC USE					
ANABOLIC STEROIDS					
ESTREN DERIVATIVES					
NANDROLONE DECANOATE					
A14AB01	PBS/RPBS	Plain	0.027	0.023	0.007
	SURVEY	Plain	0.018	0.013	0.008

B

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
BLOOD AND BLOOD FORMING ORGANS					
ANTITHROMBOTIC AGENTS					
<i>ANTITHROMBOTIC AGENTS</i>					
VITAMIN K ANTAGONISTS					
PHENINDIONE					
B01AA02	SURVEY	Plain	0.000	0.000	0.000
WARFARIN					
B01AA03	PBS/RPBS	Plain	5.125	5.330	5.239
	SURVEY	Plain	1.165	1.180	1.156
HEPARIN GROUP					
DALTEPARIN					
B01AB04	PBS/RPBS	Plain	0.051	0.047	0.048
	SURVEY	Plain	0.000	0.000	0.000
ENOXAPARIN					
B01AB05	PBS/RPBS	Plain	1.683	1.935	2.199
	SURVEY	Plain	0.016	0.023	0.029
HEPARIN CALCIUM					
B01AB01	SURVEY	Plain	0.000	0.000	0.000
HEPARIN SODIUM					
B01AB01	PBS/RPBS	Plain	0.034	0.041	0.045
	SURVEY	Plain	0.000	0.000	0.000
HEPARINISED SALINE					
B01AB01	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
BLOOD AND BLOOD FORMING ORGANS					
ANTITHROMBOTIC AGENTS					
ANTITHROMBOTIC AGENTS					
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN					
ABCIXIMAB					
B01AC13	PBS/RPBS	Plain	0.000	0.000	0.000
ASPIRIN					
B01AC06	PBS/RPBS	Plain	17.147	16.121	15.097
	PBS/RPBS	Combination	0.968	1.885	2.797
	PBS/RPBS	Total	18.115	18.006	17.894
	SURVEY	Plain	1.387	1.239	1.277
	SURVEY	Combination	0.002	0.003	0.007
	SURVEY	Total	1.389	1.242	1.284
CLOPIDOGREL					
B01AC04	PBS/RPBS	Plain	10.499	10.116	9.305
	PBS/RPBS	Combination	0.008	0.937	1.875
	PBS/RPBS	Total	10.507	11.053	11.180
	SURVEY	Plain	0.053	0.039	0.058
	SURVEY	Combination	0.000	0.002	0.005
	SURVEY	Total	0.053	0.041	0.063
DIPYRIDAMOLE					
B01AC07	PBS/RPBS	Plain	0.179	0.157	0.140
	PBS/RPBS	Combination	1.920	1.895	1.844
	PBS/RPBS	Total	2.099	2.052	1.984
	SURVEY	Plain	0.004	0.003	0.001
	SURVEY	Combination	0.004	0.003	0.003
	SURVEY	Total	0.008	0.006	0.004
EPTIFIBATIDE					
B01AC16	PBS/RPBS	Plain	0.000	0.000	0.000
ILOPROST					
B01AC11	PBS/RPBS	Plain	0.001	0.001	0.000
PRASUGREL					
B01AC22	PBS/RPBS	Plain	0.000	0.035	0.105
	SURVEY	Plain	0.000	0.000	0.001
TICLOPIDINE HYDROCHLORIDE					
B01AC05	PBS/RPBS	Plain	0.006	0.004	0.002
	SURVEY	Plain	0.000	0.000	0.000
TIROFIBAN					
B01AC17	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
BLOOD AND BLOOD FORMING ORGANS					
ANTITHROMBOTIC AGENTS					
<i>ANTITHROMBOTIC AGENTS</i>					
ENZYMES					
DROTRECOGIN ALFA					
B01AD10	PBS/RPBS	Plain	0.000	0.000	0.000
RETEPLASE					
B01AD07	PBS/RPBS	Plain	0.000	0.000	0.000
TENECTEPLASE					
B01AD11	PBS/RPBS	Plain	0.000	0.000	0.000
DIRECT THROMBIN INHIBITORS					
BIVALIRUDIN					
B01AE06	PBS/RPBS	Plain	0.000	0.000	0.000
DABIGATRAN					
B01AE07	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.009
OTHER ANTITHROMBOTIC AGENTS					
FONDAPARINUX SODIUM					
B01AX05	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
RIVAROXABAN					
B01AX06	PBS/RPBS	Plain	0.009	0.081	0.133
	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
BLOOD AND BLOOD FORMING ORGANS					
ANTIHAEMORRHAGICS					
ANTIFIBRINOLYTICS					
AMINO ACIDS					
TRANEXAMIC ACID					
B02AA02	PBS/RPBS	Plain	0.121	0.127	0.139
	SURVEY	Plain	0.003	0.003	0.003
VITAMIN K AND OTHER HAEMOSTATICS					
VITAMIN K					
PHYTOMENADIONE					
B02BA01	SURVEY	Plain	0.004	0.001	0.000
OTHER SYSTEMIC HEMOSTATICS					
ELTROMBOPAG					
B02BX05	PBS/RPBS	Plain	0.000	0.000	0.000
ROMIPLOSTIM					
B02BX04	PBS/RPBS	Plain	0.000	0.000	0.002

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
BLOOD AND BLOOD FORMING ORGANS					
ANTIANAEMIC PREPARATIONS					
IRON PREPARATIONS					
IRON BIVALENT, ORAL PREPARATIONS					
FERROUS FUMARATE					
B03AA02	PBS/RPBS	Plain	0.000	0.000	0.006
	SURVEY	Plain	0.000	0.000	0.000
FERROUS SULPHATE					
B03AA07	PBS/RPBS	Plain	0.036	0.037	0.038
	SURVEY	Plain	0.432	0.393	0.352
IRON TRIVALENT, PARENTERAL PREPARATIONS					
IRON POLYMALTOSE COMPLEX					
B03AC03	PBS/RPBS	Plain	0.035	0.037	0.039
	SURVEY	Plain	0.000	0.000	0.000
SACCHARATED IRON OXIDE					
B03AC02	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
VITAMIN B12 AND FOLIC ACID					
VITAMIN B12 (CYANOCOBALAMIN AND DERIVATIVES)					
CYANOCOBALAMIN					
B03BA01	SURVEY	Plain	0.000	0.000	0.000
HYDROXOCOBALAMIN					
B03BA03	PBS/RPBS	Plain	5.446	5.555	5.578
	SURVEY	Plain	0.744	0.747	0.765
FOLIC ACID AND DERIVATIVES					
FOLIC ACID					
B03BB01	PBS/RPBS	Plain	1.479	1.343	1.201
	SURVEY	Plain	0.157	0.134	0.115
OTHER ANTIANAEMIC PREPARATIONS					
OTHER ANTIANAEMIC PREPARATIONS					
DARBEPOETIN ALPHA					
B03XA02	PBS/RPBS	Plain	0.187	0.186	0.186
	SURVEY	Plain	0.001	0.001	0.001
EPOETIN ALPHA					
B03XA01	PBS/RPBS	Plain	0.031	0.028	0.027
	SURVEY	Plain	0.000	0.000	0.000
EPOETIN BETA					
B03XA01	PBS/RPBS	Plain	0.030	0.033	0.024
	SURVEY	Plain	0.000	0.000	0.000
EPOETIN LAMDA					
B03XA01	PBS/RPBS	Plain	0.000	0.000	0.000
ERYTHROPOIETIN					
B03XA01	PBS/RPBS	Plain	0.000	0.000	0.000
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA					
B03XA03	PBS/RPBS	Plain	0.000	0.004	0.013

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
CARDIOVASCULAR SYSTEM					
CARDIAC THERAPY					
CARDIAC GLYCOSIDES					
DIGITALIS GLYCOSIDES					
DIGOXIN					
C01AA05	PBS/RPBS	Plain	3.236	3.055	2.893
	SURVEY	Plain	0.409	0.387	0.367
<i>ANTIARRHYTHMICS CLASS I AND III</i>					
ANTIARRHYTHMICS CLASS IA					
DISOPYRAMIDE					
C01BA03	PBS/RPBS	Plain	0.030	0.027	0.025
	SURVEY	Plain	0.003	0.002	0.002
ANTIARRHYTHMICS CLASS IB					
LIGNOCAINE HYDROCHLORIDE					
C01BB01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
MEXILETINE HYDROCHLORIDE					
C01BB02	PBS/RPBS	Plain	0.015	0.011	0.000
	SURVEY	Plain	0.001	0.000	0.000
ANTIARRHYTHMICS CLASS IC					
FLECAINIDE ACETATE					
C01BC04	PBS/RPBS	Plain	0.572	0.619	0.666
	SURVEY	Plain	0.002	0.003	0.005
ANTIARRHYTHMICS CLASS III					
AMIODARONE HYDROCHLORIDE					
C01BD01	PBS/RPBS	Plain	1.123	1.086	1.059
	SURVEY	Plain	0.124	0.119	0.145
DRONEDARONE					
C01BD07	SURVEY	Plain	0.000	0.000	0.000
<i>CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES</i>					
ADRENERGIC AGENTS					
ADRENALINE					
C01CA24	PBS/RPBS	Plain	0.040	0.042	0.036
	SURVEY	Plain	0.003	0.003	0.001
EPHEDRINE					
C01CA26	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
CARDIOVASCULAR SYSTEM					
CARDIAC THERAPY					
VASODILATORS USED IN CARDIAC DISEASES					
ORGANIC NITRATES					
GLYCERYL TRINITRATE					
C01DA02	PBS/RPBS	Plain	4.114	3.843	3.626
	SURVEY	Plain	0.198	0.182	0.206
ISOSORBIDE DINITRATE					
C01DA08	PBS/RPBS	Plain	0.101	0.091	0.062
	SURVEY	Plain	0.005	0.005	0.006
ISOSORBIDE MONONITRATE					
C01DA14	PBS/RPBS	Plain	6.976	6.635	6.297
	SURVEY	Plain	0.408	0.341	0.323
OTHER VASODILATORS USED IN CARDIAC DISEASES					
NICORANDIL					
C01DX16	PBS/RPBS	Plain	0.010	0.010	0.010
	SURVEY	Plain	0.000	0.000	0.000
<i>OTHER CARDIAC PREPARATIONS</i>					
OTHER CARDIAC PREPARATIONS					
ADENOSINE					
C01EB10	SURVEY	Plain	0.000	0.000	0.000
IVABRADINE					
C01EB17	SURVEY	Plain	0.008	0.052	0.107

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
CARDIOVASCULAR SYSTEM					
ANTIHYPERTENSIVES					
ANTIADRENERGIC AGENTS CENTRALLY ACTING					
METHYLDOPA					
METHYLDOPA					
C02AB01	PBS/RPBS	Plain	0.451	0.441	0.428
	SURVEY	Plain	0.097	0.092	0.098
IMIDAZOLINE RECEPTOR AGONISTS					
CLONIDINE					
C02AC01	PBS/RPBS	Plain	0.363	0.371	0.379
	SURVEY	Plain	0.063	0.064	0.063
MOXONIDINE					
C02AC05	PBS/RPBS	Plain	0.517	0.990	1.413
	SURVEY	Plain	0.139	0.273	0.361
ANTIADRENERGIC AGENTS PERIPHERALLY ACTING					
ALPHA - ADRENOCEPTOR BLOCKING AGENTS					
PRAZOSIN HYDROCHLORIDE					
C02CA01	PBS/RPBS	Plain	2.968	2.851	2.755
	SURVEY	Plain	0.507	0.470	0.451
ARTERIOLAR SMOOTH MUSCLE AGENTS ACTING ON					
HYDRAZINOPHTHALAZINE DERIVATIVES					
HYDRALAZINE HYDROCHLORIDE					
C02DB02	PBS/RPBS	Plain	0.435	0.465	0.488
	SURVEY	Plain	0.087	0.083	0.077
PYRIMIDINE DERIVATIVES					
MINOXIDIL					
C02DC01	PBS/RPBS	Plain	0.030	0.030	0.026
	SURVEY	Plain	0.007	0.007	0.007
OTHER ANTIHYPERTENSIVES					
OTHER ANTHIHYPERTENSIVES					
AMBRISENTAN					
C02KX02	PBS/RPBS	Plain	0.000	0.002	0.002
BOSENTAN					
C02KX01	PBS/RPBS	Plain	0.031	0.029	0.009
	SURVEY	Plain	0.000	0.001	0.001
SITAXENTAN					
C02KX03	PBS/RPBS	Plain	0.005	0.005	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
CARDIOVASCULAR SYSTEM					
DIURETICS					
LOW-CEILING DIURETICS THIAZIDES					
THIAZIDES PLAIN					
HYDROCHLOROTHIAZIDE					
C03AA03	PBS/RPBS	Plain	0.904	0.908	0.884
	PBS/RPBS	Combination	10.019	10.527	10.950
	PBS/RPBS	Total	10.923	11.435	11.834
	SURVEY	Plain	0.276	0.241	0.245
	SURVEY	Combination	3.578	3.308	3.008
	SURVEY	Total	3.854	3.549	3.253
LOW-CEILING DIURETICS EXCL. THIAZIDES					
SULFONAMIDES PLAIN					
CHLORTHALIDONE					
C03BA04	PBS/RPBS	Plain	0.309	0.289	0.268
	SURVEY	Plain	0.096	0.083	0.081
INDAPAMIDE					
C03BA11	PBS/RPBS	Plain	3.792	3.438	3.070
	PBS/RPBS	Combination	2.521	2.447	2.265
	PBS/RPBS	Total	6.313	5.885	5.335
	SURVEY	Plain	1.035	0.924	0.792
	SURVEY	Combination	1.063	0.965	0.838
	SURVEY	Total	2.098	1.889	1.630
HIGH-CEILING DIURETICS					
SULFONAMIDES PLAIN					
BUMETANIDE					
C03CA02	SURVEY	Plain	0.071	0.076	0.094
FRUSEMIDE					
C03CA01	PBS/RPBS	Plain	17.302	17.214	17.079
	SURVEY	Plain	1.299	1.226	1.200
ARYLOXYACETIC ACID DERIVATIVES					
ETHACRYNIC ACID					
C03CC01	PBS/RPBS	Plain	0.026	0.028	0.029
	SURVEY	Plain	0.000	0.000	0.000
POTASSIUM-SPARING AGENTS					
ALDOSTERONE ANTAGONISTS					
EPLERENONE					
C03DA04	PBS/RPBS	Plain	0.021	0.026	0.034
	SURVEY	Plain	0.001	0.002	0.002
SPIRONOLACTONE					
C03DA01	PBS/RPBS	Plain	1.706	1.757	1.806
	SURVEY	Plain	0.653	0.573	0.635
OTHER POTASSIUM-SPARING AGENTS					
AMILORIDE HYDROCHLORIDE					
C03DB01	PBS/RPBS	Plain	0.113	0.106	0.060
	SURVEY	Plain	0.037	0.037	0.023

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
CARDIOVASCULAR SYSTEM					
PERIPHERAL VASODILATORS					
<i>PERIPHERAL VASODILATORS</i>					
IMIDAZOLINE DERIVATIVES					
PHENTOLAMINE MESYLATE					
C04AB01	SURVEY	Plain	0.000	0.000	0.000
PURINE DERIVATIVES					
OXPENTIFYLLINE					
C04AD03	SURVEY	Plain	0.004	0.002	0.007
OTHER PERIPHERAL VASODILATORS					
CILOSTAZOL					
C04AX33	SURVEY	Plain	0.000	0.000	0.000
PHENOXYBENZAMINE HYDROCHLORIDE					
C04AX02	PBS/RPBS	Plain	0.009	0.008	0.009
	SURVEY	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
CARDIOVASCULAR SYSTEM					
BETA BLOCKING AGENTS					
<i>BETA BLOCKING AGENTS PLAIN</i>					
BETA BLOCKING AGENTS PLAIN NON-SELECTIVE					
OXPRENOLOL HYDROCHLORIDE					
C07AA02	PBS/RPBS	Plain	0.021	0.019	0.019
	SURVEY	Plain	0.013	0.015	0.011
PINDOLOL					
C07AA03	PBS/RPBS	Plain	0.193	0.171	0.137
	SURVEY	Plain	0.035	0.029	0.036
PROPRANOLOL HYDROCHLORIDE					
C07AA05	PBS/RPBS	Plain	0.853	0.844	0.830
	SURVEY	Plain	0.421	0.414	0.391
SOTALOL HYDROCHLORIDE					
C07AA07	PBS/RPBS	Plain	1.761	1.756	1.753
	SURVEY	Plain	0.449	0.429	0.418
BETA BLOCKING AGENTS PLAIN SELECTIVE					
ATENOLOL					
C07AB03	PBS/RPBS	Plain	8.944	8.647	8.315
	SURVEY	Plain	2.643	2.412	2.278
BISOPROLOL					
C07AB07	PBS/RPBS	Plain	0.864	1.082	1.296
	SURVEY	Plain	0.009	0.007	0.006
METOPROLOL SUCCINATE					
C07AB02	PBS/RPBS	Plain	0.262	0.283	0.299
	SURVEY	Plain	0.001	0.000	0.002
METOPROLOL TARTRATE					
C07AB02	PBS/RPBS	Plain	6.195	6.342	6.455
	SURVEY	Plain	1.401	1.348	1.339
NEBIVOLOL					
C07AB12	PBS/RPBS	Plain	0.000	0.022	0.105
	SURVEY	Plain	0.000	0.000	0.003
ALPHA- AND BETA- ADRENOCEPTOR BLOCKING AGENTS					
CARVEDILOL					
C07AG02	PBS/RPBS	Plain	2.005	1.939	1.840
	SURVEY	Plain	0.010	0.008	0.010
LABETALOL HYDROCHLORIDE					
C07AG01	PBS/RPBS	Plain	0.089	0.088	0.085
	SURVEY	Plain	0.050	0.048	0.049

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
CARDIOVASCULAR SYSTEM					
CALCIUM CHANNEL BLOCKERS					
<i>SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS</i>					
DIHYDROPYRIDINE DERIVATIVES					
AMLODIPINE					
C08CA01	PBS/RPBS	Plain	12.672	12.603	12.181
	PBS/RPBS	Combination	4.375	6.368	9.923
	PBS/RPBS	Total	17.047	18.971	22.104
	SURVEY	Plain	4.113	3.852	3.552
	SURVEY	Combination	0.008	0.040	0.442
	SURVEY	Total	4.121	3.892	3.994
FELODIPINE					
C08CA02	PBS/RPBS	Plain	5.903	5.468	4.974
	PBS/RPBS	Combination	0.194	0.226	0.228
	PBS/RPBS	Total	6.097	5.694	5.202
	SURVEY	Plain	1.286	1.128	0.993
	SURVEY	Combination	0.104	0.104	0.099
	SURVEY	Total	1.390	1.232	1.092
LERCANIPIDINE					
C08CA13	PBS/RPBS	Plain	9.035	9.155	9.160
	PBS/RPBS	Combination	0.245	0.355	0.344
	PBS/RPBS	Total	9.280	9.510	9.504
	SURVEY	Plain	2.452	2.410	2.255
	SURVEY	Combination	0.037	0.090	0.162
	SURVEY	Total	2.489	2.500	2.417
NIFEDIPINE					
C08CA05	PBS/RPBS	Plain	3.740	3.480	3.191
	SURVEY	Plain	0.966	0.866	0.785
<i>SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS</i>					
PHENYLALKYLAMINE DERIVATIVES					
VERAPAMIL HYDROCHLORIDE					
C08DA01	PBS/RPBS	Plain	3.290	3.124	2.933
	PBS/RPBS	Combination	0.197	0.147	0.148
	PBS/RPBS	Total	3.487	3.271	3.081
	SURVEY	Plain	0.788	0.725	0.664
	SURVEY	Combination	0.006	0.098	0.095
	SURVEY	Total	0.794	0.823	0.759
BENZOTHIAZEPINE DERIVATIVES					
DILTIAZEM HYDROCHLORIDE					
C08DB01	PBS/RPBS	Plain	4.313	4.163	3.963
	SURVEY	Plain	0.832	0.793	0.769
<i>NON-SELECTIVE CALCIUM CHANNEL BLOCKERS</i>					
OTHER NON-SELECTIVE CALCIUM CHANNEL BLOCKERS					
PERHEXILINE MALEATE					
C08EX02	PBS/RPBS	Plain	0.198	0.189	0.184
	SURVEY	Plain	0.002	0.001	0.001

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
CARDIOVASCULAR SYSTEM					
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM					
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, PLAIN					
CONVERTING ENZYME BLOCKERS					
CAPTOPRIL					
C09AA01	PBS/RPBS	Plain	0.585	0.459	0.373
	SURVEY	Plain	0.023	0.031	0.020
ENALAPRIL MALEATE					
C09AA02	PBS/RPBS	Plain	3.378	2.960	2.452
	PBS/RPBS	Combination	1.287	1.399	1.303
	PBS/RPBS	Total	4.665	4.359	3.755
	SURVEY	Plain	0.778	0.643	0.616
	SURVEY	Combination	0.341	0.405	0.493
	SURVEY	Total	1.119	1.048	1.109
FOSINOPRIL					
C09AA09	PBS/RPBS	Plain	1.347	1.226	1.070
	PBS/RPBS	Combination	1.686	1.548	1.404
	PBS/RPBS	Total	3.033	2.774	2.474
	SURVEY	Plain	0.347	0.293	0.263
	SURVEY	Combination	0.609	0.516	0.444
	SURVEY	Total	0.956	0.809	0.707
LISINOPRIL					
C09AA03	PBS/RPBS	Plain	3.247	2.945	2.552
	SURVEY	Plain	0.957	0.819	0.711
PERINDOPRIL					
C09AA04	PBS/RPBS	Plain	22.589	22.911	22.136
	PBS/RPBS	Combination	6.064	6.740	8.988
	PBS/RPBS	Total	28.653	29.651	31.124
	SURVEY	Plain	9.143	8.850	8.334
	SURVEY	Combination	2.545	2.326	2.795
	SURVEY	Total	11.688	11.176	11.129
QUINAPRIL					
C09AA06	PBS/RPBS	Plain	1.334	1.134	1.005
	PBS/RPBS	Combination	0.380	0.362	0.337
	PBS/RPBS	Total	1.714	1.496	1.342
	SURVEY	Plain	0.348	0.320	0.275
	SURVEY	Combination	0.162	0.147	0.119
	SURVEY	Total	0.510	0.467	0.394
RAMIPRIL					
C09AA05	PBS/RPBS	Plain	27.674	26.741	25.454
	PBS/RPBS	Combination	0.390	0.452	0.456
	PBS/RPBS	Total	28.064	27.193	25.910
	SURVEY	Plain	10.402	9.461	8.617
	SURVEY	Combination	0.206	0.208	0.198
	SURVEY	Total	10.608	9.669	8.815

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
CARDIOVASCULAR SYSTEM					
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM					
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, PLAIN CONVERTING ENZYME BLOCKERS					
TRANDOLAPRIL					
C09AA10	PBS/RPBS	Plain	1.516	1.379	1.236
	PBS/RPBS	Combination	0.200	0.153	0.155
	PBS/RPBS	Total	1.716	1.532	1.391
	SURVEY	Plain	0.514	0.457	0.400
	SURVEY	Combination	0.008	0.102	0.099
	SURVEY	Total	0.522	0.559	0.499
ANGIOTENSIN II ANTAGONISTS					
ANGIOTENSIN II ANTAGONISTS PLAIN					
CANDESARTAN					
C09CA06	PBS/RPBS	Plain	15.599	16.800	17.246
	PBS/RPBS	Combination	5.850	7.278	9.714
	PBS/RPBS	Total	21.449	24.078	26.960
	SURVEY	Plain	3.448	3.343	3.290
	SURVEY	Combination	2.610	2.346	1.975
	SURVEY	Total	6.058	5.689	5.265
EPROSARTAN					
C09CA02	PBS/RPBS	Plain	0.345	0.302	0.266
	PBS/RPBS	Combination	0.293	0.231	0.209
	PBS/RPBS	Total	0.638	0.533	0.475
	SURVEY	Plain	0.097	0.082	0.069
	SURVEY	Combination	0.051	0.085	0.066
	SURVEY	Total	0.148	0.167	0.135
IRBESARTAN					
C09CA04	PBS/RPBS	Plain	16.699	16.378	16.013
	PBS/RPBS	Combination	17.672	17.590	16.994
	PBS/RPBS	Total	34.371	33.968	33.007
	SURVEY	Plain	6.181	5.651	5.289
	SURVEY	Combination	6.189	5.415	4.898
	SURVEY	Total	12.370	11.066	10.187
LOSARTAN					
C09CA01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.010	0.008	0.018
OLMESARTAN MEDOXOMIL					
C09CA08	PBS/RPBS	Plain	1.066	1.504	1.841
	PBS/RPBS	Combination	1.207	1.753	2.463
	PBS/RPBS	Total	2.273	3.257	4.304
	SURVEY	Plain	0.666	0.955	1.122
	SURVEY	Combination	0.307	0.454	0.506
	SURVEY	Total	0.973	1.409	1.628

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
CARDIOVASCULAR SYSTEM					
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM					
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM					
ANGIOTENSIN II ANTAGONISTS					
TELMISARTAN					
C09CA07	PBS/RPBS	Plain	8.143	8.778	9.296
	PBS/RPBS	Combination	5.254	5.426	5.719
	PBS/RPBS	Total	13.397	14.204	15.015
	SURVEY	Plain	3.751	3.974	4.080
	SURVEY	Combination	2.582	2.529	2.342
	SURVEY	Total	6.333	6.503	6.422
VALSARTAN					
C09CA03	PBS/RPBS	Plain	0.064	0.285	0.426
	PBS/RPBS	Combination	0.001	0.075	1.006
	PBS/RPBS	Total	0.065	0.360	1.432
	SURVEY	Plain	0.033	0.151	0.201
	SURVEY	Combination	0.000	0.023	0.068
	SURVEY	Total	0.033	0.174	0.269

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
CARDIOVASCULAR SYSTEM					
LIPID MODIFYING AGENTS PLAIN					
<i>LIPID MODIFYING AGENTS PLAIN</i>					
HMG REDUCTASE INHIBITORS					
ATORVASTATIN					
C10AA05	PBS/RPBS	Plain	69.592	69.981	70.047
	PBS/RPBS	Combination	10.218	13.664	14.995
	PBS/RPBS	Total	79.810	83.645	85.042
	SURVEY	Plain	0.172	0.104	0.116
	SURVEY	Combination	0.016	0.016	0.022
	SURVEY	Total	0.188	0.120	0.138
FLUVASTATIN					
C10AA04	PBS/RPBS	Plain	0.221	0.212	0.197
	SURVEY	Plain	0.024	0.017	0.018
PRAVASTATIN					
C10AA03	PBS/RPBS	Plain	6.255	5.556	4.976
	SURVEY	Plain	0.170	0.144	0.120
ROSUVASTATIN					
C10AA07	PBS/RPBS	Plain	21.926	29.765	36.158
	SURVEY	Plain	0.043	0.056	0.066
SIMVASTATIN					
C10AA01	PBS/RPBS	Plain	22.114	20.006	18.272
	PBS/RPBS	Combination	4.301	4.972	5.384
	PBS/RPBS	Total	26.415	24.978	23.656
	SURVEY	Plain	0.575	0.731	0.660
	SURVEY	Combination	0.008	0.010	0.010
	SURVEY	Total	0.583	0.741	0.670
FIBRATES					
FENOFIBRATE					
C10AB05	PBS/RPBS	Plain	1.393	1.611	1.821
	SURVEY	Plain	0.019	0.021	0.021
GEMFIBROZIL					
C10AB04	PBS/RPBS	Plain	0.608	0.551	0.495
	SURVEY	Plain	0.211	0.163	0.135
BILE ACID SEQUESTRANTS					
COLESTIPOL HYDROCHLORIDE					
C10AC02	PBS/RPBS	Plain	0.004	0.004	0.003
	SURVEY	Plain	0.000	0.000	0.000
COLESTYRAMINE					
C10AC01	PBS/RPBS	Plain	0.120	0.122	0.123
	SURVEY	Plain	0.004	0.002	0.001
NICOTINIC ACID AND DERIVATIVES					
NICOTINIC ACID					
C10AD02	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
CARDIOVASCULAR SYSTEM					
LIPID MODIFYING AGENTS PLAIN					
<i>LIPID MODIFYING AGENTS PLAIN</i>					
OTHER LIPID MODIFYING AGENTS					
EZETIMIBE					
C10AX09	PBS/RPBS	Plain	3.472	3.696	3.891
	PBS/RPBS	Combination	2.203	2.599	2.890
	PBS/RPBS	Total	5.675	6.295	6.781
	SURVEY	Plain	0.018	0.014	0.015
	SURVEY	Combination	0.004	0.005	0.008
	SURVEY	Total	0.022	0.019	0.023

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
DERMATOLOGICALS					
ANTIFUNGALS FOR DERMATOLOGICAL USE					
<i>ANTIFUNGALS FOR SYSTEMIC USE</i>					
ANTIFUNGALS FOR SYSTEMIC USE					
GRISEOFULVIN					
D01BA01	PBS/RPBS	Plain	0.070	0.106	0.113
	SURVEY	Plain	0.056	0.071	0.074
TERBINAFINE					
D01BA02	PBS/RPBS	Plain	0.451	0.434	0.430
	SURVEY	Plain	0.061	0.055	0.057

D

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
DERMATOLOGICALS					
ANTIPSORIATICS					
<i>ANTIPSORIATICS FOR SYTEMIC USE</i>					
RETINOIDS FOR TREATMENT OF PSORIASIS					
ACITRETIN					
D05BB02	PBS/RPBS	Plain	0.113	0.116	0.118
	SURVEY	Plain	0.000	0.001	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
DERMATOLOGICALS					
ANTI-ACNE PREPARATIONS					
ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE					
RETINOIDS FOR TREATMENT OF ACNE					
ISOTRETINOIN					
D10BA01	PBS/RPBS	Plain	0.786	0.826	0.797
	SURVEY	Plain	0.018	0.018	0.017

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
GENITO URINARY SYSTEM AND SEX HORMONES					
GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS					
ANTIINFECTIVES/ANTISEPT.,EXCL. COMB. WITH CORTICOSTEROIDS					
ANTIBIOTICS					
CLINDAMYCIN					
G01AA10	SURVEY	Plain	0.017	0.019	0.022
NYSTATIN					
G01AA01	PBS/RPBS	Plain	0.001	0.001	0.001
	SURVEY	Plain	0.012	0.009	0.012
IMIDAZOLE DERIVATIVES					
BUTOCONAZOLE					
G01AF15	SURVEY	Plain	0.000	0.000	0.000
CLOTRIMAZOLE					
G01AF02	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.016	0.012	0.013
ECONAZOLE NITRATE					
G01AF05	SURVEY	Plain	0.000	0.000	0.001
MICONAZOLE NITRATE					
G01AF04	PBS/RPBS	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
GENITO URINARY SYSTEM AND SEX HORMONES					
OTHER GYNAECOLOGICALS					
OXYTOCICS					
PROSTAGLANDINS					
DINOPROSTONE					
G02AD02	SURVEY	Plain	0.000	0.000	0.000
<i>OTHER GYNAECOLOGICALS</i>					
PROLACTIN INHIBITORS					
BROMOCRIPTINE MESYLATE					
G02CB01	PBS/RPBS	Plain	0.003	0.003	0.003
	SURVEY	Plain	0.004	0.005	0.005
CABERGOLINE					
G02CB03	PBS/RPBS	Plain	0.035	0.036	0.037
	SURVEY	Plain	0.002	0.002	0.002
QUINAGOLIDE					
G02CB04	PBS/RPBS	Plain	0.004	0.004	0.004
	SURVEY	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
GENITO URINARY SYSTEM AND SEX HORMONES					
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM					
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE					
PROGESTOGENS					
ETONOGESTREL					
G03AC08	PBS/RPBS	Plain	9.232	9.812	10.800
	SURVEY	Plain	0.275	0.059	0.130
MEDROXYPROGESTERONE					
G03AC06	PBS/RPBS	Plain	1.273	1.275	1.278
	SURVEY	Plain	1.410	1.307	1.160
EMERGENCY CONTRACEPTIVES					
LEVONORGESTREL					
G03AD01	PBS/RPBS	Plain	0.401	0.395	0.364
	SURVEY	Plain	1.279	1.250	1.343
ANDROGENS					
3-OXOANDROSTEN (4) DERIVATIVES					
TESTOSTERONE					
G03BA03	PBS/RPBS	Plain	0.716	0.773	0.798
	SURVEY	Plain	0.162	0.169	0.197
5-ANDROSTANON (3) DERIVATIVES					
MESTEROLONE					
G03BB01	SURVEY	Plain	0.001	0.001	0.002
ESTROGENS					
NATURAL AND SEMISYNTHETIC ESTROGENS, PLAIN					
OESTRADIOL					
G03CA03	PBS/RPBS	Plain	1.495	1.486	1.569
	SURVEY	Plain	1.250	1.220	1.227
OESTRADIOL VALERATE					
G03CA03	PBS/RPBS	Plain	0.508	0.685	0.653
	SURVEY	Plain	0.472	0.512	0.466
OESTRIOL					
G03CA04	PBS/RPBS	Plain	2.243	2.266	1.734
	SURVEY	Plain	1.003	0.986	0.761
OESTROGENS CONJUGATED					
G03CA57	PBS/RPBS	Plain	0.627	0.000	0.000
	SURVEY	Plain	0.477	0.743	0.867
OESTRONE					
G03CA07	SURVEY	Plain	0.005	0.000	0.000
OTHER ESTROGENS					
TIBOLONE					
G03CX01	SURVEY	Plain	0.977	0.953	0.860

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
GENITO URINARY SYSTEM AND SEX HORMONES					
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM					
PROGESTOGENS					
PREGNEN (4) DERIVATIVES					
MEDROXYPROGESTERONE					
G03DA02	PBS/RPBS	Plain	0.625	0.592	0.552
	SURVEY	Plain	0.817	0.777	0.665
PROGESTERONE					
G03DA04	SURVEY	Plain	0.000	0.000	0.013
PREGNADIEN DERIVATIVES					
DYDROGESTERONE					
G03DB01	PBS/RPBS	Plain	0.014	0.015	0.001
	SURVEY	Plain	0.025	0.024	0.002
ESTREN DERIVATIVES					
NORETHISTERONE					
G03DC02	PBS/RPBS	Plain	0.552	0.286	0.285
	SURVEY	Plain	0.017	0.291	0.266
<i>PROGESTOGENS AND ESTROGENS IN COMBINATION</i>					
PROGESTOGENS AND ESTROGENS, SEQUENTIAL PREPARATIONS					
OESTRADIOL with NORETHISTERONE ACETATE					
G03FB05	SURVEY	Plain	0.000	0.001	0.000
<i>GONADOTROPHINS AND OTHER OVULATION STIMULANTS</i>					
GONADOTROPHINS					
CHORIOGONADOTROPIN ALFA					
G03GA08	SURVEY	Plain	0.000	0.000	0.000
FOLLITROPIN ALFA					
G03GA05	PBS/RPBS	Plain	0.005	0.006	0.006
	SURVEY	Plain	0.000	0.000	0.000
FOLLITROPIN BETA					
G03GA06	PBS/RPBS	Plain	0.007	0.009	0.008
	SURVEY	Plain	0.000	0.000	0.000
HUMAN CHORIONIC GONADOTROPHIN					
G03GA01	PBS/RPBS	Plain	0.023	0.024	0.010
	SURVEY	Plain	0.002	0.003	0.002
OVULATION STIMULANTS, SYNTHETIC					
CLOMIPHENE CITRATE					
G03GB02	PBS/RPBS	Plain	0.148	0.258	0.264
	SURVEY	Plain	0.111	0.017	0.018

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
GENITO URINARY SYSTEM AND SEX HORMONES					
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM					
ANTIANDROGENS					
ANTIANDROGENS, PLAIN PREPARATIONS					
CYPROTERONE ACETATE					
G03HA01	PBS/RPBS	Plain	0.378	0.347	0.308
	SURVEY	Plain	0.009	0.005	0.007
ANTIGONADOTROPINS AND SIMILAR AGENTS					
DANAZOL					
G03XA01	PBS/RPBS	Plain	0.007	0.006	0.006
	SURVEY	Plain	0.000	0.001	0.001
OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM					
GESTRINONE					
G03XA02	PBS/RPBS	Plain	0.000	0.001	0.001
ANTIGONADOTROPINS AND SIMILAR AGENTS					
RALOXIFENE					
G03XC01	PBS/RPBS	Plain	0.930	0.830	0.739
	SURVEY	Plain	0.046	0.036	0.032

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
GENITO URINARY SYSTEM AND SEX HORMONES					
UROLOGICALS					
<i>OTHER UROLOGICALS, INCL. ANTISPASMODICS</i>					
URINARY ANTISPASMODICS					
DARIFENACIN					
G04BD10	SURVEY	Plain	0.012	0.026	0.045
OXYBUTYNIN					
G04BD04	PBS/RPBS	Plain	0.911	1.071	1.167
	SURVEY	Plain	0.142	0.129	0.133
SOLIFENACIN					
G04BD08	SURVEY	Plain	0.563	0.617	0.695
TOLTERODINE					
G04BD07	SURVEY	Plain	0.025	0.030	0.034
DRUGS USED IN ERECTILE DYSFUNCTION					
ALPROSTADIL					
G04BE01	PBS/RPBS	Plain	0.002	0.002	0.002
	SURVEY	Plain	0.034	0.038	0.044
SILDENAFIL					
G04BE03	PBS/RPBS	Plain	0.025	0.026	0.021
	SURVEY	Plain	0.407	0.360	0.338
TADALAFIL					
G04BE08	PBS/RPBS	Plain	0.017	0.018	0.017
	SURVEY	Plain	0.402	0.385	0.400
VARDENAFIL					
G04BE09	SURVEY	Plain	0.061	0.061	0.060

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
GENITO URINARY SYSTEM AND SEX HORMONES					
UROLOGICALS					
<i>DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY</i>					
ALPHA-ADRENORECEPTOR ANTAGONISTS					
ALFUZOSIN					
G04CA01	SURVEY	Plain	0.000	0.009	0.030
TAMSULOSIN					
G04CA02	PBS/RPBS	Plain	0.184	0.199	0.204
	PBS/RPBS	Combination	0.000	0.000	0.111
	PBS/RPBS	Total	0.184	0.199	0.315
	SURVEY	Plain	0.891	0.934	1.006
	SURVEY	Combination	0.000	0.000	0.019
	SURVEY	Total	0.891	0.934	1.025
TERAZOSIN					
G04CA03	PBS/RPBS	Plain	0.005	0.005	0.005
	SURVEY	Plain	0.014	0.011	0.015
TESTOSTERONE-5-ALPHA REDUCTASE INHIBITORS					
DUTASTERIDE					
G04CB02	PBS/RPBS	Plain	0.000	0.000	0.085
	PBS/RPBS	Combination	0.000	0.000	0.111
	PBS/RPBS	Total	0.000	0.000	0.196
	SURVEY	Plain	0.001	0.041	0.068
	SURVEY	Combination	0.000	0.000	0.019
	SURVEY	Total	0.001	0.041	0.087
FINASTERIDE					
G04CB01	PBS/RPBS	Plain	0.057	0.056	0.052
	SURVEY	Plain	0.193	0.172	0.195

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES					
PITUITARY, HYPOTHALAMIC HORMONES AND ANALOGUES					
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES					
ACTH					
TETRACOSACTRIN					
H01AA02	PBS/RPBS	Plain	0.001	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
SOMATROPIN AND ANALOGUES					
SOMATROPIN					
H01AC01	SURVEY	Plain	0.000	0.000	0.000
POSTERIOR PITUITARY LOBE HORMONES					
VASOPRESSIN AND ANALOGUES					
DESMOPRESSIN					
H01BA02	PBS/RPBS	Plain	0.270	0.269	0.274
	SURVEY	Plain	0.010	0.010	0.011
OXYTOCIN AND ANALOGUES					
OXYTOCIN					
H01BB02	SURVEY	Plain	0.000	0.000	0.000
HYPOTHALAMIC HORMONES					
GONADOTROPHIN-RELEASING HORMONES					
NAFARELIN					
H01CA02	PBS/RPBS	Plain	0.005	0.004	0.004
	SURVEY	Plain	0.011	0.010	0.008
SOMATOSTATIN AND ANALOGUES					
LANREOTIDE					
H01CB03	PBS/RPBS	Plain	0.006	0.008	0.009
OCTREOTIDE					
H01CB02	PBS/RPBS	Plain	0.012	0.014	0.016
	SURVEY	Plain	0.000	0.000	0.000
ANTI-GONADOTROPIN-RELEASING HORMONES					
GANIRELIX					
H01CC01	SURVEY	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES					
CORTICOSTEROIDS FOR SYSTEMIC USE					
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN					
MINERALOCORTICIDS					
FLUDROCORTISONE ACETATE					
H02AA02	PBS/RPBS	Plain	0.432	0.514	0.625
	SURVEY	Plain	0.241	0.184	0.092
GLUCOCORTICIDS					
BETAMETHASONE					
H02AB01	PBS/RPBS	Plain	0.129	0.117	0.066
	SURVEY	Plain	0.049	0.042	0.026
BUDESONIDE					
H02AB16	SURVEY	Plain	0.008	0.010	0.011
CORTISONE					
H02AB10	PBS/RPBS	Plain	0.127	0.126	0.120
	SURVEY	Plain	0.065	0.061	0.060
DEXAMETHASONE					
H02AB02	PBS/RPBS	Plain	0.829	0.785	0.790
	SURVEY	Plain	0.255	0.268	0.263
HYDROCORTISONE					
H02AB09	PBS/RPBS	Plain	0.104	0.113	0.120
	SURVEY	Plain	0.054	0.054	0.061
METHYLPREDNISOLONE					
H02AB04	PBS/RPBS	Plain	0.089	0.085	0.089
	SURVEY	Plain	0.016	0.016	0.017
PREDNISOLONE					
H02AB06	PBS/RPBS	Plain	5.292	5.568	5.667
	SURVEY	Plain	3.883	4.163	4.171
PREDNISONONE					
H02AB07	PBS/RPBS	Plain	2.100	2.120	2.193
	SURVEY	Plain	1.336	1.334	1.377
TRIAMCINOLONE ACETONIDE					
H02AB08	PBS/RPBS	Plain	0.003	0.005	0.014
	SURVEY	Plain	0.003	0.004	0.011

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES					
THYROID THERAPY					
<i>THYROID PREPARATIONS</i>					
THYROID HORMONES					
LEVOTHYROXINE SODIUM					
H03AA01	PBS/RPBS	Plain	10.302	10.473	10.630
	SURVEY	Plain	6.142	5.979	6.158
LIOTHYRONINE					
H03AA02	PBS/RPBS	Plain	0.048	0.049	0.053
	SURVEY	Plain	0.003	0.003	0.004
<i>ANTITHYROID PREPARATIONS</i>					
THIOURACILS					
PROPYLTHIOURACIL					
H03BA02	PBS/RPBS	Plain	0.205	0.203	0.186
	SURVEY	Plain	0.007	0.005	0.006
SULPHUR-CONTAINING IMIDAZOLE DERIVATIVES					
CARBIMAZOLE					
H03BB01	PBS/RPBS	Plain	0.383	0.425	0.466
	SURVEY	Plain	0.266	0.290	0.293

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES					
PANCREATIC HORMONES					
GLYCOGENOLYTIC HORMONES					
GLYCOGENOLYTIC HORMONES					
GLUCAGON HYDROCHLORIDE					
H04AA01	PBS/RPBS	Plain	0.006	0.006	0.007
	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONES					
CALCIUM HOMEOSTASIS					
<i>PARATHYROID HORMONES AND ANALOGUES</i>					
PARATHYROID HORMONES AND ANALOGUES					
TERIPARATIDE (RBE)					
H05AA02	PBS/RPBS	Plain	0.005	0.020	0.024
	SURVEY	Plain	0.002	0.004	0.001
<i>ANTI-PARATHYROID AGENTS</i>					
CALCITONIN PREPARATIONS					
CALCITONIN (SALMON SYNTHETIC)					
H05BA01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
OTHER ANTI-PARATHYROID AGENTS					
CINACALCET					
H05BX01	PBS/RPBS	Plain	0.024	0.037	0.044
	SURVEY	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE					
ANTIBACTERIALS FOR SYSTEMIC USE					
TETRACYCLINES					
TETRACYCLINES					
DOXYCYCLINE					
J01AA02	PBS/RPBS	Plain	1.109	1.144	1.177
	SURVEY	Plain	1.428	1.428	1.419
MINOCYCLINE					
J01AA08	PBS/RPBS	Plain	0.234	0.235	0.229
	SURVEY	Plain	0.521	0.498	0.465
BETA-LACTAM ANTIBACTERIALS, PENICILLINS					
PENICILLINS WITH EXTENDED SPECTRUM					
AMOXYCILLIN					
J01CA04	PBS/RPBS	Plain	2.587	2.649	2.667
	SURVEY	Plain	3.645	3.678	3.537
	SURVEY	Combination	0.000	0.000	0.000
	SURVEY	Total	3.645	3.678	3.537
AMPICILLIN					
J01CA01	PBS/RPBS	Plain	0.003	0.003	0.003
	SURVEY	Plain	0.000	0.000	0.000
BETA-LACTAMASE SENSITIVE PENICILLINS					
BENZATHINE PENICILLIN					
J01CE08	PBS/RPBS	Plain	0.000	0.000	0.001
	SURVEY	Plain	0.000	0.000	0.000
BENZATHINE PHENOXYMETHYLPENICILLIN					
J01CE10	PBS/RPBS	Plain	0.017	0.020	0.018
	SURVEY	Plain	0.033	0.039	0.036
BENZYL PENICILLIN					
J01CE01	PBS/RPBS	Plain	0.006	0.006	0.004
	SURVEY	Plain	0.000	0.000	0.000
PHENOXYMETHYLPENICILLIN					
J01CE02	PBS/RPBS	Plain	0.190	0.193	0.186
	SURVEY	Plain	0.454	0.458	0.441
PROCAINE PENICILLIN					
J01CE09	PBS/RPBS	Plain	0.017	0.015	0.014
	SURVEY	Plain	0.000	0.000	0.000
BETA-LACTAMASE RESISTANT PENICILLINS					
DICLOXACILLIN					
J01CF01	PBS/RPBS	Plain	0.145	0.146	0.142
	SURVEY	Plain	0.150	0.148	0.133
FLUCLOXACILLIN					
J01CF05	PBS/RPBS	Plain	0.200	0.213	0.227
	SURVEY	Plain	0.201	0.217	0.216

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE					
ANTIBACTERIALS FOR SYSTEMIC USE					
BETA-LACTAM ANTIBACTERIALS, PENICILLINS					
COMBINATIONS OF PENICILLINS, INCL. BETA-LACTAMASE INHIBITORS					
AMOXYCILLIN with CLAVULANIC ACID					
J01CR02	PBS/RPBS	Plain	1.778	1.895	2.036
	SURVEY	Plain	2.151	2.183	2.317
TICARCILLIN with CLAVULANIC ACID					
J01CR03	PBS/RPBS	Plain	0.008	0.009	0.009
	SURVEY	Plain	0.000	0.000	0.000
OTHER BETA-LACTAM ANTIBACTERIALS					
FIRST-GENERATION CEPHALOSPORINS					
CEFALEXIN					
J01DB01	PBS/RPBS	Plain	1.477	1.562	1.599
	SURVEY	Plain	1.237	1.263	1.350
CEFALOTHIN					
J01DB03	PBS/RPBS	Plain	0.013	0.009	0.005
	SURVEY	Plain	0.000	0.000	0.000
CEPHAZOLIN					
J01DB04	PBS/RPBS	Plain	0.010	0.013	0.016
	SURVEY	Plain	0.000	0.000	0.000
SECOND-GENERATION CEPHALOSPORINS					
CEFACTOR					
J01DC04	PBS/RPBS	Plain	0.203	0.189	0.179
	SURVEY	Plain	0.281	0.270	0.245
CEFUROXIME					
J01DC02	PBS/RPBS	Plain	0.053	0.055	0.056
	SURVEY	Plain	0.051	0.050	0.053
THIRD-GENERATION CEPHALOSPORINS					
CEFOTAXIME					
J01DD01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
CEFTAZIDIME					
J01DD02	SURVEY	Plain	0.000	0.000	0.000
CEFTRIAXONE					
J01DD04	PBS/RPBS	Plain	0.018	0.018	0.018
	SURVEY	Plain	0.001	0.001	0.001
FOURTH-GENERATION CEPHALOSPORINS					
CEFEPIME					
J01DE01	PBS/RPBS	Plain	0.001	0.001	0.001
	SURVEY	Plain	0.000	0.000	0.000
CARBAPENEMS					
MEROPENEM					
J01DH02	SURVEY	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE					
ANTIBACTERIALS FOR SYSTEMIC USE					
SULFONAMIDES AND TRIMETHOPRIM					
TRIMETHOPRIM AND DERIVATIVES					
TRIMETHOPRIM					
J01EA01	PBS/RPBS	Plain	0.357	0.365	0.365
	SURVEY	Plain	0.210	0.205	0.205
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS					
MACROLIDES					
AZITHROMYCIN					
J01FA10	PBS/RPBS	Plain	0.016	0.019	0.023
	SURVEY	Plain	0.092	0.109	0.127
CLARITHROMYCIN					
J01FA09	PBS/RPBS	Plain	0.367	0.403	0.475
	SURVEY	Plain	0.448	0.474	0.557
	SURVEY	Combination	0.000	0.000	0.000
	SURVEY	Total	0.448	0.474	0.557
ERYTHROMYCIN					
J01FA01	PBS/RPBS	Plain	0.439	0.450	0.467
	SURVEY	Plain	0.648	0.649	0.670
ROXITHROMYCIN					
J01FA06	PBS/RPBS	Plain	0.768	0.766	0.736
	SURVEY	Plain	0.770	0.729	0.695
LINCOSAMIDES					
CLINDAMYCIN					
J01FF01	PBS/RPBS	Plain	0.076	0.086	0.093
	SURVEY	Plain	0.043	0.044	0.039
LINCOMYCIN					
J01FF02	PBS/RPBS	Plain	0.001	0.001	0.001
	SURVEY	Plain	0.000	0.000	0.000
AMINOGLYCOSIDE ANTIBACTERIALS					
OTHER AMINOGLYCOSIDES					
GENTAMICIN SULPHATE					
J01GB03	PBS/RPBS	Plain	0.008	0.007	0.007
	SURVEY	Plain	0.001	0.001	0.002
NEOMYCIN					
J01GB05	SURVEY	Plain	0.000	0.000	0.000
TOBRAMYCIN					
J01GB01	PBS/RPBS	Plain	0.003	0.003	0.006
	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE					
ANTIBACTERIALS FOR SYSTEMIC USE					
QUINOLONE ANTIBACTERIALS					
FLUOROQUINOLONES					
CIPROFLOXACIN					
J01MA02	PBS/RPBS	Plain	0.258	0.269	0.282
	SURVEY	Plain	0.032	0.038	0.043
MOXIFLOXACIN					
J01MA14	SURVEY	Plain	0.002	0.003	0.004
NORFLOXACIN					
J01MA06	PBS/RPBS	Plain	0.148	0.148	0.145
	SURVEY	Plain	0.116	0.118	0.124
<i>OTHER ANTIBACTERIALS</i>					
GLYCOPEPTIDE ANTIBACTERIALS					
VANCOMYCIN					
J01XA01	PBS/RPBS	Plain	0.007	0.007	0.007
	SURVEY	Plain	0.000	0.000	0.000
STEROID ANTIBACTERIALS					
FUSIDIC ACID					
J01XC01	PBS/RPBS	Plain	0.034	0.034	0.035
	SURVEY	Plain	0.000	0.000	0.000
IMIDAZOLE DERIVATIVES					
METRONIDAZOLE					
J01XD01	PBS/RPBS	Plain	0.003	0.003	0.003
	SURVEY	Plain	0.000	0.000	0.000
NITROFURAN DERIVATIVES					
NITROFURANTOIN					
J01XE01	PBS/RPBS	Plain	0.184	0.191	0.190
	SURVEY	Plain	0.049	0.049	0.055
OTHER ANTIBACTERIALS					
HEXAMINE HIPPURATE					
J01XX05	PBS/RPBS	Plain	0.499	0.542	0.601
	SURVEY	Plain	0.002	0.002	0.002

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE					
ANTIMYCOTICS FOR SYSTEMIC USE					
ANTIMYCOTICS FOR SYSTEMIC USE					
ANTIBIOTICS					
AMPHOTERICIN					
J02AA01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
IMIDAZOLE DERIVATIVES					
KETOCONAZOLE					
J02AB02	PBS/RPBS	Plain	0.081	0.073	0.079
	SURVEY	Plain	0.053	0.050	0.043
TRIAZOLE DERIVATIVES					
FLUCONAZOLE					
J02AC01	PBS/RPBS	Plain	0.060	0.068	0.079
	SURVEY	Plain	0.004	0.004	0.008
ITRACONAZOLE					
J02AC02	PBS/RPBS	Plain	0.028	0.029	0.030
	SURVEY	Plain	0.005	0.010	0.013
POSACONAZOLE					
J02AC04	PBS/RPBS	Plain	0.003	0.004	0.006
	SURVEY	Plain	0.000	0.000	0.000
VORICONAZOLE					
J02AC03	PBS/RPBS	Plain	0.006	0.010	0.012
	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE					
ANTIMYCOBACTERIALS					
<i>DRUGS FOR TREATMENT OF TUBERCULOSIS</i>					
ANTIBIOTICS					
RIFABUTIN					
J04AB04	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.001	0.000	0.000
RIFAMPICIN					
J04AB02	PBS/RPBS	Plain	0.007	0.007	0.006
	SURVEY	Plain	0.013	0.012	0.012
HYDRAZIDES					
ISONIAZID					
J04AC01	PBS/RPBS	Plain	0.005	0.005	0.004
	SURVEY	Plain	0.002	0.003	0.003
OTHER DRUGS FOR TREATMENT OF TUBERCULOSIS					
ETHAMBUTOL HYDROCHLORIDE					
J04AK02	SURVEY	Plain	0.000	0.000	0.000
<i>DRUGS FOR TREATMENT OF LEPROSY</i>					
DRUGS FOR TREATMENT OF LEPROSY					
DAPSONE					
J04BA02	PBS/RPBS	Plain	0.084	0.089	0.095
	SURVEY	Plain	0.001	0.000	0.002

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE					
ANTIVIRALS FOR SYSTEMIC USE					
DIRECT ACTING ANTIVIRALS					
NUCLEOSIDES AND NUCLEOTIDES EXCL. REVERSE TRANSCRIPTASE INHIBITORS					
ACICLOVIR					
J05AB01	PBS/RPBS	Plain	0.024	0.023	0.023
	SURVEY	Plain	0.004	0.004	0.004
CIDOFOVIR					
J05AB12	PBS/RPBS	Plain	0.000	0.000	0.000
FAMCICLOVIR					
J05AB09	PBS/RPBS	Plain	0.258	0.272	0.289
	SURVEY	Plain	0.024	0.025	0.033
GANCICLOVIR					
J05AB06	PBS/RPBS	Plain	0.000	0.000	0.000
VALACICLOVIR					
J05AB11	PBS/RPBS	Plain	0.255	0.268	0.282
	SURVEY	Plain	0.008	0.009	0.011
VALGANCICLOVIR					
J05AB14	PBS/RPBS	Plain	0.000	0.001	0.001
PHOSPHONIC ACID DERIVATIVES					
FOSCARNET					
J05AD01	PBS/RPBS	Plain	0.000	0.000	0.000
PROTEINASE INHIBITORS					
ATAZANAVIR					
J05AE08	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
DARUNAVIR					
J05AE10	PBS/RPBS	Plain	0.000	0.000	0.000
INDINAVIR					
J05AE02	PBS/RPBS	Plain	0.000	0.000	0.000
RITONAVIR					
J05AE03	PBS/RPBS	Plain	0.000	0.000	0.000
SAQUINAVIR					
J05AE01	PBS/RPBS	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE					
ANTIVIRALS FOR SYSTEMIC USE					
<i>DIRECT ACTING ANTIVIRALS</i>					
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS					
ABACAVIR					
J05AF06	PBS/RPBS	Plain	0.000	0.000	0.000
ADEFOVIR DIPIVOXIL					
J05AF08	PBS/RPBS	Plain	0.025	0.017	0.012
	SURVEY	Plain	0.001	0.002	0.002
DIDANOSINE					
J05AF02	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.001	0.001	0.000
ENTECAVIR					
J05AF10	PBS/RPBS	Plain	0.074	0.095	0.109
	SURVEY	Plain	0.001	0.002	0.002
LAMIVUDINE					
J05AF05	PBS/RPBS	Plain	0.011	0.009	0.008
	SURVEY	Plain	0.002	0.002	0.003
STAVUDINE					
J05AF04	SURVEY	Plain	0.000	0.000	0.000
TELBIVUDINE					
J05AF11	PBS/RPBS	Plain	0.000	0.000	0.000
TENOFIVIR					
J05AF07	PBS/RPBS	Plain	0.001	0.025	0.047
	SURVEY	Plain	0.002	0.021	0.024
ZIDOVUDINE					
J05AF01	SURVEY	Plain	0.000	0.000	0.000
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS					
EFAVIRENZ					
J05AG03	PBS/RPBS	Plain	0.001	0.001	0.001
ETRAVIRINE					
J05AG04	PBS/RPBS	Plain	0.000	0.000	0.000
NEVIRAPINE					
J05AG01	PBS/RPBS	Plain	0.001	0.001	0.001
	SURVEY	Plain	0.019	0.023	0.031

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE					
ANTIVIRALS FOR SYSTEMIC USE					
<i>DIRECT ACTING ANTIVIRALS</i>					
NEURAMINIDASE INHIBITORS					
OSELTAMIVIR					
J05AH02	SURVEY	Plain	0.000	0.000	0.000
ZANAMIVIR					
J05AH01	SURVEY	Plain	0.005	0.001	0.002
OTHER ANTIVIRALS					
RALTEGRAVIR					
J05AX08	PBS/RPBS	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS					
ENDOCRINE THERAPY					
<i>HORMONES AND RELATED AGENTS</i>					
PROGESTOGENS					
MEDROXYPROGESTERONE					
L02AB02	PBS/RPBS	Plain	0.005	0.005	0.005
	SURVEY	Plain	0.000	0.000	0.000
MEGESTROL					
L02AB01	PBS/RPBS	Plain	0.005	0.005	0.005
	SURVEY	Plain	0.000	0.000	0.000
GONADOTROPHIN RELEASING HORMONE ANALOGUES					
GOSERELIN					
L02AE03	PBS/RPBS	Plain	0.595	0.595	0.601
	SURVEY	Plain	0.004	0.003	0.002
LEUPRORELIN ACETATE					
L02AE02	PBS/RPBS	Plain	0.836	0.828	0.813
	SURVEY	Plain	0.002	0.003	0.040
TRIPTORELIN					
L02AE04	PBS/RPBS	Plain	0.000	0.001	0.005
<i>HORMONE ANTAGONISTS AND RELATED AGENTS</i>					
ANTI-ESTROGENS					
FULVESTRANT					
L02BA03	SURVEY	Plain	0.001	0.000	0.000
TAMOXIFEN					
L02BA01	PBS/RPBS	Plain	0.917	0.889	0.904
	SURVEY	Plain	0.009	0.010	0.013
TOREMIFENE					
L02BA02	PBS/RPBS	Plain	0.008	0.006	0.006
	SURVEY	Plain	0.000	0.000	0.000
ANTI-ANDROGENS					
BICALUTAMIDE					
L02BB03	PBS/RPBS	Plain	0.128	0.126	0.134
	SURVEY	Plain	0.002	0.001	0.001
FLUTAMIDE					
L02BB01	PBS/RPBS	Plain	0.011	0.010	0.008
	SURVEY	Plain	0.000	0.000	0.000
NILUTAMIDE					
L02BB02	PBS/RPBS	Plain	0.091	0.090	0.088
AROMATASE INHIBITORS					
ANASTROZOLE					
L02BG03	PBS/RPBS	Plain	0.779	0.802	0.791
	SURVEY	Plain	0.001	0.003	0.003
EXEMESTANE					
L02BG06	PBS/RPBS	Plain	0.078	0.083	0.089
	SURVEY	Plain	0.000	0.001	0.000
LETROZOLE					
L02BG04	PBS/RPBS	Plain	0.412	0.471	0.504
	SURVEY	Plain	0.006	0.005	0.008



<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS					
ENDOCRINE THERAPY					
<i>HORMONE ANTAGONISTS AND RELATED AGENTS</i>					
OTHER HORMONE ANTAGONISTS AND RELATED AGENTS					
DEGARELIX					
L02BX02	PBS/RPBS	Plain	0.000	0.000	0.004

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS					
IMMUNOSTIMULANTS					
CYTOKINES AND IMMUNOMODULATORS					
COLONY STIMULATING FACTORS					
FILGRASTIM					
L03AA02	PBS/RPBS	Plain	0.006	0.006	0.006
	SURVEY	Plain	0.000	0.000	0.000
LENOGRASTIM					
L03AA10	PBS/RPBS	Plain	0.000	0.000	0.000
PEGFILGRASTIM					
L03AA13	PBS/RPBS	Plain	0.042	0.042	0.044
	SURVEY	Plain	0.000	0.000	0.000
INTERFERONS					
INTERFERON BETA-1a					
L03AB07	PBS/RPBS	Plain	0.349	0.370	0.361
	SURVEY	Plain	0.003	0.001	0.001
INTERFERON BETA-1b					
L03AB08	PBS/RPBS	Plain	0.123	0.119	0.106
	SURVEY	Plain	0.001	0.001	0.001
INTERFERON-ALFA-2a					
L03AB04	PBS/RPBS	Plain	0.006	0.006	0.005
	SURVEY	Plain	0.000	0.000	0.000
INTERFERON-ALFA-2b					
L03AB05	PBS/RPBS	Plain	0.004	0.004	0.005
INTERFERON-GAMMA					
L03AB03	PBS/RPBS	Plain	0.000	0.000	0.000
PEGINTERFERON ALFA-2a					
L03AB11	PBS/RPBS	Plain	0.001	0.001	0.001
	SURVEY	Plain	0.000	0.000	0.001
PEGINTERFERON ALFA-2b					
L03AB10	PBS/RPBS	Plain	0.000	0.000	0.000
OTHER IMMUNOSTIMULANTS					
GLATIRAMER ACETATE					
L03AX13	PBS/RPBS	Plain	0.080	0.088	0.091
	SURVEY	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS					
IMMUNOSUPPRESSANTS					
IMMUNOSUPPRESSANTS					
SELECTIVE IMMUNOSUPPRESSANTS					
ABATACEPT					
L04AA24	PBS/RPBS	Plain	0.015	0.021	0.014
	SURVEY	Plain	0.000	0.000	0.001
EFALIZUMAB					
L04AA21	PBS/RPBS	Plain	0.009	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
EVEROLIMUS					
L04AA18	PBS/RPBS	Plain	0.004	0.006	0.008
	SURVEY	Plain	0.000	0.000	0.000
FINGOLIMOD					
L04AA27	PBS/RPBS	Plain	0.000	0.000	0.018
LEFLUNOMIDE					
L04AA13	PBS/RPBS	Plain	0.564	0.574	0.566
	SURVEY	Plain	0.001	0.001	0.004
MYCOPHENOLIC ACID					
L04AA06	PBS/RPBS	Plain	0.051	0.060	0.067
	SURVEY	Plain	0.003	0.004	0.003
NATALIZUMAB					
L04AA23	PBS/RPBS	Plain	0.012	0.015	0.018
SIROLIMUS					
L04AA10	PBS/RPBS	Plain	0.004	0.004	0.004
	SURVEY	Plain	0.000	0.000	0.000
TUMOR NECROSIS FACTOR ALPHA INHIBITORS					
ADALIMUMAB					
L04AB04	PBS/RPBS	Plain	0.263	0.322	0.364
	SURVEY	Plain	0.000	0.001	0.001
CERTOLIZUMAB PEGOL					
L04AB05	PBS/RPBS	Plain	0.000	0.001	0.014
	SURVEY	Plain	0.000	0.000	0.001
ETANERCEPT					
L04AB01	PBS/RPBS	Plain	0.219	0.248	0.250
	SURVEY	Plain	0.001	0.000	0.001
GOLIMUMAB					
L04AB06	PBS/RPBS	Plain	0.000	0.012	0.058
	SURVEY	Plain	0.000	0.000	0.000
INFLIXIMAB					
L04AB02	PBS/RPBS	Plain	0.187	0.163	0.080
	SURVEY	Plain	0.000	0.001	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS					
IMMUNOSUPPRESSANTS					
<i>IMMUNOSUPPRESSANTS</i>					
INTERLEUKIN INHIBITORS					
ANAKINRA					
L04AC03	PBS/RPBS	Plain	0.001	0.001	0.000
	SURVEY	Plain	0.000	0.000	0.000
TOCILIZUMAB					
L04AC07	PBS/RPBS	Plain	0.000	0.008	0.025
	SURVEY	Plain	0.000	0.000	0.000
USTEKINUMAB					
L04AC05	PBS/RPBS	Plain	0.000	0.020	0.040
	SURVEY	Plain	0.000	0.000	0.000
CALCINEURIN INHIBITORS					
CYCLOSPORIN					
L04AD01	PBS/RPBS	Plain	0.080	0.083	0.075
	SURVEY	Plain	0.004	0.005	0.006
TACROLIMUS					
L04AD02	PBS/RPBS	Plain	0.042	0.052	0.057
	SURVEY	Plain	0.000	0.000	0.000
OTHER IMMUNOSUPPRESSANTS					
AZATHIOPRINE					
L04AX01	PBS/RPBS	Plain	0.572	0.607	0.643
	SURVEY	Plain	0.004	0.004	0.012
LENALIDOMIDE					
L04AX04	PBS/RPBS	Plain	0.002	0.016	0.011
THALIDOMIDE					
L04AX02	PBS/RPBS	Plain	0.010	0.014	0.018
	SURVEY	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
MUSCULO-SKELETAL SYSTEM					
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS					
ANTIINFLAMMATORY/ANTIRHEUMATIC PRODUCTS, NON-STEROIDS					
ACETIC ACID DERIVATIVES AND RELATED SUBSTANCES					
DICLOFENAC					
M01AB05	PBS/RPBS	Plain	1.994	1.787	1.552
	PBS/RPBS	Combination	0.003	0.002	0.002
	PBS/RPBS	Total	1.997	1.789	1.554
	SURVEY	Plain	1.727	1.552	1.409
	SURVEY	Combination	0.002	0.003	0.002
	SURVEY	Total	1.729	1.555	1.411
INDOMETHACIN					
M01AB01	PBS/RPBS	Plain	0.618	0.602	0.575
	SURVEY	Plain	0.582	0.549	0.541
KETOROLAC					
M01AB15	SURVEY	Plain	0.002	0.002	0.003
SULINDAC					
M01AB02	PBS/RPBS	Plain	0.033	0.030	0.016
	SURVEY	Plain	0.012	0.011	0.004
OXICAMS					
MELOXICAM					
M01AC06	PBS/RPBS	Plain	5.606	5.473	5.195
	SURVEY	Plain	2.226	2.207	2.140
PIROXICAM					
M01AC01	PBS/RPBS	Plain	0.483	0.424	0.366
	SURVEY	Plain	0.266	0.236	0.201
PROPIONIC ACID DERIVATIVES					
IBUPROFEN					
M01AE01	PBS/RPBS	Plain	0.712	0.664	0.623
	SURVEY	Plain	0.388	0.356	0.327
	SURVEY	Combination	0.069	0.094	0.088
	SURVEY	Total	0.457	0.450	0.415
KETOPROFEN					
M01AE03	PBS/RPBS	Plain	0.522	0.458	0.398
	SURVEY	Plain	0.240	0.221	0.181
NAPROXEN					
M01AE02	PBS/RPBS	Plain	2.109	2.006	1.985
	SURVEY	Plain	1.691	1.599	1.569
TIAPROFENIC ACID					
M01AE11	PBS/RPBS	Plain	0.030	0.026	0.022
	SURVEY	Plain	0.008	0.008	0.008
FENAMATES					
MEFENAMIC ACID					
M01AG01	PBS/RPBS	Plain	0.037	0.038	0.038
	SURVEY	Plain	0.035	0.036	0.034

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
MUSCULO-SKELETAL SYSTEM					
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS					
ANTIINFLAMMATORY/ANTIRHEUMATIC PRODDUCTS, NON-STEROIDS					
COXIBS					
CELECOXIB					
M01AH01	PBS/RPBS	Plain	4.728	4.431	4.243
	SURVEY	Plain	1.438	1.379	1.388
ETORICOXIB					
M01AH05	SURVEY	Plain	0.000	0.033	0.050
SPECIFIC ANTIRHEUMATIC AGENTS					
GOLD PREPARATIONS					
AURANOFIN					
M01CB03	PBS/RPBS	Plain	0.011	0.010	0.009
	SURVEY	Plain	0.000	0.000	0.000
SODIUM AUROTHIOMALATE					
M01CB01	PBS/RPBS	Plain	0.046	0.039	0.038
	SURVEY	Plain	0.001	0.000	0.001
PENICILLAMINE					
PENICILLAMINE					
M01CC01	PBS/RPBS	Plain	0.031	0.030	0.028
	SURVEY	Plain	0.001	0.001	0.001

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
MUSCULO-SKELETAL SYSTEM					
MUSCLE RELAXANTS					
<i>MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS</i>					
ETHERS, CHEMICALLY CLOSE TO ANTIHISTAMINES					
ORPHENADRINE CITRATE					
M03BC01	SURVEY	Plain	0.057	0.073	0.097
ORPHENADRINE CITRATE with PARACETAMOL					
M03BC51	SURVEY	Plain	0.008	0.022	0.038
OTHER CENTRALLY ACTING AGENTS					
BACLOFEN					
M03BX01	PBS/RPBS	Plain	0.560	0.576	0.590
	SURVEY	Plain	0.047	0.051	0.056
<i>MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS</i>					
DANTROLENE AND DERIVATIVES					
DANTROLENE SODIUM					
M03CA01	PBS/RPBS	Plain	0.033	0.033	0.033
	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
MUSCULO-SKELETAL SYSTEM					
ANTIGOUT PREPARATIONS					
<i>ANTIGOUT PREPARATIONS</i>					
PREPARATIONS INHIBITING URIC ACID PRODUCTION					
ALLOPURINOL					
M04AA01	PBS/RPBS	Plain	4.594	4.579	4.546
	SURVEY	Plain	1.893	1.807	1.767
PREPARATIONS INCREASING URIC ACID EXCRETION					
PROBENECID					
M04AB01	PBS/RPBS	Plain	0.113	0.113	0.113
	SURVEY	Plain	0.001	0.001	0.001
PREPARATIONS WITH NO EFFECT ON URIC ACID METABOLISM					
COLCHICINE					
M04AC01	PBS/RPBS	Plain	1.033	1.988	16.489
	SURVEY	Plain	0.514	0.833	7.332

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
MUSCULO-SKELETAL SYSTEM					
DRUGS FOR TREATMENT OF BONE DISEASES					
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION					
BISPHOSPHONATES					
ALENDRONIC ACID					
M05BA04	PBS/RPBS	Plain	3.384	2.570	2.036
	PBS/RPBS	Combination	3.279	3.367	3.338
	PBS/RPBS	Total	6.663	5.937	5.374
	SURVEY	Plain	0.119	0.084	0.073
	SURVEY	Combination	0.069	0.059	0.055
	SURVEY	Total	0.188	0.143	0.128
CLODRONIC ACID					
M05BA02	PBS/RPBS	Plain	0.055	0.048	0.040
	SURVEY	Plain	0.000	0.000	0.000
DISODIUM ETIDRONATE					
M05BA01	PBS/RPBS	Plain	0.001	0.002	0.001
	PBS/RPBS	Combination	0.016	0.012	0.010
	PBS/RPBS	Total	0.017	0.014	0.011
	SURVEY	Plain	0.001	0.001	0.000
	SURVEY	Combination	0.001	0.001	0.000
	SURVEY	Total	0.002	0.002	0.000
DISODIUM PAMIDRONATE					
M05BA03	PBS/RPBS	Plain	0.001	0.001	0.001
	SURVEY	Plain	0.000	0.000	0.000
IBANDRONIC ACID					
M05BA06	PBS/RPBS	Plain	0.115	0.188	0.241
	SURVEY	Plain	0.000	0.001	0.006
RISEDRONIC ACID					
M05BA07	PBS/RPBS	Plain	1.608	2.169	2.419
	PBS/RPBS	Combination	3.014	2.723	2.342
	PBS/RPBS	Total	4.622	4.892	4.761
	SURVEY	Plain	0.054	0.067	0.073
	SURVEY	Combination	0.080	0.052	0.042
	SURVEY	Total	0.134	0.119	0.115
TILUDRONIC ACID					
M05BA05	PBS/RPBS	Plain	0.002	0.002	0.002
	SURVEY	Plain	0.000	0.000	0.000
ZOLEDRONIC ACID					
M05BA08	PBS/RPBS	Plain	0.572	1.028	1.272
	SURVEY	Plain	0.009	0.008	0.004
BISPHOSPHONATES, COMBINATIONS					
ALENDRONATE SODIUM with COLECALCIFEROL and CALCIUM CARBONATE					
M05BB05	PBS/RPBS	Plain	0.000	0.163	0.798
	SURVEY	Plain	0.000	0.002	0.012

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
MUSCULO-SKELETAL SYSTEM					
DRUGS FOR TREATMENT OF BONE DISEASES					
<i>DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION</i>					
OTHER DRUGS AFFECTING BONE STRUCTURE					
DENOSUMAB					
M05BX04	PBS/RPBS	Plain	0.000	0.003	0.303
	SURVEY	Plain	0.000	0.001	0.010
STRONTIUM RANELATE					
M05BX03	PBS/RPBS	Plain	0.816	0.999	1.114
	SURVEY	Plain	0.034	0.037	0.042

M

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
MUSCULO-SKELETAL SYSTEM					
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST.					
<i>OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST.</i>					
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST.					
HYALURONIC ACID					
M09AX01	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
ANALGESICS					
<i>OPIOIDS</i>					
NATURAL OPIUM ALKALOIDS					
HYDROMORPHONE					
N02AA03	PBS/RPBS	Plain	0.108	0.178	0.277
	SURVEY	Plain	0.003	0.005	0.014
MORPHINE					
N02AA01	PBS/RPBS	Plain	1.470	1.402	1.304
	SURVEY	Plain	0.089	0.077	0.075
OXYCODONE					
N02AA05	PBS/RPBS	Plain	2.246	2.480	2.650
	SURVEY	Plain	0.214	0.224	0.233
PHENYLPIPERIDINE DERIVATIVES					
FENTANYL					
N02AB03	PBS/RPBS	Plain	0.891	1.078	1.183
	SURVEY	Plain	0.007	0.009	0.008
PETHIDINE HYDROCHLORIDE					
N02AB02	SURVEY	Plain	0.003	0.004	0.005
DIPHENYLPROPYLAMINE DERIVATIVES					
DEXTROPROPOXYPHENE NAPSYLATE					
N02AC04	PBS/RPBS	Plain	0.019	0.017	0.013
	SURVEY	Plain	0.038	0.043	0.040
	SURVEY	Combination	0.205	0.194	0.175
	SURVEY	Total	0.243	0.237	0.215
ORIPAVINE DERIVATIVES					
BUPRENORPHINE					
N02AE01	PBS/RPBS	Plain	0.413	0.502	0.576
	SURVEY	Plain	0.011	0.009	0.011
OTHER OPIOIDS					
TRAMADOL					
N02AX02	PBS/RPBS	Plain	2.730	2.830	2.886
	SURVEY	Plain	0.596	0.621	0.651

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
ANALGESICS					
OTHER ANALGESICS AND ANTIPYRETICS					
SALICYLIC ACID DERIVATIVES					
ASPIRIN					
N02BA01	PBS/RPBS	Plain	0.146	0.115	0.093
	PBS/RPBS	Combination	0.000	0.000	0.000
	PBS/RPBS	Total	0.146	0.115	0.093
	SURVEY	Plain	0.009	0.006	0.005
	SURVEY	Combination	0.003	0.003	0.003
	SURVEY	Total	0.012	0.009	0.008
ANILIDES					
PARACETAMOL					
N02BE01	PBS/RPBS	Plain	20.218	23.100	25.996
	PBS/RPBS	Combination	2.953	2.984	2.993
	PBS/RPBS	Total	23.171	26.084	28.989
	SURVEY	Plain	1.009	1.151	1.301
	SURVEY	Combination	1.375	1.234	1.254
	SURVEY	Total	2.384	2.385	2.555
ANTIMIGRAINE PREPARATIONS					
ERGOT ALKALOIDS					
DIHYDROERGOTAMINE					
N02CA01	PBS/RPBS	Plain	0.001	0.001	0.001
	SURVEY	Plain	0.000	0.000	0.000
METHYSERGIDE					
N02CA04	PBS/RPBS	Plain	0.024	0.023	0.022
	SURVEY	Plain	0.001	0.001	0.000
SELECTIVE 5HT RECEPTOR AGONISTS					
ELETRIPTAN					
N02CC06	PBS/RPBS	Plain	0.000	0.000	0.014
	SURVEY	Plain	0.000	0.000	0.011
NARATRIPTAN					
N02CC02	PBS/RPBS	Plain	0.020	0.020	0.018
	SURVEY	Plain	0.026	0.026	0.023
RIZATRIPTAN					
N02CC04	PBS/RPBS	Plain	0.000	0.008	0.023
	SURVEY	Plain	0.000	0.010	0.028
SUMATRIPTAN					
N02CC01	PBS/RPBS	Plain	0.096	0.109	0.108
	SURVEY	Plain	0.102	0.122	0.120
ZOLMITRIPTAN					
N02CC03	PBS/RPBS	Plain	0.033	0.032	0.030
	SURVEY	Plain	0.039	0.038	0.037
OTHER ANTIMIGRAINE PREPARATIONS					
PIZOTIFEN MALATE					
N02CX01	PBS/RPBS	Plain	0.382	0.386	0.381
	SURVEY	Plain	0.194	0.189	0.189

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
ANTIEPILEPTICS					
<i>ANTIEPILEPTICS</i>					
BARBITURATES AND DERIVATIVES					
PHENOBARBITONE					
N03AA02	PBS/RPBS	Plain	0.091	0.087	0.082
	SURVEY	Plain	0.023	0.024	0.024
PRIMIDONE					
N03AA03	PBS/RPBS	Plain	0.079	0.078	0.075
	SURVEY	Plain	0.000	0.001	0.001
HYDANTOIN DERIVATIVES					
PHENYTOIN					
N03AB02	PBS/RPBS	Plain	1.053	1.019	0.965
	SURVEY	Plain	0.308	0.268	0.253
SUCCINIMIDE DERIVATIVES					
ETHOSUXIMIDE					
N03AD01	PBS/RPBS	Plain	0.018	0.020	0.022
	SURVEY	Plain	0.001	0.000	0.001
BENZODIAZEPINE DERIVATIVES					
CLONAZEPAM					
N03AE01	PBS/RPBS	Plain	0.133	0.130	0.127
	SURVEY	Plain	0.222	0.228	0.218
CARBOXAMIDE DERIVATIVES					
CARBAMAZEPINE					
N03AF01	PBS/RPBS	Plain	1.400	1.391	1.376
	SURVEY	Plain	0.290	0.279	0.274
OXCARBAZEPINE					
N03AF02	PBS/RPBS	Plain	0.071	0.074	0.076
	SURVEY	Plain	0.001	0.002	0.001
FATTY ACID DERIVATIVES					
SODIUM VALPROATE					
N03AG01	PBS/RPBS	Plain	3.736	3.558	3.576
	SURVEY	Plain	0.071	0.253	0.247
TIAGABINE					
N03AG06	PBS/RPBS	Plain	0.008	0.008	0.007
	SURVEY	Plain	0.000	0.000	0.000
VIGABATRIN					
N03AG04	PBS/RPBS	Plain	0.042	0.039	0.037
	SURVEY	Plain	0.000	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
ANTIEPILEPTICS					
<i>ANTIEPILEPTICS</i>					
OTHER ANTIEPILEPTICS					
GABAPENTIN					
N03AX12	PBS/RPBS	Plain	0.291	0.289	0.289
	SURVEY	Plain	0.181	0.185	0.205
LACOSAMIDE					
N03AX18	PBS/RPBS	Plain	0.000	0.014	0.043
	SURVEY	Plain	0.000	0.000	0.000
LAMOTRIGINE					
N03AX09	PBS/RPBS	Plain	0.827	0.843	0.858
	SURVEY	Plain	0.121	0.126	0.133
LEVETIRACETAM					
N03AX14	PBS/RPBS	Plain	0.689	0.802	0.924
	SURVEY	Plain	0.008	0.009	0.007
PREGABALIN					
N03AX16	PBS/RPBS	Plain	0.060	0.075	0.087
	SURVEY	Plain	0.406	0.494	0.580
SULTHIAME					
N03AX03	PBS/RPBS	Plain	0.024	0.023	0.022
	SURVEY	Plain	0.000	0.000	0.000
TOPIRAMATE					
N03AX11	PBS/RPBS	Plain	0.352	0.382	0.401
	SURVEY	Plain	0.024	0.023	0.024
ZONISAMIDE					
N03AX15	PBS/RPBS	Plain	0.000	0.000	0.008
	SURVEY	Plain	0.000	0.000	0.001

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
ANTI-PARKINSON DRUGS					
ANTICHOLINERGIC AGENTS					
TERTIARY AMINES WITH CARBON CHAIN					
BENZHEXOL HYDROCHLORIDE					
N04AA01	PBS/RPBS	Plain	0.110	0.101	0.100
	SURVEY	Plain	0.013	0.012	0.014
BIPERIDEN HYDROCHLORIDE					
N04AA02	PBS/RPBS	Plain	0.057	0.055	0.053
	SURVEY	Plain	0.006	0.006	0.005
ETHERS OF TROPINE OR TROPINE DERIVATIVES					
BENZTROPINE MESYLATE					
N04AC01	PBS/RPBS	Plain	0.425	0.416	0.384
	SURVEY	Plain	0.036	0.031	0.034
DOPAMINERGIC AGENTS					
DOPA AND DOPA DERIVATIVES					
LEVODOPA and DECARBOXYLASE INHIBITOR					
N04BA02	PBS/RPBS	Plain	0.000	0.000	0.003
LEVODOPA with BENSERAZIDE					
N04BA02	PBS/RPBS	Plain	0.570	0.605	0.615
	SURVEY	Plain	0.003	0.004	0.003
LEVODOPA with CARBIDOPA					
N04BA02	PBS/RPBS	Plain	0.846	0.784	0.773
	SURVEY	Plain	0.004	0.003	0.003
LEVODOPA with CARBIDOPA and ENTACAPONE					
N04BA03	PBS/RPBS	Plain	0.000	0.007	0.024
	SURVEY	Plain	0.000	0.000	0.000
LEVODOPA,DECARBOXYLASE INHIBITOR and COMT INHIBITOR					
N04BA03	PBS/RPBS	Plain	0.111	0.153	0.171
	SURVEY	Plain	0.000	0.002	0.000
ADAMANTANE DERIVATIVES					
AMANTADINE HYDROCHLORIDE					
N04BB01	PBS/RPBS	Plain	0.094	0.094	0.094
	SURVEY	Plain	0.001	0.001	0.001

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
ANTI-PARKINSON DRUGS					
DOPAMINERGIC AGENTS					
DOPAMINE AGONISTS					
APOMORPHINE					
N04BC07	PBS/RPBS	Plain	0.010	0.011	0.012
	SURVEY	Plain	0.000	0.000	0.000
BROMOCRIPTINE MESYLATE					
N04BC01	PBS/RPBS	Plain	0.010	0.008	0.005
	SURVEY	Plain	0.002	0.001	0.001
CABERGOLINE					
N04BC06	PBS/RPBS	Plain	0.096	0.067	0.048
	SURVEY	Plain	0.000	0.000	0.001
PERGOLIDE					
N04BC02	PBS/RPBS	Plain	0.008	0.006	0.005
	SURVEY	Plain	0.001	0.000	0.000
PRAMIPEXOLE					
N04BC05	PBS/RPBS	Plain	0.172	0.253	0.336
	SURVEY	Plain	0.000	0.002	0.004
ROPINIROLE					
N04BC04	SURVEY	Plain	0.005	0.004	0.004
MONOAMINE OXIDASE TYPE B INHIBITORS					
SELEGILINE HYDROCHLORIDE					
N04BD01	PBS/RPBS	Plain	0.073	0.070	0.071
	SURVEY	Plain	0.002	0.004	0.005
OTHER DOPAMINERGIC AGENTS					
ENTACAPONE					
N04BX02	PBS/RPBS	Plain	0.080	0.072	0.063
	SURVEY	Plain	0.001	0.001	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
PSYCHOLEPTICS					
ANTIPSYCHOTICS					
PHENOTHIAZINE WITH DIMETHYLAMINOPROPYL GROUP					
CHLORPROMAZINE HYDROCHLORIDE					
N05AA01	PBS/RPBS	Plain	0.146	0.138	0.134
	SURVEY	Plain	0.016	0.015	0.013
PHENOTHIAZINE WITH PIPERAZINE STRUCTURE					
FLUPHENAZINE DECANOATE					
N05AB02	PBS/RPBS	Plain	0.205	0.192	0.180
	SURVEY	Plain	0.006	0.005	0.003
PROCHLORPERAZINE					
N05AB04	PBS/RPBS	Plain	0.117	0.115	0.114
	SURVEY	Plain	0.044	0.043	0.042
TRIFLUOPERAZINE HYDROCHLORIDE					
N05AB06	PBS/RPBS	Plain	0.058	0.054	0.050
	SURVEY	Plain	0.010	0.007	0.006
PHENOTHIAZINE WITH PIPERIDINE STRUCTURE					
PERICYAZINE					
N05AC01	PBS/RPBS	Plain	0.054	0.052	0.050
	SURVEY	Plain	0.007	0.008	0.009
BUTYROPHENONE DERIVATIVES					
HALOPERIDOL					
N05AD01	PBS/RPBS	Plain	0.226	0.217	0.211
	SURVEY	Plain	0.016	0.016	0.016
INDOLE DERIVATIVES					
ZIPRASIDONE					
N05AE04	PBS/RPBS	Plain	0.156	0.181	0.203
	SURVEY	Plain	0.048	0.052	0.050
THIOXANTHENE DERIVATIVES					
FLUPENTHIXOL					
N05AF01	PBS/RPBS	Plain	0.117	0.120	0.121
	SURVEY	Plain	0.003	0.002	0.009
ZUCLOPENTHIXOL					
N05AF05	PBS/RPBS	Plain	0.210	0.223	0.121
	SURVEY	Plain	0.012	0.010	0.039
DIPHENYLBUTYLPYPERIDINE DERIVATIVES					
PIMOZIDE					
N05AG02	SURVEY	Plain	0.000	0.001	0.000

N

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
PSYCHOLEPTICS					
ANTIPSYCHOTICS					
DIAZEPINES, OXAZEPINES, THIAZEPINES AND OXEPINES					
ASENAPINE					
N05AH05	PBS/RPBS	Plain	0.000	0.000	0.002
	SURVEY	Plain	0.000	0.000	0.000
CLOZAPINE					
N05AH02	PBS/RPBS	Plain	0.053	0.056	0.060
	SURVEY	Plain	0.187	0.199	0.226
OLANZAPINE					
N05AH03	PBS/RPBS	Plain	3.044	3.047	3.085
	SURVEY	Plain	0.066	0.043	0.034
QUETIAPINE					
N05AH04	PBS/RPBS	Plain	1.659	1.974	2.246
	SURVEY	Plain	0.113	0.100	0.103
BENZAMIDES					
AMISULPRIDE					
N05AL05	PBS/RPBS	Plain	0.419	0.408	0.401
	SURVEY	Plain	0.007	0.004	0.006
LITHIUM					
LITHIUM CARBONATE					
N05AN01	PBS/RPBS	Plain	0.914	0.946	0.975
	SURVEY	Plain	0.248	0.238	0.231
OTHER ANTIPSYCHOTICS					
ARIPRAZOLE					
N05AX12	PBS/RPBS	Plain	0.526	0.565	0.612
	SURVEY	Plain	0.012	0.009	0.012
PALIPERIDONE					
N05AX13	PBS/RPBS	Plain	0.081	0.099	0.115
	SURVEY	Plain	0.000	0.000	0.001
RISPERIDONE					
N05AX08	PBS/RPBS	Plain	1.491	1.510	1.506
	SURVEY	Plain	0.018	0.021	0.022

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
PSYCHOLEPTICS					
ANXIOLYTICS					
BENZODIAZEPINE DERIVATIVES					
ALPRAZOLAM					
N05BA12	PBS/RPBS	Plain	3.919	3.873	3.735
	SURVEY	Plain	2.325	2.324	2.444
BROMAZEPAM					
N05BA08	PBS/RPBS	Plain	0.006	0.005	0.004
	SURVEY	Plain	0.135	0.122	0.128
CLOBAZAM					
N05BA09	SURVEY	Plain	0.069	0.073	0.079
DIAZEPAM					
N05BA01	PBS/RPBS	Plain	4.855	4.732	4.641
	SURVEY	Plain	1.528	1.564	1.611
LORAZEPAM					
N05BA06	SURVEY	Plain	0.407	0.413	0.398
OXAZEPAM					
N05BA04	PBS/RPBS	Plain	1.893	1.772	1.659
	SURVEY	Plain	0.412	0.392	0.381
AZASPIRODECANEDIONE DERIVATIVES					
BUSPIRONE HYDROCHLORIDE					
N05BE01	PBS/RPBS	Plain	0.002	0.002	0.002
	SURVEY	Plain	0.008	0.007	0.011
<i>HYPNOTICS AND SEDATIVES</i>					
ALDEHYDES AND DERIVATIVES					
CHLORAL HYDRATE					
N05CC01	SURVEY	Plain	0.000	0.001	0.000
BENZODIAZEPINE DERIVATIVES					
FLUNITRAZEPAM					
N05CD03	PBS/RPBS	Plain	0.037	0.032	0.027
	SURVEY	Plain	0.291	0.266	0.243
MIDAZOLAM					
N05CD08	SURVEY	Plain	0.007	0.008	0.011
NITRAZEPAM					
N05CD02	PBS/RPBS	Plain	1.561	1.435	1.304
	SURVEY	Plain	0.288	0.286	0.271
TEMAZEPAM					
N05CD07	PBS/RPBS	Plain	3.290	3.108	2.963
	SURVEY	Plain	1.050	0.984	1.001
TRIAZOLAM					
N05CD05	SURVEY	Plain	0.017	0.021	0.028

N

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
PSYCHOLEPTICS					
<i>HYPNOTICS AND SEDATIVES</i>					
BENZODIAZEPINE RELATED DRUGS					
ZOLPIDEM					
N05CF02	SURVEY	Plain	0.810	0.744	0.783
ZOPICLONE					
N05CF01	PBS/RPBS	Plain	0.100	0.098	0.095
	SURVEY	Plain	0.382	0.411	0.513
BENZODIAZEPINE RELATED DRUGS					
MELATONIN					
N05CH01	SURVEY	Plain	0.000	0.106	0.177

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
PSYCHOANALEPTICS					
ANTIDEPRESSANTS					
NON SELECTIVE MONOAMINE REUPTAKE INHIBITORS					
AMITRIPTYLINE HYDROCHLORIDE					
N06AA09	PBS/RPBS	Plain	2.871	2.981	3.088
	SURVEY	Plain	0.889	0.873	0.908
CLOMIPRAMINE HYDROCHLORIDE					
N06AA04	PBS/RPBS	Plain	0.193	0.192	0.193
	SURVEY	Plain	0.055	0.054	0.057
DOTHIEPIN HYDROCHLORIDE					
N06AA16	PBS/RPBS	Plain	0.798	0.762	0.693
	SURVEY	Plain	0.307	0.281	0.291
DOXEPIN HYDROCHLORIDE					
N06AA12	PBS/RPBS	Plain	0.682	0.640	0.596
	SURVEY	Plain	0.128	0.109	0.101
IMIPRAMINE HYDROCHLORIDE					
N06AA02	PBS/RPBS	Plain	0.224	0.208	0.197
	SURVEY	Plain	0.056	0.049	0.045
NORTRIPTYLINE HYDROCHLORIDE					
N06AA10	PBS/RPBS	Plain	0.184	0.195	0.210
	SURVEY	Plain	0.081	0.082	0.079
TRIMIPRAMINE MALEATE					
N06AA06	SURVEY	Plain	0.016	0.015	0.016
SELECTIVE SEROTONIN REUPTAKE INHIBITORS					
CITALOPRAM					
N06AB04	PBS/RPBS	Plain	5.869	5.780	5.381
	SURVEY	Plain	2.007	1.767	2.080
ESCITALOPRAM					
N06AB10	PBS/RPBS	Plain	6.136	7.114	7.958
	SURVEY	Plain	4.602	4.886	5.072
FLUOXETINE HYDROCHLORIDE					
N06AB03	PBS/RPBS	Plain	4.351	4.428	3.814
	SURVEY	Plain	2.105	2.069	2.448
FLUVOXAMINE					
N06AB08	PBS/RPBS	Plain	1.401	1.353	1.297
	SURVEY	Plain	0.595	0.534	0.502
PAROXETINE					
N06AB05	PBS/RPBS	Plain	3.686	3.568	3.487
	SURVEY	Plain	1.639	1.497	1.453
SERTRALINE					
N06AB06	PBS/RPBS	Plain	12.444	12.516	12.532
	SURVEY	Plain	6.675	6.276	6.392

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
PSYCHOANALEPTICS					
ANTIDEPRESSANTS					
MONOAMINE OXIDASE INHIBITORS, NON-SELECTIVE					
PHENELZINE SULPHATE					
N06AF03	PBS/RPBS	Plain	0.029	0.030	0.030
	SURVEY	Plain	0.000	0.000	0.000
TRANLYCYPROMINE SULPHATE					
N06AF04	PBS/RPBS	Plain	0.244	0.247	0.234
	SURVEY	Plain	0.003	0.004	0.034
MONOAMINE OXIDASE TYPE A INHIBITORS					
MOCLOBEMIDE					
N06AG02	PBS/RPBS	Plain	0.825	0.759	0.698
	SURVEY	Plain	0.295	0.242	0.279
OTHER ANTIDEPRESSANTS					
AGOMELATINE					
N06AX22	SURVEY	Plain	0.000	0.010	0.133
BUPROPION					
N06AX12	PBS/RPBS	Plain	0.064	0.062	0.052
	SURVEY	Plain	0.015	0.015	0.019
DESVENLAFAXINE					
N06AX23	PBS/RPBS	Plain	1.467	3.976	6.059
	SURVEY	Plain	0.013	0.027	0.045
DULOXETINE					
N06AX21	PBS/RPBS	Plain	1.511	2.550	3.423
	SURVEY	Plain	0.026	0.037	0.049
MIANSERIN HYDROCHLORIDE					
N06AX03	PBS/RPBS	Plain	0.135	0.129	0.123
	SURVEY	Plain	0.021	0.018	0.017
MIRTAZAPINE					
N06AX11	PBS/RPBS	Plain	4.735	5.113	5.460
	SURVEY	Plain	0.820	0.763	0.740
REBOXETINE					
N06AX18	PBS/RPBS	Plain	0.305	0.269	0.234
	SURVEY	Plain	0.003	0.001	0.001
VENLAFAXINE					
N06AX16	PBS/RPBS	Plain	13.278	12.586	12.150
	SURVEY	Plain	0.198	0.156	0.154

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
PSYCHOANALEPTICS					
PSYCHOSTIMULANTS AND NOOTROPICS					
CENTRALLY ACTING SYMPATHOMIMETICS					
ATOMOXETINE					
N06BA09	PBS/RPBS	Plain	0.086	0.097	0.102
	SURVEY	Plain	0.006	0.007	0.005
DEXAMPHETAMINE SULPHATE					
N06BA02	PBS/RPBS	Plain	1.064	1.087	0.993
	SURVEY	Plain	0.730	0.735	0.677
METHYLPHENIDATE					
N06BA04	PBS/RPBS	Plain	1.574	1.733	1.882
	SURVEY	Plain	0.293	0.271	0.295
MODAFINIL					
N06BA07	PBS/RPBS	Plain	0.013	0.021	0.028
	SURVEY	Plain	0.014	0.015	0.024
<i>ANTI-DEMENTIA DRUGS</i>					
ANTICHOLINESTERASES					
DONEPEZIL					
N06DA02	PBS/RPBS	Plain	1.005	1.013	1.032
	SURVEY	Plain	0.014	0.017	0.019
GALANTAMINE					
N06DA04	PBS/RPBS	Plain	0.395	0.379	0.358
	SURVEY	Plain	0.006	0.007	0.006
RIVASTIGMINE					
N06DA03	PBS/RPBS	Plain	0.080	0.106	0.129
	SURVEY	Plain	0.001	0.002	0.003
OTHER ANTI-DEMENTIA DRUGS					
MEMANTINE HYDROCHLORIDE					
N06DX01	PBS/RPBS	Plain	0.041	0.058	0.069
	SURVEY	Plain	0.035	0.033	0.035

N

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
OTHER NERVOUS SYSTEM DRUGS					
PARASYMPATHOMIMETICS					
ANTICHOLINESTERASES					
PYRIDOSTIGMINE BROMIDE					
N07AA02	PBS/RPBS	Plain	0.111	0.116	0.118
	SURVEY	Plain	0.002	0.002	0.002
CHOLINE ESTERS					
BETHANECHOL CHLORIDE					
N07AB02	PBS/RPBS	Plain	0.019	0.018	0.016
	SURVEY	Plain	0.005	0.005	0.005
<i>DRUGS USED IN ADDICTIVE DISORDERS</i>					
DRUGS USED IN NICOTINE DEPENDENCE					
NICOTINE					
N07BA01	PBS/RPBS	Plain	0.008	0.010	1.147
	SURVEY	Plain	0.001	0.004	0.009
VARENICLINE					
N07BA03	PBS/RPBS	Plain	2.069	2.152	1.778
	SURVEY	Plain	0.087	0.101	0.068
DRUGS USED IN ALCOHOL DEPENDENCE					
ACAMPROSATE					
N07BB03	PBS/RPBS	Plain	0.114	0.114	0.118
	SURVEY	Plain	0.002	0.001	0.002
NALTREXONE					
N07BB04	PBS/RPBS	Plain	0.087	0.091	0.092
	SURVEY	Plain	0.003	0.002	0.004
DRUGS USED IN OPIOID DEPENDENCE					
BUPRENORPHINE					
N07BC01	SURVEY	Plain	0.000	0.000	0.000
BUPRENORPHINE with NALOXONE					
N07BC51	SURVEY	Plain	0.000	0.000	0.000
METHADONE HYDROCHLORIDE					
N07BC02	PBS/RPBS	Plain	0.372	0.367	0.377
	SURVEY	Plain	0.166	0.256	0.142
<i>ANTIVERTIGO PREPARATIONS</i>					
ANTIVERTIGO PREPARATIONS					
BETAHISTINE					
N07CA01	SURVEY	Plain	0.370	0.395	0.367

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
NERVOUS SYSTEM					
OTHER NERVOUS SYSTEM DRUGS					
<i>OTHER NERVOUS SYSTEM DRUGS</i>					
OTHER NERVOUS SYSTEM DRUGS					
FAMPRIDINE					
N07XX07	SURVEY	Plain	0.000	0.000	0.000
RILUZOLE					
N07XX02	PBS/RPBS	Plain	0.027	0.027	0.027
	SURVEY	Plain	0.000	0.000	0.000
TETRABENAZINE					
N07XX06	PBS/RPBS	Plain	0.022	0.022	0.023
	SURVEY	Plain	0.000	0.001	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS					
ANTIPROTOZOALS					
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES					
NITROIMIDAZOLE DERIVATIVES					
METRONIDAZOLE					
P01AB01	PBS/RPBS	Plain	0.135	0.140	0.143
	SURVEY	Plain	0.173	0.172	0.172
TINIDAZOLE					
P01AB02	PBS/RPBS	Plain	0.006	0.006	0.006
	SURVEY	Plain	0.014	0.014	0.014
OTHER AGENTS AGAINST AMOEBIASIS					
ATOVAQUONE					
P01AX06	PBS/RPBS	Plain	0.000	0.000	0.000
ANTIMALARIALS					
QUINOLINE DERIVATIVES					
CHLOROQUINE					
P01BA01	SURVEY	Plain	0.000	0.000	0.000
HYDROXYCHLOROQUINE SULPHATE					
P01BA02	PBS/RPBS	Plain	0.646	0.700	0.753
	SURVEY	Plain	0.006	0.007	0.007
PRIMAQUINE PHOSPHATE					
P01BA03	SURVEY	Plain	0.000	0.000	0.000
BIGUANIDES					
PROGUANIL					
P01BB01	SURVEY	Plain	0.001	0.000	0.000
METHANOLQUINOLINES					
MEFLOQUINE					
P01BC02	SURVEY	Plain	0.003	0.004	0.004
QUININE					
P01BC01	PBS/RPBS	Plain	0.007	0.005	0.004
	SURVEY	Plain	0.176	0.120	0.091

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS					
ANTHELMINTICS					
ANTITREMATODALS					
QUINOLINE DERIVATIVES					
PRAZIQUANTEL					
P02BA01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
ANTINEMATODAL AGENTS					
BENZIMIDAZOLE DERIVATIVES					
ALBENDAZOLE					
P02CA03	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.001	0.001
MEBENDAZOLE					
P02CA01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
TETRAHYDROPYRIMIDINE DERIVATIVES					
PYRANTEL EMBONATE					
P02CC01	PBS/RPBS	Plain	0.001	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.000
AVERMECTINES					
IVERMECTIN					
P02CF01	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.000	0.000	0.001

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
RESPIRATORY SYSTEM					
NASAL PREPARATIONS					
<i>DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE</i>					
SYMPATHOMIMETICS, PLAIN					
OXYMETAZOLINE					
R01AA05	PBS/RPBS	Plain	0.004	0.002	0.002
	SURVEY	Plain	0.004	0.003	0.002
XYLOMETAZOLINE					
R01AA07	SURVEY	Plain	0.001	0.001	0.001
ANTIALLERGIC AGENTS, EXCL. CORTICOSTEROIDS					
LEVOCABASTINE					
R01AC02	PBS/RPBS	Plain	0.002	0.001	0.001
	SURVEY	Plain	0.001	0.000	0.001
SODIUM CROMOGLYCATE					
R01AC01	PBS/RPBS	Plain	0.001	0.001	0.001
	SURVEY	Plain	0.000	0.000	0.000
CORTICOSTEROIDS					
BECLOMETHASONE DIPROPIONATE					
R01AD01	SURVEY	Plain	0.008	0.010	0.009
BUDESONIDE					
R01AD05	PBS/RPBS	Plain	0.090	0.083	0.078
	SURVEY	Plain	1.117	0.945	0.901
FLUTICASONE					
R01AD08	SURVEY	Plain	0.007	0.019	0.038
FLUTICASONE FUROATE					
R01AD12	SURVEY	Plain	0.196	0.387	0.123
MOMETASONE FUROATE					
R01AD09	SURVEY	Plain	2.371	2.377	2.522
OTHER NASAL PREPARATIONS					
IPRATROPIUM BROMIDE					
R01AX03	PBS/RPBS	Plain	0.043	0.039	0.036
	SURVEY	Plain	0.014	0.015	0.015
<i>NASAL DECONGESTANTS FOR SYSTEMIC USE</i>					
SYMPATHOMIMETICS					
PSEUDOEPHEDRINE					
R01BA02	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.007	0.009	0.006
	SURVEY	Combination	0.000	0.000	0.000
	SURVEY	Total	0.007	0.009	0.006

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
RESPIRATORY SYSTEM					
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES					
ADRENERGICS, INHALANTS					
SELECTIVE BETA-2-ADRENOCEPTOR AGONISTS					
EFORMOTEROL					
R03AC13	PBS/RPBS	Plain	0.299	0.267	0.238
	PBS/RPBS	Combination	4.709	5.238	5.644
	PBS/RPBS	Total	5.008	5.505	5.882
	SURVEY	Plain	0.007	0.006	0.004
	SURVEY	Combination	0.020	0.020	0.019
	SURVEY	Total	0.027	0.026	0.023
INDACATEROL					
R03AC18	PBS/RPBS	Plain	0.000	0.000	0.009
	SURVEY	Plain	0.000	0.000	0.001
SALBUTAMOL					
R03AC02	PBS/RPBS	Plain	15.775	16.093	16.246
	SURVEY	Plain	4.864	4.737	4.527
SALMETEROL					
R03AC12	PBS/RPBS	Plain	0.150	0.139	0.132
	PBS/RPBS	Combination	11.125	11.314	11.554
	PBS/RPBS	Total	11.275	11.453	11.686
	SURVEY	Plain	0.001	0.001	0.001
	SURVEY	Combination	0.027	0.028	0.028
	SURVEY	Total	0.028	0.029	0.029
TERBUTALINE SULPHATE					
R03AC03	PBS/RPBS	Plain	1.276	1.166	1.065
	SURVEY	Plain	0.509	0.424	0.377

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
RESPIRATORY SYSTEM					
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES					
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS					
GLUCOCORTICIDS					
BECLOMETHASONE DIPROPIONATE					
R03BA01	PBS/RPBS	Plain	0.261	0.235	0.159
	SURVEY	Plain	0.010	0.009	0.057
BUDESONIDE					
R03BA02	PBS/RPBS	Plain	1.624	1.449	1.300
	PBS/RPBS	Combination	4.634	5.159	5.563
	PBS/RPBS	Total	6.258	6.608	6.863
	SURVEY	Plain	0.202	0.178	0.174
	SURVEY	Combination	0.019	0.020	0.019
	SURVEY	Total	0.221	0.198	0.193
CICLESONIDE					
R03BA08	PBS/RPBS	Plain	1.126	1.188	1.297
	SURVEY	Plain	0.035	0.040	0.043
FLUTICASONE					
R03BA05	PBS/RPBS	Plain	1.131	1.109	1.079
	PBS/RPBS	Combination	14.569	14.920	15.346
	PBS/RPBS	Total	15.700	16.029	16.425
	SURVEY	Plain	0.392	0.383	0.366
	SURVEY	Combination	0.030	0.032	0.030
	SURVEY	Total	0.422	0.415	0.396
ANTICHOLINERGICS					
IPRATROPIUM BROMIDE					
R03BB01	PBS/RPBS	Plain	3.693	3.388	3.030
	SURVEY	Plain	0.033	0.030	0.118
TIOTROPIUM BROMIDE					
R03BB04	PBS/RPBS	Plain	6.023	6.382	6.672
	SURVEY	Plain	0.006	0.007	0.006
ANTIALLERGIC AGENTS, EXCL. CORTICOSTEROIDS					
NEDOCROMIL					
R03BC03	PBS/RPBS	Plain	0.215	0.209	0.209
	SURVEY	Plain	0.003	0.002	0.002
SODIUM CROMOGLYCATE					
R03BC01	PBS/RPBS	Plain	0.058	0.052	0.047
	SURVEY	Plain	0.003	0.004	0.004
ADRENERGICS FOR SYSTEMIC USE					
SELECTIVE BETA-2-ADRENOCEPTOR AGONISTS					
SALBUTAMOL					
R03CC02	PBS/RPBS	Plain	0.037	0.034	0.032
	SURVEY	Plain	0.013	0.012	0.012
TERBUTALINE SULPHATE					
R03CC03	PBS/RPBS	Plain	0.000	0.000	0.000
	SURVEY	Plain	0.143	0.134	0.103

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
RESPIRATORY SYSTEM					
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES					
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES					
XANTHINES					
THEOPHYLLINE					
R03DA04	PBS/RPBS	Plain	0.386	0.360	0.341
	SURVEY	Plain	0.083	0.065	0.077
LEUKOTRIENERECEPTOR ANTAGONISTS					
MONTELUKAST					
R03DC03	PBS/RPBS	Plain	0.291	0.328	0.350
	SURVEY	Plain	0.160	0.162	0.165
ZAFIRLUKAST					
R03DC01	SURVEY	Plain	0.000	0.000	0.000
OMALIZUMAB					
R03DX05	PBS/RPBS	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
RESPIRATORY SYSTEM					
COUGH AND COLD PREPARATIONS					
EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES					
MUCOLYTICS					
ACETYLCYSTEINE					
R05CB01	PBS/RPBS	Plain	0.016	0.002	0.000
	SURVEY	Plain	0.000	0.000	0.000
BROMHEXINE HYDROCHLORIDE					
R05CB02	SURVEY	Plain	0.013	0.014	0.017
DORNASE ALFA (DESOXYRIBONUCLEASE)					
R05CB13	PBS/RPBS	Plain	0.000	0.000	0.000
COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS					
OPIUM ALKALOIDS AND DERIVATIVES					
CODEINE					
R05DA04	PBS/RPBS	Plain	0.127	0.127	0.126
	PBS/RPBS	Combination	5.286	5.346	5.365
	PBS/RPBS	Total	5.413	5.473	5.491
	SURVEY	Plain	0.035	0.035	0.039
	SURVEY	Combination	2.181	1.892	1.920
	SURVEY	Total	2.216	1.927	1.959
CODEINE with PSEUDOEPHEDRINE					
R05DA20	SURVEY	Plain	0.000	0.000	0.000
PHOLCODINE					
R05DA08	PBS/RPBS	Plain	0.001	0.001	0.001
	SURVEY	Plain	0.001	0.001	0.002
PHOLCODINE with PSEUDOEPHEDRINE					
R05DA20	SURVEY	Plain	0.001	0.000	0.000

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
RESPIRATORY SYSTEM					
ANTIHISTAMINES FOR SYSTEMIC USE					
<i>ANTIHISTAMINES FOR SYSTEMIC USE</i>					
AMINOALKYL ETHERS					
DIMENHYDRINATE					
R06AA02	SURVEY	Plain	0.000	0.000	0.000
DIPHENHYDRAMINE					
R06AA02	SURVEY	Plain	0.000	0.000	0.000
SUBSTITUTED ALKYLAMINES					
BROMPHENIRAMINE COMBINATIONS					
R06AB51	SURVEY	Plain	0.003	0.000	0.000
CHLORPHENIRAMINE					
R06AB04	SURVEY	Plain	0.000	0.000	0.000
	SURVEY	Combination	0.000	0.000	0.000
	SURVEY	Total	0.000	0.000	0.000
DEXCHLORPHENIRAMINE					
R06AB02	SURVEY	Plain	0.044	0.022	0.018
PHENIRAMINE					
R06AB05	SURVEY	Plain	0.005	0.004	0.005
PHENOTHIAZINE DERIVATIVES					
PROMETHAZINE					
R06AD02	PBS/RPBS	Plain	0.104	0.092	0.091
	SURVEY	Plain	0.235	0.220	0.220
TRIMEPRAZINE					
R06AD01	SURVEY	Plain	0.004	0.003	0.006
PIPERAZINE DERIVATIVES					
CETIRIZINE					
R06AE07	PBS/RPBS	Plain	0.051	0.048	0.046
	SURVEY	Plain	0.020	0.020	0.028
OTHER ANTIHISTAMINES FOR SYSTEMIC USE					
CYPROHEPTADINE HYDROCHLORIDE					
R06AX02	PBS/RPBS	Plain	0.277	0.269	0.263
	SURVEY	Plain	0.046	0.041	0.038
DESLORATADINE					
R06AX27	SURVEY	Plain	0.000	0.000	0.000
FEXOFENADINE					
R06AX26	PBS/RPBS	Plain	0.534	0.504	0.462
	SURVEY	Plain	0.077	0.041	0.052
LORATADINE					
R06AX13	PBS/RPBS	Plain	0.128	0.121	0.114
	SURVEY	Plain	0.024	0.030	0.028
LORATADINE with PSEUDOEPHEDRINE					
R06AX13	SURVEY	Plain	0.000	0.000	0.000

ATC	SOURCE	PLAIN/ COMBINATION	2009	2010	2011
SENSORY ORGANS					
OPHTHALMOLOGICALS					
ANTIGLAUCOMA PREPARATIONS AND MIOTICS					
SYMPATHOMIMETICS IN GLAUCOMA THERAPY					
APRACLONIDINE					
S01EA03	PBS/RPBS	Plain	0.030	0.032	0.027
	SURVEY	Plain	0.001	0.001	0.000
BRIMONIDINE					
S01EA05	PBS/RPBS	Plain	0.589	0.584	0.632
	SURVEY	Plain	0.067	0.065	0.069
DIPIVEFRINE					
S01EA02	SURVEY	Plain	0.000	0.000	0.000
PARASYMPATHOMIMETICS					
CARBACHOL					
S01EB02	SURVEY	Plain	0.000	0.000	0.000
PILOCARPINE					
S01EB01	PBS/RPBS	Plain	0.280	0.242	0.221
	SURVEY	Plain	0.034	0.031	0.029
CARBONIC ANHYDRASE INHIBITORS					
ACETAZOLAMIDE					
S01EC01	PBS/RPBS	Plain	0.082	0.083	0.083
	SURVEY	Plain	0.040	0.038	0.041
BRINZOLAMIDE					
S01EC04	PBS/RPBS	Plain	0.601	0.663	0.709
	SURVEY	Plain	0.078	0.085	0.083
DORZOLAMIDE					
S01EC03	PBS/RPBS	Plain	0.109	0.107	0.107
	SURVEY	Plain	0.017	0.015	0.015
BETA BLOCKING AGENTS					
BETAXOLOL HYDROCHLORIDE					
S01ED02	PBS/RPBS	Plain	0.310	0.264	0.227
	SURVEY	Plain	0.037	0.034	0.030
TIMOLOL MALEATE					
S01ED01	PBS/RPBS	Plain	1.106	0.975	0.861
	SURVEY	Plain	0.171	0.149	0.141
PROSTAGLANDIN ANALOGUES					
BIMATOPROST					
S01EE03	PBS/RPBS	Plain	1.108	1.043	1.002
	SURVEY	Plain	0.004	0.003	0.004
LATANOPROST					
S01EE01	PBS/RPBS	Plain	4.702	4.726	4.726
	SURVEY	Plain	0.015	0.015	0.014
TRAVOPROST					
S01EE04	PBS/RPBS	Plain	0.417	0.448	0.465
	SURVEY	Plain	0.002	0.003	0.004

<i>ATC</i>	<i>SOURCE</i>	<i>PLAIN/ COMBINATION</i>	<i>2009</i>	<i>2010</i>	<i>2011</i>
VARIOUS					
ALL OTHER THERAPEUTIC PRODUCTS					
<i>ALL OTHER THERAPEUTIC PRODUCTS</i>					
DRUGS FOR TREATMENT OF HYPERKALEMIA AND HYPERPHOSPHATEMIA					
LANTHANUM CARBONATE					
V03AE03	PBS/RPBS	Plain	0.003	0.013	0.021
	SURVEY	Plain	0.000	0.000	0.000
SEVELAMER					
V03AE02	PBS/RPBS	Plain	0.054	0.056	0.058
	SURVEY	Plain	0.000	0.000	0.000
DETOXIFYING AGENTS FOR CYTOSTATIC TREATMENT					
CALCIUM FOLINATE					
V03AF03	PBS/RPBS	Plain	0.032	0.030	0.030
	SURVEY	Plain	0.000	0.000	0.000

ATC INDEX 2012

This is a version of the World Health Organization (WHO) ATC index and, as such, contains some substances for which data are not available in the two tables. This ATC index is sorted alphabetically according to generic/substance International Nonproprietary Name (INN). There may be some variance in the spelling of the generic name.

A		D 06 B B 53	Aciclovir, combinations
A 03 A B 16	(2-benzhydryloxyethyl) diethyl-methylammonium iodide	C 10 A D 06	Acipimox
D 01 A E 06	2-(4-chlorphenoxy)-ethanol	D 05 B B 02	Acitretin
V 03 A B 27	4-dimethylaminophenol	L 01 D B 04	Aclarubicin
J 05 A F 06	Abacavir	R 02 A A 13	Acriflavinium chloride
L 02 B X 01	Abarelix	R 06 A X 18	Acrivastine
L 04 A A 24	Abatacept	L 04 A B 04	Adalimumab
B 01 A C 13	Abciximab	D 10 A D 03	Adapalene
L 04 A A 22	Abetimus	D 10 A D 53	Adapalene, combinations
L 02 B X 03	Abiraterone	J 05 A F 08	Adefovir dipivoxil
B 02 B C 01	Absorbable gelatin sponge	A 16 A A 02	Ademetionine
C 01 E B 13	Acadesine	C 01 E B 10	Adenosine
N 07 B B 03	Acamprostate	N 05 B A 07	Adinazolam
A 10 B F 01	Acarbose	V 08 A C 04	Adipiodone
C 07 A B 04	Acebutolol	N 06 B X 17	Adrafinil
C 07 B B 04	Acebutolol and thiazides	A 01 A D 06	Adrenalone
S 01 E B 08	Aceclidine	B 02 B C 05	Adrenalone
S 01 E B 58	Aceclidine, combinations	L 01 X E 13	Afatinib
M 01 A B 16	Aceclofenac	L 04 A B 03	Afelimomab
M 02 A A 25	Aceclofenac	S 01 L A 05	Aflibercept
R 03 D A 09	Acefylline piperazine	A 16 A B 03	Agalsidase alfa
M 01 A B 11	Acemetacin	A 16 A B 04	Agalsidase beta
B 01 A A 07	Acenocoumarol	D 11 A H	Agents for atopic dermatitis, excluding corticosteroids
N 05 A A 04	Acepromazine	N 06 A X 22	Agomelatine
A 07 A X 02	Acetarsol	C 01 B A 05	Ajmaline
G 01 A B 01	Acetarsol	B 05 X B 02	Alanyl glutamine
P 01 C D 02	Acetarsol	N 06 A B 07	Alaproclate
S 01 E C 01	Acetazolamide	P 02 C A 03	Albendazole
G 01 A D 02	Acetic Acid	L 03 A B 12	Albinterferon alfa-2b
S 02 A A 10	Acetic Acid	B 05 A A 01	Albumin
A 10 B B 31	Acetohexamide	A 07 X A 01	Albumin tannate
G 04 B X 03	Acetohydroxamic acid	A 07 X A 51	Albumin tannate, combinations
N 05 A B 07	Acetophenazine	M 01 A B 06	Alclofenac
A 02 B X 09	Acetoxolone	D 07 A B 10	Alclometasone
V 08 A A 07	Acetrizoic acid	S 01 B A 10	Alclometasone
N 06 B X 12	Acetylcarnitine	M 03 A A 01	Alcuronium
S 01 E B 09	Acetylcholine	L 03 A C 01	Aldesleukin
R 05 C B 01	Acetylcysteine	J 04 B A 03	Aldesulfone sodium
S 01 X A 08	Acetylcysteine	H 02 A A 01	Aldosterone
V 03 A B 23	Acetylcysteine	L 04 A A 15	Alefacept
C 01 A A 01	Acetyldigitoxin	L 01 X C 04	Alemtuzumab
C 01 A A 02	Acetyldigoxin	M 05 B A 04	Alendronic acid
C 01 A A 52	Acetyldigoxin, combinations	M 05 B B 05	Alendronic acid, calcium and colecalciferol, sequential
R 05 D A 12	Acetyldihydrocodeine	M 05 B B 03	Alendronic acid and colecalciferol
N 05 C C 03	Acetylglycinamide chloral hydrate	B 02 A B 02	Alfal antitrypsin
N 07 C A 04	Acetylleucine	A 11 C C 03	Alfacalcidol
A 01 A D 05	Acetylsalicylic acid	N 01 A X 05	Alfaxalone
B 01 A C 06	Acetylsalicylic acid	N 01 A H 02	Alfentanil
N 02 B A 01	Acetylsalicylic acid	G 04 C A 51	Alfuzosin and finasteride
M 01 B A 03	Acetylsalicylic acid and corticosteroids	G 04 C A 01	Alfuzosin
B 01 A C 56	Acetylsalicylic acid and esomeprazole	A 02 A B 02	Algeldrate
N 02 B A 51	Acetylsalicylic acid, comb. excl. psycholeptics	A 02 B X 13	Alginic acid
N 02 B A 71	Acetylsalicylic acid, comb. with psycholeptics	A 16 A B 01	Alglucerase
D 06 B B 03	Aciclovir	A 16 A B 07	Alglucosidase alfa
J 05 A B 01	Aciclovir	R 06 A D 01	Alimemazine
S 01 A D 03	Aciclovir	C 10 A X 10	Alipogene tiparvovec
		C 09 X A 02	Aliskiren

C 09 X A 53	Aliskiren and amlodipine	L 01 X D 04	Aminolevulinic acid
C 09 X A 54	Aliskiren, amlodipine and hydrochlorothiazide	B 02 A A 03	Aminomethylbenzoic acid
C 09 X A 52	Aliskiren and hydrochlorothiazide	N 02 B B 03	Aminophenazone
D 11 A H 04	Alitretinoin	N 02 B B 53	Aminophenazone, combinations excl. psycholeptics
L 01 X X 22	Alitretinoin	N 02 B B 73	Aminophenazone, combinations with psycholeptics
A 03 F A 05	Alizapride	R 03 D A 05	Aminophylline
N 05 C A 21	Allobarbitol	R 03 D B 05	Aminophylline and adrenergics
M 04 A A 01	Allopurinol	R 03 D A 55	Aminophylline, combinations
M 04 A A 51	Allopurinol, combinations	J 04 A A 01	Aminosalicic acid
G 03 D C 01	Allylestrenol	C 01 B D 01	Amiodarone
A 02 A D 03	Almagate	N 05 A L 05	Amisulpride
A 02 A D 03	Almasilate	N 06 A A 09	Amitriptyline
M 01 A E 16	Alminoprofen	N 06 C A 01	Amitriptyline and psycholeptics
R 07 A B 07	Almitrine	A 01 A D 07	Amlexanox
N 02 C C 05	Almotriptan	R 03 D X 01	Amlexanox
A 10 B H 04	Alogliptin	C 08 C A 01	Amlodipine
A 02 A B 06	Aloglutamol	B 05 X A 04	Ammonium chloride
A 03 A E 01	Alosetron	G 04 B A 01	Ammonium chloride
B 01 A C 15	Aloxiprin	N 05 C A 02	Amobarbital
N 02 B A 02	Aloxiprin	P 01 B A 06	Amodiaquine
N 05 B A 12	Alprazolam	D 01 A E 16	Amorolfine
C 07 A A 01	Alprenolol	N 06 A A 17	Amoxapine
C 01 E A 01	Alprostadil	J 01 C A 04	Amoxycillin
G 04 B E 01	Alprostadil	J 01 C R 02	Amoxycillin and enzyme inhibitor
V 04 C H 04	Alsactide	A 01 A B 04	Amphotericin B
B 01 A D 02	Alteplase	A 07 A A 07	Amphotericin B
S 01 X A 13	Alteplase	G 01 A A 03	Amphotericin B
R 05 C A 05	Althea root	J 02 A A 01	Amphotericin B
C 03 E A 04	Altizide and potassium-sparing agents	J 01 C A 01	Ampicillin
L 01 X X 03	Altretamine	S 01 A A 19	Ampicillin
S 01 X A 07	Alum	J 01 C R 01	Ampicillin and enzyme inhibitor
A 02 A B 05	Aluminium acetoacetate	J 01 C A 51	Ampicillin, combinations
S 02 A A 04	Aluminium acetotartrate	J 05 A E 05	Amprenavir
D 10 A X 01	Aluminium chloride	C 01 C E 01	Amrinone
D 09 A A 08	Aluminium Chlorohydrate	L 01 D B 10	Amrubicin
M 05 B X 02	Aluminium Chlorohydrate	L 01 X X 01	Amsacrine
C 10 A B 03	Aluminium clofibrate	V 03 A B 22	Amyl nitrite
A 02 A B 07	Aluminium glycinate	L 01 X X 35	Anagrelide
A 02 A B 01	Aluminium hydroxide	L 04 A C 03	Anakinra
C 10 A D 04	Aluminium nicotinate	S 02 D A	Analgesics and anesthetics
D 10 A X 04	Aluminium oxide	L 02 B G 03	Anastrozole
A 02 A B 03	Aluminium phosphate	L 03 A A 12	Ancestim
C 05 A X 01	Aluminium preparations	B 01 A D 09	Ancrod
A 03 A X 08	Alverine	A 14 A A 01	Androstanolone
A 03 A X 58	Alverine, combinations	G 03 B B 02	Androstanolone
A 06 A H 02	Alvimopan	S 01 X A 16	Anecortave
N 04 B B 01	Amantadine	A 16 A X 02	Anethole trithione
R 02 A A 01	Ambazone	C 09 D B	Angiotensin II anatagonists and calcium channel blockers
N 07 A A 30	Ambenonium	C 09 D X	Angiotensin II anatagonists, other combinations
C 02 K X 02	Ambriesentan	C 01 C X 06	Angiotensinamide
R 05 C B 06	Ambroxol	J 02 A X 06	Anidulafungin
A 03 C A 07	Ambutonium and psycholeptics	N 01 A H 05	Anileridine
D 07 A C 11	Amcinonide	V 01 A A 11	Animals
C 01 C A 25	Amezinium metilsulfate	N 06 B X 11	Aniracetam
A 08 A A 03	Amfepramone	B 01 A D 03	Anistreplase
N 06 B A 01	Amfetamine	A 02 A X	Antacids, other combinations
N 07 X X 05	Amifampridine	R 01 A C 04	Antazoline
V 03 A F 05	Amifostine	R 06 A X 05	Antazoline
D 06 A X 12	Amikacin	J 07 A C 01	Anthrax antigen
J 01 G B 06	Amikacin	D 06 A X	Antibiotics for topical use, other
S 01 A A 21	Amikacin	S 01 A A 20	Antibiotics in combination with other drugs
C 03 D B 01	Amiloride	J 06 B B 01	Anti-D (Rh) immunoglobulin
N 06 A A 19	Amineptine	A 02 D A	Antiflatulents
B 05 B A 01	Amino acids	H 01 C B	Antigrowth hormones
N 03 A B 03	Amino (diphenylhydantoin) valeric acid	D 11 A A	Antihidrotics
D 08 A A 02	Aminoacridine	S 03 A A	Antiinfectives
D 02 B A 01	Aminobenzoic acid	S 02 A A 30	Antiinfectives, combinations
N 03 A G 03	Aminobutyric acid	S 03 A A 30	Antiinfectives, combinations
B 02 A A 01	Aminocaproic acid	L 04 A A 03	Antilymphocyte immunoglobulin (horse)
L 02 B G 01	Aminoglutethimide	R 05 C A 07	Antimony pentasulfide
V 04 C H 30	Aminohippuric acid	D 04 A X	Antipruritics, other

B 01 A B 02 Antithrombin III
 L 04 A A 04 Antithymocyte immunoglobulin (rabbit)
 G 04 B E 07 Apomorphine
 N 04 B C 07 Apomorphine
 S 01 E A 03 Apraclonidine
 A 04 A D 12 Aprepitant
 C 01 B B 04 Aprindine
 N 05 C A 05 Aprobarbital
 N 05 C M 12 Apronal
 B 02 A B 01 Aprotinin
 J 01 G B 12 Arbekacin
 C 01 C A 22 Arbutamine
 B 01 A E 03 Argatroban
 A 05 B A 01 Arginine glutamate
 B 05 X B 01 Arginine hydrochloride
 H 01 B A 06 Argipressin
 N 05 A X 12 Aripiprazole
 L 01 X X 27 Arsenic trioxide
 P 01 A R 01 Arsthinol
 P 01 B E 02 Artemether
 P 01 B F 01 Artemether and lumefantrine
 P 01 B E 01 Artemisinin
 P 01 B E Artemisinin and derivatives, plain
 P 01 B F Artemisinin and derivatives, combinations
 P 01 B E 04 Artemotil
 P 01 B E 05 Artenimol
 P 01 B F 05 Artenimol and piperazine
 P 01 B E 03 Artesunate
 P 01 B F 03 Artesunate and amodiaquine
 P 01 B F 02 Artesunate and mefloquine
 P 01 B F 06 Artesunate and pyronaridine
 P 01 B F 04 Artesunate, sulphamethopyrazine and pyrimethamine
 N 01 B B 08 Articaïne
 N 01 B B 58 Articaïne, combinations
 S 01 X A 20 Artificial tears and other indifferent preparations
 G 01 A D 03 Ascorbic acid
 S 01 X A 15 Ascorbic acid
 A 11 G A 01 Ascorbic acid (vit C)
 A 11 G B 01 Ascorbic acid (vit C) and calcium
 N 05 A H 05 Asenapine
 L 01 X X 02 Asparaginase
 J 01 C A 19 Aspoxicillin
 R 06 A X 11 Astemizole
 J 05 A E 08 Atazanavir
 C 07 A B 03 Atenolol
 C 07 F B 03 Atenolol and other hypertensives
 C 07 C B 03 Atenolol and other diuretics
 C 07 C B 53 Atenolol and other diuretics, combinations
 C 07 B B 03 Atenolol and thiazides
 C 07 D B 01 Atenolol, thiazides and other diuretics
 N 06 B A 09 Atomoxetine
 C 10 A A 05 Atorvastatin
 C 10 B X 03 Atorvastatin and amlodipine
 G 02 C X 01 Atosiban
 P 01 A X 06 Atovaquone
 M 03 A C 04 Atracurium
 A 03 B A 01 Atropine
 S 01 F A 01 Atropine
 A 03 C B 03 Atropine and psycholeptics
 A 07 B C 04 Attapulgit
 A 07 B C 54 Attapulgit, combinations
 M 01 C B 03 Auranofin
 M 01 C B 04 Aurothioglucose
 M 01 C B 05 Aurotioprol
 M 01 A X 26 Avocado and soyabean, unsaponifiables
 L 01 X E 17 Axitinib
 L 01 B C 07 Azacitadine
 G 01 A F 13 Azanidazole
 P 01 A B 04 Azanidazole
 C 04 A X 30 Azapetine
 M 01 A X 04 Azapropazone

R 06 A X 09 Azatadine
 L 04 A X 01 Azathioprine
 D 10 A X 03 Azelaic acid
 R 01 A C 03 Azelastine
 R 06 A X 19 Azelastine
 S 01 G X 07 Azelastine
 S 01 A A 25 Azidamfenicol
 J 01 C E 04 Azidocillin
 C 09 C A 09 Azilsartan medoxomil
 J 01 F A 10 Azithromycin
 S 01 A A 26 Azithromycin
 J 01 C A 09 Azlocillin
 J 01 D F 01 Aztreonam

B

J 01 C A 06 Bacampicillin
 D 06 A X 05 Bacitracin
 J 01 X X 10 Bacitracin
 R 02 A B 04 Bacitracin
 M 03 B X 01 Baclofen
 J 07 A X Bacterial vaccines, other
 A 07 E C 04 Balsalazide
 R 03 C C 12 Bambuterol
 C 04 A A 31 Bamethan
 R 03 D A 08 Bamifylline
 D 04 A A 15 Bamipine
 R 06 A X 01 Bamipine
 N 03 A A 04 Barbexaclone
 N 05 C A 04 Barbitol
 N 05 C B 02 Barbituates in combination with other drugs
 V 08 B A 01 Barium sulphate with suspending agents
 V 08 B A 02 Barium sulphate without suspending agents
 C 08 C A 12 Barnidipine
 L 04 A C 02 Basiliximab
 B 02 B X 03 Batroxobin
 G 03 X C 02 Bazedoxifene
 L 03 A X 03 BCG vaccine
 D 03 A X 06 Becaplermin
 A 01 A D 08 Becaplermin
 N 03 A X 30 Beclamide
 A 07 E A 07 Beclometasone
 D 07 A C 15 Beclometasone
 R 01 A D 01 Beclometasone
 R 03 B A 01 Beclometasone
 D 07 C C 04 Beclometasone and antibiotics
 S 01 E D 06 Befunolol
 J 01 G B 13 Bekanamycin
 L 04 A A 28 Belatacept
 L 04 A A 26 Belimumab
 A 03 B B Belladonna alkaloids, semisynthetic quarter ammonium compounds
 A 03 B A Belladonna alkaloids, tertiary amines
 A 03 B A 04 Belladonna total alkaloids
 A 03 C B 02 Belladonna total alkaloids and psycholeptics
 R 07 A B 05 Bemegride
 B 01 A B 12 Bemiparin
 C 09 A A 07 Benazepril
 C 09 B A 07 Benazepril and diuretics
 C 04 A X 11 Bencyclane
 L 01 A A 09 Bendamustine
 M 02 A A 11 Bendazac
 S 01 B C 07 Bendazac
 C 03 A A 01 Bendroflumethiazide
 C 03 A B 01 Bendroflumethiazide and potassium
 C 03 E A 13 Bendroflumethiazide and potassium-sparing agents
 A 10 B X 06 Benfluorex
 A 11 D A 03 Benfotiamine
 C 08 C A 15 Benidipine
 N 02 B A 10 Benorylate
 M 01 A E 06 Benoxaprofen

N 05 A D 07	Benperidol	A 03 A B 13	Bevonium
R 05 D B 02	Benproperine	A 03 D A 03	Bevonium and analgesics
V 04 C K 03	Bentiramide	A 03 C A 06	Bevonium and psycholeptics
D 08 A J 01	Benzalkonium	L 01 X X 25	Bexarotene
D 09 A A 11	Benzalkonium	C 10 A B 02	Bezafibrate
R 02 A A 16	Benzalkonium	N 02 A C 05	Bezitramide
J 01 C E 08	Benzathine benzylpenicillin	J 01 D H 05	Biapenem
J 01 C E 10	Benzathine phenoxymethylpenicillin	R 05 D B 12	Bibenzonium bromide
N 04 A C 01	Benzatropine	S 01 A X 05	Bibrocatol
M 04 A B 03	Benzbromarone	L 02 B B 03	Bicalutamide
R 02 A A 09	Benzethonium	C 02 A A 07	Bietaserpine
D 08 A J 08	Benzethonim chloride	C 02 L A 07	Bietaserpine and diuretics
D 08 A J 58	Benzethonium chloride, combinations	C 02 A A 57	Bietaserpine, combinations
A 03 A B 01	Benzilone	N 06 A X 08	Bifemelane
C 01 D X 04	Benziodarone	D 01 A C 10	Bifonazole
C 01 D X 54	Benziodarone, combinations	D 01 A C 60	Bifonazole, combinations
P 01 C A 02	Benznidazole	R 06 A X 29	Bilastine
C 05 A D 03	Benzocaine	S 01 E E 03	Bimatoprost
D 04 A B 04	Benzocaine	P 03 A C 02	Bioallethrin
N 01 B A 05	Benzocaine	P 03 A C 52	Bioallethrin, combinations
R 02 A D 01	Benzocaine	A 11 H A 05	Biotin
N 05 B D 01	Benzocetamine	N 04 A A 02	Biperiden
D 09 A A 05	Benzododecinium	D 08 A E 06	Biphenylol
R 05 D B 01	Benzonate	A 06 A B 02	Bisacodyl
A 01 A B 14	Benzoxonium chloride	A 06 A G 02	Bisacodyl
D 08 A J 05	Benzoxonium chloride	A 06 A B 52	Bisacodyl, combinations
D 10 A E 01	Benzoyl peroxide	C 05 A X 02	Bismuth preparations, combinations
D 10 A E 51	Benzoyl peroxide, combinations	A 02 B X 05	Bismuth subcitrate
A 01 A D 02	Benzydamine	A 02 B D 08	Bismuth subcitrate, tetracycline and metronidazole
G 02 C C 03	Benzydamine	A 02 B X 12	Bismuth subnitrate
M 01 A X 07	Benzydamine	C 07 A B 07	Bisoprolol
M 02 A A 05	Benzydamine	C 07 B B 07	Bisoprolol and thiazides
P 03 A X 01	Benzyl benzoate	C 07 F B 07	Bisoprolol and other antihypertensives
J 01 C E 01	Benzylpenicillin	C 07 A B 57	Bisoprolol, combinations
S 01 A A 14	Benzylpenicillin	A 06 A B 09	Bisoxatin
H 03 B A 03	Benzylthiouracil	D 10 A B 01	Bithionol
P 02 C X 02	Bephenium	P 02 B X 01	Bithionol
C 08 E A 02	Bepriidil	R 03 A C 17	Bitolterol
B 01 A C 19	Beraprost	B 01 A E 06	Bivalirudin
D 05 B A 03	Bergapten	L 01 D C 01	Bleomycin
S 01 A X 23	Besifloxacin	B 05 A X 03	Blood plasma
A 11 C A 02	Betacarotene	C 07 A A 17	Bopindolol
D 02 B B 01	Betacarotene	C 07 C A 17	Bopindolol and other diuretics
N 07 C A 01	Betahistine	S 02 A A 03	Boric acid
A 16 A A 06	Betaine	N 04 A A 11	Bornaprine
A 09 A B 02	Betaine hydrochloride	L 01 X X 32	Bortezomib
A 07 E A 04	Betamethasone	C 02 K X 01	Bosentan
C 05 A A 05	Betamethasone	L 01 X E 14	Bosutinib
D 07 A C 01	Betamethasone	J 06 A A 04	Botulinum antitoxin
D 07 X C 01	Betamethasone	M 03 A X 01	Botulinum toxin
H 02 A B 01	Betamethasone	L 01 X C 12	Brentuximab vedotin
R 01 A D 06	Betamethasone	C 01 B D 02	Bretylum tosilate
R 03 B A 04	Betamethasone	L 04 A C 09	Briakinumab
S 01 B A 06	Betamethasone	S 01 E A 05	Brimonidine
S 01 C B 04	Betamethasone	B 01 A D 06	Brinase
S 02 B A 07	Betamethasone	S 01 E C 04	Brinzolamide
S 03 B A 03	Betamethasone	J 05 A B 15	Brivudine
D 07 C C 01	Betamethasone and antibiotics	J 01 E A 02	Brodiprim
S 01 C A 05	Betamethasone and antiinfectives	N 05 B A 08	Bromazepam
S 03 C A 06	Betamethasone and antiinfectives	R 06 A A 01	Bromazine
D 07 B C 01	Betamethasone and antiseptics	B 06 A A 11	Bromelains
S 01 B B 04	Betamethasone and mydriatics	S 01 B C 11	Bromfenac
C 02 C C 01	Betanidine	R 05 C B 02	Bromhexine
C 07 A B 05	Betaxolol	N 05 C M 11	Bromides
S 01 E D 02	Betaxolol	N 05 C M 03	Bromisoval
S 01 E D 52	Betaxolol, combinations	D 01 A E 01	Bromochlorosalicylanilide
V 04 C G 02	Betazole	G 02 C B 01	Bromocriptine
N 07 A B 02	Bethanechol	N 04 B C 01	Bromocriptine
L 01 X C 07	Bexacizumab	A 03 F A 04	Bromopride
C 07 A B 06	Bexantolol	N 05 A D 06	Bromperidol
C 07 B B 06	Bevantolol and thiazides	R 06 A B 01	Brompheniramine

R 06 A B 51	Brompheniramine, combinations	A 11 C C 04	Calcitriol
N 05 C D 09	Brotizolam	D 05 A X 03	Calcitriol
A 07 A X 01	Broxyquinoline	A 12 A A	Calcium
G 01 A C 06	Broxyquinoline	A 12 A A 20	Calcium (different salts in combination)
P 01 A A 01	Broxyquinoline	V 03 A E 04	Calcium acetate and magnesium carbonate
J 07 A D 01	Brucella antigen	A 12 A A 12	Calcium acetate anhydrous
N 02 B E 04	Bucetin	B 02 B C 08	Calcium alginate
N 02 B E 54	Bucetin, combinations excl. psycholeptics	J 04 A A 03	Calcium aminosalicilate
N 02 B E 74	Bucetin, combinations with psycholeptics	N 07 B B 02	Calcium carbimide
M 01 C C 02	Bucillamine	A 02 A C 01	Calcium carbonate
C 01 C E 04	Bucladesine	A 12 A A 04	Calcium carbonate
R 06 A E 01	Bucizine	A 12 A A 07	Calcium chloride
R 06 A E 51	Bucizine, combinations	B 05 X A 07	Calcium chloride
A 07 E A 06	Budesonide	G 04 B A 03	Calcium chloride
D 07 A C 09	Budesonide	A 12 A A 09	Calcium citrate lysine complex
R 01 A D 05	Budesonide	A 12 A X	Calcium, combinations with vitamin D and/or other drugs
R 03 B A 02	Budesonide	A 07 X A 03	Calcium compounds
N 04 B X 03	Budipine	C 05 B X 01	Calcium dobesilate
M 01 A B 17	Bufexamac	C 05 B X 51	Calcium dobesilate, combinations
M 02 A A 09	Bufexamac	V 03 A F 03	Calcium folinate
C 04 A X 20	Buflomedil	A 12 A A 02	Calcium glubionate
A 10 B A 03	Buformin	A 12 A A 10	Calcium glucoheptonate
R 03 D A 10	Bufliline	A 12 A A 03	Calcium gluconate
M 01 A B 07	Bumadizone	D 11 A X 03	Calcium gluconate
C 03 C A 02	Bumetanide	A 12 A A 08	Calcium glycerylphosphate
C 03 C B 02	Bumetanide and potassium	R 01 A X 01	Calcium hexamine thiocyanate
C 03 E B 02	Bumetanide and potassium-sparing agents	V 08 A C 10	Calcium iopodate
C 01 B D 03	Bunaftine	A 12 A A 05	Calcium lactate
C 04 A A 02	Buphenine	A 12 A A 06	Calcium lactate gluconate
G 02 C A 02	Buphenine	A 12 A A 30	Calcium laevulate
N 01 B B 01	Bupivacaine	V 03 A F 04	Calcium levofolinate
N 01 B B 51	Bupivacaine, combinations	A 12 A A 11	Calcium pangamate
C 07 A A 19	Bupranolol	A 11 H A 31	Calcium pantothenate
N 02 A E 01	Buprenorphine	D 03 A X 04	Calcium pantothenate
N 07 B C 01	Buprenorphine	A 12 A A 01	Calcium phosphate
N 07 B C 51	Buprenorphine, combinations	A 02 A C 02	Calcium silicate
N 06 A X 12	Bupropion	N 05 B A 15	Camazepam
L 02 A E 01	Buserelin	B 02 A B 04	Camostat
N 05 B E 01	Buspirone	C 01 E B 02	Camphora
L 01 A B 01	Busulfan	A 03 A A 03	Camylofin
C 04 A X 23	Butalamine	A 03 D A 05	Camylofin and analgesics
R 05 D B 13	Butamirate	C 09 C A 06	Candesartan
N 01 B B 05	Butanilcaine	C 09 D A 06	Candesartan and diuretics
N 05 A B 09	Butaperazine	G 01 A A 04	Candicidin
D 01 A E 23	Butenafine	L 04 A C 08	Canakinumab
C 03 E A 14	Butizide and potassium-sparing agents	C 03 D A 03	Canrenone
N 05 C A 03	Butobarbital	L 01 B C 06	Capecitabine
G 01 A F 15	Butoconazole	J 04 A B 30	Capreomycin
N 02 A F 01	Butorphanol	M 02 A B 01	Capsaicin
N 06 A A 15	Butriptyline	N 01 B X 04	Capsaicin
A 03 B B 01	Butylscopolamine	N 05 B B 02	Captodiamine
A 03 D B 04	Butylscopolamine and analgesics	C 09 A A 01	Captopril
		C 09 B A 01	Captopril and diuretics
		N 07 A B 01	Carbachol
		S 01 E B 02	Carbachol
		N 03 A F 01	Carbamazepine
		B 05 B C 02	Carbamide
		D 02 A E 01	Carbamide
		D 02 A E 51	Carbamide, combinations
		B 01 A C 08	Carbasalate calcium
		N 02 B A 15	Carbasalate calcium
		N 02 B A 65	Carbasalate calcium combinations excl. psycholeptics
		B 02 B X 02	Carbazochrome
		J 01 C A 03	Carbenicillin
		A 02 B X 01	Carbenoxolone
		A 02 B X 51	Carbenoxolone, combinations excl. psycholeptics
		A 02 B X 71	Carbenoxolone, combinations with psycholeptics
		H 01 B B 03	Carbetocin
		H 03 B B 01	Carbimazole
		R 06 A A 08	Carbinoxamine
		R 05 C B 03	Carbocisteine
C			
B 06 A C 01	C1 – inhibitor		
L 01 C D 04	Cabazitaxel		
G 02 C B 03	Cabergoline		
N 04 B C 06	Cabergoline		
D 03 A X 01	Cadexomer iodine		
D 11 A C 02	Cadmium compounds		
C 02 D B 04	Cadralazine		
C 01 C A 21	Cafedrine		
N 06 B C 01	Caffeine		
V 04 C G 30	Caffeine and sodium benzoate		
A 11 C C 06	Calcifediol		
D 05 A X 02	Calcipotriol		
D 05 A X 52	Calcipotriol, combinations		
H 05 B A 03	Calcitonin (human synthetic)		
H 05 B A 02	Calcitonin (pork natural)		
H 05 B A 01	Calcitonin (salmon synthetic)		

C 01 D X 05	Carbocromen	J 01 D B 09	Cefradine
B 05 B A 03	Carbohydrates	J 01 D B 11	Cefroxadine
V 03 A N 02	Carbon dioxide	J 01 D D 03	Cefsulodin
A 06 A X 02	Carbon dioxide producing drugs	J 01 D I 02	Ceftaroline fosamil
L 01 X A 02	Carboplatin	J 01 D D 02	Ceftazidime
G 02 A D 04	Carboprost	J 01 D B 12	Ceftazole
L 01 A C 03	Carboquone	J 01 D D 14	Ceftibuten
N 05 C M 04	Carbromal	J 01 D D 07	Ceftizoxime
A 10 B B 06	Carbutamide	J 01 D I 01	Ceftobiprole medocaril
R 03 A C 10	Carbuterol	J 01 D D 04	Ceftriaxone
R 03 C C 10	Carbuterol	J 01 D D 54	Ceftriaxone, combinations
B 05 X A 16	Cardiplegia solutions	J 01 D C 02	Cefuroxime
G 01 A A 08	Carfecillin	J 01 R A 03	Cefuroxime, combinations with other antibacterials
A 16 A A 05	Carglumic acid	L 01 X X 33	Celecoxib
J 01 C A 05	Carindacillin	M 01 A H 01	Celecoxib
N 03 A X 19	Carisbamate	C 07 A B 08	Celiprolol
M 03 B A 02	Carisoprodol	A 07 X A 02	Ceratonia
M 03 B A 52	Carisoprodol, combinations excl. psycholeptics	A 04 A D 02	Cerium oxalate
M 03 B A 72	Carisoprodol, combinations with psycholeptics	C 10 A A 06	Cerivastatin
L 01 B C 04	Carmofur	L 04 A B 05	Certolizumab pegol
L 01 A D 01	Carmustine	V 04 C C 04	Ceruletide
A 03 A X 11	Caroverine	C 04 A X 26	Cetiedil
C 07 A A 15	Carteolol	R 06 A E 07	Cetirizine
S 01 E D 05	Carteolol	D 08 A J 04	Cetrimide
S 01 E D 55	Carteolol, combinations	D 11 A C 01	Cetrimide
J 01 D F 02	Carumonam	D 08 A J 02	Cetrimonium
C 07 A G 02	Carvedilol	R 02 A A 17	Cetrimonium
A 06 A B 07	Cascara	H 01 C C 02	Cetrorelix
A 06 A B 57	Cascara, combinations	L 01 X C 06	Cetuximab
A 04 A D 13	Casopitant	B 05 C A 01	Cetylpyridinium
J 02 A X 04	Casposungin	D 08 A J 03	Cetylpyridinium
A 06 A B 05	Castor oil	D 09 A A 07	Cetylpyridinium
L 01 X C 09	Catamoxomab	R 02 A A 06	Cetylpyridinium
A 08 A A 07	Cathine	N 07 A X 03	Cevimeline
V 04 C G 01	Cation exchange resins	A 05 A A 01	Chenodeoxycholic acid
B 02 B D 11	Catridecacog	P 01 A X 01	Chiniofon
J 01 D B 10	Cefacetrile	N 05 C C 01	Chloral hydrate
J 01 D C 04	Cefaclor	N 05 C C 02	Chloralodol
J 01 D B 05	Cefadroxil	L 01 A A 02	Chlorambucil
J 01 D B 01	Cefalexin	D 06 A X 02	Chloramphenicol
J 01 D B 02	Cefaloridine	D 10 A F 03	Chloramphenicol
J 01 D B 03	Cefalotin	G 01 A A 05	Chloramphenicol
J 01 D C 03	Cefamandole	J 01 B A 01	Chloramphenicol
J 01 D B 08	Cefapirin	S 01 A A 01	Chloramphenicol
J 01 D B 07	Cefatrizine	S 02 A A 01	Chloramphenicol
J 01 D B 06	Cefazedone	S 03 A A 08	Chloramphenicol
J 01 D B 04	Cefazolin	A 03 A X 03	Chlorbenzoxamine
J 01 D C 13	Cefbuperazone	R 06 A E 04	Chlorcyclizine
J 01 D D 17	Cefcapene	N 05 B A 02	Chlordiazepoxide
J 01 D D 15	Cefdinir	A 01 A B 03	Chlorhexidine
J 01 D D 16	Cefditoren	B 05 C A 02	Chlorhexidine
J 01 D E 01	Cefepime	D 08 A C 02	Chlorhexidine
J 01 D D 10	Cefetamet	D 09 A A 12	Chlorhexidine
J 01 D D 08	Cefixime	R 02 A A 05	Chlorhexidine
J 01 D D 05	Cefmenoxime	S 01 A X 09	Chlorhexidine
J 01 D C 09	Cefmetazole	S 02 A A 09	Chlorhexidine
J 01 D C 12	Cefminox	S 03 A A 04	Chlorhexidine
J 01 D D 09	Cefodizime	D 08 A C 52	Chlorhexidine, combinations
J 01 D C 06	Cefonicide	G 03 D B 06	Chlormadinone
J 01 D D 12	Cefoperazone	G 03 A A 15	Chlormadinone and oestrogen
J 01 D D 62	Cefoperazone, combinations	G 03 A B 07	Chlormadinone and oestrogen
J 01 D C 11	Ceforanide	G 03 F B 03	Chlormadinone and oestrogen
J 01 D D 01	Cefotaxime	L 01 A A 05	Chlormethine
J 01 D C 05	Cefotetan	M 03 B B 02	Chlormezanone
J 01 D C 07	Cefotiam	M 03 B B 52	Chlormezanone, combinations excl. psycholeptics
J 01 D C 01	Cefoxitin	M 03 B B 72	Chlormezanone, combinations with psycholeptics
J 01 D E 03	Cefozopran	D 01 A C 04	Chlormidazole
J 01 D D 11	Cefpiramide	A 04 A D 04	Chlorobutanol
J 01 D E 02	Cefpirome	A 04 A D 54	Chlorobutanol, combinations
J 01 D D 13	Cefpodoxime	N 01 A B 02	Chloroform
J 01 D C 10	Cefprozil	S 01 C A 09	Chloroprednisone and antiinfectives

N 01 B A 04	Chlorprocaine	C 09 B A 08	Gilazapril and diuretics
D 04 A A 09	Chloropyramine	C 08 C A 14	Cilnidipine
R 06 A C 03	Chloropyramine	B 01 A C 23	Cilostazol
R 06 A C 53	Chloropyramine, combinations	A 02 B A 01	Cimetidine
P 01 B A 01	Chloroquine	A 02 B A 51	Cimetidine, combinations
C 03 A A 04	Chlorothiazide	A 03 B B 05	Cimetropium bromide
C 03 A B 04	Chlorothiazide and potassium	H 05 B X 01	Cinacalcet
C 03 A H 01	Chlorothiazide, combinations	C 05 A D 04	Cinchocaine
G 03 C A 06	Chlorotrianisene	D 04 A B 02	Cinchocaine
D 08 A E 05	Chloroxylenol	N 01 B B 06	Cinchocaine
R 06 A B 04	Chlorpheniramine	S 01 H A 06	Cinchocaine
R 06 A B 54	Chlorpheniramine, combinations	S 02 D A 04	Cinchocaine
D 01 A E 07	Chlorphenesin	M 04 A C 02	Cinchophen
D 04 A A 34	Chlorphenoxamine	C 01 D X 14	Cinepazet
R 06 A A 06	Chlorphenoxamine	C 04 A X 27	Cinepazide
R 06 A A 56	Chlorphenoxamine, combinations	N 07 C A 02	Cinnarizine
N 05 A A 07	Chlorprothazine	N 07 C A 52	Cinnarizine, combinations
N 05 A A 01	Chlorpromazine	N 05 C D 13	Cinolazepam
A 10 B B 02	Chlorpropamide	J 01 M B 06	Cinoxacin
N 05 A F 03	Chlorprothixene	C 10 A B 08	Ciprofibrate
D 08 A H 02	Chlorquinaldol	J 01 M A 02	Ciprofloxacin
G 01 A C 03	Chlorquinaldol	S 01 A X 13	Ciprofloxacin
P 01 A A 04	Chlorquinaldol	S 02 A A 15	Ciprofloxacin
R 02 A A 11	Chlorquinaldol	S 03 A A 07	Ciprofloxacin
C 03 B A 04	Chlorthalidone	A 03 F A 02	Cisapride
C 03 B B 04	Chlorthalidone and potassium	M 03 A C 11	Cisatracurium
C 03 E A 06	Chlorthalidone and potassium-sparing agents	L 01 X A 01	Cisplatin
A 01 A B 21	Chlortetracycline	N 06 A B 04	Citalopram
D 06 A A 02	Chlortetracycline	N 06 B X 06	Citicoline
J 01 A A 03	Chlortetracycline	A 05 B A 04	Citiolone
S 01 A A 02	Chlortetracycline	A 09 A B 04	Citric acid
M 03 B B 03	Chlorzoxazone	L 01 B B 04	Cladribine
M 03 B B 53	Chlorzoxazone, combinations excl. psycholeptics	J 01 F A 09	Clarithromycin
M 03 B B 73	Chlorzoxazone, combinations with psycholeptics	A 03 F A 06	Clebopride
J 07 A E 51	Cholera, combinations with typhoid vaccine, inactivated, whole cell	P 01 A C 02	Clefamide
J 07 A E 01	Cholera, inactivated, whole cell	D 04 A A 14	Clemastine
J 07 A E 02	Cholera, live attenuated	R 06 A A 04	Clemastine
C 10 A C 01	Cholestyramine	R 06 A A 54	Clemastine, combinations
A 05 A A 03	Cholic acid	R 03 A C 14	Clenbuterol
N 07 A X 02	Choline alfoscerate	R 03 C C 13	Clenbuterol
C 10 A B 11	Choline fenofibrate	C 08 C A 16	Clevudipine
N 02 B A 03	Choline salicylate	J 05 A F 12	Clevudine
R 03 D A 02	Choline theophyllinate	A 03 C A 02	Clidinium and psycholeptics
R 03 D B 02	Choline theophyllinate and adrenergics	D 10 A F 01	Clindamycin
V 03 A B 29	Cholinesterase	J 01 F F 01	Clindamycin
M 09 A X 02	Chondrocytes, autologous	G 01 A A 10	Clindamycin
M 01 A X 25	Chondroitin sulfate	D 10 A F 51	Clindamycin, combinations
M 01 A X 25	Chondrotin sulfate	D 08 A H 30	Clioquinol
B 03 A B 07	Chondroitin sulfate-iron complex	D 09 A A 10	Clioquinol
G 03 G A 08	Choriogonadotropin alfa	P 01 A A 02	Clioquinol
G 03 G A 01	Chorionic gonadotrophin	G 01 A C 02	Clioquinol
V 09 G X 03	Chromium (⁵¹ Cr) chromate labeled cells	S 02 A A 05	Clioquinol
V 09 C X 04	Chromium (⁵¹ Cr) edetate	P 01 A A 52	Clioquinol, Combinations
M 09 A B 01	Chymopapain	N 05 B A 09	Clobazam
B 06 A A 04	Chymotrypsin	A 08 A A 08	Clobenzorex
S 01 K X 01	Chymotrypsin	D 07 A D 01	Clobetasol
C 01 B G 07	Cibenzoline	D 07 C D 01	Clobetasol and antibiotics
D 03 A X	Cicatrizants, other	D 07 A B 01	Clobetasone
R 03 B A 08	Ciclesonide	S 01 B A 09	Clobetasone
C 03 B X 03	Cicletanine	S 01 C A 11	Clobetasone and antiinfectives
P 02 C A 04	Ciclobendazole	R 05 D B 03	Clobutinol
C 04 A C 07	Ciclonicate	D 07 A B 21	Clocortolone
A 03 D A 04	Ciclonium and analgesics	G 01 A X 01	Clodantoin
D 01 A E 14	Ciclopirox	M 05 B A 02	Clodronic acid
G 01 A X 12	Ciclopirox	L 01 B B 06	Clofarabine
L 04 A D 01	Ciclosporin	J 04 B A 01	Clofazimine
S 01 X A 18	Ciclosporin	R 05 D B 10	Clofedanol
J 05 A B 12	Cidofovir	C 03 B A 07	Clofenamide
A 03 A E 03	Cilansetron	C 03 B B 07	Clofenamide and potassium
C 09 A A 08	Cilazapril	P 03 A B 01	Clofenotane
		P 03 A B 51	Clofenotane, combinations

M 01 A A 05	Clofezone	A 02 A C 10	Combinations
M 02 A A 03	Clofezone	A 06 A G 20	Combinations
C 10 A B 01	Clofibrate	A 07 B C 30	Combinations
C 10 A B 10	Clofibrade	A 10 A B 30	Combinations
J 01 X X 03	Clofoctol	A 10 A C 30	Combinations
N 05 C M 02	Clomethiazole	A 10 A D 30	Combinations
N 05 C X 04	Clomethiazole, combinations	A 10 A E 30	Combinations
J 01 C E 07	Clometocillin	A 11 C C 20	Combinations
G 03 G B 02	Clomifene	A 12 B A 30	Combinations
N 06 A A 04	Clomipramine	B 01 A C 30	Combinations
J 01 A A 11	Clomocycline	B 02 B C 30	Combinations
N 03 A E 01	Clonazepam	B 05 B A 10	Combinations
C 02 A C 01	Clonidine	B 05 C A 10	Combinations
N 02 C X 02	Clonidine	B 05 C B 10	Combinations
S 01 E A 04	Clonidine	B 05 C X 10	Combinations
C 02 L C 01	Clonidine and diuretics	C 01 C A 30	Combinations
C 02 L C 51	Clonidine and diuretics, combinations with other drugs	D 01 A A 20	Combinations
C 03 B A 03	Clopamide	D 01 A C 20	Combinations
C 03 B B 03	Clopamide and potassium	D 01 A E 20	Combinations
N 05 A F 02	Clopendthixol	G 03 G A 30	Combinations
R 05 D B 21	Cloperastine	G 04 B E 30	Combinations
B 01 A C 04	Clopidogrel	J 01 C A 20	Combinations
H 02 A B 14	Cloprednol	J 01 C E 30	Combinations
C 07 A A 27	Cloranolol	J 01 E B 20	Combinations
C 03 B A 12	Clorexolone	J 01 E C 20	Combinations
C 03 B A 82	Clorexolone, combinations with psycholeptics	J 01 E D 20	Combinations
B 01 A C 02	Cloricromen	J 05 A F 30	Combinations
C 01 D X 15	Cloridarol	J 06 B B 30	Combinations
B 01 A A 09	Clorindione	J 07 B C 20	Combinations
D 03 B A 02	Clostridiopeptidase	N 01 B B 20	Combinations
D 03 B A 52	Clostridiopeptidase, combinations	R 01 A X 30	Combinations
N 05 A H 06	Clotiapine	R 05 C A 10	Combinations
N 05 B A 21	Clotiazepam	R 05 C B 10	Combinations
A 01 A B 18	Clotrimazole	R 05 D A 20	Combinations
D 01 A C 01	Clotrimazole	R 05 D B 20	Combinations
G 01 A F 02	Clotrimazole	R 07 A A 30	Combinations
J 01 C F 02	Cloxacillin	S 01 H A 30	Combinations
N 05 B A 22	Cloxazolam	S 02 D A 30	Combinations
N 05 A H 02	Clozapine	A 02 A D	Combinations and complexes of aluminium, calcium and magnesium compounds
B 02 B D 04	Coagulation factor IX	N 05 C B 01	Combinations of barbiturates
B 02 B D 01	Coagulation factor IX, II, VII and X in combination	D 07 A B 30	Combinations of corticosteroids
B 02 B D 05	Coagulation factor VII	D 07 X B 30	Combinations of corticosteroids
B 02 B D 02	Coagulation factor VIII	S 01 A A 30	Combinations of different antibiotics
B 02 B D 07	Coagulation factor XIII	B 05 X A 30	Combinations of electrolytes
V 09 X X 01	Cobalt (⁵⁷ Co) cyanocobalamine	G 01 A F 20	Combinations of imidazole derivatives
V 09 X X 02	Cobalt (⁵⁸ Co) cyanocobalamine	H 03 A A 03	Combinations of levothyroxine and liothyronine
B 03 B A 04	Cobamamide	J 01 C R 50	Combinations of penicillins
N 01 B C 01	Cocaine	C 02 A A 03	Combinations of rauwolfia alkaloids
R 02 A D 03	Cocaine	C 02 A A 53	Combinations of rauwolfia alkaloids, combinations
S 01 H A 01	Cocaine	G 01 A E 10	Combinations of sulfonamides
S 02 D A 02	Cocaine	J 01 A A 20	Combinations of tetracyclines
R 05 D A 04	Codeine	R 03 D A 20	Combinations of xanthines
N 02 A A 59	Codeine, combinations excl. psycholeptics	B 06 A C 04	Conestat alfa
N 02 A A 79	Codeine, combinations with psycholeptics	C 03 X A 02	Conivaptan
M 04 A C 01	Colchicine	G 03 C A 57	Conjugated estrogens
A 11 C C 05	Colecalciferol	A 06 A B 20	Contact laxatives in combination
C 10 A C 02	Colesevelam	A 06 A B 30	Contact laxatives in combination with belladonna alkaloids
C 10 A C 02	Colestipol	P 03 A X 02	Copper oleinate
C 10 A C 03	Colextran	V 03 A B 20	Copper sulphate
R 07 A A 01	Colfosceril palmitate	G 01 A X 15	Copper usnate
A 07 A A 10	Colistin	G 03 G A 09	Corifollitropin alfa
J 01 X B 01	Colistin	V 04 C D 04	Corticoreslin
B 02 B C 07	Collagen	H 01 A A 01	Corticotrophin
G 04 B X 11	Collagen	H 02 A B 10	Cortisone
D 11 A X 57	Collagen, combinations	S 01 B A 03	Cortisone
M 09 A B 02	Collagenase clostridium histolyticum	H 02 A B 17	Cortivazol
C 01 L A 50	Combination of rauwolfia alkaloids and diuretics incl. other combinations	R 05 F B 02	Cough suppressants and expectorants
A 01 A A 30	Combinations	R 05 F B 01	Cough suppressants and mucolytics
A 02 A A 10	Combinations	C 01 E B 04	Crataegus glycosides
A 02 A B 10	Combinations	C 01 E B 05	Creatinolfosfate

R 05 C A 08 Creosote
D 03 A X 09 Crilanomer
L 01 X E 16 Crizotinib
A 07 E B 01 Cromoglicic acid
D 11 A H 03 Cromoglicic acid
R 01 A C 01 Cromoglicic acid
R 03 B C 01 Cromoglicic acid
S 01 G X 01 Cromoglicic acid
R 01 A C 51 Cromoglicic acid, combinations
S 01 G X 51 Cromoglicic acid, combinations
A 07 B C 03 Crossoverone
N 05 A A 06 Cyamemazine
B 03 B A 01 Cyanocobalamin
B 03 B A 02 Cyanocobalamin tannin complex
B 03 B A 51 Cyanocobalamin, combinations
C 04 A X 01 Cyclandelate
R 06 A E 03 Cyclizine
R 06 A E 53 Cyclizine, combinations
N 05 C A 10 Cyclobarbitol
M 03 B X 08 Cyclobenzaprine
A 05 A X 03 Cyclobutylol
G 03 G B 01 Cyclofenil
P 01 B B 02 Cycloguanil embonate
R 01 A A 02 Cyclopentamine
C 03 A A 07 Cyclopenthiiazide
C 03 A B 07 Cyclopenthiiazide and potassium
C 03 E A 07 Cyclopenthiiazide and potassium-sparing agents
S 01 F A 04 Cyclopentolate
L 01 A A 01 Cyclophosphamide
J 04 A B 01 Cycloserine
L 04 A A 01 Cyclosporin
C 03 A A 09 Cyclothiazide
C 03 A B 09 Cyclothiazide and potassium
P 03 B A 01 Cyfluthrin
C 01 A C 03 Cymarin
P 03 B A 02 Cypermethrin
R 06 A X 02 Cyproheptadine
G 03 H A 01 Cyproterone
G 03 H B 01 Cyproterone and oestrogen
L 01 B C 01 Cytarabine
J 06 B B 09 Cytomegalovirus immunoglobulin

D

B 01 A E 07 Dabigatran etexilate
L 01 A X 04 Dacarbazine
L 04 A C 01 Daclizumab
L 01 D A 01 Dactinomycin
B 01 A B 04 Dalteparin sodium
J 01 X A 04 Dalbavancin
B 01 A B 09 Danaparoid
G 03 X A 01 Danazol
M 03 C A 01 Dantrolene
A 06 A B 03 Dantron
A 06 A B 53 Dantron, combinations
A 06 A G 03 Dantron, incl. combinations
A 10 B X 09 Dapagliflozin
S 01 E X 02 Dapiprazole
G 04 B X 14 Dapoxetine
J 04 B A 02 Dapsone
D 10 A X 05 Dapsone
J 01 X X 09 Daptomycin
B 03 X A 02 Darbepoetin alfa
G 04 B D 10 Darifenacin
J 05 A E 10 Darunavir
L 01 X E 06 Dasatinib
L 01 D B 02 Daunorubicin
N 06 B X 04 Deanol
C 02 C C 04 Debrisoquine
P 03 B A 03 Decamethrin
L 01 B C 08 Decitabine

V 03 A C 03 Deferasirox
V 03 A C 02 Deferiprone
V 03 A C 01 Deferoxamine
B 01 A X 01 Defibrotide
H 02 A B 13 Deflazacort
L 02 B X 02 Degarelix
C 09 A A 12 Delapril
C 09 B A 12 Delapril and diuretics
C 09 B B 12 Delapril and manidipine
J 05 A G 02 Delavirdine
S 01 E B 04 Demecarium
D 06 A A 01 Demeclocycline
J 01 A A 01 Demeclocycline
L 01 C C 01 Demecolcine
G 03 D B 05 Demegestone
H 01 B B 01 Demoxytocin
L 01 X X 29 Denileukin diftitox
M 05 B X 04 Denosumab
R 06 A X 16 Deptropine
D 08 A H 01 Dequalinium
G 01 A C 05 Dequalinium
R 02 A A 02 Dequalinium
B 01 A X 04 Dermatan sulfate
D 11 A X Dermatologicals, other
P 02 D X 01 Desaspidin
C 02 A A 05 Deserpidine
C 02 L A 03 Deserpidine and diuretics
N 01 A B 07 Desflurane
N 06 A A 01 Desipramine
B 01 A E 01 Desirudin
C 01 A A 07 Deslanoside
R 06 A X 27 Desloratadine
H 01 B A 02 Desmopressin
G 03 A C 09 Desogestrel
G 03 A A 09 Desogestrel and estrogen
G 03 A B 05 Desogestrel and estrogen
G 03 F B 10 Desogestrel and estrogen
D 07 A B 08 Desonide
S 01 B A 11 Desonide
D 07 B B 02 Desonide and antiseptics
D 07 A C 03 Desoximetasone
D 07 X C 02 Desoximetasone
H 02 A A 03 Desoxycortone
B 06 A A 10 Desoxyribonuclease
N 06 A X 23 Desvenlafaxine
A 01 A C 02 Dexamethasone
C 05 A A 09 Dexamethasone
D 07 A B 19 Dexamethasone
D 07 X B 05 Dexamethasone
D 10 A A 03 Dexamethasone
H 02 A B 02 Dexamethasone
R 01 A D 03 Dexamethasone
S 01 B A 01 Dexamethasone
S 01 C B 01 Dexamethasone
S 02 B A 06 Dexamethasone
S 03 B A 01 Dexamethasone
D 07 C B 04 Dexamethasone and antibiotics
S 01 C A 01 Dexamethasone and antiinfectives
S 02 C A 06 Dexamethasone and antiinfectives
S 03 C A 01 Dexamethasone and antiinfectives
R 01 A D 53 Dexamethasone, combinations
N 06 B A 02 Dexamphetamine
R 06 A B 06 Dexbrompheniramine
R 06 A B 56 Dexbrompheniramine, combinations
R 06 A B 02 Dexchlorpheniramine
R 06 A B 52 Dexchlorpheniramine, combinations
N 04 A A 08 Dextimide
A 08 A A 04 Dexfenfluramine
M 01 A E 14 Dexibuprofen
M 01 A E 17 Dextetopofen
A 02 B C 06 Dexlansoprazole

N 05 C M 18	Dexmedetomidine	N 02 A A 58	Dihydrocodeine combinations
N 06 B A 11	Dexmethylphenidate	P 01 A X 09	Dihydroemetine
A 11 H A 30	Dexpanthenol	C 04 A E 04	Dihydroergocristine
D 03 A X 03	Dexpanthenol	C 04 A E 54	Dihydroergocristine, combinations
S 01 X A 12	Dexpanthenol	N 04 B C 03	Dihydroergocryptine mesylate
V 03 A F 02	Dexrazoxane	N 02 C A 01	Dihydroergotamine
B 05 A A 05	Dextran	N 02 C A 51	Dihydroergotamine, combinations
D 03 A X 02	Dextranomer	S 01 A A 15	Dihydrostreptomycin
R 05 D A 09	Dextromethorphan	A 11 C C 02	Dihydrotachysterol
N 02 A C 01	Dextromoramide	A 02 A B 04	Dihydroxialumini sodium carbonate
N 02 A C 04	Dextropropoxyphene	D 08 A G 04	Diiodohydroxypropane
N 02 A C 54	Dextropropoxyphene, excl psycholeptics	G 01 A C 01	Diiodohydroxyquinoline
N 02 A C 74	Dextropropoxyphene, with psycholeptics	H 03 B X 01	Diiodotyrosine
C 10 A X 01	Dextrothyroxine	A 03 A X 02	Diisopromine
N 02 A X 03	Dezocine	C 01 D X 10	Dilazep
M 01 A X 21	Diacerin	P 01 A C 01	Diloxanide
N 02 A A 09	Diamorphine	C 08 D B 01	Diltiazem
A 09 A A 01	Diastase	D 01 A E 17	Dimazole
V 08 A A 01	Diatrizoic acid	R 07 A B 08	Dimefline
N 05 B A 01	Diazepam	R 05 D A 11	Dimemorfan
V 03 A H 01	Diazoxide	V 03 A B 09	Dimercaprol
C 02 D A 01	Diazoxide	N 06 A A 18	Dimetacrine
J 01 G B 09	Dibekacin	P 03 A X 05	Dimeticone
N 06 A A 08	Dibenzepin	R 05 D B 28	Dimethoxanate
M 05 B C 01	Diboterin alfa	G 04 B X 13	Dimethyl sulfoxide
H 03 B X 02	Dibromotyrosine	M 02 A X 03	Dimethyl sulfoxide
D 08 A C 01	Dibrompropamide	A 03 A C 02	Dimethylaminoprop-ionylphenothiazine
S 01 A X 14	Dibrompropamide	P 03 B X 05	Dimethylcarbate
R 05 D B 16	Dibunate	P 03 B X 02	Dimethylphthalate
P 03 B X 03	Dibutylphthalate	M 03 A A 04	Dimethyltubocurarine
P 03 B X 04	Dibutylsuccinate	D 04 A A 13	Dimetindene
N 05 C C 04	Dichloralphenazone	R 06 A B 03	Dimetindene
R 02 A A 03	Dichlorobenzyl alcohol	C 01 C A 12	Dimetofrine
P 02 D X 02	Dichlorophen	N 02 C X 05	Dimetotiazine
D 11 A X 18	Diclofenac	G 02 A D 01	Dinoprost
M 01 A B 05	Diclofenac	G 02 A D 02	Dinoprostone
M 02 A A 15	Diclofenac	V 08 A A 10	Diodone
S 01 B C 03	Diclofenac	A 07 B C 05	Diosmectite
S 01 C C 01	Diclofenac and antiinfectives	C 05 C A 03	Diosmin
M 01 A B 55	Diclofenac, combinations	C 05 C A 53	Diosmin, combinations
S 01 E C 02	Diclofenamide	A 03 A B 15	Diphemanil
J 01 C F 01	Dicloxacillin	A 03 C A 08	Diphemanil and psycholeptics
J 05 A F 02	Didanosine	B 01 A A 10	Diphenadione
G 03 C B 01	Dienestrol	D 04 A A 32	Diphenhydramine
G 03 C C 02	Dienestrol	R 06 A A 02	Diphenhydramine
G 03 D B 08	Dienogest	D 04 A A 33	Diphenhydramine methylbromide
G 03 A B 08	Dienogest and oestrogen	R 06 A A 52	Diphenhydramine, combinations
P 02 C B 02	Diethylcarbamazine	A 07 D A 01	Diphenoxylate
G 03 C B 02	Diethylstilbestrol	R 06 A A 07	Diphenylpyraline
G 03 C C 05	Diethylstilbestrol	R 06 A A 57	Diphenylpyraline, combinations
L 02 A A 01	Diethylstilbestrol	J 06 A A 01	Diphtheria antitoxin
P 03 B X 01	Diethyltoluamide	J 07 C A 13	Diphtheria-haemophilus influenzae B-pertussis-tetanus-hepatitis B-meningococcus A + C
A 03 A A 09	Difemerine	J 06 B B 10	Diphtheria immunoglobulin
A 07 D A 04	Difenoxin	J 07 A F 01	Diphtheria toxoid
M 01 A B 12	Difenpiramide	J 07 C A 06	Diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus
P 01 A R 02	Difetarosone	J 07 C A 09	Diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B
D 07 A C 10	Diflorasone	J 07 C A 11	Diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B
D 07 A C 06	Diflucortolone	J 07 C A 05	Diphtheria-hepatitis B-pertussis-tetanus
D 07 X C 04	Diflucortolone	J 07 C A 07	Diphtheria-hepatitis B-tetanus
D 07 B C 04	Diflucortolone and antiseptics	J 07 C A 02	Diphtheria-pertussis-poliomyelitis-tetanus
N 02 B A 11	Diflunisal	J 07 C A 12	Diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B
D 07 A C 19	Difluprednate	J 07 C A 01	Diphtheria-poliomyelitis-tetanus
V 03 A B 24	Digitalis antitoxin	J 07 C A 03	Diphtheria-rubella-tetanus
C 01 A A 03	Digitalis leaves	N 05 C X 06	Dipiperonylaminoethanol, combinations
C 01 A A 04	Digitoxin	S 01 E A 02	Dipivefrine
C 01 A A 05	Digoxin	R 03 D A 01	Diprophylline
A 03 A A 08	Dihexyverine	R 03 D B 01	Diprophylline and adrenergics
C 02 D B 01	Dihydralazine	R 03 D A 51	Diprophylline, combinations
C 02 L G 01	Dihydralazine and diuretics		
C 02 L G 51	Dihydralazine and diuretics, combinations with other drugs		
N 02 A A 08	Dihydrocodeine		

B 01 A C 07	Dipyridamole
N 02 B A 09	Dipyrocetyl
M 01 B A 02	Dipyrocetyl and corticosteroids
N 02 B A 59	Dipyrocetyl, combinations excluding psycholeptics
N 02 B A 79	Dipyrocetyl, combinations with psycholeptics
J 01 F A 13	Dirithromycin
C 01 B A 03	Disopyramide
N 07 A A 03	Distigmine
N 07 B B 01	Disulfiram
P 03 A A 04	Disulfiram
P 03 A A 54	Disulfiram, combinations
B 01 A C 01	Ditazole
D 05 A C 01	Dithranol
D 05 A C 51	Dithranol, combinations
P 03 A A 01	Dixanthogen
N 05 A B 01	Dixyrazine
C 01 C A 07	Dobutamine
L 01 C D 02	Docetaxel
D 06 B B 11	Docosanol
A 06 A A 02	Docusate sodium
A 06 A G 10	Docusate sodium, including combinations
D 08 A J 59	Dodeclonium bromide, combinations
C 01 B D 04	Dofetilide
A 04 A A 04	Dolasetron
R 05 C B 08	Domiodol
A 01 A B 06	Domiphen
A 03 F A 03	Domperidone
N 06 D A 02	Donepezil
N 06 D A 52	Donepezil and memantine
C 01 C A 04	Dopamine
C 01 C A 14	Dopexamine
J 01 D H 04	Doripenem
R 05 C B 13	Dornase alfa (desoxyribonuclease)
S 01 E C 03	Dorzolamide
N 06 A A 16	Dosulepin
M 03 A C 07	Doxacurium chloride
R 07 A B 01	Doxapram
C 02 C A 04	Doxazosin
H 05 B X 03	Doxercalciferol
N 05 C D 12	Doxefazepam
N 06 A A 12	Doxepin
R 03 D A 11	Doxofylline
L 01 D B 01	Doxorubicin
A 01 A B 22	Doxycycline
J 01 A A 02	Doxycycline
R 06 A A 09	Doxylamine
R 06 A A 59	Doxylamine, combinations
A 04 A D 10	Dronabinol
C 01 B D 07	Dronedarone
N 01 A X 01	Droperidol
N 05 A D 08	Droperidol
R 05 D B 19	Dropropizine
G 03 A A 12	Drospirenone and estrogen
G 03 F A 17	Drospirenone and estrogen
A 03 A D 02	Drotaverine
B 01 A D 10	Drotrecogin alfa (activated)
M 01 A C 04	Droxicam
R 05 D B 17	Droxypropine
V 03 A G	Drugs for treatment of hypercalcemia
B 06 A C	Drugs used in hereditary angioedema
N 06 A X 21	Duloxetine
G 04 C B 02	Dutasteride
N 01 B X 02	Dyclonine
R 02 A D 04	Dyclonine
G 03 D B 01	Dydrogesterone
G 03 F A 14	Dydrogesterone and estrogen
G 03 F B 08	Dydrogesterone and estrogen
V 10 A X 03	Dysprosium (¹⁶⁵ DY) colloid
E	
R 06 A X 22	Ebastine
B 06 A C 03	Ecallantide
D 01 A C 03	Econazole
G 01 A F 05	Econazole
S 01 E B 03	Ecothiopate
L 04 A A 25	Ecuzumab
V 03 A B 03	Edetates
D 06 B B 09	Edoxudine
L 01 X C 01	Edrecolomab
L 04 A A 21	Efalizumab
L 01 X D 06	Efaproxiral
J 05 A G 03	Efavirenz
D 11 A X 16	Eflornithine
P 01 C X 03	Eflornithine
C 01 D X 13	Efloxate
H 05 B A 04	Elcatonin
B 05 B B 01	Electrolytes
B 05 X A 31	Electrolytes in combination with other drugs
B 05 B B 02	Electrolytes with carbohydrates
N 02 C C 06	Eletriptan
B 02 B X 05	Eltrombopag
S 01 G X 06	Emedastine
G 04 B D 01	Emepromium
A 03 C A 30	Emepromium and psycholeptics
N 05 C X 05	Emepromium, combinations
G 03 A D	Emergency contraceptives
P 01 A X 02	Emetine
P 01 A X 52	Emetine, combinations
D 02 A X	Emollients and protectives, other
J 05 A F 09	Emtricitabine
J 05 A R 06	Emtricitabine, tenofovir disoproxil and efavirenz
J 05 A R 08	Emtricitabine, tenofovir disoproxil and rilpivirine
N 05 B C 03	Emylcamate
C 09 A A 02	Enalapril
C 09 B A 02	Enalapril and diuretics
C 09 B B 02	Enalapril and lercanidipine
C 09 B B 06	Enalapril and nitrendipine
C 01 B C 08	Encainide
J 07 B A 02	Encephalitis, Japanese, inactivated, whole virus
J 06 B B 12	Encephalitis, tick borne immunoglobulin
J 07 B A 01	Encephalitis, tick borne, inactivated, whole virus
C 02 D B 03	Endralazine
N 01 A B 04	Enflurane
J 05 A X 07	Enfuvirtide
J 01 M A 04	Enoxacin
B 01 A B 05	Enoxaparin
C 01 C E 03	Enoximone
D 03 A X 10	Enoxolone
A 02 B B 02	Enprostil
N 04 B X 02	Entacapone
J 05 A F 10	Entecavir
L 02 B G	Enzyme inhibitors
D 08 A X 02	Eosin
C 07 A B 10	Epanolol
M 03 B X 09	Eperisone
C 01 C A 26	Ephedrine
R 01 A A 03	Ephedrine
R 01 A B 05	Ephedrine
R 03 C A 02	Ephedrine
S 01 F B 02	Ephedrine
A 08 A A 56	Ephedrine, combinations
J 01 C A 07	Epicillin
G 03 G B 03	Epimestrol
R 06 A X 24	Epinastine
S 01 G X 10	Epinastine
A 01 A D 01	Epinephrine
B 02 B C 09	Epinephrine
C 01 C A 24	Epinephrine
R 01 A A 14	Epinephrine
R 03 A A 01	Epinephrine

S 01 E A 01	Epinephrine	N 02 B A 77	Ethenzamide, combinations with psycholeptics
R 03 A K 01	Epinephrine and other drugs for obstructive airway diseases	G 03 C A 01	Ethinylestradiol
S 01 E A 51	Epinephrine, combinations	L 02 A A 03	Ethinylestradiol
L 01 D B 03	Epirubicin	J 04 A D 03	Ethionamide
C 03 E A 03	Epitizide and potassium-sparing agents	G 03 D C 04	Ethisterone
C 03 D A 04	Eplerenone	G 03 F A 03	Ethisterone and estrogen
A 05 B A 05	Epomediol	N 03 A D 01	Ethosuximide
B 01 A C 09	Epoprostenol	N 03 A D 51	Ethosuximide, combinations
R 05 C B 04	Eprazinone	N 03 A B 01	Ethotoin
C 09 C A 02	Eprosartan	A 06 A C 02	Ethulose
C 09 D A 02	Eprosartan and diuretics	B 01 A A 08	Ethyl biscoumacetate
R 03 D X 02	Eprozinol	N 01 B X 01	Ethyl chloride
B 02 B D 08	Eptacog alfa (activated)	V 08 A D 01	Ethyl esters of iodised fatty acids
B 01 A C 16	Eptifibatide	D 01 A E 10	Ethyl hydroxybenzoate
M 05 B C 02	Eptotermin alfa	N 05 B A 18	Ethyl loflazepate
V 10 A X 04	Erbium (¹⁶⁹ Er) citrate colloid	A 14 A B 02	Ethylestrenol
R 05 C B 15	Erdosteine	R 05 D A 01	Ethylmorphine
A 11 C C 01	Ergocalciferol	S 01 X A 06	Ethylmorphine
C 04 A E 01	Ergoloid mesylates	N 01 B B 07	Etidocaine
C 04 A E 51	Ergoloid mesylates, combinations	N 01 B B 57	Etidocaine, combinations
G 02 A B 03	Ergometrine	M 05 B A 01	Etidronic acid
G 02 A B 02	Ergot alkaloids	M 05 B B 01	Etidronic acid and calcium, sequential
N 02 C A 02	Ergotamine	N 05 B X 03	Etifoxine
N 02 C A 52	Ergotamine, combinations excluding psycholeptics	A 08 A A 06	Etilamfetamine
N 02 C A 72	Ergotamine, combinations with psycholeptics	C 01 C A 01	Etilefrine
L 01 X X 41	Eribulin	C 01 C A 51	Etilefrine, combinations
C 01 D A 13	Erythrityl tetranitrate	N 04 B A 06	Etilevodopa and decarboxylase inhibitor
C 01 D A 63	Erythrityl tetranitrate, combinations	N 05 B A 19	Etizolam
L 01 X E 03	Erlotinib	M 01 A B 08	Etodolac
J 01 D H 03	Ertapenem	P 01 A C 03	Etofamide
B 05 A X 01	Erythrocytes	M 02 A A 06	Etofenamate
D 10 A F 02	Erythromycin	C 10 A B 09	Etofibrate
J 01 F A 01	Erythromycin	C 04 A D 04	Etofilline nicotinate
S 01 A A 17	Erythromycin	L 01 A G 01	Eto glucid
D 10 A F 52	Erythromycin, combinations	P 03 B X 06	Etohexadiol
B 03 X A 01	Erythropoietin	N 01 A X 07	Etomidate
N 06 A B 10	Escitalopram	G 03 A C 08	Etonogestrel
N 01 A X 14	Esketamine	N 06 A B 09	Eto peridone
N 03 A F 04	Eslicarbazepine	L 01 C B 01	Etoposide
C 07 A B 09	Esmolol	M 01 A H 05	Etoricoxib
A 02 B C 05	Esomeprazole	C 03 C X 01	Etozolin
A 02 B D 06	Esomeprazole, amoxicillin and clarithromycin	J 05 A G 04	Etravirine
N 05 C D 04	Estazolam	D 05 B B 01	Etretnate
G 03 C A 03	Estradiol	N 04 A C 30	Etybenzatropine
G 03 C A 53	Estradiol, combinations	G 03 D C 06	Etyndiol
L 01 X X 11	Estramustine	G 03 A A 01	Etyndiol and estrogen
G 03 C A 04	Estriol	G 03 F A 06	Etyndiol and estrogen
G 03 C C 06	Estriol	D 08 A A 03	Euflavine
G 03 C A 07	Estrone	L 04 A A 18	Everolimus
G 03 C C 04	Estrone	L 01 X E 10	Everolimus
N 05 C F 04	Eszopiclone	L 02 B G 06	Exemestane
C 03 C C 01	Etacrynic acid	A 10 B X 04	Exenatide
C 01 D X 07	Etafenone	R 05 C A	Expectorants
N 05 C A 20	Etallobarbital	C 10 A X 09	Ezetimibe
R 03 D A 06	Etamiphylline		
R 03 D B 06	Etamiphylline and adrenergics		
R 07 A B 04	Etamivan		
B 02 B X 01	Etamsylate		
N 04 A B 01	Etanautine		
L 04 A B 01	Etanercept		
B 05 C A 08	Ethacridine lactate		
D 08 A A 01	Ethacridine lactate		
N 03 A C 03	Ethadione		
J 04 A K 02	Ethambutol		
J 04 A M 03	Ethambutol and isoniazid		
D 08 A X 08	Ethanol		
V 03 A B 16	Ethanol		
V 03 A Z 01	Ethanol		
N 05 C M 08	Ethchlorvynol		
N 02 B A 07	Ethenzamide		
N 02 B A 57	Ethenzamide, combinations excluding psycholeptics		
		F	
		B 02 B D 03	Factor VIII inhibitor bypassing activity
		J 05 A B 09	Famciclovir
		S 01 A D 07	Famciclovir
		A 02 B A 03	Famotidine
		A 02 B A 53	Famotidine, combinations
		N 07 X X 07	Fampridine
		C 04 A X 32	Fasudil
		B 05 B A 02	Fat emulsions
		M 03 A C 08	Fazadinium bromide
		V 01 A A 01	Feather
		M 03 B A 05	Febarbamate
		M 04 A A 03	Febuxostat
		R 05 D B 14	Fedrilate
		N 03 A X 10	Felbamate

M 02 A A 08	Felbinac	D 11 A X 10	Finasteride
C 08 C A 02	Felodipine	G 04 C B 01	Finasteride
P 02 C A 06	Fenbendazole	L 04 A A 27	Fingolimod
M 01 A E 05	Fenbufen	N 06 B X 05	Fipexide
N 06 B A 06	Fencamfamin	G 04 B D 02	Flavoxate
C 08 E A 01	Fendiline	C 01 B C 04	Flecainide
N 06 B A 10	Fenetylline	J 01 M A 08	Fleroxacin
A 08 A A 02	Fenfluramine	N 02 B G 04	Floctafenine
C 10 A B 05	Fenofibrate	J 01 D C 14	Flomoxef
C 01 C A 19	Fenoldopam	C 01 D B 01	Flosequinan
M 01 A E 04	Fenoprofen	V 01 A A 10	Flowers
G 02 C A 03	Fenoterol	N 05 A D 09	Fluanisone
R 03 A C 04	Fenoterol	P 02 C A 05	Flubendazole
R 03 C C 04	Fenoterol	D 07 A C 02	Fluclorolone
R 03 A K 03	Fenoterol and other drugs for obstructive airway diseases	J 01 C F 05	Flucloxacillin
A 03 A X 05	Fenoverine	D 01 A C 15	Fluconazole
R 01 A A 12	Fenoxazoline	J 02 A C 01	Fluconazole
N 06 B A 08	Fenozolone	D 01 A E 21	Flucytosine
A 03 A X 01	Fenpiprane	J 02 A X 01	Flucytosine
A 03 A B 21	Fenpiverinium	L 01 B B 05	Fludarabine
C 03 B A 13	Fenquizone	V 09 I X 04	Fludeoxyglucose (¹⁸ F)
R 03 B X 01	Fenspiride	N 05 B A 17	Fludiazepam
R 03 D X 03	Fenspiride	H 02 A A 02	Fludrocortisone
N 01 A H 01	Fentanyl	S 01 C A 06	Fludrocortisone and antiinfectives
N 02 A B 03	Fentanyl	S 02 C A 07	Fludrocortisone and antiinfectives
N 01 A H 51	Fentanyl, combinations	S 03 C A 05	Fludrocortisone and antiinfectives
M 01 A B 10	Fentiazac	D 07 A C 07	Fludroxycortide
M 02 A A 14	Fentiazac	D 07 C C 03	Fludroxycortide and antibiotics
D 01 A C 12	Fenticonazole	M 01 A G 03	Flufenamic acid
G 01 A F 12	Fenticonazole	B 01 A A 12	Fluindione
A 03 B B 04	Fentonium	V 03 A B 25	Flumazenil
M 03 B X 30	Fenylamidol	D 07 A B 03	Flumetasone
M 01 A X 18	Feprazone	D 07 X B 01	Flumetasone
M 02 A A 16	Feprazone	D 07 C B 05	Flumetasone and antibiotics
M 01 A X 68	Feprazone, combinations	S 02 C A 02	Flumetasone and antiinfectives
V 09 X X 04	Ferric (⁵⁹ Fe) citrate	D 07 B B 01	Flumetasone and antiseptics
B 03 A B 08	Ferric acetyl transferring	N 07 C A 03	Flunarizine
V 08 C A 07	Ferric ammonium citrate	R 01 A D 04	Flunisolide
B 03 A B 06	Ferric citrate	R 03 B A 03	Flunisolide
B 03 A B 04	Ferric hydroxide	N 05 C D 03	Flunitrazepam
B 03 A C 06	Ferric oxide dextran complexes	G 02 C C 04	Flunoxaprofen
B 03 A B 05	Ferric oxide polymaltose complexes	M 01 A E 15	Flunoxaprofen
B 03 A C 01	Ferric oxide polymaltose complexes	C 05 A A 10	Fluocinolone acetonide
B 03 A D 04	Ferric oxide polymaltose complexes	S 02 B A 08	Fluocinolone acetonide
B 03 A B 09	Ferric proteinsuccinylate	D 07 A C 04	Fluocinolone acetonide
B 03 A B 01	Ferric sodium citrate	S 01 B A 15	Fluocinolone acetonide
B 03 A C 07	Ferric sodium gluconate complex	D 07 C C 02	Fluocinolone acetonide and antibiotics
B 03 A C 05	Ferric sorbitol gluconic acid complex	S 01 C A 10	Fluocinolone acetonide and antiinfectives
V 08 C B 02	Ferristene	S 02 C A 05	Fluocinolone acetonide and antiinfectives
B 03 A D 01	Ferrous amino acid complex	D 07 B C 02	Fluocinolone acetonide and antiseptics
B 03 A A 10	Ferrous ascorbate	C 05 A A 11	Fluocinonide
B 03 A A 09	Ferrous aspartate	D 07 A C 08	Fluocinonide
B 03 A A 04	Ferrous carbonate	D 07 C C 05	Fluocinonide and antibiotics
B 03 A A 05	Ferrous chloride	D 07 A B 04	Fluocortin
B 03 A A 02	Ferrous fumarate	C 05 A A 08	Fluocortolone
B 03 A D 02	Ferrous fumarate	D 07 A C 05	Fluocortolone
B 03 A A 03	Ferrous gluconate	H 02 A B 03	Fluocortolone
B 03 A A 01	Ferrous glycine sulphate	D 07 C C 06	Fluocortolone and antibiotics
B 03 A A 11	Ferrous iodine	S 01 C A 04	Fluocortolone and antiinfectives
B 03 A A 06	Ferrous succinate	D 07 B C 03	Fluocortolone and antiseptics
B 03 A A 07	Ferrous sulphate	S 01 J A 01	Fluorescein
B 03 A D 03	Ferrous sulphate	S 01 J A 51	Fluorescein, combinations
B 03 A A 08	Ferrous tartrate	A 12 C D 51	Fluoride, combinations
V 08 C B 01	Ferumoxsil	B 05 A A 03	Fluorocarbon blood substitutes
G 04 B D 11	Fesoterodine	V 09 I X 05	Fluorodopa (¹⁸ F)
R 06 A X 26	Fexofenadine	V 09 I X 08	Fluoroethylcholine (18 F)
V 09 G B 01	Fibrinogen (¹²⁵ I)	C 05 A A 06	Fluorometholone
B 02 B C 10	Fibrinogen, human	D 07 A B 06	Fluorometholone
B 01 A D 05	Fibrinolysin	D 07 X B 04	Fluorometholone
B 06 A A 02	Fibrinolysin and desoxyribonuclease	D 10 A A 01	Fluorometholone
L 03 A A 02	Filgrastim	S 01 B A 07	Fluorometholone

S 01 C B 05	Fluorometholone	D 09 A A 02	Fusidic acid
D 07 C B 03	Fluorometholone and antibiotics	J 01 X C 01	Fusidic acid
S 01 C A 07	Fluorometholone and antiinfectives	S 01 A A 13	Fusidic acid
S 01 B B 03	Fluorometholone and mydriatics		
V 09 I X 07	Fluoromethylcholine (18 F)		
L 01 B C 02	Fluorouracil	G	
L 01 B C 52	Fluorouracil, combinations	N 03 A X 12	Gabapentin
S 01 E B 07	Fluostigmine	V 08 C A 08	Gadobenic acid
N 06 A B 03	Fluoxetine	V 08 C A 09	Gadobutrol
G 03 B A 01	Fluoxymesterone	V 08 C A 03	Gadodiamide
N 05 A F 01	Flupentixol	V 08 C A 11	Gadofosveset
D 07 A B 05	Fluperolone	V 08 C A 01	Gadopentetic acid
N 05 A B 02	Fluphenazine	V 08 C A 02	Gadoteric acid
N 02 B G 07	Flupirtine	V 08 C A 04	Gadoteridol
D 07 A B 07	Fluprednidene	V 08 C A 06	Gadoversetamide
D 07 X B 03	Fluprednidene	V 08 C A 10	Gadoxetic acid
D 07 C B 02	Fluprednidene and antibiotics	V 04 C E 01	Galactose
N 05 C D 01	Flurazepam	N 06 D A 04	Galantamine
M 01 A E 09	Flurbiprofen	M 03 A C 02	Gallamine
M 02 A A 19	Flurbiprofen	V 09 H X 01	Gallium (⁶⁷ Ga) citrate
S 01 B C 04	Flurbiprofen	C 08 D A 02	Gallopamil
R 02 A X 01	Flurbiprofen	A 16 A B 08	Galsulfase
J 01 F A 14	Flurithromycin	D 11 A X 02	Gamolenic acid
N 05 A G 01	Fluspirilene	D 11 A X 52	Gamolenic acid, combinations
L 02 B B 01	Flutamide	J 05 A B 06	Ganciclovir
D 07 A C 17	Fluticasone	S 01 A D 09	Ganciclovir
R 01 A D 08	Fluticasone	H 01 C C 01	Ganirelix
R 03 B A 05	Fluticasone	J 01 M A 19	Garenoxacin
R 01 A D 12	Fluticasone furoate	J 06 A A 05	Gas-gangrene sera
D 01 A C 16	Flutrimazole	J 01 M A 16	Gatifloxacin
G 01 A F 18	Flutrimazole	S 01 A X 21	Gatifloxacin
C 10 A A 04	Fluvastatin	N 05 B X 02	Gedocarnil
N 06 A B 08	Fluvoxamine	A 02 B X 07	Gefarnate
B 03 B B 01	Folic acid	A 02 B X 07	Gefarnate, combinations with psycholeptics
B 03 B B 51	Folic acid, combinations	L 01 X E 02	Gefitinib
G 03 G A 05	Follitropin alfa	B 05 A A 06	Gelatin agents
G 03 G A 06	Follitropin beta	L 01 B C 05	Gemcitabine
V 03 A B 34	Fomepizole	G 02 A D 03	Gemeprost
S 01 A D 08	Fomivirsen	C 10 A B 04	Gemfibrozil
B 01 A X 05	Fondaparinux	J 01 M A 15	Gemifloxacin
V 01 A A 08	Food	L 01 X C 05	Gemtuzumab
L 02 B G 02	Formestane	D 06 A X 07	Gentamicin
S 01 B A 12	Formocortal	J 01 G B 03	Gentamicin
R 03 A C 13	Formoterol	S 01 A A 11	Gentamicin
R 03 A K 07	Formoterol and other drugs for obstructive airway diseases	S 02 A A 14	Gentamicin
J 05 A E 07	Fosamprenavir	S 03 A A 06	Gentamicin
J 05 A D 01	Foscarnet	C 01 C A 15	Gepefrine
L 02 A A 04	Fosfestrol	N 06 A X 19	Gepirone
C 01 E B 06	Fosfocreatine	G 03 A A 10	Gestodene and estrogen
J 01 X X 01	Fosfomycin	G 03 A B 06	Gestodine and estrogen
J 05 A D 02	Fosfonet	G 03 D A 01	Gestonorone
C 09 A A 09	Fosinopril	L 02 A B 03	Gestonorone
C 09 B A 09	Fosinopril and diuretics	G 03 X A 02	Gestrinone
N 03 A B 05	Fosphenytoin	N 06 D X 02	Ginkgo folium
L 01 A D 05	Fotemustine	C 01 A A 09	Gitoformate
D 09 A A 01	Framycetin	N 02 B G 03	Glafenine
R 01 A X 08	Framycetin	L 03 A X 13	Glatiramer acetate
S 01 A A 07	Framycetin	A 10 B B 01	Glibenclamide
N 02 C C 07	Frovatriptan	A 10 B B 04	Glibornuride
V 06 D C 02	Fructose	A 10 B B 09	Gliclazide
C 01 E B 07	Fructose 1,6-diphosphate	A 10 B B 12	Glimepiride
L 02 B A 03	Fulvestrant	A 10 B D 06	Glimepiride and pioglitazone
P 01 A X 10	Fumagillin	A 10 B D 04	Glimepiride and rosiglitazone
D 05 A X 01	Fumaric acid	A 10 B B 07	Glipizide
D 05 B X 51	Fumaric acid derivatives, combinations	A 10 B B 08	Gliquidone
G 01 A X 06	Furazolidone	A 10 B B 11	Glisoxepide
C 03 C A 01	Furosemide	L 04 A B 06	Golimumab
C 03 C B 01	Furosemide and potassium	H 04 A A 01	Glucagon
C 03 E B 01	Furosemide and potassium-sparing agents	V 03 A F 09	Glucarpidase
R 02 A B 03	Fusafungine	M 01 A X 05	Glucosamine
D 06 A X 01	Fusidic acid	M 01 A X 12	Glucosaminoglycan polysulfate

B 05 C X 01	Glucose	C 05 B A 03	Heparin
V 04 C A 02	Glucose	S 01 X A 14	Heparin
V 06 D C 01	Glucose	B 01 A B 51	Heparin, combinations
C 05 B B 56	Glucose, combinations	C 05 B A 53	Heparin, combinations
A 09 A B 01	Glutamic acid hydrochloride	C 05 B A 51	Heparinoid, combinations
V 03 A B 32	Glutathione	J 06 B B 11	Hepatitis A immunoglobulin
N 05 C E 01	Glutethimide	J 07 B C 02	Hepatitis A, inactivated, whole virus
A 06 A G 04	Glycerol	J 06 B B 04	Hepatitis B immunoglobulin
A 06 A X 01	Glycerol	J 07 B C 01	Hepatitis B, purified antigen
C 01 D A 02	Glyceryl trinitrate	N 05 C A 11	Heptabarbital
C 05 A E 01	Glyceryl trinitrate	C 01 D X 08	Heptaminol
C 01 D A 52	Glyceryl trinitrate, combinations	J 01 C A 18	Hetacillin
B 05 C X 03	Glycine	D 08 A E 01	Hexachlorophene
P 01 A R 03	Glycobiarsol	M 03 A C 05	Hexafluronium
P 01 A R 53	Glycobiarsol, combinations	D 08 A C 04	Hexamidine
A 03 A B 02	Glycopyrronium	R 01 A X 07	Hexamidine
A 03 C A 05	Glycopyrronium and psychleptics	R 02 A A 18	Hexamidine
A 05 B A 08	Glycyrrhizic acid	S 01 A X 08	Hexamidine
A 10 B C 01	Glymidine	S 03 A A 05	Hexamidine
V 10 A X 06	Gold (¹⁹⁹ Au) colloidal	N 05 C M 10	Hexapropymate
H 01 C A 01	Gonadorelin	A 01 A B 12	Hexetidine
V 04 C M 01	Gonadorelin	N 01 A F 02	Hexobarbital
L 02 A E 03	Goserelin	N 05 C A 16	Hexobarbital
R 02 A B 30	Gramicidin	C 01 D X 06	Hexobendine
A 04 A A 02	Granisetron	A 03 A B 10	Hexocyclium
V 01 A A 02	Grass pollen	R 03 A C 06	Hexoprenaline
J 01 M A 11	Grepafloxacin	R 03 C C 05	Hexoprenaline
D 01 A A 08	Griseofulvin	R 02 A A 12	Hexylresorcinol
D 01 B A 01	Griseofulvin	C 05 C A 05	Hidrosmin
C 01 A C 01	G-strophanthin	C 05 C X 03	Hippocastani semen
N 02 B A 14	Guacetisal	L 03 A X 14	Histamine dihydrochloride
R 05 C A 09	Guaiacolsulfonate	V 04 C G 03	Histamine phosphate
S 01 X A 01	Guaiazulen	R 06 A C 02	Histapyrridine
R 05 C A 03	Guaifenesin	R 06 A C 52	Histapyrridine, combinations
C 02 C C 06	Guanazodine	H 01 C A 03	Histrelin
C 02 C C 02	Guanethidine	S 01 F A 05	Homatropine
S 01 E X 01	Guanethidine	V 01 A A 03	House dust
C 02 L F 01	Guanethidine and diuretics	B 02 B B 01	Human fibrinogen
C 02 A C 02	Guanfacine	G 03 G A 02	Human menopausal gonadotrophin
C 02 C C 05	Guanoclor	D 03 A X 05	Hyaluronic acid
C 02 C C 07	Guanoxabenz	M 09 A X 01	Hyaluronic acid
C 02 C C 03	Guanoxan	R 01 A X 09	Hyaluronic acid
A 10 B X 01	Guar gum	S 01 K A 01	Hyaluronic acid
L 04 A A 19	Gusperimus	S 01 K A 51	Hyaluronic acid, combinations
		B 06 A A 03	Hyaluronidase
		C 02 D B 02	Hydralazine
		C 02 L G 02	Hydralazine and diuretics
		A 09 A B 03	Hydrochloric acid
		B 05 X A 13	Hydrochloric acid
		C 03 A A 03	Hydrochlorothiazide
		C 03 A B 03	Hydrochlorothiazide and potassium
		C 03 E A 01	Hydrochlorothiazide and potassium-sparing agents
		C 03 A X 01	Hydrochlorothiazide, combinations
		R 05 D A 03	Hydrocodone
		A 01 A C 03	Hydrocortisone
		A 07 E A 02	Hydrocortisone
		C 05 A A 01	Hydrocortisone
		D 07 A A 02	Hydrocortisone
		D 07 X A 01	Hydrocortisone
		H 02 A B 09	Hydrocortisone
		S 01 B A 02	Hydrocortisone
		S 01 C B 03	Hydrocortisone
		S 02 B A 01	Hydrocortisone
		D 07 A C 16	Hydrocortisone aceponate
		D 07 C A 01	Hydrocortisone and antibiotics
		S 01 C A 03	Hydrocortisone and antiinfectives
		S 02 C A 03	Hydrocortisone and antiinfectives
		S 03 C A 04	Hydrocortisone and antiinfectives
		D 07 B A 04	Hydrocortisone and antiseptics
		S 01 B B 01	Hydrocortisone and mydriatics
		D 07 A B 11	Hydrocortisone buteprate
H			
D 01 A A 03	Hachimycin		
G 01 A A 06	Hachimycin		
J 02 A A 02	Hachimycin		
N 05 B A 13	Halazepam		
D 07 A D 02	Halcinonide		
P 01 B X 01	Halofantrine		
D 07 A C 12	Halometasone		
N 05 A D 01	Haloperidol		
D 01 A E 11	Haloproglin		
N 01 A B 01	Halothane		
V 03 A N 03	Helium		
B 06 A B 01	Hermatin		
B 05 A A 08	Hemoglobin crosfumaril		
B 05 A A 10	Hemoglobin glutamer (bovine)		
B 05 A A 09	Hemoglobulin raffimer		
J 07 C A 08	Hemophilus influenzae B and hepatitis B		
J 07 C A 04	Hemophilus influenzae B and poliomyelitis		
J 07 A G 53	Hemophilus influenzae B, combinations with meningococcus C, conjugated		
J 07 A G 52	Hemophilus influenzae B, combinations with pertussis and toxoids		
J 07 A G 51	Hemophilus influenzae B, combinations with toxoids		
J 07 A G 01	Hemophilus influenzae B, purified antigen conjugated		
B 01 A B 01	Heparin		

D 07 A B 02	Hydrocortisone butyrate	L 03 A X 10	Immunocyanin
D 07 B B 04	Hydrocortisone butyrate and antiseptics	J 06 B A 01	Immunoglobulins, normal human for extravascular administration
R 01 A D 60	Hydrocortisone, combinations	J 06 B A 02	Immunoglobulins, normal human for intravascular administration
C 03 A A 02	Hydroflumethiazide	C 01 D X 09	Imolamine
C 03 A B 02	Hydroflumethiazide and potassium	R 03 A C 18	Indacaterol
C 03 A H 02	Hydroflumethiazide, combinations	C 03 B A 11	Indapamide
A 01 A B 02	Hydrogen peroxide	S 02 D C	Indifferent preparations
D 08 A X 01	Hydrogen peroxide	V 04 C H 02	Indigo carmine
S 02 A A 06	Hydrogen peroxide	J 05 A E 02	Indinavir
N 02 A A 03	Hydromorphone	V 09 I B 03	Indium (¹¹¹ In) antiovariumcarcinoma antibody
N 02 A G 04	Hydromorphone and antispasmodics	V 09 I B 04	Indium (¹¹¹ In) capromab pendetide
M 09 A A 01	Hydroquinine	V 09 G X 02	Indium (¹¹¹ In) imciromab
D 11 A X 11	Hydroquinone	V 09 H B 01	Indium (¹¹¹ In) oxinate labelled cells
A 02 A D 04	Hydrotalcite	V 09 A X 01	Indium (¹¹¹ In) pentetic acid
B 03 B A 03	Hydroxocobalamin	V 09 I B 01	Indium (¹¹¹ In) pentetreotide
V 03 A B 33	Hydroxocobalamin	V 09 I B 02	Indium (¹¹¹ In) satumomab pendetide
B 03 B A 53	Hydroxocobalamin, combinations	V 09 H B 02	Indium (¹¹¹ In) tropolonate labelled cells
N 07 X X 04	Hydroxybutyric acid	B 01 A C 10	Indobufen
L 01 X X 05	Hydroxycarbamide	C 01 E B 03	Indometacin
P 01 B A 02	Hydroxychloroquine	M 01 A B 01	Indometacin
R 06 A D 05	Hydroxyethylpromethazine	M 02 A A 23	Indometacin
R 06 A D 55	Hydroxyethylpromethazine, combinations	S 01 B C 01	Indometacin
B 05 A A 07	Hydroxyethylstarch	M 01 A B 51	Indometacin, combinations
G 03 D A 03	Hydroxyprogesterone	M 01 A E 10	Indoprofen
G 03 F A 02	Hydroxyprogesterone and estrogen	C 02 C A 02	Indoramin
N 05 B B 01	Hydroxyzine	L 04 A B 02	Infliximab
N 05 B B 51	Hydroxyzine, combinations	J 07 B B 01	Influenza, inactivated, whole virus
A 05 A X 02	Hymecromone	J 07 B B 03	Influenza, live attenuated
A 03 B A 03	Hyoscyamine	J 07 B B 02	Influenza, purified antigen
A 03 C B 31	Hyoscyamine and psycholeptics	D 06 B B 05	Inosine
N 06 A X 25	Hyperici herba	G 01 A X 02	Inosine
S 01 K A 02	Hypromellose	S 01 X A 10	Inosine
		J 05 A X 05	Inosine pranobex
		A 11 H A 07	Inositol
		C 04 A C 03	Inositol nicotinate
		V 01 A A 07	Insects
		A 10 A B 02	Insulin (beef, fast acting)
		A 10 A C 02	Insulin (beef, intermediate acting)
		A 10 A D 02	Insulin (beef, intermediate acting + fast acting)
		A 10 A E 02	Insulin (beef, long-acting)
		A 10 A B 01	Insulin (human, fast acting)
		A 10 A C 01	Insulin (human, intermediate acting)
		A 10 A D 01	Insulin (human, intermediate acting + fast acting)
		A 10 A E 01	Insulin (human, long-acting)
		A 10 A F 01	Insulin (human)
		A 10 A B 03	Insulin (pork, fast-acting)
		A 10 A C 03	Insulin (pork, intermediate acting)
		A 10 A D 03	Insulin (pork, intermediate acting + fast acting)
		A 10 A E 03	Insulin (pork, long-acting)
		A 10 A B 05	Insulin aspart
		A 10 A D 05	Insulin aspart
		A 10 A E 05	Insulin detemir
		A 10 A E 04	Insulin glargine
		A 10 A B 06	Insulin glulisine
		A 10 A B 04	Insulin lispro
		A 10 A C 04	Insulin lispro
		A 10 A D 04	Insulin lispro
		S 01 A D 05	Interferon
		L 03 A B 01	Interferon-alfa-natural
		L 03 A B 04	Interferon-alfa-2a
		L 03 A B 05	Interferon-alfa-2b
		L 03 A B 09	Interferon alfacon-1
		L 03 A B 06	Interferon-alfa-n1
		L 03 A B 02	Interferon-beta-natural
		L 03 A B 07	Interferon-beta-1a
		L 03 A B 08	Interferon-beta-1b
		L 03 A B 03	Interferon-gamma
		V 04 C H 01	Inulin and other polyfructosans
		C 05 B B 03	Invert sugar
I			
D 06 B B 08	Ibacinabine		
M 05 B A 06	Ibandronic acid		
C 01 C A 16	Ibopamine		
S 01 F B 03	Ibopamine		
V 10 X X 02	Ibritumomab tiuxetan (⁹⁰ Y)		
R 03 D C 04	Ibudilast		
C 01 E B 16	Ibuprofen		
G 02 C C 01	Ibuprofen		
M 01 A E 01	Ibuprofen		
M 02 A A 13	Ibuprofen		
M 01 A E 51	Ibuprofen, combinations		
M 01 A E 13	Ibuproxam		
C 01 B D 05	Ibutilide		
B 06 A C 02	Icatibant		
D 10 B X 01	Ichtasol		
J 01 E A 03	Iclaprim		
A 03 A X 06	Idanpramine		
L 01 D B 06	Idarubicin		
N 06 B X 13	Idebenone		
D 06 B B 01	Idoxuridine		
J 05 A B 02	Idoxuridine		
S 01 A D 01	Idoxuridine		
M 02 A X 05	Idrocilamide		
A 16 A B 09	Idursulfase		
C 04 A X 28	Ifenprodil		
L 01 A A 06	Ifosfamide		
N 05 A X 14	Iloperidone		
B 01 A C 11	Iloprost		
L 01 X E 01	Imatinib		
C 09 A A 16	Imidapril		
N 02 B A 16	Imidazolesalicylate		
A 16 A B 02	Imiglucerase		
J 01 D H 51	Imipenem and enzyme inhibitor		
N 06 A A 02	Imipramine		
N 06 A A 03	Imipramine oxide		
D 06 B B 10	Imiquimod		

A 06 A D 61	Lactulose, combinations	H 03 A A 02	Liothyronine sodium
A 02 B A 08	Lafutidine	A 06 A A 01	Liquid paraffin
J 05 A F 05	Lamivudine	A 06 A A 51	Liquid paraffin, combinations
N 03 A X 09	Lamotrigine	A 10 B X 07	Liraglutide
C 01 A A 06	Lanatoside C	N 06 B A 12	Lisdexamfetamine
H 01 C B 03	Lanreotide	C 09 A A 03	Lisinopril
A 02 B C 03	Lansoprazole	C 09 B B 03	Lisinopril and amlodipine
A 02 B D 07	Lansoprazole, amoxicillin and clarithromycin	C 09 B A 03	Lisinopril and diuretics
A 02 B D 03	Lansoprazole, amoxicillin and metronidazole	G 02 C B 02	Lisuride
A 02 B D 02	Lansoprazole, tetracycline and metronidazole	N 02 C A 07	Lisuride
V 03 A E 03	Lanthanum carbonate	N 05 A N 01	Lithium
L 01 X E 08	Nilotinib	D 11 A X 04	Lithium succinate
A 16 A B 05	Laronidase	S 01 G X 05	Lodoxamide
G 03 X C 03	Lasofoxifene	N 06 A A 07	Lofepramine
J 01 D D 06	Latamoxef	N 07 B C 04	Lofexidine
S 01 E E 01	Latanoprost	J 01 M A 07	Lomefloxacin
A 06 A G 11	Laurilsulfate, including combinations	S 01 A X 17	Lomefloxacin
L 04 A A 13	Leflunomide	L 01 A D 02	Lomustine
L 04 A X 04	Lenalidomide	M 01 A B 09	Lonazolac
L 03 A A 10	Lenograstim	L 01 X X 07	Lonidamine
L 03 A X 01	Lentinan	A 07 D A 03	Loperamide
B 01 A E 02	Lepirudin	A 07 D A 05	Loperamide oxide
C 08 C A 13	Lercanidipine	A 07 D A 53	Loperamide, combinations
R 05 C B 09	Letosteine	J 05 A E 06	Lopinavir
L 02 B G 04	Letrozole	N 05 C D 11	Loprazolam
L 02 A E 02	Leuporelin	J 01 D C 08	Loracarbef
N 07 B C 03	Levacetylmethadol	C 01 B A 12	Lorajmine
P 02 C E 01	Levamisole	R 06 A X 13	Loratadine
N 03 A X 14	Levetiracetam	N 05 B A 06	Lorazepam
S 01 E D 03	Levobunolol	N 05 B A 56	Lorazepam, combinations
N 01 B B 10	Levobupivacaine	C 01 B C 07	Lorcainide
R 01 A C 02	Levocabastin	N 05 C D 06	Lormetazepam
S 01 G X 02	Levocabastin	M 01 A C 05	Lornoxicam
A 16 A A 01	Levocarnitine	C 09 C A 01	Losartan
R 06 A E 09	Levocetirizine	C 09 D B 06	Losartan and amlodipine
N 04 B A 01	Levodopa	C 09 D A 01	Losartan and diuretics
N 04 B A 02	Levodopa and decarboxylase inhibitor	S 01 B A 14	Loteprednol
N 04 B A 03	Levodopa, decarboxylase inhibitor and COMT inhibitor	C 10 A A 02	Lovastatin
R 05 D B 27	Levodropropizine	C 10 B A 01	Lovastatin and nicotinic acid
J 01 M A 12	Levofloxacin	N 05 A H 01	Loxapine
S 01 A X 19	Levofloxacin	A 06 A X 03	Lubiprostone
A 16 A A 03	Levoglutamide	M 01 A H 06	Lumiracoxib
N 05 A A 02	Levomepromazine	G 03 G A 07	Lutropin alfa
N 07 B C 05	Levomethadone	J 01 A A 04	Lymecycline
G 03 A D 01	Levonorgestrel	G 03 A C 02	Lynestrenol
G 03 A A 07	Levonorgestrel and estrogen	G 03 D C 03	Lynestrenol
G 03 A B 03	Levonorgestrel and estrogen	G 03 A A 03	Lynestrenol and estrogen
G 03 F A 11	Levonorgestrel and estrogen	G 03 A B 02	Lynestrenol and estrogen
G 03 F B 09	Levonorgestrel and estrogen	G 03 F A 07	Lynestrenol and estrogen
C 01 C X 08	Levosimendan	G 03 F B 02	Lynestrenol and estrogen
N 05 A L 07	Levosulpiride	H 01 B A 03	Lypressin
H 03 A A 01	Levothyroxine sodium	B 05 X B 03	Lysine
R 05 C A 11	Levoverbenone	D 06 B B 07	Lysozyme
C 01 B B 01	Lidocaine	J 05 A X 02	Lysozyme
C 05 A D 01	Lidocaine		
D 04 A B 01	Lidocaine		
N 01 B B 02	Lidocaine		
R 02 A D 02	Lidocaine		
S 01 H A 07	Lidocaine		
S 02 D A 01	Lidocaine		
N 01 B B 52	Lidocaine		
C 08 E X 01	Lidoflazine		
A 10 B H 05	Linagliptin		
J 01 F F 02	Lincomycin		
P 03 A B 02	Lindane		
J 01 X X 08	Linezolid		
N 06 B X 09	Linopirdine		
A 06 A C 05	Linseed		
A 06 A C 55	Linseed, combinations		
C 01 D X 18	Linsidomine		
		M	
		A 06 A D 15	Macrogol
		A 06 A D 65	Macrogol, combinations
		D 06 B A 03	Marenide
		A 02 A D 02	Magaldrate
		A 02 A F 01	Magaldrate and antifatulents
		A 12 C C 30	Magnesium (different salts in combination)
		A 12 C C 05	Magnesium aspartate
		A 02 A A 01	Magnesium carbonate
		A 06 A D 01	Magnesium carbonate
		A 12 C C 01	Magnesium chloride
		B 05 X A 11	Magnesium chloride
		A 06 A D 19	Magnesium citrate
		A 12 C C 04	Magnesium citrate
		B 05 C B 03	Magnesium citrate

A 12 C C 03	Magnesium gluconate	G 03 F A 12	Medroxyprogesterone and estrogen
A 02 A A 04	Magnesium hydroxide	G 03 F B 06	Medroxyprogesterone and estrogen
G 04 B X 01	Magnesium hydroxide	S 01 B A 08	Medrysone
A 12 C C 06	Magnesium lactate	M 01 A G 01	Mefenamic acid
A 12 C C 07	Magnesium levulinate	A 08 A A 09	Mefenorex
A 12 C C 09	Magnesium orotate	P 01 B C 02	Mefloquine
A 02 A A 02	Magnesium oxide	C 03 B A 05	Mefruside
A 06 A D 02	Magnesium oxide	C 03 B B 05	Mefruside and potassium
A 12 C C 10	Magnesium oxide	G 03 A C 05	Megestrol
A 02 A A 03	Magnesium peroxide	G 03 D B 02	Megestrol
A 06 A D 03	Magnesium peroxide	L 02 A B 01	Megestrol
B 05 X A 10	Magnesium phosphate	G 03 A A 04	Megestrol and estrogen
A 12 C C 08	Magnesium pidolate	G 03 A B 01	Megestrol and estrogen
C 10 A X 07	Magnesium pyridoxal 5-phosphate glutamate	G 03 F A 08	Megestrol and estrogen
A 02 A A 05	Magnesium silicate	G 03 F B 04	Megestrol and estrogen
A 06 A D 04	Magnesium sulfate	P 01 D B 01	Megulumine antimonate
A 12 C C 02	Magnesium sulfate	C 10 A X 05	Meglutol
B 05 X A 05	Magnesium sulfate	G 04 B D 03	Meladrazine
D 11 A X 05	Magnesium sulfate	B 01 A E 04	Melagatran
V 04 C C 02	Magnesium sulfate	L 03 A X 12	Melanoma vaccine
P 03 A X 03	Malathion	P 01 C D 01	Melarsoprol
B 05 C A 06	Mandelic acid	N 05 C H 01	Mealtonin
J 01 X X 06	Mandelic acid	N 04 B A 04	Melevodopa
V 08 C A 05	Mangafodipir	N 04 G A 05	Melevodopa and decarboxylase inhibitor
C 08 C A 11	Manidipine	N 06 A A 14	Melitracen
A 06 A D 16	Mannitol	N 06 C A 02	Melitracen and psycholeptics
B 05 B C 01	Mannitol	M 01 A C 06	Meloxicam
B 05 C X 04	Mannitol	M 01 A C 56	Meloxicam, combinations
R 05 C B 16	Mannitol	N 05 A D 03	Melperone
L 01 A B 03	Mannosulfan	L 01 A A 03	Melphalan
N 06 A A 21	Maprotiline	N 06 D X 01	Memantine
J 05 A X 09	Maraviroc	B 02 B A 02	Menadione
J 05 A X 10	Maribavir	J 07 A H 01	Meningococcus A, purified polysaccharides antigen
L 01 X X 10	Masoprocol	J 07 A H 09	Meningococcus B, multicomponent vaccine
N 04 A A 10	Mazaticol	J 07 A H 06	Meningococcus B, outer membrane vesicle vaccine
A 08 A A 05	Mazindol	J 07 A H 07	Meningococcus C, purified polysaccharides antigen conjugated
J 06 B B 14	Measles immunoglobulin	J 07 A H 03	Meningococcus A,C, bivalent purified polysaccharides antigen
J 07 B D 52	Measles, combinations with mumps and rubella, live attenuated	J 07 A H 08	Meningococcus A,C,Y,W-135 tetravalent purified polysacchariades antigen conjugated
J 07 B D 51	Measles, combinations with mumps, live attenuated	J 07 A H 04	Meningococcus, A,C,Y,W-135,tetravalent purified polysaccharides antigen
J 07 B D 54	Measles, combinations with mumps, rubella and varicella, live attenuated	P 01 A X 05	Mepacrine
J 07 B D 53	Measles, combinations with rubella, live attenuated	A 01 A B 16	Mepartricin
J 07 B D 01	Measles, live attenuated	D 01 A A 06	Mepartricin
P 02 C A 01	Mebendazole	G 01 A A 09	Mepartricin
P 02 C A 51	Mebendazole, combinations	G 04 C X 03	Mepartricin
A 03 A A 04	Mebeverine	A 03 A B 12	Mepenzolate
R 06 A X 15	Mebhydrolin	M 03 B X 06	Mephenesin
N 05 B C 04	Mebutamate	N 05 B X 01	Mephenoxalone
C 03 A A 13	Mebutizide	C 01 C A 11	Mephentermine
C 03 E A 05	Mebutizide and potassium-sparing agents	N 03 A B 04	Mephentyoin
C 02 B B 01	Mecamylamine	N 03 A B 54	Mephentyoin, combinations
H 01 A C 03	Mecasermin	C 07 A A 14	Mepindolol
H 01 A C 05	Mecasermin rinfabate	N 01 B B 03	Mepivacaine
J 01 C A 11	Mecillinam	N 01 B B 53	Mepivacaine, combinations
D 10 A F 04	Meclocycline	R 07 A B 09	Mepixanox
M 01 A G 04	Mecllo	L 04 A C 06	Mepolizumab
R 06 A E 05	Meclozine	H 02 A B 15	Meprednisone
R 06 A E 55	Meclozine, combinations	N 05 B C 01	Meprobamate
B 03 B A 05	Mecobalamin	N 05 B C 51	Meprobamate, combinations
N 05 B A 03	Medazepam	N 05 C X 01	Meprobamate, combinations
V 03 A N 05	Medical air	R 05 D B 22	Meprotixol
A 07 B A 01	Medicinal charcoal	N 02 A X 05	Meptazinol
A 07 B A 51	Medicinal charchoal, combinations	D 04 A A 02	Mepyramine
N 06 A X 13	Medifoxamine	R 06 A C 01	Mepyramine
G 03 D B 03	Medrogestone	D 11 A X 06	Mequinol
G 03 F B 07	Medrogestone and estrogen	R 06 A D 07	Mequitazine
G 03 A C 06	Medroxyprogesterone	A 16 A A 04	Mercaptamine
G 03 D A 02	Medroxyprogesterone	L 01 B B 02	Mercaptopurine
L 02 A B 02	Medroxyprogesterone	D 08 A K 01	Mercuric amidochloride
G 03 A A 08	Medroxyprogesterone and estrogen	D 08 A K 03	Mercuric chloride

D 08 A K 30	Mecuric iodide	C 02 A B 02	Methyldopa (racemic)
D 08 A K 04	Mercurochrome	G 02 A B 01	Methylergometrine
S 01 A X 01	Mercury compounds	G 02 A C 01	Methylergometrine and oxytocin
D 08 A K 05	Mercury, metallic	G 03 D C 31	Methylestrenolone
J 01 D H 02	Meropenem	A 03 C B 04	Methylhomatropine and psycholeptics
C 03 B C 01	Mersalyl	A 06 A H 01	Methylnaltrexone bromide
A 07 E C 02	Mesalazine	G 03 F A 05	Methylnortestosterone and estrogen
R 05 C B 05	Mesna	N 05 C M 15	Methylpentynol
V 03 A F 01	Mesna	N 05 C X 03	Methylpentynol, combinations
N 05 A C 03	Mesoridazine	N 06 B A 04	Methylphenidate
G 03 B B 01	Mesterolone	N 03 A A 01	Methylphenobarbital
D 10 A B 05	Mesulfen	D 07 A A 01	Methylprednisolone
P 03 A A 03	Mesulfen	D 10 A A 02	Methylprednisolone
N 03 A D 03	Mesuximide	H 02 A B 04	Methylprednisolone
N 01 B A 01	Metabuthetamine	D 07 A C 14	Methylprednisolone aceponate
J 01 A A 05	Metacycline	D 07 C A 02	Methylprednisolone and antibiotics
A 10 B B 10	Metahexamide	S 01 C A 08	Methylprednisolone and antiinfectives
N 06 B A 03	Metamfetamine	H 02 B X 01	Methylprednisolone, combinations
N 02 B B 02	Metamizole sodium	C 01 D A 04	Methylpropylpropanediol dinitrate
N 02 B B 52	Metamizole sodium, combinations excluding psycholeptics	C 01 D A 54	Methylpropylpropanediol dinitrate, combinations
N 02 B B 72	Metamizole sodium, combinations with psycholeptics	D 01 A E 02	Methylrosaniline
J 01 C A 14	Metampicillin	G 01 A X 09	Methylrosaniline
A 14 A A 03	Metandienone	A 03 B B 03	Methylscopolamine
D 11 A E 01	Metandienone	S 01 F A 03	Methylscopolamine
C 01 C A 09	Metaraminol	A 03 F A 03	Methylscopolamine and psycholeptics
A 14 A A 04	Metenolone	G 03 B A 02	Methyltestosterone
G 02 C B 05	Metergoline	G 03 E K 01	Methyltestosterone
A 10 B A 02	Metformin	G 03 E A 01	Methyltestosterone and estrogen
A 10 B D 11	Metformin and linagliptin	V 03 A B 17	Methylthionium chloride
A 10 B D 05	Metformin and pioglitazone	V 04 C G 05	Methylthionium chloride
A 10 B D 03	Metformin and rosiglitazone	H 03 B A 01	Methylthiouracil
A 10 B D 10	Metformin and saxagliptin	N 05 C E 02	Methyprylon
A 10 B D 07	Metformin and sitagliptin	N 02 C A 04	Methysergide
A 10 B D 02	Metformin and sulfonamides	J 01 C F 03	Meticillin
A 10 B D 08	Metformin and vildagliptin	C 03 B A 09	Metricrane
N 07 B C 02	Methadone	C 01 A A 08	Metildigoxin
N 02 A C 52	Methadone, combinations excluding psycholeptics	S 01 E D 04	Metipranolol
G 03 C B 03	Methallenestril	C 07 B A 68	Metipranolol and thiazides, combinations
G 03 C C 03	Methallenestril	S 01 E D 54	Metipranolol, combinations
A 03 A B 07	Methantheline	C 02 K B 01	Metirosine
R 06 A C 05	Methapyrilene	J 05 A A 01	Metisazone
N 05 C M 01	Methaqualone	N 04 A A 03	Metixene
N 05 C X 02	Methaqualone, combinations	R 01 A A 10	Metizoline
N 03 A A 30	Metharbital	A 03 F A 01	Metoclopramide
S 01 E C 05	Methazolamide	C 03 B A 08	Metolazone
R 06 A D 04	Methdilazine	C 03 E A 12	Metolazone and potassium-sparing agents
J 01 X X 05	Methenamine	A 04 A D 05	Metopimazine
V 08 A A 09	Methiodal	C 07 A B 02	Metoprolol
V 08 A B 26	Methionine	C 07 F B 02	Metoprolol and other antihypertensives
A 02 B X 04	Methiosulfonium chloride	C 07 C B 02	Metoprolol and other diuretics
M 03 B A 03	Methocarbamol	C 07 B B 02	Metoprolol and thiazides
M 03 B A 53	Methocarbamol, combinations excluding psycholeptics	C 07 B B 52	Metoprolol and thiazides, combinations
M 03 B A 73	Methocarbamol, combinations with psycholeptics	C 07 A B 52	Metoprolol, combination packages
N 01 A F 01	Methohexital	B 03 X A 03	Methoxy polyethylene glycol-epoetin beta
N 05 C A 15	Methohexital	P 02 B B 01	Metrifonate
C 02 A A 06	Methoserpidine	V 08 A B 01	Metrizamide
C 02 L A 04	Methoserpidine and diuretics	V 08 A A 02	Metrizoic acid
L 01 B A 01	Methotrexate	A 01 A B 17	Metronidazole
L 04 A X 03	Methotrexate	D 06 B X 01	Metronidazole
C 01 C A 10	Methoxamine	G 01 A F 01	Metronidazole
D 05 B A 02	Methoxsalen	J 01 X D 01	Metronidazole
D 05 A D 02	Methoxsalen	P 01 A B 01	Metronidazole
N 02 B G 09	Methoxyflurane	V 04 C D 01	Metyrapone
R 03 C B 02	Methoxyphenamine	C 01 B B 02	Mexiletine
C 03 A A 08	Methyclothiazide	J 01 C A 10	Mezlocillin
C 03 A B 08	Methyclothiazide and potassium	N 06 A X 03	Mianserin
L 01 X D 03	Methyl aminolevulinate	C 08 C X 01	Mibefradil
A 03 B B 02	Methylatropine	J 02 A X 05	Micafungin
A 06 A C 06	Methylcellulose	A 01 A B 09	Miconazole
C 02 A B 01	Methyldopa (levorotatory)	D 01 A C 02	Miconazole
C 02 L B 01	Methyldopa (levorotatory) and diuretics	A 07 A C 01	Miconazole

C 10 A X 06 Omega-3-triglycerides incl. other esters and acids
 A 02 B C 01 Omeprazole
 A 02 B D 05 Omeprazole, amoxicillin and clarithromycin
 A 02 B D 01 Omeprazole, amoxicillin and metronidazole
 D 01 A C 13 Omoconazole
 G 01 A F 16 Omoconazole
 A 04 A A 01 Ondansetron
 N 06 A A 05 Pipramol
 A 07 D A 02 Opium
 N 02 A A 02 Opium
 R 05 D A 05 Opium alkaloids with morphine
 R 05 F A 02 Opium derivatives and expectorants
 R 05 F A 01 Opium derivatives and mucolytics
 L 03 A C 02 Oprelvekin
 A 07 C A Oral rehydration salt formulations
 R 03 C B 03 Orciprenaline
 R 03 A B 03 Orciprenaline
 R 03 C B 53 Orciprenaline, combinations
 A 02 A D 01 Ordinary salt combinations
 A 02 A F 02 Ordinary salt combinations and antifatulents
 C 01 D A 20 Organic nitrates in combination
 C 01 D A 70 Organic nitrates in combination with psycholeptic
 C 05 B A 01 Organo-heparinoid
 M 01 A X 14 Orgotein
 J 01 X A 05 Oritavancin
 A 08 A B 01 Orlistat
 G 01 A F 06 Ornidazole
 J 01 X D 03 Ornidazole
 P 01 A B 03 Ornidazole
 H 01 B A 05 Ornipressin
 A 05 B A 06 Ornithine oxoglurate
 N 04 A B 02 Orphenadrine (chloride)
 M 03 B C 01 Orphenadrine (citrate)
 M 03 B C 51 Orphenadrine, combinations
 J 05 A H 02 Oseltamivir
 A 06 A D Osmotically acting laxatives
 C 01 B G Other antiarrhythmics, class I and III
 B 05 A X Other blood products
 R 05 X Other cold combination preparations
 J 07 A H 02 Other meningococcal monovalent purified polysaccharides antigen
 J 07 A H 05 Other meningococcal polyvalent purified polysaccharides antigen
 B 05 A A 02 Other plasma protein fractions
 C 05 A X 03 Other preparations, combinations
 R 02 A X Other throat preparations
 A 03 A B 06 Otilonium bromide
 A 03 C A 04 Otilonium bromide and psycholeptics
 A 14 A B 03 Oxabolone cipationate
 D 11 A X 09 Oxaceprol
 M 01 A X 24 Oxaceprol
 J 01 C F 04 Oxacillin
 N 06 A X 10 Oxaflozane
 L 01 X A 03 Oxaliplatin
 M 01 A B 13 Oxametacin
 P 02 B A 02 Oxamniquine
 A 14 A A 08 Oxandrolone
 P 02 C C 02 Oxantel
 M 01 A E 12 Oxaprozin
 R 06 A E 06 Oxatamide
 N 05 B A 04 Oxazepam
 N 03 A F 02 Oxcarbazepine
 C 01 C A 08 Oxedrine
 S 01 G A 06 Oxedrine
 S 01 G A 56 Oxedrine, combinations
 R 05 D B 09 Oxeladin
 C 05 A D 06 Oxetacaine
 N 02 C X 06 Oxetorone
 D 01 A C 11 Oxiconazole
 G 01 A F 17 Oxiconazole
 B 02 B C 02 Oxidized cellulose

N 06 B X 07 Oxiracetam
 N 06 A X 01 Oxitriptan
 R 03 B B 02 Oxitropium bromide
 R 05 D B 07 Oxolamine
 J 01 M B 05 Oxolinic acid
 R 06 A D 08 Oxomemazine
 C 07 A A 02 Oxprenolol
 C 07 C A 02 Oxprenolol and other diuretics
 C 07 B A 02 Oxprenolol and thiazides
 D 04 A B 03 Oxybuprocaine
 S 01 H A 02 Oxybuprocaine
 G 04 B D 04 Oxybutynin
 M 01 C A 03 Oxycinchophen
 N 02 A A 05 Oxycodone
 N 02 A A 55 Oxycodone, combinations
 C 01 D X 03 Oxyfedrine
 C 01 D X 53 Oxyfedrine, combinations
 V 03 A N 01 Oxygen
 R 01 A A 05 Oxymetazoline
 R 01 A B 07 Oxymetazoline
 S 01 G A 04 Oxymetazoline
 A 14 A A 05 Oxymetholone
 N 05 A E 01 Oxyptertine
 M 01 A A 03 Oxyphenbutazone
 M 02 A A 04 Oxyphenbutazone
 S 01 B C 02 Oxyphenbutazone
 A 03 A A 01 Oxyphencyclimine
 A 03 C A 03 Oxyphencyclimine and psycholeptics
 A 06 A B 01 Oxyphenisatine
 A 03 A B 03 Oxyphenonium
 A 03 A B 53 Oxyphenonium, combinations
 A 01 A B 07 Oxyquinoline
 D 08 A H 03 Oxyquinoline
 G 01 A C 30 Oxyquinoline
 R 02 A A 14 Oxyquinoline
 D 06 A A 03 Oxytetracycline
 G 01 A A 07 Oxytetracycline
 J 01 A A 06 Oxytetracycline
 S 01 A A 04 Oxytetracycline
 J 01 A A 56 Oxytetracycline, combinations
 H 01 B B 02 Oxytocin

P

L 01 C D 01 Paclitaxel
 L 01 C D 03 Paclitaxel poliglumex
 V 03 A F 08 Palifermin
 N 05 A X 13 Paliperidone
 J 06 B B 16 Palivizumab
 A 04 A A 05 Palonosetron
 M 05 B A 03 Pamidronic acid
 V 04 C K 02 Pancreozymin (cholecystokinin)
 M 03 A C 01 Pancuronium
 J 01 D H 55 Panipenem and betamipron
 L 01 X C 08 Panitumumab
 L 01 X X 42 Panobinostat
 A 11 H A 32 Pantethine
 A 02 B C 02 Pantoprazole
 A 02 B D 04 Pantoprazole, amoxicillin and clarithromycin
 N 02 A A 10 Papaveretum
 A 03 A D 01 Papaverine
 G 04 B E 02 Papaverine
 G 04 B E 52 Papaverine, combinations
 J 07 B M Papillomavirus vaccines
 J 07 B M 01 Papillomavirus (human types 6, 11, 16, 18)
 J 07 B M 02 Papillomavirus (human types 16, 18)
 N 02 B E 01 Paracetamol
 N 02 B E 51 Paracetamol, combinations excl psycholeptics
 N 02 B E 71 Paracetamol, combinations with psycholeptics
 N 05 C C 05 Paraldehyde
 N 03 A C 01 Paramethadione

H 02 A B 05	Paramethasone	J 07 A J 01	Pertussis, inactivated, whole cell
S 01 E B 10	Paraoxon	J 07 A J 51	Pertussis, inactivated, whole cell, combinations with toxoids
H 05 A A 01	Parathyroid gland extract	J 07 A J 02	Pertussis, purified antigen
H 05 A A 03	Parathyroid hormone	J 07 A J 52	Pertussis, purified antigen, combinations with toxoids
M 01 A H 04	Parecoxib	C 01 A X 02	Peruvoside
C 02 K C 01	Pargyline	N 02 A B 02	Pethidine
C 02 L L 01	Pargyline and diuretics	N 02 A G 03	Pethidine and antispasmodics
H 05 B X 02	Paricalcitol	N 02 A B 52	Pethidine combinations excluding psycholeptics
B 01 A B 07	Parnaparin	N 02 A B 72	Pethidine combinations with psycholeptics
A 07 A A 06	Paromomycin	P 01 A X 04	Phanquinone
N 06 A B 05	Paroxetine	N 03 A X 07	Phenacemide
H 01 C B 05	Pasireotide	N 02 B E 03	Phenacetin
L 01 X E 11	Pazopanib	N 02 B E 53	Phenacetin, combinations excluding psycholeptics
J 01 M A 18	Pazufloxacin	N 02 B E 73	Phenacetin, combinations with psycholeptics
D 01 A A 04	Pecilocin	N 02 A D 02	Phenazocine
A 07 B C 01	Pectin	N 02 B B 01	Phenazone
J 01 M A 03	Pefloxacin	S 02 D A 03	Phenazone
L 03 A X 04	Pegademase	N 02 B B 51	Phenazone, combinations excluding psycholeptics
S 01 X A 17	Pegaptanib	N 02 B B 71	Phenazone, combinations with psycholeptics
L 01 X X 24	Pegaspargase	G 04 B X 06	Phenazopyridine
L 03 A A 13	Pegfilgrastim	N 06 A F 03	Phenelzine
L 03 A B 11	Peginterferon alfa-2a	J 01 C E 05	Phenethicillin
L 03 A B 61	Peginterferon alfa-2a, combinations	N 03 A X 13	Pheneturide
L 03 A B 10	Peginterferon alfa-2b	A 10 B A 01	Phenformin
M 04 A X 02	Pegloticase	A 10 B A 01	Phenformin and sulfonamides
H 01 A X 01	Pegvisomant	N 04 A A 09	Phenylglutarimide
L 01 B A 04	Pemetrexed	R 06 A X 04	Phenindamine
N 06 B A 05	Pemoline	B 01 A A 02	Phenindione
J 01 C E 06	Penamocillin	R 06 A B 05	Pheniramine
C 07 A A 23	Penbutolol	N 03 A A 02	Phenobarbital
C 07 C A 23	Penbutolol and other diuretics	C 05 B B 05	Phenol
D 06 B B 06	Penciclovir	D 08 A E 03	Phenol
J 05 A B 13	Penciclovir	N 01 B X 03	Phenol
N 05 A G 03	Penfluridol	R 02 A A 19	Phenol
M 01 C C 01	Penicillamine	A 06 A B 04	Phenolphthalein
J 01 R A 01	Penicillins, combinations with other antibacterials	V 04 C H 03	Phenolsulphonphthalein
J 01 A A 10	Penimepicycline	N 01 A H 04	Phenoperidine
A 06 A D 14	Pentaerithrityl	P 03 A C 03	Phenothrin
C 01 D A 05	Pentaerithrityl tetranitrate	P 03 A C 53	Phenothrin, combinations
C 01 D A 55	Pentaerithrityl tetranitrate, combinations	C 04 A X 02	Phenoxybenzamine
V 04 C G 04	Pentagastrin	J 01 C E 02	Phenoxymethylpenicillin
P 01 C X 01	Pentamidine isethionate	M 03 B A 01	Phenprobamate
G 01 A A 11	Pentamycin	M 03 B A 51	Phenprobamate, combinations excluding psycholeptics
N 02 A D 01	Pentazocine	M 03 B A 71	Phenprobamate, combinations with psycholeptics
R 07 A B 03	Pentetrazol	B 01 A A 04	Phenprocoumon
R 07 A B 53	Pentetrazol, combinations	N 03 A D 02	Phensuximide
A 03 A B 04	Penthienate	A 08 A A 01	Phentermine
C 04 A D 01	Pentifylline	C 04 A B 01	Phentolamine
N 05 C A 01	Pentobarbital	V 03 A B 36	Phentolamine
C 05 B A 04	Pentosan polysulfate sodium	G 04 B X 12	Phenyl salicylate
G 04 B X 15	Pentosan polysulfate sodium	M 01 A A 01	Phenylbutazone
L 01 X X 08	Pentostatin	M 02 A A 01	Phenylbutazone
C 04 A D 03	Pentoxifylline	M 01 B A 01	Phenylbutazone and corticosteroids
R 05 D B 05	Pentoxyverine	C 01 C A 06	Phenylephrine
A 09 A A 03	Pepsin	R 01 A A 04	Phenylephrine
A 09 A C 01	Pepsin and acid preparations	R 01 A B 01	Phenylephrine
N 03 A X 22	Perampanel	R 01 B A 03	Phenylephrine
N 05 A B 10	Perazine	S 01 F B 01	Phenylephrine
V 08 D A 03	Perflenapent	S 01 G A 05	Phenylephrine
V 08 C X 01	Perflubron	R 01 B A 53	Phenylephrine, combinations
N 04 B C 02	Pergolide	S 01 G A 55	Phenylephrine, combinations
C 08 E X 02	Perhexiline	D 08 A K 02	Phenylmercuric borate
N 05 A C 01	Pericyazine	D 09 A A 04	Phenylmercuric nitrate
C 09 A A 04	Perindopril	R 01 B A 01	Phenylpropanolamine
C 09 B B 04	Perindopril and amlodipine	R 01 B A 51	Phenylpropanolamine, combinations
C 09 B A 04	Perindopril and diuretics	N 03 A B 02	Phenytol
A 06 A H	Peripheral opioid receptor antagonists	N 03 A B 52	Phenytol, combinations
P 03 A C 04	Permethrin	A 03 A X 12	Phloroglucinol
P 03 A C 54	Permethrin, combinations	R 05 D A 08	Pholcodine
N 05 A B 03	Perphenazine	V 10 A X 01	Phosphorous (32P) chromicphosphate colloid
J 06 B B 13	Pertussis immunoglobulin	A 07 A B 02	Phthalylsulfathiazole

S 01 E B 05	Physostigmine	C 10 A X 08	Policosanol
V 03 A B 19	Physostigmine	D 08 A E 02	Policresulen
B 02 B A 01	Phytomenadione	G 01 A X 03	Policresulen
S 01 A X 16	Picloxydine	C 05 B B 02	Polidocanol
C 02 L G 03	Picodralazine and diuretics	D 08 A C 05	Polihexanide
C 02 L G 73	Picodralazine and diuretics, combinations with psycholeptics	J 07 B F 01	Poliomyelitis oral, monovalent live attenuated
B 01 A C 03	Picotamide	J 07 B F 02	Poliomyelitis oral, trivalent live attenuated
L 03 A X 05	Pidotimod	J 07 B F 03	Poliomyelitis, trivalent, inactivated, whole virus
N 07 A X 01	Pilocarpine	L 03 A X 07	Poly I:C
S 01 E B 01	Pilocarpine	L 03 A X 08	Poly ICLC
S 01 E B 51	Pilocarpine, combinations	A 06 A C 08	Polycarbofil calcium
D 11 A H 02	Pimecolimus	L 02 A A 02	Polyestradiol phosphate
R 06 A X 23	Pimethixene	A 07 A A 05	Polymyxin B
N 05 A G 02	Pimozide	J 01 X B 02	Polymyxin B
C 02 D G 01	Pinacidil	S 01 A A 18	Polymyxin B
C 02 L X 01	Pinacidil and diuretics	S 02 A A 11	Polymyxin B
A 03 A X 04	Pinaverium	S 03 A A 03	Polymyxin B
N 05 B A 14	Pinazepam	A 01 A B 05	Polynoxylin
C 07 A A 03	Pindolol	D 01 A E 05	Polynoxylin
C 07 C A 03	Pindolol and other diuretics	L 01 X A 05	Polyplattilen
A 10 B G 03	Pioglitazone	V 03 A E 01	Polystyrene sulfonate
A 10 B D 09	Pioglitazone and alogliptin	C 03 A A 05	Polythiazide
N 05 A D 05	Pipamperone	C 03 A B 05	Polythiazide and potassium
R 05 D B 11	Pipazetate	L 01 X D 01	Porfimer sodium
M 03 A C 06	Pipecuronium bromide	J 02 A C 04	Posaconazole
J 01 M B 04	Pipemidic acid	B 05 X A 17	Potassium acetate
A 03 A B 14	Pipenzolate	C 03 D A 02	Potassium canrenoate
J 01 C A 12	Piperacillin	A 12 B A 01	Potassium chloride
J 01 C R 05	Piperacillin and enzyme inhibitor	B 05 X A 01	Potassium chloride
P 02 C B 01	Piperazine	A 12 B A 51	Potassium chloride, combinations
R 05 D B 23	Piperidione	A 12 B A 02	Potassium citrate
A 03 A A 30	Piperidolate	N 05 B A 05	Potassium clorazepate
L 01 A X 02	Pipobroman	A 12 B A 05	Potassium gluconate
N 05 A C 04	Pipotiazine	A 12 B A 04	Potassium hydrogencarbonate
N 06 B X 15	Pipradrol	A 12 B A 03	Potassium hydrogentartrate
A 05 A X 01	Piprozolin	R 05 C A 02	Potassium iodide
N 06 B X 03	Piracetam	S 01 X A 04	Potassium iodide
L 01 D B 08	Pirarubicin	V 03 A B 21	Potassium iodide
R 03 A C 08	Pirbuterol	B 05 X A 15	Potassium lactate
R 03 C C 07	Pirbuterol	H 03 B C 01	Potassium perchlorate
A 02 B X 03	Pirenzepine	D 08 A X 06	Potassium permanganate
C 03 C A 03	Piretanide	V 03 A B 18	Potassium permanganate
L 04 A C 10	Pirfenidone	B 05 X A 06	Potassium phosphate, combinations with other potassium salts
N 04 B C 08	Piribedil	P 03 A A 02	Potassium polysulfide
N 06 B X 08	Pirisudanol	N 02 B A 12	Potassium salicylate
N 02 A C 03	Piritramide	D 08 A G 02	Povidone-iodine
J 01 M B 03	Piromidic acid	D 09 A A 09	Povidone iodine
M 01 A C 01	Piroxicam	D 11 A C 06	Povidone-iodine
M 02 A A 07	Piroxicam	G 01 A X 11	Povidone-iodine
S 01 B C 06	Piroxicam	R 02 A A 15	Povidone-iodine
M 01 A E 08	Pirprofen	S 01 A X 18	Povidone-iodine
C 10 A A 08	Pitavastatin	C 07 A B 01	Practolol
A 03 D A 02	Pitofenone and analgesics	C 01 B A 08	Prajmaline
N 06 A X 15	Pivagabine	L 01 B A 05	Pralatrexate
J 01 C A 02	Pivampicillin	V 03 A B 04	Pralidoxime
J 01 C A 08	Pivmecillinam	N 04 B C 05	Pramipexole
L 01 D B 11	Pixantrone	N 06 B X 16	Pramiracetam
N 02 C X 01	Pizotifen	A 10 B X 05	Pramlintide
J 07 A K 01	Plague, inactivated, whole cell	C 05 A D 07	Pramocaine
G 02 B A 01	Plastic IUD	D 04 A B 07	Pramocaine
G 02 B A 02	Plastic IUD with copper	R 03 D C 02	Pranlukast
G 02 B A 03	Plastic IUD with progestogen	S 01 B C 09	Pranoprofen
J 05 A X 06	Pleconaril	A 14 A A 07	Prasterone
L 03 A X 16	Plerixafor	G 03 E A 03	Prasterone and estrogen
L 01 D C 02	Plicamycin	B 01 A C 22	Prasugrel
J 07 A L 01	Pneumococcus, purified polysaccharides antigen	C 10 A A 03	Pravastatin
J 07 A L 52	Pneumococcus, purified polysaccharides antigen and Haemophilus influenzae, conjugated	C 10 B X 02	Pravastatin and acetylsalicylic acid
		C 10 B A 03	Pravastatin and fenofibrate
J 07 A L 02	Pneumococcus, purified polysaccharides antigen conjugated	N 05 B A 11	Prazepam
D 06 B B 04	Podophyllotoxin	P 02 B A 01	Praziquantel
A 03 A B 11	Poldine	C 02 C A 01	Prazosin

C 03 B A 02 Quinethazone
 C 03 B B 02 Quinethazone and potassium
 G 03 A C 04 Quingestanol
 G 03 A A 02 Quingestanol and estrogen
 C 01 B A 01 Quinidine
 C 01 B A 51 Quinidine, combinations excluding psycholeptics
 C 01 B A 71 Quinidine, combinations with psycholeptics
 P 01 B C 01 Quinine
 M 09 A A 72 Quinine, combinations with psycholeptics
 D 04 A B 05 Quinisocaine
 N 06 A A 23 Quinupramine
 J 01 F G 02 Quinupristin/dalfopristin

R

A 02 B C 04 Rabeprazole
 J 06 B B 05 Rabies immunoglobulin
 J 06 A A 06 Rabies serum
 J 07 B G 01 Rabies, inactivated, whole virus
 A 07 X A 04 Racecadotril
 G 03 X C 01 Raloxifene
 J 05 A X 08 Raltegravir
 L 01 B A 03 Raltitrexed
 N 05 C H 02 Ramelteon
 C 09 A A 05 Ramipril
 C 09 B B 07 Ramipril and amlodipine
 C 09 B A 05 Ramipril and diuretics
 C 09 B B 05 Ramipril and felodipine
 S 01 L A 04 Ranibizumab
 L 01 A D 07 Ranimustine
 A 02 B A 02 Ranitidine
 A 02 B A 07 Ranitidine bismuth citrate
 C 01 E B 18 Ranolazine
 N 04 B D 02 Rasagiline
 V 03 A F 07 Rasburicase
 C 02 A A 04 Rauwolfia alkaloids, whole root
 C 02 L A 08 Rauwolfia alkaloids, whole root and diuretics
 N 06 A X 18 Reboxetine
 C 01 E B 21 Regadenoson
 N 01 A H 06 Remifentanyl
 C 09 X A 01 Remikiren
 N 05 A L 04 Remoxipride
 A 10 B X 02 Repaglinide
 N 05 C A 12 Reposal
 R 03 A C 15 Reproterol
 R 03 C C 14 Reproterol
 R 03 A K 05 Reproterol and other drugs for obstructive airway diseases
 C 02 A A 01 Rescinnamine
 C 02 L A 02 Rescinnamine and diuretics
 C 02 L A 52 Rescinnamine and diuretics, combinations with other drugs
 C 02 A A 02 Reserpine
 C 02 L A 01 Reserpine and diuretics
 C 02 L A 51 Reserpine and diuretics, combinations with other drugs
 C 02 L A 71 Reserpine and diuretics, combinations with psycholeptics
 C 02 A A 52 Reserpine, combinations
 D 10 A X 02 Resorcinol
 S 01 A X 06 Resorcinol
 D 06 A X 13 Retapamulin
 B 01 A D 07 Reteplase
 N 03 A X 21 Retigabine
 D 10 A D 02 Retinol
 R 01 A X 02 Retinol
 S 01 X A 02 Retinol
 A 11 C A 01 Retinol (Vitamin A)
 B 01 A B 08 Reviparin
 V 10 B X 03 Rhenium (¹⁸⁶Re) etidronic acid
 V 10 A X 05 Rhenium (¹⁸⁶Re) sulfide colloid
 J 05 A B 04 Ribavirin
 J 05 A B 54 Ribavirin, combinations
 A 11 H A 04 Riboflavin (Vitamin B₂)

J 01 G B 10 Ribostamycin
 J 04 A B 04 Rifabutin
 J 04 A B 02 Rifampicin
 J 04 A M 02 Rifampicin and isoniazid
 J 04 A M 05 Rifampicin, pyrazinamide and isoniazid
 J 04 A M 06 Rifampicin, pyrazinamide, ethambutol and isoniazid
 J 04 A B 03 Rifamycin
 S 01 A A 16 Rifamycin
 S 02 A A 12 Rifamycin
 J 04 A B 05 Rifapentine
 A 07 A A 11 Rifaximin
 D 06 A X 11 Rifaximin
 C 02 A C 06 Rilmenidine
 L 04 A C 04 Rilonacept
 J 05 A G 05 Rilpivirine
 N 07 X X 02 Riluzole
 J 05 A C 02 Rimantadine
 N 02 B G 02 Rimazolium
 H 02 A B 12 Rimexolone
 S 01 B A 13 Rimexolone
 R 03 A C 05 Rimiterol
 A 08 A X 01 Rimonabant
 M 05 B A 07 Risedronic acid
 M 05 B B 02 Risedronic acid and calcium, sequential
 M 05 B B 04 Risedronic acid, calcium and colecalciferol, sequential
 N 05 A X 08 Risperidone
 R 01 A X 05 Ritiometan
 G 02 C A 01 Ritodrine
 J 05 A E 03 Ritonavir
 L 01 X C 02 Rituximab
 B 01 A X 06 Rivaroxaban
 N 06 D A 03 Rivastigmine
 N 02 C C 04 Rizatriptan
 A 03 A A 06 Rociverine
 M 03 A C 09 Rocuronium bromide
 M 01 A H 02 Rofecoxib
 R 03 D X 07 Roflumilast
 J 01 F A 12 Rokitamycin
 J 01 A A 09 Rolitetracycline
 L 01 X X 39 Romidepsin
 B 02 B X 04 Romiplostim
 C 10 A B 07 Ronifibrate
 N 04 B C 04 Ropinirole
 N 01 B B 09 Ropivacaine
 L 03 A X 02 Roquinimex
 S 01 J A 02 Rose bengal sodium
 A 10 B G 02 Rosiglitazone
 J 01 M B 01 Rosoxacin
 C 10 A A 07 Rosuvastatin
 J 07 B H 01 Rota virus, live attenuated
 J 07 B H 02 Rota virus, pentavalent, live, reassorted
 N 04 B C 09 Rotigotine
 A 02 B A 06 Roxatidine
 J 01 F A 06 Roxithromycin
 J 06 B B 06 Rubella immunoglobulin
 J 07 B J 51 Rubella, combinations with mumps, live attenuated
 J 07 B J 01 Rubella, live attenuated
 N 03 A F 03 Rufinamide
 J 01 M A 10 Rifaximin
 R 06 A X 28 Rupatadine
 C 05 C A 01 Rutoside
 C 05 C A 51 Rutoside, combinations
 L 01 X E 18 Ruxolitinib

S

B 03 A B 02 Saccharated iron oxide
 B 03 A C 02 Saccharated iron oxide
 A 07 F A 02 Saccharomyces boulardii
 A 16 A B 06 Sacrosidase
 R 03 A C 02 Salbutamol

R 03 C C 02	Salbutamol	J 06 A A 03	Snake venom antiserum
R 03 A K 04	Salbutamol and other drugs for obstructive airway diseases	R 05 C B 07	Sobrerol
N 02 B A 05	Salicylamide	B 05 X A 08	Sodium acetate
N 02 B A 55	Salicylamide, combinations excl psycholeptics	J 04 A A 02	Sodium aminosalicylate
N 02 B A 75	Salicylamide, combinations with psycholeptics	C 05 B A 02	Sodium apolate
D 01 A E 12	Salicylic acid	M 01 C B 01	Sodium aurothiomalate
S 01 B C 08	Salicylic acid	M 01 C B 02	Sodium aurotiosulfate
R 03 A C 12	Salmeterol	B 05 C B 04	Sodium bicarbonate
R 03 A K 06	Salmeterol and other drugs for obstructive airway diseases	B 05 X A 02	Sodium bicarbonate
N 02 B A 06	Salsalate	S 01 A X 07	Sodium borate
V 10 A X 02	Samarium (¹⁵² Sm) hydroxyapatite colloid	V 03 A G 01	Sodium cellulose phosphate
V 10 B X 02	Samarium (¹⁵³ Sm) lexicidronam	A 12 C A 01	Sodium chloride
A 16 A X 07	Sapropterin	B 05 C B 01	Sodium chloride
J 05 A E 01	Saquinavir	B 05 X A 03	Sodium chloride
L 03 A A 09	Sargramostim	S 01 X A 03	Sodium chloride, hypertonic
B 01 A D 08	Saruplase	B 05 C B 02	Sodium citrate
C 07 A B 11	S-atenolol	S 01 X A 05	Sodium edetate
L 01 X A 04	Satraplatin	B 03 A B 03	Sodium feredetate
A 10 B H 03	Saxagliptin	A 01 A A 01	Sodium fluoride
A 04 A D 01	Scopolamine	A 12 C D 01	Sodium fluoride
N 05 C M 05	Scopolamine	V 09 I X 06	Sodium fluoride (18F)
S 01 F A 02	Scopolamine	V 09 F X 04	Sodium iodine (124I)
A 04 A D 51	Scopolamine, combinations	A 01 A A 51	Sodium fluoride, combinations
P 01 A B 07	Secnidazole	V 03 A F 06	Sodium folinate
N 05 C A 06	Secobarbital	B 05 X A 14	Sodium glycerophosphate
V 04 C K 01	Secretin	D 08 A X 07	Sodium hypochlorite
L 04 A C 10	Secukinumab	V 09 F X 02	Sodium iodide (¹²³ I)
N 04 B D 01	Selegiline	V 09 F X 03	Sodium iodide (¹³¹ I)
V 09 X X 03	Selenium (⁷⁵ Se) norcholesterol	V 10 X A 01	Sodium iodide (¹³¹ I)
V 09 D X 01	Selenium (⁷⁵ Se) tauroselcholic acid	V 09 C X 01	Sodium iodohippurate (¹²³ I)
D 11 A C 03	Selenium compounds	V 09 C X 02	Sodium iodohippurate (¹³¹ I)
D 01 A E 13	Selenium sulfide	V 08 A C 08	Sodium iopodate
L 01 A D 03	Semustine	V 09 C X 03	Sodium iothalamate (¹²⁵ I)
R 05 C A 06	Senega	V 03 A F 10	Sodium levofolinate
A 06 A B 06	Senna glycosides	A 01 A A 02	Sodium monofluorophosphate
A 06 A B 56	Senna glycosides, combinations	A 12 C D 02	Sodium monofluorophosphate
R 03 D X 06	Seratrodast	V 03 A B 08	Sodium nitrite
G 04 C X 02	Sabalís serrulatae fructus	N 01 A X 11	Sodium oxybate
H 01 A C 04	Sermorelin	A 01 A B 19	Sodium perborate
V 04 C D 03	Sermorelin	A 16 A X 03	Sodium phenylbutyrate
D 01 A C 14	Sertaconazole	A 06 A D 17	Sodium phosphate
N 05 A E 03	Sertindole	A 06 A G 01	Sodium phosphate
N 06 A B 06	Sertraline	B 05 X A 09	Sodium phosphate
G 03 G A 03	Serum gonadotrophin	V 10 X X 01	Sodium phosphate (³² P)
V 03 A E 02	Sevelamer	A 06 A B 08	Sodium picosulfate
N 01 A B 08	Sevoflurane	A 06 A B 58	Sodium picosulfate, combinations
A 08 A A 10	Sibutramine	S 01 A X 10	Sodium propionate
G 04 B E 03	Sildenafil	N 02 B A 04	Sodium salicylate
D 02 A A	Silicone products	A 12 C E 01	Sodium selenate
A 03 A X 13	Silicones	A 12 C E 02	Sodium selenite
G 04 C A 04	Silodosin	P 01 C B 02	Sodium stibogluconate
D 08 A L 30	Silver	A 06 A D 13	Sodium sulfate
S 01 A X 02	Silver compounds	A 12 C A 02	Sodium sulfate
D 08 A L 01	Silver nitrate	A 06 A D 21	Sodium tartrate
D 06 B A 01	Silver sulfadiazine	C 05 B B 04	Sodium tetradecyl sulphate
D 06 B A 51	Silver sulfadiazine, combinations	A 06 A A	Softeners, emollients
A 05 B A 03	Silymarin	D 02 A C	Soft paraffin and fat products
C 10 A B 06	Simfibrate	D 09 A X	Soft paraffin dressings
C 10 A A 01	Simvastatin	G 04 B D 08	Solifenacin
C 10 B X 01	Simvastatin and acetylsalicylic acid	V 04 C D 05	Somatorelin
C 10 B X 04	Simvastatin, acetylsalicylic acid and ramipril	H 01 C B 01	Somatostatin
C 10 B A 02	Simvastatin and ezetimibe	H 01 A C 02	Somatrem
V 04 C C 03	Sinacalide	H 01 A C 01	Somatropin
D 06 B B 12	Sinecatechins	L 01 X E 05	Sorafenib
L 03 A X 17	Sipuleucel-T	A 06 A D 18	Sorbitol
L 04 A A 10	Sirolimus	A 06 A G 07	Sorbitol
J 01 G B 08	Sisomicin	B 05 C X 02	Sorbitol
J 01 M A 21	Sitafloracin	V 04 C C 01	Sorbitol
A 10 B H 01	Sitagliptin	C 07 A A 07	Sotalol
C 02 K X 03	Sitaxentan	C 07 B A 07	Sotalol and thiazides
L 01 X X 37	Sitimagene ceradenovec	C 07 A A 57	Sotalol, combination packages

V 09 G A 05	Technetium (^{99m} Tc) furifosmin	G 02 C B 06	Terguride
V 09 D A 05	Technetium (^{99m} Tc) galtifenin	H 05 A A 02	Teriparatide
V 09 C A 04	Technetium (^{99m} Tc) gluceptate	J 04 A K 03	Terizidone
V 09 C A 05	Technetium (^{99m} Tc) gluconate	H 01 B A 04	Terlipressin
V 09 G A 04	Technetium (^{99m} Tc) human albumin	G 04 B D 05	Terodiline
V 09 H A 01	Technetium (^{99m} Tc) human immunoglobulin	C 07 A A 16	Tertatolol
V 09 I A 07	Technetium (^{99m} Tc) hynic-octreotide	H 01 A C 06	Tesamorelin
V 09 D A 03	Technetium (^{99m} Tc) lidofenin	G 03 B A 03	Testosterone
V 09 E B 01	Technetium (^{99m} Tc) macrosalib	G 03 E A 02	Testosterone and estrogen
V 09 D A 04	Technetium (^{99m} Tc) mebrofenin	J 06 A A 02	Tetanus antitoxin
V 09 B A 02	Technetium (^{99m} Tc) medronic acid	J 06 B B 02	Tetanus immunoglobulin
V 09 C A 03	Technetium (^{99m} Tc) mertiatide	J 07 A M 01	Tetanus toxoid
V 09 D B 02	Technetium (^{99m} Tc) microcolloid	J 07 A M 51	Tetanus toxoid, combinations with diphtheria toxoid
V 09 E B 02	Technetium (^{99m} Tc) microspheres	J 07 A M 52	Tetanus toxoid, combinations with tetanus immunoglobulin
V 09 D B 03	Technetium (^{99m} Tc) millimicrospheres	N 07 X X 06	Tetrabenazine
V 09 D B 01	Technetium (^{99m} Tc) nanocolloid	C 05 A D 02	Tetracaine
V 09 E A 03	Technetium (^{99m} Tc) nanocolloid	D 04 A B 06	Tetracaine
V 09 B A 01	Technetium (^{99m} Tc) oxidronic acid	N 01 B A 03	Tetracaine
V 09 I A 03	Technetium (^{99m} Tc) pentavalent succimer	S 01 H A 03	Tetracaine
V 09 C A 01	Technetium (^{99m} Tc) pentetic acid	D 03 A X 11	Tetrachlorodecaoxide
V 09 E A 01	Technetium (^{99m} Tc) pentetic acid	H 01 A A 02	Tetracosactide
V 09 F X 01	Technetium (^{99m} Tc) pertechnetate	A 01 A B 13	Tetracycline
V 09 D B 07	Technetium (^{99m} Tc) phytate	D 06 A A 04	Tetracycline
V 09 B A 03	Technetium (^{99m} Tc) pyrophosphate	J 01 A A 07	Tetracycline
V 09 D B 06	Technetium (^{99m} Tc) rheniumsulfide colloid	S 01 A A 09	Tetracycline
V 09 G A 01	Technetium (^{99m} Tc) sestamibi	S 02 A A 08	Tetracycline
V 09 G A 06	Technetium (^{99m} Tc) stannous agent labeled cells	S 03 A A 02	Tetracycline
V 09 C A 02	Technetium (^{99m} Tc) succimer	B 02 B C 03	Tetragalacturonic acid hydroxymethylester
V 09 H A 04	Technetium (^{99m} Tc) sulesomab	P 03 B A 03	Tetramethrin
V 09 D B 05	Technetium (^{99m} Tc) sulfur colloid	M 03 B X 07	Tetrazepam
V 09 G A 03	Technetium (^{99m} Tc) teboroxime	R 01 A A 06	Tetryzoline
V 09 E A 02	Technetium (^{99m} Tc) technegas	R 01 A B 03	Tetryzoline
V 09 G A 02	Technetium (^{99m} Tc) tetrafosmin	S 01 G A 02	Tetryzoline
V 09 D B 04	Technetium (^{99m} Tc) tin colloid	S 01 G A 52	Tetryzoline, combinations
V 09 I A 04	Technetium (^{99m} Tc) votumumab	V 01 A A 09	Textiles
P 01 A C 04	Teclozan	L 04 A X 02	Thalidomide
C 01 E B 12	Tedisamil	V 09 G X 01	Thallium (²⁰¹ Tl) chloride
A 16 A X 08	Teduglutide	R 05 D A 10	Thebacon
L 01 B C 03	Tegafur	D 04 A A 03	Thenalidine
L 01 B C 53	Tegafur, combinations	R 06 A X 03	Thenalidine
A 03 A E 02	Tegaserod	R 06 A X 53	Thenalidine, combinations
J 01 X A 02	Teicoplanin	C 03 B D 01	Theobromide
J 05 A E 11	Telaprevir	R 03 D A 07	Theobromide
J 01 X A 03	Telavancin	R 03 D A 57	Theobromide, combinations
J 05 A F 11	Telbivudine	C 01 C A 23	Theodrenaline
J 01 F A 15	Telithromycin	R 03 D A 04	Theophylline
C 09 C A 07	Telmisartan	R 03 D B 04	Theophylline and adrenergics
C 09 D B 04	Telmisartan and amlodipine	R 03 D A 54	Theophylline, combinations excluding psycholeptics
C 09 D A 07	Telmisartan and diuretics	R 03 D A 74	Theophylline, combinations with psycholeptics
J 01 M A 05	Temafloxacin	H 03 B B 02	Thiamazole
N 05 C D 07	Temazepam	H 03 B B 52	Thiamazole, combinations
C 09 A A 14	Temocapril	A 11 D A 01	Thiamine (Vit B ₁)
J 01 C A 17	Temocillin	J 01 B A 02	Thiamphenicol
L 01 X D 05	Temoporfin	J 01 B A 52	Thiamphenicol, combinations
L 01 A X 03	Temozolomide	R 06 A D 06	Thiazinam
L 01 X E 09	Temsirolimus	R 06 A D 03	Thiethylperazine
B 01 A D 11	Tenecteplase	J 04 A M 04	Thioacetazone and isoniazid
M 01 A X 23	Tenidap	M 03 B X 05	Thiocolchicoside
L 01 C B 02	Teniposide	D 08 A K 06	Thiomersal
C 01 D A 38	Tenitramine	N 01 A F 03	Thiopental
J 05 A F 07	Tenofovir disoproxil	N 05 C A 19	Thiopental
P 01 A X 08	Tenonitrozone	N 05 A B 05	Thiopropazate
M 01 A C 02	Tenoxicam	N 05 A B 08	Thiopropazine
G 04 C A 03	Terazosin	N 05 A C 02	Thioridazine
D 01 A E 15	Terbinafine	V 03 A B 06	Thiosulfate
D 01 B A 02	Terbinafine	L 01 A C 01	Thiotepa
R 03 A C 03	Terbutaline	P 03 A A 05	Thiram
R 03 C C 03	Terbutaline	D 04 A A 01	Thonzylamine
R 03 C C 53	Terbutaline, combinations	R 01 A C 06	Thonzylamine
G 01 A G 02	Terconazole	R 06 A C 06	Thonzylamine
R 06 A X 12	Terfenadine	B 02 B C 06	Thrombin

B 02 B D 30	Thrombin	M 02 A X 02	Tolazoline
B 05 A X 02	Thrombocytes	A 10 B B 03	Tolbutamide
L 03 A X 09	Thymopentin	V 04 C A 01	Tolbutamide
H 03 A A 05	Thyroid gland preparations	N 04 B X 01	Tolcapone
H 01 A B 01	Thyrotropin	D 01 A E 19	Tolciclate
V 04 C J 01	Thyrotropin	M 01 A G 02	Tolfenamic acid
D 01 A C 06	Tiabendazole	M 01 A B 03	Tolmetin
P 02 C A 02	Tiabendazole	M 02 A A 21	Tolmetin
C 10 A X 03	Tiadenol	D 01 A E 18	Tolnaftate
N 03 A G 06	Tiagabine	C 02 A C 04	Tolonidine
N 06 A X 14	Tianeptine	N 06 A G 03	Toloxatone
N 05 A L 03	Tiapride	M 03 B X 04	Tolperisone
M 01 A E 11	Tiaprofenic acid	D 04 A A 12	Tolpropamine
L 01 X X 18	Tiazofurine	A 10 X A 01	Tolrestat
A 01 A B 15	Tibezonium iodide	G 04 B D 07	Tolterodine
G 03 C X 01	Tibolone	C 03 X A 01	Tolvaptan
B 01 A C 24	Ticagrelor	N 03 A X 11	Topiramate
J 01 C A 13	Ticarcillin	L 01 X X 17	Topotecan
J 01 C R 03	Ticarcillin and enzyme inhibitor	C 03 C A 04	Torasemide
D 01 A E 08	Ticlatone	L 02 B A 02	Toremifene
B 01 A C 05	Ticlopidine	V 10 X A 53	Tositumomab/iodine (¹³¹ I) tositumomab
A 05 B A 07	Tidiac arginine	D 08 A X 04	Tosylchloramide sodium
A 03 A B 17	Tiemonium iodide	L 01 C X 01	Trabectedin
A 03 D A 07	Tiemonium iodide and analgesics	N 02 A X 02	Tramadol
C 03 C C 02	Tienilic acid	N 02 A X 52	Tramadol, combinations
J 01 A A 12	Tigecycline	R 01 A A 09	Tramazoline
A 09 A A 04	Tilactase	C 09 A A 10	Trandolapril
P 01 A A 05	Tilbroquinol	C 09 B B 10	Trandolapril and verapamil
N 02 A X 01	Tilidine	B 02 A A 02	Tranexamic acid
M 05 B A 05	Tiludronic acid	N 06 A F 04	Tranylcypromine
A 03 A B 19	Timepidium bromide	C 01 D X 11	Trapidil
C 07 A A 06	Timolol	L 01 X C 03	Trastuzumab
S 01 E D 01	Timolol	S 01 E E 04	Travoprost
C 07 B A 06	Timolol and thiazides	N 06 A X 05	Trazodone
S 01 E D 51	Timolol, combinations	V 01 A A 05	Tree pollen
C 07 D A 06	Timolol, thiazides and other diuretics	L 01 A B 02	Treosulfan
J 01 X D 02	Tinidazole	A 03 A X 09	Trepibutone
P 01 A B 02	Tinidazole	B 01 A C 21	Treprostinil
B 01 A B 10	Tinzaparin	D 10 A D 01	Tretinoin
J 04 A D 02	Tiocarlide	L 01 X X 14	Tretinoin
B 01 A A 11	Tiocloamarol	D 10 A D 51	Tretinoin, combinations
D 01 A C 07	Tioconazole	R 03 A C 09	Tretoquinol
G 01 A F 08	Tioconazole	R 03 C C 09	Tretoquinol
A 16 A X 01	Tioctic acid	A 01 A C 01	Triamcinolone
L 01 B B 03	Tioguanine	C 05 A A 12	Triamcinolone
R 05 C B 12	Tiopronin	D 07 A B 09	Triamcinolone
N 05 A F 04	Tiotixene	D 07 X B 02	Triamcinolone
R 03 B B 04	Tiotropium bromide	H 02 A B 08	Triamcinolone
D 10 A B 03	Tioxolone	R 01 A D 11	Triamcinolone
R 05 D B 24	Tipepidine	R 03 B A 06	Triamcinolone
J 05 A E 09	Tipranavir	S 01 B A 05	Triamcinolone
C 01 E B 11	Tiracizine	D 07 C B 01	Triamcinolone and antibiotics
D 11 A X 08	Tiratricol	S 02 C A 04	Triamcinolone and antiinfectives
H 03 A A 04	Tiratricol	D 07 B B 03	Triamcinolone and antiseptics
N 07 X X 01	Tirilazad	C 03 D B 02	Triamterene
B 01 A C 17	Tirofiban	L 01 A C 02	Triaziquone
A 03 A C 05	Tiropamide	N 05 C D 05	Triazolam
M 04 A A 02	Tisopurine	C 05 A X 05	Tribenoside
A 07 E A 05	Tixocortol	C 05 C X 01	Tribenoside
R 01 A D 07	Tixocortol	D 01 A E 03	Tribromometacresol
R 01 A D 57	Tixocortol, combinations	C 03 A A 06	Trichlormethiazide
M 03 B X 02	Tizanidine	C 03 A B 06	Trichlormethiazide and potassium
J 01 G B 01	Tobramycin	C 03 E A 02	Trichlormethiazide and potassium-sparing agents
S 01 A A 12	Tobramycin	N 01 A B 05	Trichloroethylene
C 01 B B 03	Tocainide	P 02 B X 04	Triclabendazole
L 04 A C 07	Tocilizumab	N 05 C M 07	Triclofos
A 11 H A 08	Tocofersolan	D 08 A E 04	Triclosan
A 11 H A 03	Tocopherol (Vit E)	D 09 A A 06	Triclosan
N 05 B A 23	Tofisopam	A 03 A B 08	Tridihexethyl
A 10 B B 05	Tolazamide	N 05 A B 06	Trifluoperazine
C 04 A B 02	Tolazoline	N 05 A D 02	Trifluoperidol

N 05 A A 05 Triflupromazine
 S 01 A D 02 Trifluridine
 B 01 A C 18 Triflusal
 N 04 A A 01 Trihexyphenidyl
 H 02 C A 01 Trilostane
 C 02 C A 03 Trimazosin
 A 03 A A 05 Trimebutine
 G 03 F A 16 Trimegestone and estrogen
 G 03 F B 11 Trimegestone and estrogen
 C 02 B A 01 Trimetaphan
 C 01 E B 15 Trimetazidine
 N 03 A C 02 Trimethadione
 J 01 E A 01 Trimethoprim
 A 03 A X 30 Trimethyldiphenylpropylamine
 P 01 A X 07 Trimetrexate
 N 06 A A 06 Trimipramine
 D 05 A D 01 Trioxysalen
 D 05 B A 01 Trioxysalen
 D 04 A A 04 Tripelennamine
 R 06 A C 04 Tripelennamine
 R 06 A X 07 Triprolidine
 L 02 A E 04 Triptorelin
 A 06 A C 07 Triticum (wheat fibre)
 R 06 A X 21 Tritoqualine
 L 01 A A 07 Trofosfamide
 A 10 B G 01 Troglitazone
 J 01 F A 08 Troleandomycin
 C 01 D A 09 Trolnitrate
 C 01 D A 59 Trolnitrate, combinations
 D 06 B B 02 Tromantadine
 J 05 A C 03 Tromantadine
 B 05 B B 03 Trometamol
 B 05 X X 02 Trometamol
 N 04 A A 12 Tropatepine
 A 03 D A 01 Tropenzilone and analgesics
 S 01 F A 06 Tropicamide
 S 01 F A 56 Tropicamide, combinations
 A 04 A A 03 Tropisetron
 G 04 B D 09 Trospium
 A 03 D A 06 Trospium and analgesics
 J 01 M A 13 Trovafloxacin
 C 05 C A 04 Troxerutin
 C 05 C A 54 Troxerutin, combinations
 A 02 B X 11 Troxipide
 B 06 A A 07 Trypsin
 D 03 B A 01 Trypsin
 M 09 A B 52 Trypsin, combinations
 N 06 A X 02 Tryptophan
 R 01 A A 11 Tuaminoheptane
 R 01 A B 08 Tuaminoheptane
 V 04 C F 01 Tuberculin
 J 07 A N 01 Tuberculosis, live attenuated
 M 03 A A 02 Tubocurarine
 R 03 A C 11 Tulobuterol
 R 03 C C 11 Tulobuterol
 R 05 C A 01 Tyloxapol
 R 01 A A 13 Tymazoline
 J 07 C A 10 Typhoid – hepatitis A
 J 07 A P 10 Typhoid, combinations with paratyphi types
 J 07 A P 02 Typhoid, inactivated, whole cell
 J 07 A P 01 Typhoid, oral, live attenuated
 J 07 A P 03 Typhoid, purified polysaccharide antigen
 J 07 A R 01 Typhus exanthematicus, inactivated, whole cell
 V 08 A C 09 Tyropanoic acid
 D 06 A X 08 Tyrothricin
 R 02 A B 02 Tyrothricin
 S 01 A A 05 Tyrothricin

U

C 01 E B 09 Ubidecarenone
 G 03 A D 02 Ulipristal
 D 07 A C 21 Ulobetasol
 D 01 A E 04 Undecylenic acid
 D 01 A E 54 Undecylenic acid, combinations
 S 01 E E 02 Unoprostone
 C 02 C A 06 Urapidil
 M 04 A X 01 Urate oxidase
 G 03 G A 04 Urofollitrophin
 B 01 A D 04 Urokinase
 G 04 B X Urologicals, other
 A 05 A A 02 Ursodeoxycholic acid
 L 04 A C 05 Ustekinumab

V

J 06 B B 07 Vaccinia immunoglobulin
 G 02 B B 01 Vaginal ring with progestogen and estrogen
 J 05 A B 11 Valaciclovir
 M 01 A H 03 Valdecoxib
 N 05 C M 09 Valerianae radix
 J 05 A B 14 Valganciclovir
 N 05 C M 13 Valnoctamide
 N 03 A G 01 Valproic acid
 N 03 A G 02 Valpromide
 L 01 D B 09 Valrubicin
 C 09 C A 03 Valsartan
 C 09 D X 02 Valsartan and aliskiren
 C 09 D B 01 Valsartan and amlodipine
 C 09 D X 01 Valsartan, amlodipine and hydrochlorothiazide
 C 09 D A 03 Valsartan and diuretics
 A 07 A A 09 Vancomycin
 J 01 X A 01 Vancomycin
 L 01 X E 12 Vandetanib
 H 01 C B 04 Vapreotide
 G 04 B E 09 Vardenafil
 N 07 B A 03 Varenicline
 J 07 B K 01 Varicella, live attenuated
 J 06 B B 03 Varicella/zoster immunoglobulin
 A 01 A B 11 Various
 A 01 A D 11 Various
 M 02 A X 10 Various
 R 01 A X 10 Various
 R 02 A A 20 Various
 V 01 A A 20 Various
 B 03 A E 10 Various combinations
 D 10 A X 30 Various combinations
 H 01 B A 01 Vasopressin
 M 03 A C 03 Vecuronium
 A 16 A B 10 Velaglucerase alfa
 L 01 X E 15 Vemurafenib
 N 06 A X 16 Venlafaxine
 N 05 A L 06 Veralipride
 C 08 D A 01 Verapamil
 C 08 D A 51 Verapamil, combinations
 C 02 K A 01 Veratrum
 C 02 L K 01 Veratrum and diuretics
 C 01 B G 11 Vernakalant
 S 01 L A 01 Verteporfin
 J 05 A B 03 Vidarabine
 S 01 A D 06 Vidarabine
 N 03 A G 04 Vigabatrin
 N 06 A X 24 Vilazodone
 A 10 B H 02 Vildagliptin
 N 06 A X 09 Viloxazine
 N 02 B G 05 Viminol
 N 05 C A 09 Vinbarbital
 L 01 C A 01 Vinblastine
 C 04 A X 17 Vinburnine
 C 04 A X 07 Vincamine

L 01 C A 02 Vincristine
 L 01 C A 03 Vindesine
 L 01 C A 05 Vinflunine
 L 01 C A 04 Vinorelbine
 N 06 B X 18 Vinpocetine
 N 01 A A 02 Vinyl ether
 N 05 C A 08 Vinylbital
 D 06 A X 10 Virginiamycin
 C 04 A X 24 Visnadine
 V 04 C B 01 Vitamin A concentrates
 A 11 E A Vitamin B complex, plain
 A 11 E B Vitamin B complex with vitamin C
 A 11 J B Vitamins with minerals
 L 04 A D 03 Voclosporin
 A 10 B F 03 Voglibose
 B 02 B D 10 Von Willebrand factor
 B 02 B D 06 Von Willebrand factor and coagulation factor VIII in combination
 J 02 A C 03 Voriconazole
 L 01 X X 38 Vorinostat
 L 02 B G 05 Vorozole

W

B 01 A A 03 Warfarin
 D 11 A F Wart and anti-corn preparations

X

N 07 X X 03 Xaliproden
 C 01 C X 07 Xamoterol
 C 04 A D 02 Xantinol nicotinate
 N 01 A X 15 Xenon
 V 09 E X 02 Xenon (¹²⁹Xe) gas
 V 09 E X 03 Xenon (¹³³Xe) gas
 D 11 A C 09 Xenysalate
 J 01 X X 02 Xibornol
 B 01 A E 05 Ximelagatran
 C 03 B A 10 Xipamide
 R 01 A A 07 Xylometazoline
 R 01 A B 06 Xylometazoline
 S 01 G A 03 Xylometazoline
 S 01 G A 53 Xylometazoline, combinations

Y

J 07 B L 01 Yellow fever, live attenuated
 G 04 B E 04 Yohimbine
 V 10 A A 01 Yttrium (⁹⁰Y) citrate colloid
 V 10 A A 02 Yttrium (⁹⁰Y) ferrihydroxide colloid
 V 10 A A 03 Yttrium (⁹⁰Y) silicate colloid

Z

R 03 D C 01 Zafirlukast
 J 05 A F 03 Zalcitabine
 N 05 C F 03 Zaleplon
 J 05 A H 01 Zanamivir
 N 02 B G 08 Ziconotide
 J 05 A F 01 Zidovudine
 J 05 A R 01 Zidovudine and lamivudine
 J 05 A R 04 Zidovudine, and lamivudine and abacavir
 J 05 A R 05 Zidovudine, lamivudine and nevirapine
 N 06 A B 02 Zimeldine
 A 16 A X 05 Zinc acetate
 D 09 A B 02 Zinc bandage with supplements
 D 09 A B 01 Zinc bandage without supplements
 B 05 X A 12 Zinc chloride
 S 01 A X 03 Zinc compounds
 A 12 C B 02 Zinc gluconate
 C 05 A X 04 Zinc preparations
 A 12 C B 03 Zinc protein complex
 A 12 C B 01 Zinc sulfate
 R 05 D B 15 Zipeprol
 N 05 A E 04 Ziprasidone
 C 09 A A 15 Zofenopril
 C 09 B A 15 Zofenopril and diuretics
 M 05 B A 08 Zoledronic acid
 A 02 B X 10 Zolimidine
 N 02 C C 03 Zolmitriptan
 N 05 C F 02 Zolpidem
 M 01 A B 04 Zomepirac
 N 03 A X 15 Zonisamide
 N 05 C F 01 Zopiclone
 L 01 D B 05 Zorubicin
 J 05 B K 02 Zoster, live attenuated
 N 05 A X 11 Zotepine
 M 02 A B 02 Zucapsaicin
 N 05 A F 05 Zuclopenthixol

www.pbs.gov.au

All information in this publication is correct as at December 2013